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Prostate cancer is the second most frequent cancer in men. Patients with a localized disease are 
treated with local therapies such as prostatectomy or radiation therapy whereas patients with a 
metastatic disease are treated with androgen deprivation therapies (ADT). However, patients 
ultimately develop resistance to ADT, thereby leading to a castrate resistant prostate cancer (CRPC). 
The treatment options for such disease are limited and not curative, with a median survival from 
diagnosis of 14 months. Among these treatments, the Sipuleucel-T based vaccine, FDA approved in 
2010, has been shown to prolong the overall survival by 4 months.  However, while this approach 
demonstrated the efficacy of targeting the Prostatic Acid Phosphatase (PAP) antigen, 
overexpressed in prostate cancer, to stimulate the patient’s immune system to treat CRPC, it 
remains extremely expensive and limited in its efficacy.  
The aim of the study was to develop a new, less expensive and more effective PAP-based vaccine 
for the treatment of advanced prostate cancer. A 15mer PAP-derived vaccine, when injected as a 
DNA vaccine, was previously shown to induce PAP-specific T-cell responses and to reduce tumour 
growth in a syngeneic heterotopic murine prostate cancer model. A new form of the vaccine was 
subsequently developed by elongating (to 42mer) and introducing a single mutation to the PAP-
derived peptide. 
Two pre-clinical murine models (C57Bl/6 mice and HHDII/DR1 transgenic) were used to assess the 
efficacy of the vaccine. The mutated PAP42mer sequence was the most immunogenic sequence in 
both models when administered as a peptide-based vaccine, as demonstrated by the higher 
number of IFNγ-releasing splenocytes following in vitro stimulation with PAP-derived class-I and 
class-II epitopes and by the higher functional avidity obtained. The vaccine immunogenicty was 
further enhanced by using stronger adjuvants and delivery systems. CAF09 adjuvant and 
ImmunoBody® DNA vaccine were superior to CpG adjuvant in inducing PAP-specific immune 
responses. This was demonstrated by the expression of activation and inhibitory markers, by the 
induction of a memory response and by the functional phenotype (cytokines release, proliferation, 
and degranulation) of CD8+ T cells following in vitro stimulation with shorter-vaccine-derived 
peptides. Splenocytes from vaccinated mice were capable of lysing target cells in a PAP-dependant 
manner in vitro. Vaccination slowed down the growth of human-PAP+ expressing tumours 
implanted in the HHDII/DR1 model but no anti-tumour effect was observed against TRAMP-C1 
tumours in the C57Bl/6 model. Finally, circulating PAP42mer derived-specific CD8+ T cells were 
detected in the blood of patients with prostate cancer. 
In summary, this study demonstrated that a unique vaccine strategy could induce a robust anti-PAP 
immunity but with little effect on the growth of implanted PAP-expressing cancer cell-derived 
tumours in vivo. The presence of PAP-specific CD8+ T cells in the periphery of patients with advanced 
prostate cancer suggests that these patients could benefit from this new approach.  
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Chapter 1: Introduction 
1.1. Prostate cancer  
1.1.1.Epidemiology and risk factors 
Prostate cancer (PCa) is the second most frequent cancer in men worldwide and the fifth cause of 
death due to cancer in men (Ferlay, et al. 2015). Worldwide, deaths due to PCa represents 6.6% of 
total deaths from cancer in male. In the UK, deaths from PCa represent 7% of deaths from all 
cancers in male (Cancer research UK website: https://www.cancerresearchuk.org/health-
professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer#heading-One). 
Over the last decade, PCa age-standardised mortality rates decreased by 12%. PCa mortality rates 
are expected to decrease by 16% by 2035. 
The survival rate is estimated at 84% in the UK (Cancer research UK website: 
https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-
type/prostate-cancer#heading-One). Following diagnosis, the 1-year survival rate is estimated at 
96.6%, the 5 years survival rate at 86.6% and the 10 years survival rate at 77.6%. The age range at 
which the survival rate is the highest is between 60 to 69 years old with 94% and drops to 66% for 
80-99 years old. In the last 40 years, there has been an improvement of the overall survival (OS) 
rate from 25 to 84%. The survival rate depends on the stage of the disease at diagnosis, going from 
100% for stage I to 30% for stage IV. In Europe, the mean age-standardised 5-year survival rate is 
at 83.4%. It is the highest between 55-64 years of age and the lowest from 85 years of age (De 
Angelis, et al. 2014). In African Americans, the 5-year survival is nearly 100% for early diagnosis 
(localised disease) but drops to 32.6% for late diagnosis (distant metastases) (Taitt 2018). 
 
In 2012, almost 70% of all prostate cancers were diagnosed in developed regions. Indeed, the 
incidence rate is the highest in Australia/New Zealand, followed by Northern America, Western 
Europe, Northern Europe, the Caribbean, Southern Africa, Southern America and then Asia where 
the incidence rate is relatively low. The variation for prostate cancer incidence worldwide is partially 
due to more frequent diagnosis using Prostate Specific Antigen (PSA) testing in developed regions, 
with 23-42% of new PCa cases in Europe and the United States which could be due to over diagnosis 
(Quinn and Babb 2002). There is less variation in mortality rates than in incidence rates, with a 
higher number of deaths due to PCa in less developed regions. The mortality rate is high in 
populations of African descent, intermediate in the Americas and Oceania and low in Asia (Ferlay, 
et al. 2015). According to Taitt it seems clear that men of African descent outside the African 
continent are at higher risk of developing PCa, although it is less evident for Black men living in 
Africa, suggesting that environmental factors could be implicated (Taitt 2018). The same was 
observed for Asian men. The access to diagnostic, health-care services and recommendations for 
PCa testing are factors than vary depending on countries, which increases the fluctuations in 
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incidence and mortality rates worldwide. Overall, the incidence and mortality rates are decreasing 
in developed regions but incidence seem to be increasing worldwide. 
The difference in incidence rate across racial and ethnic groups is also due to genetic factors. 
Multiple PCa genetic risk loci identified in a genome-wide association study in men of European and 
Asian descent allowed to identify variants that are more common in men of African than European 
descent (Haiman, et al. 2011). 
Hassanipour-Azgomi et al. conducted a study assessing the incidence and mortality of PCa and their 
relationship with the Human Development Index (life expectancy at birth, mean years of schooling 
and income level per person of the population) worldwide (Hassanipour-Azgomi, et al. 2018). They 
concluded that there was a positive correlation between the Standardized Incidence Rate of PCa 
and the Human Development Index and a negative correlation between the standardized mortality 
rate and the Human Development Index. Despite the high incidence rate, the mortality rate is 
decreasing for PCa patients with increasing levels of Human Development Index, due to the 
improvement of diagnosis and efficacy of treatment. 
 
Family history of PCa has been shown to impact the risk of PCa. There is a two to three-fold 
increased risk of PCa for men whose brother or father have had PCa and a nine fold increase in the 
case of both having had PCa (Hemminki and Czene 2002). Another study associated the risk of dying 
from PCa with family history of PCa. In that case, the risk of death from PCa is two times higher for 
a man whose brother or father died of PCa (Brandt, et al. 2012). More than 105 prostate cancer risk 
loci explain about one-third of the heritability (Hoffmann, et al. 2015). However, the majority of 
identified germline risk loci are not strongly associated with lethal or nonlethal prostate cancer 
(Shui, et al. 2014), suggesting that inherited factors may be involved early in prostate carcinogenesis 
(Pernar, et al. 2018). 
 
PCa incidence is highly related to age with the highest incidence rates occurring in older men, with 
a peak in the 75-79 age group (Cancer research UK website: 
https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-
type/prostate-cancer#heading-One). The implementation of PSA screening in the U.S. led to a shift 
in the average age at PCa diagnosis, which is now 66 years of age (Howlader, et al. 2016). By the 
age of 79, the probability to develop PCa is 1 in 14 for men worldwide, 1 in 47 for men in low to 
middle sociodemographic index countries and 1 in 6 for men in high sociodemographic index 
countries (Fitzmaurice, et al. 2017). Although PCa occurs mainly in older men, 10% of men 
diagnosed with PCa in the U.S. in 2012 were 55 years old or less. This early onset PCa may have 




Pernar et al. have summarized in a comprehensive review the risk factors for advanced and fatal 
PCa specifically (Pernar, et al. 2018). 
 Obesity, weight gain and waist circumference. Obesity was shown to be associated with a 
higher risk of PCa recurrence and mortality. Weight gain was also linked to higher risk of 
recurrence after a prostatectomy. Waist circumference was suggested to be positively 
associated with the risk of advanced PCa. 
 Taller height probably increases the risk of PCa, in particular the risk advanced PCa. 
 Smoking was positively associated with increased risk of death from PCa and of advanced 
PCa. 
 Calcium and dairy products have both been positively associated with PCa and in some 
studies with advanced or lethal PCa. 
On the contrary, some factors have been identified as protective against PCa. 
 Fish consumption has been linked with decreased PCa mortality and recurrence. 
 Coffee intake has shown no association with PCa but some studies showed an inverse 
association with risk of advanced PCa. 
 Lycopene and tomatoes. Lycopene is a strong anti-oxidant and is present in tomatoes. 
Higher consumption of tomato-based products and higher concentrations of lycopene in 
the serum/plasma were linked to a lower risk of PCa and possibly a lower risk of PCa 
progression. 
 Cholesterol and statins. Cholesterol was shown to increase the risk of PCa. Inversely, the 
use of statins was negatively associated with lethal PCa. Moreover, the use of statins during 
Androgen Deprivation Therapy (ADT) showed a slower progression of the disease (Van 
Rompay, et al. 2019) 
 Physical activity was linked to a lower risk of developing advanced and aggressive PCa. For 
men diagnosed with PCa, physical activity was shown to improve the survival and to 
decrease the progression of the disease. 
 
1.1.2.Pathophysiology 
The prostate is an exocrine gland composed of three zones: peripheral (70% of total volume), 
central (25%) and transition (5%) zones. The majority of PCa cases develop from the peripheral zone 
(75%), 20% develop from the transitional zone, while 5% arise from the central zone (McNeal 1988). 
Most PCa cases are adenocarcinomas as they are derived from the prostate epithelium (Nelson, et 
al. 2003). Although the exact aetiology of prostate cancer is unknown, literature supports the 
hypothesis that both genetic and environmental factors are responsible (Kolonel, et al. 2004). 
Human studies indicate that inflammation might have a role in the development of PCa (De Marzo, 
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et al. 2007), and in particular in the progression from localized to metastatic disease (Ammirante, 
et al. 2010; Luo, et al. 2007). 
Several molecular mechanisms, involved in infection or inflammation, lead to a proliferative 
inflammatory atrophy, then leading to prostatic intraepithelial neoplasia, to localised PCa, to 
metastatic PCa and finally to Androgen-independent PCa (Nelson, et al. 2003). 
PCa is usually a slow developing cancer, offering a large therapeutic window. The 5-year survival 
rate for patients diagnosed with a localized or regional disease is nearly 100%, however, it 
decreases to 28% for patients with a metastatic disease at diagnosis (Siegel, et al. 2015). 
 
1.1.3.Screening and diagnostic 
Early stages PCa are usually asymptomatic, while locally advanced and metastatic PCa are 
symptomatic. Specific tests are therefore needed for diagnosis, as early diseases are potentially 
curable. 
Prostate cancer is usually diagnosed by a PSA blood test and a digital rectal exam (DRE), followed 
by a transrectal ultrasonography (TRUS). More than 60% of PCas are diagnosed in asymptomatic 
patients with normal DRE and elevated PSA (Descotes 2019). 
 Since the 1990s, PSA testing has become the most common screening tool used to diagnose PCa 
(Borley and Feneley 2009). PSA is a serine protease that was first purified in 1979 (Wang, et al. 
1979). It is produced by the prostatic epithelium and the periurethral glands. Its expression is 
prostate-specific but not cancer specific as it is present in normal prostate tissue. As a result, its 
expression increases with age, concurrently with the volume of the prostate. The introduction of 
PSA screening is responsible for the increased incidence of PCa due to over diagnosis (Telesca, et 
al. 2008). 
PSA has a low sensitivity, with 15% of men who have a PSA value between 0 and 4 ng/ml, having 
PCa and 15% of those are high Gleason score (Thompson, et al. 2004; Lucia, et al. 2008). 
Although PSA testing reduced the mortality due to PCa (Shroder, et al. 2014), the resulting over 
diagnosis leads to unnecessary biopsies (Loeb, et al. 2014). 
The use of PSA screening led to diagnosis at an earlier stage of the disease because of the lead time 
(time from screen detection to clinical diagnosis) of PCa, estimated from 3 to 10 years (Etzioni, et 
al. 2008). 
Due to the controversial PSA threshold to recommend a biopsy, new PSA-derived methods have 
been developed (Descotes., 2019): 1) implementation of age-adjusted PSA thresholds, 2) 
calculation of the ratio free-PSA to total-PSA, 3) calculation of the PSA density (total-PSA divided by 
the total prostate volume) and 4) the PSA velocity/PSA doubling time, which considers the increase 
of total-PSA over time. 
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Along with the PSA test, the DRE is one of the primary tests for the diagnosis of PCa. This test allows 
to detect non-PSA secreting tumours (Borley and Feneley 2009). However, it fails to detect many 
cancers and detects them at more advanced stages, in comparison to the PSA test (Smith and 
Catalona 1995). The European randomized study of screening for prostate cancer (ERSPC), 
Rotterdam, reported that the positive predictive value of an abnormal DRE, alongside an elevated 
PSA value, for detecting the presence of PCa was 48.6% in the first round of screening, decreasing 
to 29.9% and 21.2% in the second and third rounds, respectively (Gosselaar, et al. 2008). 
Nonetheless, there was a significant increase of risk of PCa with a Gleason score superior than 7 in 
men with a suspicious DRE in each screening rounds. 
Once there is suspicion of PCa, a TRUS-guided biopsy is performed. TRUS procures imaging of the 
prostate and seminal vesicles. 
This technique was demonstrated to be superior to digitally directed biopsies (Hodge, et al. 1989). 
However, TRUS-guided biopsies give 15 to 46% of false negatives and under-grade the Gleason 
score up to 38% in comparison to the result at radical prostatectomy (Kvale, et al. 2009). TRUS 
biopsy can lead to error such as sampling errors, missing a high-grade cancer or over diagnosing a 
low-grade cancer (Descotes, et al. 2019). To avoid these mistakes, improved TRUS biopsy 
techniques have been developed using Magnetic Resonance Imaging (MRI) in order to localise PCa 
within the prostate gland more accurately. Moreover, transperineal template prostate biopsy 
(TPTPB) was shown to increase the PCa detection rate in comparison to TRUS biopsies in biopsy 
naive patients with PSA <20ng/mL (Nafie, et al. 2014). 
 
1.1.4.Classification of prostate cancer: grades and stages 
The Gleason score, described by Gleason and Mellinger in 1974, is the most commonly used grading 
system (Gleason and Mellinger 1974). It is based on the histology of carcinoma cells in Haematoxylin 
and eosin stained sections conferring a score from 1 to 5 (least to most aggressive). Two grades are 
assigned for each patient, the first one describing the largest tumour area and the second one 
describing the second largest tumour area. Both grades are added up to obtain a histologic score 




Figure 1.1: Gleason’s pattern scale (adapted from Humphrey 2004) (Reprinted by permission from 
[Springer Nature Customer Service Centre GmbH]: [Springer Nature] [MODERN PATHOLOGY] [GLEASON 
GRADING AND PROGNOSTIC FACTORS IN CARCINOMA OF THE PROSTATE, HUMPHREY), [COPYRIGHT] (2004)) 
 
The Gleason grading system evolved following two meetings organised by the international Society 
of Urologic Pathology in 2005 and 2014, resulting into a new Grade Group system which was 
adopted by the 2016 World Health Organization classification of tumours of the prostate (Chen and 
Zhou 2016). 
According to the new Grade Group system, Gleason Scores range from 6-10. A score of 6 describes 
a cancer that will progress slowly, while a score of 7 suggests an intermediate risk for aggressive 
cancer. However, a score of 7 can be divided into two grade groups: a 3+4 suggests a better 
prognostic than a 4+3. A score ≥ 8 suggests a high risk for aggressive cancer that will metastasize 
rapidly. 
The Gleason grade is related to clinical end points such as the clinical stage, the PSA value, the 
progression to metastatic disease, the response to different therapies and the survival (Humphrey 
2004). 
 
The Tumour-Node-Metastasis (TNM) system is used to determine the pathological stage of the 
disease. The American Joint Committee on Cancer published in 2017 the eighth edition Cancer 
staging manual (Buyyounouski, et al. 2017). Staging of PCa is necessary to categorise the severity 
of the disease, estimate the prognosis and recommend treatment. The vast majority of prostate 
cancer, approximately 95%, are clinically localized to the prostate without definite evidence of 
metastasis. The T category, referring to the size and extent of the primary tumour, is based on 
physical examination, imaging, endoscopy, biopsy and biochemical tests. The N category, indicating 
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if the tumour has spread to the lymph nodes, is evaluated via clinical examination and imaging. 
Finally, the M category, indicative of the extent of the metastases, is based on physical examination, 
imaging, skeletal studies and biochemical tests (Sobin and Witterkind 2002). 
 
The D’amico classification, introduced in 1999, divides patients with localized disease into three 
categories: low, intermediate or high risk (D’amico, et al. 1999). It combines the PSA value, the 
Gleason score, and the TNM stage (table 1.1: Risk stratification for clinically localized cancer). 
 
Table 1.1: Risk stratification for clinically localized cancer (adapted from 
https://www.cancernetwork.com/cancer-management/prostate-cancer/page/0/1) 
 PSA value (ng/mL)  Highest biopsy Gleason score  Clinical stage 
Low risk <10 and ≤6 and T1c or T2a 
Intermediate risk ≥10 but <20 or 7 or T2b 




Treatments options for PCa patients depend on the stage of the disease. 
The treatments available for patients diagnosed with localised disease include active surveillance, 
external beam radiotherapy and radical prostatectomy (surgery). Active surveillance, which 
consists in monitoring the evolution of the disease using PSA testing, DRE and a confirmatory biopsy, 
is recommended for low risk patients (Gleason 6, grade I), to provide better quality of life 
(Witherspoon, et al. 2019). The possibility of managing some intermediate risk patients (Gleason 7 
(3+4), grade II) through active surveillance is considered but controversial (Loeb, et al. 2019). 
According to a 2010 study by Schymura et al., 39.7% of patients with localized PCa undergo radical 
prostatectomy, 31.4% receive radiation therapy, 10.3% receive hormone therapy and 18.6% are 
managed with active surveillance (Schymura, et al. 2010). The two major side effects following 
radiotherapy and prostatectomy are urinary incontinence and erectile dysfunction (Potosky, et al. 
2004). Ultimately, one third of these patients develop recurrence or metastasis and require 
Androgen Deprivation Therapy (ADT) (McNeel, et al. 2016). ADT is obtained by surgical castration 
or chemical castration in order to suppress androgen production (Velcheti, et al. 2008). However, 
ADT has a limited period of efficacy as patients eventually become resistant and develop Castrate 
Resistant prostate cancer (CRPC) which requires secondary hormonal interventions, chemotherapy 
or other treatments (De Maeseneer, et al. 2015). 
Mechanisms of hormone resistance are classified into three categories: DNA-based alterations in 
the androgen receptor (AR) gene, AR-growth factors cross-talk and activation of alternative 
pathways of survival and proliferation (Velcheti, et al. 2008). 
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A recent study characterised the involvement of IL-23-secreting Myeloid-Derived Suppressor Cells 
(MDSCs) in the development of CRPC, thereby establishing a role of immunosuppression in the 
pathophysiology of CRPC (Calcinotto, et al. 2018). 
Treatments for mCRPC include androgen signalling inhibitors (Enzalutamide and Abiraterone), 
chemotherapy (Carbazitaxel and Docetaxel), the radiopharmaceutical agent radium-223 and 
Sipuleucel-T vaccine (Figure 1.2) (Kirby, et al. 2011). 
 
Figure 1.2: Typical progression of metastatic castration-resistant prostate cancer (Reprinted from 
The Lancet Oncology, Volume 16, Issue 6, Lorente, et al., Sequencing of agents in castration-resistant prostate 
cancer, pages e279-e292, Copyright (2015), with permission from Elsevier.) 
 
The survival benefit of Docetaxel was confirmed in two 2004 trials: the TAX-327 and the SWOG-99-
16, which reported an improved median OS of 2.9 months and 1.9 months respectively (Berthold, 
et al. 2008; Petrylak, et al. 2004). Docetaxel in combination with prednisone was established as the 
standard of care. Prednisone is a corticosteroid providing both palliative benefits and anti-tumour 
responses in PCa (Teply, et al. 2016). 
Carbazitaxel, another chemotherapy, was approved in 2010 for post-docetaxel patients. The 
TROPIC trial showed an improved median OS of 2.4 months (Bahl, et al. 2013). 
 
Enzalutamide and abiraterone acetate are used in chemotherapy-naive and docetaxel-treated 
mCRPC patients (Lorente, et al. 2015). Enzalutamide, FDA-approved in 2012, is a second-generation 
androgen that blocks the AR at three levels: 1) binding to androgens to inhibit their binding to ARs, 
2) inhibition of nuclear translocation of ARs and 3) inhibition of binding of ARs to chromosomal DNA 
(Saad 2013). It showed an improved median OS of 4.8 months over placebo in the phase 3 AFFIRM 
trial (Scher, et al. 2012). Abiraterone acetate, approved in 2011, suppresses the synthesis of 
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androgen through inhibition of the cytochrome p450 17A1 (Richards, et al. 2012). An improved 
median OS of 4.6 months was observed in the COU-AA-301 trial between abiraterone acetate and 
prednisone or prednisone alone (Fizazi, et al. 2012). 
 
The radiopharmaceutical agent radium-223 is recommended for CRPC patients with bone 
metastasis but no visceral metastasis (Lorente, et al. 2015). It emits high energy α-particles to break 
double-strand DNA in increased bone turn-over areas. The ALSYMPCA trial reported an improved 
median OS of 5.1 months (Parker, et al. 2013). 
 
Sipuleucel-T therapeutic vaccine, approved in 2010, is recommended in early stage CRPC. It is based 
on the in vitro stimulation of patient’s Peripheral Blood Mononuclear Cells (PBMCs) with a fusion 
protein composed of Prostatic Acid Phosphatase (PAP) and Granulocyte/Monocyte Colony 
Stimulating Factor (GM-CSF), followed by the re-infusion of these cells into the patients. Its efficacy 
was demonstrated in the phase 3 IMPACT trial which reported an improved median OS of 4.1 
months (Kantoff, et al. 2010). However, although patients had a Gleason score ≤7, the vaccine had 
no effect on the time to disease progression. 
 
Overall, between 10% and 20% of prostate cancer patients progress to CRPC within 5 years 
following diagnosis, a state for which the treatments options are limited and not curative, with a 
median survival from diagnosis of 14 months (Kirby, et al. 2011). Indeed, patients ultimately 
developed resistance to AR-targeted therapies and to taxane-based chemotherapy (Galletti, et al. 
2017). 
New therapies are therefore needed for the treatment of mCRPC patients. 
As demonstrated with Sipuleucel-T vaccine, immunotherapies are promising for the treatment of 
PCa. There is currently an abundance of ongoing clinical trials assessing immunotherapies for the 
treatment of PCa, as stand-alone, in combination with other immunotherapies or in combination 
with conventional therapies (McNeel, et al. 2016). 
 
1.2. The immune system 
Understanding of the immune system and its cellular components is necessary to comprehend the 
principle of cancer immunotherapy. 
 
1.2.1.Overview of the immune system 




The innate response is the first line of defence against pathogens and foreign molecules, it is rapidly 
put into place and not antigen-specific. The cells providing this first line of defence are granulocytes 
(neutrophils, eosinophils and basophils), monocytes, macrophages, natural killer (NK) cells, NKT 
cells and γδ T-cells. 
 
NK cells are lymphocytes capable of recognizing and lyse abnormal cells such as virus-infected cells 
or tumour cells via three mechanisms (Abel, et al. 2018). The first one involves the binding of their 
own immunoglobulin receptor (FcR) to antibodies on the surface of target cells, called Antibody-
Dependant Cellular Cytotoxicity (ADCC) (Wang, et al. 2015). The other mechanism depends on the 
recognition of MHC class-I molecule on the surface of target cells (Abel, et al. 2018). The absence 
of MHC class-I molecules on target cells leads to the secretion of perforins which creates pores in 
the membrane of the target cells, through which granzymes are injected to induce the apoptosis of 
the cell. The third one relies on the expression of ligands for death receptor: Fas-L and Tumour 
Necrosis Factor (TNF)-Related Apoptosis Inducing Ligand (TRAIL), inducing the apoptosis of the 
target cell. 
 
The adaptive response is much more complex, slower to develop and is antigen-specific (Chaplin 
2010). T and B lymphocytes recognise antigens via their T-Cell Receptor (TCR) and B-Cell Receptor, 
respectively. T and B cells derive from progenitor cells in the bone marrow. While B-cells remain in 
the bone marrow until becoming mature, T-cells migrate to the thymus as thymocytes.  
 
1.2.2.T-cells development 
TCRs are the product of a process of random rearrangement and splicing of multiple DNA segments 
coding for the areas of the receptor responsible for the antigen binding, which happens before 
exposure to the antigen (Kumar, et al. 2018). This process leads to a naive repertoire of over 108 
TCRs (Arstila, et al. 1999). The TCR molecule is a heterodimer composed either of an α and a β chain, 
each containing a constant and a variable domain or composed of γ and δ chains (~5% of T-cells) 
(Koch and Radtke 2011). The TCR forms a complex with the CD3 molecule and binds to 8 to 10mer 
peptides which are derived from previously broken-down proteins by intracellular processing. 
Following TCR rearrangement, thymocytes migrate to the thymus for maturation and selection 
processes (Koch and Radtke 2011). Positive selection consists of selection of TCRs recognizing self-
MHC molecule with peptide with sufficient affinity. However, TCRs that bind too strongly to self-
MHC molecule with peptide will undergo apoptosis (negative selection). At that stage, T-cells 
express both CD4 and CD8 co-receptors and will lose one of them before exiting the thymus and 
circulating in the periphery. 
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Naive T-cells enter lymph nodes to encounter Antigen Presenting Cells (APCs) which will present 
antigens at the surface of Major Histocompatibility Complex (MHC) class-I and class-II molecules 
(Gaudino and Kumar 2019). Different cell types can hold the function of APCs. Dendritic cells (DCs) 
are “professional” APCs and are essential for activating naive T-cells, but macrophages and B-cells 
can also present antigens at their surface. 
 
1.2.3.MHC and antigen presentation 
There are two types of MHC molecules: class-I and class-II, each composed of 2 chains and four 
domains (Figure 1.3) (Janeway, et al. 2001). MHC class-I molecules are expressed by almost all 
nucleated cells of an organism and present at their surface endogenous antigens (normal, viral or 
tumour proteins) to CD8+ T-cells. They are composed of 3 α domains and one β2-microglobulin 
domain. 
MHC class-II molecules are only expressed by APCs and present at their surface exogenous antigens, 
taken up by endocytosis, to CD4+ T-cells. There are composed of 2 α domains and 2 β domains. 
 
 




In both cases, the antigen processing differs (Blum, et al. 2013). 
Briefly, the pathway of endogenous antigen begins with self- (mutated, overexpressed or misfolded 
in the case of a tumour cell) or viral proteins produced and released into the cytoplasm where they 
are digested by the proteasome (a group of enzymes specialised in digesting ubiquitinated proteins). 
The peptides produced are then chaperoned to the endoplasmic reticulum where they enter with 
the help of the Transporter associated with Antigen Processing (TAP) systems. Peptide/MHC 
complexes then detach from the TAP transporter to be delivered to the cell surface in order to be 
available for CD8 TCR recognition. 
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In the case of exogenous antigens, protein antigens enter the cell by endocytosis and are digested 
into peptides fragments in acidic endosomes. Acidic endosomes then fuse with MHC class-II 
molecules containing endosomes which will bind to the antigen peptide. Finally, the complex 
migrates to the cell surface for CD4 TCR recognition. 
 
1.2.4.T-cell priming and activation 
T-cells are primed by APCs in secondary lymphoid organs such as lymph nodes or spleens. The 
activation of T-cells is based on three signals (Condotta and Richer 2017). The first signal is initiated 
by the binding of the appropriate peptide-MHC complex to the TCR of the T-cell. This binding 
induces the phosphorylation of the CD3 complex and the transmission of signals through 
downstream pathways (Huse 2009). The second signal depends on the binding of ligands such as 
CD80 (B7-1) and CD86 (B7-2), expressed on the surface of DCs, to the activating co-receptor CD28 
(Chen, et al. 2013). DCs express high levels of CD80 and CD86, rendering them highly capable of 
activating naive T-cells (Lim, et al. 2012). The third signal rely upon the secretion of cytokines by 
DCs to guide the T-cell response (De Jong, et al. 2005).  These 3 signals lead to the division and 
clonal expansion of the primed T-cell. Effector cells then migrate to the disease site through the 
attraction of organ-specific adhesion molecules (Sallusto, et al. 1999), where they can recognise 
target cells. A portion of these effector cells will become memory cells, characterised by a long 
lifespan and a fast reaction upon subsequent exposure to their antigen (Omilusik and Goldrath 
2017). 
Since the discovery of the CD28 to CD80/CD86 interaction, many other co-receptors/ligands were 
discovered (Figure 1.4) (Chen, et al. 2013). Depending on their impact on T-cells, they are divided 
into co-stimulatory and co-inhibitory receptors. The first one leading to immunity and the second 





Figure 1.4: Co-signalling interactions in T cells (Reprinted by permission from [Springer Nature Customer 
Service Centre GmbH]: [Springer Nature] [NATURE REVIEWS IMMUNOLOGY] [MOLECULAR MECHANISMS OF 
T CELL CO-STIMULATION AND CO-INHIBITION, CHEN AND FLIES), [COPYRIGHT] (2013)) 
 
 
1.2.5.Role of CD4+ and CD8+ T-cells 
As mentioned earlier, T-cells are divided into CD4+, helper, and CD8+, cytotoxic, T-cells, each 
exhibiting distinctive roles. 
 
1.2.5.1.CD4+ T-cells 
CD4+ T-cells are involved in infectious diseases, autoimmune diseases, asthma, allergic responses 
and tumour immunity. They are defined by their role of helping other immune cells such as B cells, 
CD8+ T-cells or macrophages. They are highly plastic cells that can differentiate into several subsets. 
Each subset is defined by the cytokines and transcription factors inducing them and the cytokine 
pattern they secrete following TCR activation. Caza et al. describes 8 subsets: Th1, Th2, Th9, Th17, 
Th22, Th25, follicular T-cells and regulatory T- cells (Tregs) (Caza, et al. 2015). Among other roles, 
Th1 cells have a role in the clearance of tumours cells. On the other hand, Tregs have an inhibitory 
role on other T-cells, such as cytotoxic CD8+ T-cells. 
 
1.2.5.2.CD8+ T-cells 
CD8+ T-cells are characterised by their direct cytotoxicity against cells presenting their specific 
antigen onto MHC class-I molecules. They induce cytotoxicity by two mechanisms (Martinez-Lostao, 
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et al. 2015). One is through perforation of the target cell membrane with perforin and injection of 
cytotoxic granzyme molecules into its cytoplasm leading to apoptosis. The other mechanism 
induces apoptosis via the expression of death ligands: FAS-ligand and TRAIL.  The expression of FAS-
L and TRAIL at the surface of CD8+ T-cells leads to their binding to FAS and TRAIL receptors on the 
surface of the target cell. Both mechanisms involve caspases to induce apoptosis. CD8+ T-cells are 
classified into different subsets according to their capacity to proliferate and their differentiation 
state (Golubovskaya, et al. 2017). Subsequent to priming by DCs, naive T-cells become T stem cell 
memory cells, then T central memory cells, T effector memory cells and finally, T effector cells. The 
loss of the memory function is inversely proportional to the gain of effector function. Effector CD8+ 
T-cell, also called Cytotoxic T Lymphocyte (CTL), are characterised by the expression of IFN-γ, TNF-
α, perforin and granzyme (Zhang, et al. 2011). 
 
1.3. Cancer immunology 
The concept of using the immune system of a patient against their own tumour is recent as it relied 
on the acceptance by the scientific community that the immune system is able to distinguish 
transformed from normal cells and to eradicate tumours. The concept of immunosurveillance 
evolved slowly since the beginning of the past century. Indeed, Paul Ehrlich formulated the 
hypothesis that the immune system could prevent transformed cells from developing into tumors 
more than a century ago (Ehrlich 1909). The hypothesis of immunological surveillance was 
proposed by Burnet (Burnet 1970) on the basis of previous theories formulated both by Burnet and 
Thomas from the year 1957. Over the years, several arguable experiments contradicted this 
hypothesis leading to its dismissal. Stutman demonstrated that athymic nude mice, lacking T-cells, 
developed as many spontaneous or methylcholantrene-induced tumors than control mice, 
suggesting no active role of thymus-dependent immunity against tumour growth (Stuman 1974). 
The regained interest for the immunological surveillance hypothesis followed findings 
demonstrating the implication of both IFNγ and perforin molecules and of lymphocytes in 
controlling tumour growth (Street, et al. 2001; Russel and Ley 2002). 
These findings led to the concept of immune-editing. 
 
1.3.1.Concept of cancer immuno-editing 
In 2002, Dunn described the concept of immuno-editing (Dunn, et al. 2002). This concept is based 
on three consecutive processes: elimination, equilibrium and escape. 
The elimination process incorporates the concept of immunological surveillance. Briefly, the 
tumour causes an inflammation leading to the recruitment firstly of innate immune cells such as 
NK, NKT, γδ T-cells, macrophages and DCs. NK, NKT and γδ T-cells secrete IFNγ and induce apoptosis 
in tumour cells. DCs ingest tumours debris and migrate to the lymph nodes to present tumour 
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antigens to CD4+ and CD8+ specific T-cells which then migrate to the tumour site where CD8+ T-cells 
can lyse tumour cells in an antigen-specific manner. 
The equilibrium process relies on the hypothesis that non-immunogenic tumour cells have been 
selected during the elimination process, rendering them “invisible” to the immune system. This 
process can last for years as it relies on the balance between the capacity of immune cells to kill 
tumours cells and the capacity of tumours cells to resist to the immune system’s cytotoxic 
mechanisms. 
Finally, the escape process consists in the uncontrollable proliferation of resistant tumour cells 
variants leading to tumour growth and development of metastasis. 
This concept holds the idea that the immune system has two contradictory roles in cancer: it 
destroys tumour cells, but by doing so, it selects for immune-resistant tumour cells. 
 
1.3.2.Immune tolerance and cancer 
Immune tolerance aims at avoiding auto-immunity and is classified into two categories: central and 
peripheral tolerance. Central tolerance consists in the destruction of self-reactive T-cells during the 
negative selection in the thymus (Kyewski, et al. 2006). Self-reactive cells that escaped the central 
tolerance process are eliminated in the periphery by peripheral tolerance, which is regulated via 
two different types of mechanisms (Nurieva, et al. 2013). The first mechanism is intrinsic to the T-
cell: induction of anergy and apoptosis. The second mechanism is controlled by immunosuppressive 
immune cells such as Tregs and tolerogenic DCs. 
Both categories of tolerance have different implications in cancer. Central tolerance renders the 
detection of Tumour Associated Antigen (TAA) difficult as most T-cell clones carrying TCRs specific 
for a TAA would have been depleted.  Therapies such as vaccination aim at stimulating TAA-specific 
T-cell clones that might have escaped central tolerance. On the other hand, peripheral tolerance 
mechanisms are regulated by molecules and cells at the tumour site that therapies aim to neutralize 
with treatments such as Immune Checkpoint Blockade (ICB). These mechanisms will be described 
in details in the next section. 
 
1.3.3.Tumour microenvironment 
Several factors influence the induction of immunity or tolerance in a tumour: tumour 
genetics/epigenetics, host genetics, the microbiome and the tumour microenvironment (TME). 
The gut microbiome affects oncogenesis (Yoshimoto, et al. 2013) (Dapito, et al. 2012), tumor 
progression, as well as the response to anti-cancer therapy (Zitvogel, et al. 2015). For instance, 
some species of intestinal bacteria were shown to modulates the anticancer immune effects of 
cyclophosphamide chemotherapy by generating specific T helper 17 cells and memory Th1 immune 
responses (Viaud, et al. 2013). Moreover, abnormal gut microbiome composition can lead to 
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resistance to ICB, such as anti PD-1/PD-L1 antibodies, which lead to the possibility of improving ICB 
efficacy through Fecal microbiota transplantation (Routy, et al. 2018).  
As discussed previously, although the immune system develops an anti-tumour immunity, several 
immuno-suppressive mechanisms are put in place within the micro-environment. 
Chen et al. describes three types of immune profiles within tumours from patients (Chen, et al. 
2017). The first type is called immune-inflamed as it is characterized by the presence of T-cells, 
myeloid cells and monocytic cells in the tumour parenchyma. The second profile, named immune-
excluded, is characterized by the presence of immune cells contained in the stroma, unable to enter 
the tumour. Finally, the profile characterised by the rarity of T-cells is called immune-desert. This 
phenotype suggests the absence of tumour-specific T-cells. The last two phenotypes are considered 
as non-inflamed tumours. 
The TME is defined by the type of cytokines and cells (immune and non-immune) present in a 
tumour. The remaining of this section will focus on describing these elements, to understand the 
mechanisms put in place to counteract the establishment of an anti-tumour immune response or 
the efficacy of a pre-existing one. 
 
1.3.3.1.Direct immunosuppressive mechanisms of tumour cells 
Tumour cells employ various mechanisms to escape the immune system and induce immune 
tolerance. To avoid T-cells recognition, antigen presentation is downregulated by antigen loss, 
downregulation of MHC class-I molecules and of antigen-processing machineries such as TAP 
molecules (Marincola, et al. 2000). Mutations in death receptor signalling pathways (FAS and TRAIL) 
(Takahashi, et al. 2006 and Shin, et al. 2001, respectively) and over-expression of anti-apoptotic 
molecules render tumour cells less sensitive to lymphocytes killing (Hinz, et al. 2000). 
Tumour cells induce T-cell anergy by expression of ligands to inhibitory receptors expressed by 
lymphocytes (Figure 1.5), such as Programmed death ligand 1 (PD-L1) which binds to Programmed 
death 1 (PD-1) (Dong, et al. 2002; Yamamoto, et al. 2008), galectin-9 which binds to Tim-3 (Zhou, 
et al. 2018), galectin-1 (Liu, et al. 2005), HLA-G (Agaugue, et al. 2011) or HLA-E (Derré, et al. 2006). 
Galectin-1 inhibits the activation, the proliferation and the secretion of pro-inflammatory cytokines 
by T-cells, and induces the apoptosis of activated T-cells (Liu, et al. 2005). 
HLA-G induces MDSCs, inhibits T-cells and promotes the pro-tumorigenic Th2 profile (Agauge, et al. 
2011). It also inhibits NK cells through the Human inhibitory receptors Ig-Like Transcript 2 (ILT2) 
receptor (Favier, et al. 2010). 
HLA-E is induced by IFNγ and inhibits NK cells and CTL via binding to NKG2A inhibitory receptor 
(Derré, et al. 2006).  
Other mechanisms employed by tumour cells consists in the secretion of immunosuppressive 




1.3.3.2.Immunosuppressive soluble factors 
A number of immunosuppressive chemokines and cytokines are produced by tumour cells within 
the tumour environment. The mechanism of action of some of the critical ones are described below. 
 
Tumour Growth Factor-β (TGF-β) inhibits T-cell priming and infiltration (Mariathasan, et al. 2018), 
and suppresses effector cell cytotoxicity by inhibiting the expression of perforin, granzyme A, 
granzyme B, Fas ligand, and IFNγ (Thomas and Massague 2005). 
Vascular Endothelial Growth Factor (VEGF) promotes the angiogenesis. It also inhibits the effector 
function and the proliferation of T-cells via enhancing the expression of PD-1, CTLA-4, LAG-3 and 
Tim-3 on T-cells, as well as PD-L1 on DCs (Khan, et al. 2018). It can inhibit DCs maturation and 
therefore antigen presentation to T-cells (Gabrilovich, et al. 1996). 
Interleukin-10 (IL-10) is a cytokine inducing T-cell anergy via CTLA-4 inhibitory receptor (Steinbrink, 
et al. 2002). It inhibits the cytokine secretion by activated macrophages (Fiorentino, et al. 1991) and 
inducible Nitric Oxide Synthase (iNOS) production by macrophages (Dokka, et al. 2001). 
Indoleamine 2,3-dioxygenase (IDO) production by stromal cells is induced by the secretion of IFNγ 
by CD8+ T-cells in the TME (Labadie, et al. 2019). IDO is also produced by MDSCs. This enzyme 
catalyses the conversion of tryptophan to kynurenine leading to a depletion in tryptophan 
(essential amino acid) responsible for inducing cell cycle arrest and anergy in T-cells. Moreover, the 
accumulation of kynurenine was shown to induce Tregs (Mellor, et al. 2004). 
 
1.3.3.3.Immunosuppressive cells 
Tregs are part of the T-cell compartment and are divided into natural Tregs and inducible Tregs 
(Sakaguchi, et al. 2008). Naive CD4+ T-cells can differentiate into inducible Tregs in the presence of 
TGF-β (Josefowicz, et al. 2012). Tregs not only suppress the functions of T-cells but also of NK cells, 
NKT cells, macrophages and DCs (Sakaguchi, et al. 2008). Mechanisms to induce 
immunosuppression include the secretion of immunosuppressive factors such as TGFβ and IL-10, 
IL-2 deprivation and cell-contact dependant suppression. 
MDSCs derive either from monocytes or granulocytes. MDSCs immunosuppressive mechanisms are 
directed both on the immune system and on other non-immune elements (Ugel, et al. 2015).  
MDSCs secrete TGF-β and IL-10 which promotes the formation of Tregs and blocks the activation of 
NK cells. MDSCs also inhibit T-cell migration to the tumour site and induce T-cells anergy by 
expressing markers such as PD-L1. They produce Reactive Oxygen Species (ROS) and reactive 
nitrogen species (RNS) thereby inhibiting the activation and proliferation of T-cells. Finally, they 
deplete the environment in metabolites essential to lymphocytes survival: L-arginine (due to 
expression of arginase) and L-tryptophan (due to expression of IDO). 
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Other mechanisms that promote tumour growth include the induction of angiogenesis and 
vasculogenesis, the promotion of metastasis and of tumour cells stemness. 
Tumour Associated Macrophages (TAMs) are similar to immunosuppressive M2 polarised 
macrophages and differentiate from circulating monocytes. Once in the tumour they are found in 
areas of hypoxia and necrosis (Li, et al. 2007). Similarly to MDSCs, TAMs use immunosuppressive 
mechanisms directly on the immune system as well as induce angiogenesis, vasculogenesis, 
metastasis and tumour cells stemness (Ugel, et al. 2015). TAMs induce apoptosis in T-cells via the 
expression of TRAIL-R and of FAS and the secretion of TGF-β. They induce T-cell anergy via 
expression of PD-L1 and PD-L2, B7-1/2 (binding to CTLA-4) and production of RNS. They promote 
Tregs via secretion of IL-10 and TGF-β and recruit them to the TME. Finally, they also deplete 
lymphocytes of essential metabolites. 
Cancer-associated Fibroblasts (CAFs) are part of the tumour stroma therefore promoting the 
proliferation of tumour cells and the creation of a metastatic niche through production of growth 
factors, chemotactic factors and angiogenesis factors (Li, et al. 2007). Moreover, CAFs recruit 
monocytes to the tumour site and induce their differentiation into PD-1 expressing TAMs (Gok 
Yavuz, et al. 2019). 
 
1.3.4.T-cells in cancer 
DCs can capture tumour cells debris and cross-present TAAs to T-cells, leading to the expansion of 
TAA-specific CD8+ and CD4+ T-cells (Nouri-Shirazi, et al. 2000). The presence of CD8+ and CD4+ T-
cells in the tumour correlates with a good prognosis (Naito, et al. 1998; Galon, et al. 2006; Meng, 
et al. 2018). 
 
1.3.4.1.CD8+ T-cells 
Activated CD8+ T-cells differentiate into effector cells under cytokines such as IL-2, IL-12, IL-21 and 
IL-27 (Zhang, et al. 2011). As described section 1.2.5.2, anti-tumour CTL effector functions relies on 
both the secretion of pro-inflammatory cytokines (IFNγ and TNFα) and on the killing of tumour cells. 
 
1.3.4.1.1.Cytotoxicity 
CTLs use diverse mechanisms to lyse target cells (Martinez-Lostao, et al. 2015). 
The perforin/Granzyme B pathway was described as the most efficient mechanism to kill tumour 
cells. Granzyme B enters target cells through perforin pores and induces cell death by different 
pathways. Firstly, by direct cleavage and activation of pro-apoptotic caspases 3 and 7. Secondly, by 
cleavage of pro-apoptotic molecule Bid (part of Bcl-2 family) inducing a cascade of event leading to 
the release of cytochrome C from the mitochondria. This event leads to the formation of the 
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apoptosome activating the pro-apoptotic caspase 9. The third mechanism involves the release of 
Bim (part of Bcl-2 family) to activated the mitochondrial pathway. 
On the contrary, the effect of granzyme A to induce apoptosis is not as clear. Granzyme A is believed 
to contribute to the inflammasome leading to the caspase 1-dependant production of IL-1β. 
Another pathway involves mitochondrial depolarization and the production of ROS leading to DNA 
damage-driven cell death.  
Other Granzymes molecules have been described: C, F, H, K and M. Granzymes K and M were shown 
to regulate the production of pro-inflammatory cytokines. 
 
The death ligands pathway is characterised by the binding of Fas-L and TRAIL to their respective 
receptors (Fas and TRAIL-receptor 1 and 2) which promotes receptors oligomerization leading to 
the recruitment of Fas-associated death domain (FADD) and activation of the caspase 8. Caspase 8 
can trigger two different apoptotic pathways: caspase 3 induces direct apoptosis while Bid triggers 
the mitochondrial pathway. 
Apoptosis via this pathway can be inhibited and replaced by necrotic cell death. Moreover, 
mechanisms blocking the apoptosis can lead to TRAIL-driven proliferation and survival signals. 
 
1.3.4.1.2.Secretion of pro-inflammatory cytokines 
IFNγ is secreted by CTLs, CD4+ T-cells, NK cells, γδ T-cells and macrophages (Albini, et al. 2018; Xiang, 
et al. 2018). It promotes anti-tumour M1 rather than pro-tumour M2 macrophages. This cytokine 
stimulates adaptive immunity (Smyth, et al. 2002) and was shown to mediate anti-metastatic effect 
through inhibition of angiogenesis (Hayakawa, et al. 2002). IFNγ promotes the motility and 
cytotoxic functions of CTLs (Bhat, et al. 2017). It also increased the expression of MHC class-I 
molecules at the surface of tumour cells (Zhou 2009) rendering them more sensitive to CTL killing. 
IFNγ also induces the expression of the immunoproteasome (Tanaka et Kasahara, 1998), allowing 
the presentation of different epitopes by MHC-class I molecules at the surface of tumour cells and 
therefore their recognition by T-cells. Moreover, IFNγ induces the expression of MHC class-II 
molecules by cancer cells (Steimle, et al. 1994), which can lead to recognition and killing of tumour 
cells via cytotoxic CD4+ T-cells in an MHC-II-CD4 restricted manner (Quezada, et al. 2010) (Xie, et al. 
2010). 
Howerer, IFNγ also exhibits anti-inflammatory properties such as the induction of PD-L1 expression 
(Abiko, et al. 2015) and the production of IDO by CD8+ T-cells cells and MDSCs (Labadie, et al. 2019). 
 
TNFα is produced by CTLs and macrophages and is identified both as a pro-tumour and an anti-
tumour cytokine (Balkwill 2009). It can induce the activation and proliferation of T-cells or the 
apoptosis of highly activated effector T-cells (Mehta, et al. 2018) and is known to induce apoptosis 
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or necrosis of tumour cells (Wang, et al. 2008). However, its anti-tumour role is characterised by: 1) 
promotion of Tregs, regulatory B cells and MDSCs, 2) inhibition of CTL responses, 3) induction of 
PD-L1 on tumour cells and 4) induction of angiogenesis and metastasis (Bertrand, et al. 2017; Wang, 
et al. 2008).  
 
IL-2 is mainly produced by antigen-simulated CD4+ T cells but is also produced by CD8+ T-cells, NK 
cells and DCs (Jiang, et al. 2016). It has a major role in maintaining Tregs, but also promotes the 
proliferation of NK cells, CD4+ T-cells and CTLs. Moreover, it favours the differentiation of CD8+ T-
cells into CTLs rather than memory cells (Pipkin, et al. 2010). IL-2 also stimulates the production of 
IFN-, perforin and granzyme as well as promotes the migration of CTL to peripheral tissues (Rollings, 
et al. 2018). This cytokine has been used as a cancer treatment since it showed cancer regression 
in a patient, who remained disease free for 29 years, in 1984 (Rosenberg 2014). 
 
1.3.4.1.3.Concept of exhaustion 
Antigen persistence and sustained pro-inflammatory milieu induce the expression of co-inhibitory 
receptors in CTLs. This state called exhaustion is characterised by the loss of effector functions and 
the incapacity to develop memory cells (Figure 1.5) (Wherry and Kurachi 2015). Exhausted tumour-
specific CD8+ T-cells have been described by many (Baitsch, et al. 2011). 
Exhausted T-cells lose their capacity to proliferate, to secrete pro-inflammatory cytokines (IL-2, IFNγ, 
and TNFα) and to degranulate (Wherry and Kurachi 2015). Moreover, they lose their memory 
phenotype characterised by the expression of CD44, CD62L, CD127 or CXCR3. Finally, they co-
express several inhibitory co-receptors: CTLA-4, PD-1, LAG-3, Tim-3, TIGIT, 2B4, BTLA or also CD160. 
It is however important to note that exhausted T-cells are not inactive and maintain some 
functional capacities. 
Although the concept of exhaustion in cancer is mainly attributed to CTLs, CD4+ T-cells can also 
express co-inhibitory receptors and lose their effector functions (Goding, et al. 2013). 
The existence of inhibitory receptors is essential as these negative regulatory pathways control auto 
reactivity and maintain peripheral tolerance (Sharpe, et al. 2007). Their expression appears 




Figure 1.5: Progressive development of T-cell exhaustion (Reprinted by permission from [Springer 
Nature Customer Service Centre GmbH]: [Springer Nature] [NATURE REVIEWS IMMUNOLOGY] [MOLECULAR 
AND CELLULAR INSIGHTS INTO T CELL EXHAUSTION, WHERRY AND KURACHI], [COPYRIGHT] (2015)) 
 
1.3.4.1.4.Memory T-cells 
The generation of memory T-cells is crucial in cancer to obtain a long-lasting anti-tumour immune 
response (Reading, et al. 2018). Differentiation of T-cells into memory T-cells is facilitated by 
antigen exposure and inflammatory milieu (Shaulo, et al. 2008). Memory T-cells are characterised 
by a long lifespan and a proliferative potential upon antigen re-challenge. 
Three subsets of circulating memory CD8+ T-cells were described: Stem central memory (Tscm), 
Central memory (Tcm) and effector memory (Tem). Tscm have the capacity to differentiate into 
Tcm or Tem upon antigen stimulation and display a naive phenotype (Gattinoni, et al. 2011). Tcm 
can differentiate into Tem upon antigen stimulation and hold a stem-cell like phenotype. Tem are 
more differentiated and display similar functions to effector T-cells. 
Tissue resident memory T-cells (Trm) were described as skin resident T-cells enhancing local 
immunity against pathogens following an infection (Gebhardt, et al. 2009). They can derive from 
either Tcm or Tem cells, secrete pro-inflammatory cytokines (IFNγ, IL-2 and TNFα) upon TCR 
activation, thereby recruiting NK cells and DCs, and produce Granzyme B (Schenkel, et al. 2014). 
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The incapacity to generate functional tumour-specific memory T-cells can be due to several 
mechanisms such as the deletion of tumour associated self-antigen, the low avidity of TCR-peptide 
and MHC interactions, the dysfunction of T-cells (anergy, tolerance, exhaustion) or their incapacity 
to migrate to the tumour site (Reading, et al. 2018). 
 
1.3.4.1.5.TCR affinity and avidity 
The TCR affinity depends on the strength of the interaction between a TCR and an MHC-peptide 
complex (Figure 1.6) (Stone, et al. 2009). A high TCR affinity was shown to correlate with higher 
cytotoxicity and IFNγ production (Tian, et al. 2007). The avidity is defined as the strength between 
multiple TCRs and MHC-peptide complexes (Vigano, et al. 2012). The functional avidity relates to 
the overall clonal T-cell response towards its antigen. Although it is often the case, the TCR affinity 
does not always correlate with the TCR avidity. Indeed, external factors such as inhibitory molecules 
can dampen the T-cell response in spite of a strong TCR/MHC-peptide interaction. 
In cancer, high avidity T-cells have been described as highly cytotoxic (Dutoit, et al. 2001; Pudney, 
et al. 2010). High avidity TCR/MHC-peptide interaction correlates with the expression of PD-1 
(Harari, et al. 2007; Simon, et al. 2015). However, supra-optimal TCR stimulation of high avidity T-
cells was described to induce exhausted T-cells with impaired cytotoxic functions (Brentville, et al. 
2010). Indeed, Janicki et al. described high avidity CD8+ T-cells differentiating into CTL within the 
tumour-draining lymph node but losing their effector function once reaching the tumour site 





Figure 1.6: Schematic representation, definition, technique of measurement and readout of TCR 
affinity and functional avidity (Reprinted by permission from [CREATIVE COMMONS ATTRIBUTION 
LICENSE]: [Clinical & Developmental Immunology], [Vigano, et al., FUNCTIONAL AVIDITY: A MEASURE TO 
PREDICT THE EFFICACY OF EFFECTOR T CELLS?, (2012)]) 
 
1.3.4.2.CD4+ T-cells 
CD4+ T-cells have various roles in anti-tumour immunity. Mainly, they provide help to CD8+ T-cells 
during the priming phase in the secondary lymphoid organs, allowing the generation of a strong 
and lasting CTL response (Borst, et al. 2018). 
According to Borst et al., the priming of T-cells occurs in two consecutive distinct steps. During the 
first step, DCs independently present antigens to CD4+ and CD8+ T-cells in the lymph node or spleen. 
During the second step, both activated CD4 and CD8+ T-cells interact with the same DC in the same 
lymph node allowing the delivery of the help signal (Eickhoff, et al. 2015; Hor, et al. 2015). The CD4+ 
T-cell/DC interaction induces the expression of CD40L in the CD4+ T-cell, triggering CD40 signalling 
in the DC, thus increasing its antigen presentation ability by an increased expression of the co-
stimulatory ligands CD80/CD86, CD70 and the secretion of type I interferons and of IL-12 and IL-15 
interleukines. CD80/CD86 and CD70 interact with CD28 and CD27, respectively, on the surface of 
CD8+ T-cells, promoting their differentiation and survival (Feau, et al. 2012). DC-derived cytokines 
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promote the differentiation of CD8+ T-cell into CTLs. Moreover, CD4+ T-cells-derived IL-2 and IL-21 
promote the CTL response. 
As a result, CD4+ T-cell help promotes both the effector and the memory CD8+ T-cell responses 
(Ahrends, et al. 2017). 
Help signals promote cytotoxicity mechanisms by inducing the production of IFNγ, TNFα, FAS-L, 
granzyme A and B (Ahrends, et al. 2017). Moreover, in the absence of help, non-cytotoxic exhausted 
CTLs expressing high levels of co-inhibitory receptors such as PD-1 and LAG-3 are generated. CD4+ 
T-cells help selectively promotes functional anti-tumour high avidity antigen-specific CD8+ T-cells 
(Zhu, et al. 2015). Helper T-cells are also required for the induction of a memory response (Janssen, 
et al. 2003) as in their absence, CD8+ T-cells die due to apoptosis during the secondary expansion 
phase (Janssen, et al. 2005). 
 
Other anti-tumour roles of CD4+ T-cells include 1) the recruitment of APCs and NK cells, 2) the 
inhibition of angiogenesis by Th1 cells, 3) the recruitment of eosinophils by Th2 cells and 4) the 
secretion of IFNγ and granzyme B by cytolytic CD4+ T-cells in some cases (Kim, et al. 2014). Indeed, 
cytotoxic CD4+ T-cells-driven anti-tumour immunity relying on the MHC class-II restricted 
recognition of tumour cells was described (Quezada, et al. 2010). 
Moreover, Th1 cells were shown to induce senescence in cancer cells via an IFNγ/TNFα-dependant 
mechanism (Braumuller, et al. 2013). 
 
1.4. Immunotherapies for PCa 
The recognition of the role of the immune system in fighting cancer and the understanding of the 
mechanisms involved lead to the development over the years of numerous immunotherapies. 
Immunotherapies for cancer can be divided into two categories based on their ability to stimulate 
the immune system against tumour cells: passive or active (Galluzzi, et al. 2014). Passive 
immunotherapies have a direct anti-cancer effect, such as tumour-targeting antibodies, adoptive 
transfer of in vitro activated immune cells or oncolytic viruses. On the contrary, active 
immunotherapies aim at stimulating the host immune system, as DC-based immunotherapies, 
peptide- and DNA-based vaccines, immunostimulatory cytokines, immunomodulatory monoclonal 
antibodies or immunogenic cell death inducers. 
The remainder of this section will focus on the main immunotherapies for PCa that are either 




1.4.1.Immune infiltration in PCa 
To understand the rationale for using immunotherapies for the treatment of PCa, it is crucial to 
comprehend the immune status in prostate tumours. This will also help understanding the difficulty 
of developing immunotherapies for PCa that could generate a complete response in patients. 
Tumours can be categorised as “hot”, inflamed, or “cold”, non-inflamed. Although the development 
of prostate tumours is believed to be partly driven by inflammation (Sfanos and De Marzo 2012), 
prostate tumours are described as cold tumours, with a poor immune infiltrate (Vitkin, et al. 2019). 
One explanation for this is their low mutational burden that renders them less immunogenic due 
to the lack of tumour-associated antigens (Vitkin, et al. 2019). Other factors are: 1) defects in the 
DNA damage response, 2) decreased MHC Class I expression, 3) dysfunctional IFN1 signalling and 4) 
loss of PTEN protein. The latest has been associated with a decrease of IFNγ, granzyme B and of 
CD8+ Tumour Infiltrating Lymphocytes (TILs) (Sharma, et al. 2018). Futhermore, chronic exposure 
to type I IFNs is associated with therapy resistance and immunosuppression. Indeed, the subset of 
interferon-stimulated genes activated after prolonged IFN1 exposure causes radiation and 
chemotherapy resistance (Minn. Et al, 2015) and promotes cancer growth and metastasis (Cheon, 
2014). Chronic IFN1 signaling can also diminish the effect of immunotherapies, such as ICBs, CAR T-
cell therapies and oncolytic virus therapies (Budhwani, et al. 2018). 
 
The presence of TILs, in particular of CTLs and helper T-cells is associated with a good prognosis 
(Fridman, et al. 2017). However, the implication of CD8+ TILs in PCa is not clear. Some studies have 
demonstrated that the presence of TILs is associated with a poor prognosis (Ness, et al. 2014; 
Leclerc, et al. 2016) with one study linking the presence of TILs and macrophages with worse distant 
metastasis-free survival (Zhao, et al. 2019). Ness et al. suggested that TILs in prostate tumours are 
dysfunctional (Ness, et al. 2014), which is supported by the fact that the expression of IFNγ and 
granzyme B was decreased in TILs in comparison to those in normal prostate tissue and was 
accompanied by an increased PD-1 expression (Ebelt, et al. 2008). Furthermore, the expression of 
PD-1 on TILs and of PD-L1 on tumour cells have been observed in 19% of a 16 CRPC patients’ cohort 
(Massari, et al. 2016) while an increased expression of PD-L1 and PD-L2 on DCs and of PD-1 on T-
cells has been observed in the blood of Enzatulamide-resistant PCa patients (Bishop, et al. 2015). 
The presence of CD8+ TILs exhibiting a restricted TCR repertoire was associated with the expression 
of PD-1 (Sfanos, et al. 2009). The dysfunction of TILs could also be due to the presence of 
immunosuppressive factors and cells. The presence in high proportions of both CD4+ and CD8+ Tregs 
has been reported (Kiniwa, et al. 2007; Kaur, et al. 2018) and associated with worse progression-
free survival and OS (Davidsson, et al. 2013; Nardone, et al. 2016). There is also evidence that 
soluble factors generate immunosuppressive PD-L1/CD209 (DC marker)-expressing monocytes in 
the tumour, unable to cross-present tumour-antigens to CD8+ T cells and suppressing T-cell 
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proliferation (Spary, et al. 2014). The decreased proportion of DCs correlates with high Gleason 
score and worse progression free survival (Liu, et al. 2013). The presence of TAMs was observed in 
PCa; however, they were abundant in early clinical stages and decreased in the presence of lymph-
node metastases (Shimura, et al. 2000). A study on a cohort of 234 patients showed that most TAMs 
had an immunosuppressive phenotype alongside inactive T-cells (Lundholm, et al. 2015). An 
increase of MDSCs and Tregs was observed in the blood of PCa patients in comparison to healthy 
donors (Idorn, et al. 2014). The mechanism of T-cell suppression by MDSCs observed relied on the 
expression of iNOS enzyme. Another study demonstrated the role of MDSCs-derived IL-23 in the 
development of CRPC by activation of the androgen receptor pathway in tumour cells, promoting 
their survival and proliferation in an androgen-independent manner (Calcinotto, et al. 2018). A 
preclinical study determined that the loss of PTEN lead to the expansion of MDSCs in the TME 
(Garcia, et al. 2014). 
On the other hand, the presence of DCs and NK cells was associated with improved distant 
metastasis-free survival (Zhao, et al. 2019) and the increase of CD8+ T-cells was associated with 
longer progression free survival following radiotherapy (Nardone, et al. 2016). The presence of NK 
cells in great amount correlated with lower risk of disease progression (Gannon, et al. 2009). The 
expression of IFNγ on TILs was increased in PCa patients in comparison to benign prostatic 
hyperplasia cases (Elsässer-Beile, et al. 2000). 






Figure 1.7: Tumour Immune Microenvironnement in PCa (Reprinted by permission from [CREATIVE 
COMMONS ATTRIBUTION LICENSE]: [FRONTIERS IN IMMUNOLOGY], [Vitkin, et al., THE TUMOR IMMUNE 
CONTEXTURE OF PROSTATE CANCER, (2019)]) 
 
1.4.2.Cancer vaccines 
Cancer vaccines can be divided into four categories: tumour cell vaccines, DC-based vaccines, 
protein- or peptide-based cancer vaccines and genetic vaccines, either DNA, RNA or viral-based 
(Guo, et al. 2013). 
Regardless of the category, every cancer vaccine aims at delivering tumour antigens to DCs and 
activating DCs in order for them to induce TAA-specific CD4+ and CD8+ T-cell responses.  
 
The choice of the antigen is crucial as the antigen needs to be expressed only (tumour specific 
antigen) or preferentially (TAA) by cancer cells but not by cells belonging to vital organs in order to 
avoid any potential side effects. In addition, the antigen needs to be both immunogenic and 
required by the tumour cells to limit antigen loss due to immuno-editing (Dunn, et al. 2002). The 
antigen also needs to be expressed by the primary tumour and the metastasis. 
The delivery vehicle or the adjuvant to combine with the antigen enhances its immunogenicity.  
They can be divided into six categories: cytokines/endogenous immunomodulators such as GM-CSF, 
microbes and microbial derivatives such as CpG or poly I:C, mineral salts, oil emulsions, particulates 
and viral vectors such as adenovirus, vaccinia or fowl pox (Melero, et al. 2014). 
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To date, Sipuleucel-T is the only FDA-approved therapeutic cancer vaccine. Despite many attempts, 
the development of therapeutic cancer vaccine for all types of cancer has not been so successful, 
many vaccines failed in phase 3 clinical trial because of inexistent or disappointing clinical efficacy. 
It becomes clear that therapeutic cancer vaccines as a monotherapy cannot overcome the 
immunosuppressive TME and the mechanisms of tolerance that T-cells have to face. Therefore, a 
number of ongoing clinical trials are assessing the effect of multiple therapies together. 
Moreover, cancer vaccines are more likely to have a greater benefit for patient with less advanced-
stage cancers (Melero, et al. 2014). 
 
1.4.2.1.Sipuleucel-T 
Sipuleucel-T was briefly described section 1.1.5. 
Its processing is described in figure 1.8. Briefly, isolated PBMCs from patient’s blood were 
stimulated for 36-44 hours with a fusion protein composed of GM-CSF and PAP antigen. GM-CSF is 
a cytokine that promotes the differentiation and activation of DCs (Steinman, et al. 1991). It was 
shown to enhance T-cell cross-priming (Zhan, et al. 2011). The cells reinfused back into the patient 
are believed to induce CD4+ and CD8+ T-cell responses. 
The Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial confirmed the 
improved survival effect of Sipuleucel-T (Kantoff, et al. 2010).  521 mCRPC patients were enrolled, 
with 2/3 receiving Sipuleucel-T and 1/3 placebo, and received 3 infusions every two weeks. The 
improved OS was of 4.1 months, with one patient who had a partial remission. PSA decline of ≥50% 
was only observed in 2.6% of patients. Antibodies against the fusion protein were detected in 66.2% 
of patients (2.9% for placebo group) while antibodies against PAP were detected in 28.5% of 
patients (1.4% in the placebo group). In vitro stimulation with the fusion protein induced T-cell 
proliferation in 73% of Sipuleucel-T treated patients (against 12.1% in the placebo group) while 27.3% 
of patients exhibited T-cell proliferation in response to PAP stimulation (against 8% in the placebo 
group). Interestingly, the increase of antibodies targeting PAP or the fusion protein correlated with 
an improved OS while the T-cell proliferation observed did not. 
The majority of patients received docetaxel chemotherapy following either Sipuleucel-T treatment 
or placebo. 
Despite the improved OS in patients with asymptomatic or minimally symptomatic mCRPC, no 





Figure 1:8: Processing of Sipuleucel-T (Reprinted by permission from [SAGE PUBLICATIONS], gratis reuse 
for doctoral dissertations: [THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY], [GARCIA, SIPULEUCEL-T IN 
PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: AN INSIGHT FOR ONCOLOGISTS, 
(2011)]) 
 
Since its FDA-approval, Sipuleucel-T has been studied further to understand its mechanism of action, 
and has been assessed in combination with diverse (immuno)therapies. 
 
Analysis and comparison of the IMPACT trial with two previous phase III clinical trials 
(D9901/D9902A) confirmed the in vitro expansion and activation of APCs, characterised by the 
increased expression of CD54, and suggests the establishment of both cellular and humoral immune 
responses, all of these parameters correlating with improved OS (Sheikh, et al. 2013). Antonarakis 
et al. demonstrated the lytic phenotype of circulating PAP-specific CD8+ T-cells in Sipuleucel-T 
treated patients, determined by CD107a degranulation marker expression (Antonarakis, et al. 2018). 
Moreover, the expression of both IFNγ and granzyme B in PAP-specific T-cells was observed 
(Wargowski, et al. 2018). 
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When Sipuleucel-T was administered prior to prostatectomy, it was shown to induce the 
recruitment of T-cells to the TME (Fong, et al. 2014). The majority of these T-cells expressed PD-1, 
proliferated, and secreted IFNγ following stimulation with the PAP protein. 
Interestingly, the presence of antibodies against other antigens was observed following Sipuleucel-
T treatment, in particular against PSA, suggesting antigen spread, and correlated with improved OS 
(GuhaThakurta, et al. 2015). The transient increase of eosinophils was found to correlate as well 
with increased OS (McNeel, et al. 2014). As expected, the IMPACT trial showed that a low PSA 
baseline correlated strongly with improved OS, suggesting that patients with less advanced disease 
benefit more from the vaccine (Schellhammer, et al. 2013). 
 
The combination of Sipuleucel-T with other currently used treatments for mCRPC, such as 
Enzatulamide and Abiraterone Acetate, was well tolerated and did not alter the immunological 
effects observed when Sipuleucel-T was administered alone (Quinn, et al. 2014; Small, et al. 2015). 
Sipuleucel-T followed by ADT induced stronger anti-tumour responses than ADT followed by 
Sipuleucel-T in non-metastatic patients with recurrent disease (Antonarakis, et al. 2017). 
 
Although Sipuleucel-T demonstrated clinical benefit for mCRPC patients by improving the OS, there 
is still no cure for advanced PCa and new therapies are needed. The next section describes some of 
the vaccines in development for PCa. 
 
1.4.2.2.Vaccines in phase III clinical trials 
Considering the great number of PCa therapeutic vaccines under investigation, this section will 
focus on vaccines that have reach phase III clinical stage or phase II trials that target PAP protein 
(Table 1.2). 
 
PROSTVAC (also named PSA-TRICOM) is a poxviral-based vaccine that encodes for PSA, its target 
antigen, and three costimulatory molecules: B7.1 (CD80), ICAM-1 (CD54) and LFA-3 (CD58). To avoid 
the development of neutralising antibodies against viral proteins which would alter the immune 
response, a heterologous prime-boost strategy is used. The vaccinia virus rV-PSA is used for priming 
while the fowlpox virus rF-PSA is used for boosting (6 boosters). The phase II trial showed an 
improved OS of 8.5 months and a death rate reduction of 44% (Kantoff, et al. 2010), however the 
results from the PROSPECT phase III trial (NCT01322490) of PROSTVAC in combination with GM-
CSF did not reveal any improvement on the OS, leading to its early discontinuation (Gulley, et al. 
2015). Nonetheless PROSTVAC was shown to increase the number of PSA-specific T-cells as well as 
inducing antigen spreading (Gulley, et al. 2014). It is now being assessed in combination with 
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Enzatulamide (NCT01867333), docetaxel (NCT02649855) and immune checkpoint inhibitors anti-
CTLA-4 (NCT02506114) and anti-PD-1 (NCT02933255). 
 
GVAX-PCa is a whole tumour cell vaccine composed of LNCaP and PC3 PCa cell lines, transduced to 
secrete GM-CSF. These two cell lines are derived from lymph node and bone metastases 
respectively. LNCap expresses PCa associated antigens such as PSA, PAP or Prostate-Specific 
Membrane Antigen (PSMA) (Simons and Sacks 2006). 
Despite two phase II trials demonstrating decreased blood PSA and development of anti-vaccine 
antibodies, both phase III trials, VITAL-1 and VITAL-2, assessing the effect of GVAX-PCa on OS were 
terminated early (Sonpavde, et al. 2010). VITAL-1, evaluating GVAX-PCa versus docetaxel + 
prednisone in asymptomatic chemo-naïve mCRPC patients, was terminated due to the low probably 
of leading to an improved OS, its endpoint. VITAL-2, evaluating GVAX-PCa + docetaxel versus 
docetaxel + prednisone in symptomatic chemo-naïve mCRPC patients, was terminated due to the 
toxicity of GVAC-PCa leading to an increased number of deaths. 
 
DCVAC/PCa autologous vaccine consists of in vitro activated DCs pulsed with killed LNCaP cells. The 
single-arm phase I/II trial revealed an OS of 19 months, while predicted median OS was of 11.8 or 
13 months (Halabi and MSKCC monograms respectively) (Podrazil, et al. 2015). Circulating PSA-
specific T-cells were detected alongside a reduction of Tregs. The VIABLE phase III trial is ongoing 
(NCT02111577) and results are expected by June 2020. 
 
Another therapeutic vaccine worth mentioning, although it did not reach phase III clinical trial, is a 
DNA vaccine encoding the whole PAP protein: pTVG-HP. Its evaluation in a phase I/IIa trial 
demonstrated its capacity to induce PAP-specific T-cell responses, characterised by IFNγ secretion 
and proliferation in response to PAP stimulation, and to increase the PSA doubling time (McNeel, 
et al. 2009). Moreover, the immune response observed was amplified by booster immunisations 
(Becker, et al. 2010). Adaptation of the immunisation schedule based on real-time immune 
monitoring did not increase the frequency of patients developing PAP-specific T-cell responses 
(McNeel, et al. 2014). However, the study revealed the presence of effector and effector memory 
Th1 PAP-specific T-cell responses. A phase II trial is currently ongoing (NCT01341652) to test the 
effect of pTVG-HP, with GM-CSF versus GM-CSF alone, on metastasis free-survival and is expected 
to be completed by April 2020. 
A pilot study assessed the effect of vaccinating with Sipuleucel-T (as per usual regimen: 3 times with 
2 weeks intervals) and boosting with pTVG-HP (4 times with two weeks intervals + 2 immunisations 
with 3 months intervals), versus no boosting (Wargowski, et al. 2018). The aim was to determine 
whether additional immunisation with the pTVG-HP vaccine could prolong or increase the PAP-
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specific immune response. However, there was no increased immune response or effect on OS or 
PSA doubling time. Subsequent studies will assess this combination using pTVG-HP first and 
boosting with Sipuleucel-T as this strategy is believed to elicit stronger Th1 cellular immunity rather 
than Th2 immunity. 
 
Therapeutic cancer vaccines are an attractive therapy for cancer patients as, unlike other therapies, 
they are well tolerated and side effects are usually minimal. However, vaccines were shown to have 
more clinical benefit in patients with low tumour burden and less aggressive disease. Indeed, 
efficacy is dampened by the immunosuppressive microenvironment. Therefore, other therapies 




Table 1:2: Completed or ongoing phase II and III clinical trials assessing therapeutic vaccines for the treatment of PCa 
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1.4.3.Immune checkpoint blockade 
ICB have demonstrated their efficacy in a number of cancers since the FDA-approval of Ipilimumab 
(anti CTLA-4) for the treatment of melanoma in 2011. Subsequently, antibodies targeting PD-1, PD-
L1, PD-L2, LAG-3, TIM-3 or VISTA have gained interest and been evaluated. 
The outcome of clinical trials assessing ICB targeting the CTLA-4 or PD-1/PD-L1 axis as stand-alone 
(Table 1.3) and in combination with vaccines (Table 1.4) in PCa are summarised below. 
 
Ipilimumab was tested in mCRPC in two phase III clinical trials: one before (Beer, et al. 2017) and 
one after chemotherapy treatment (Kwon, et al. 2014). In the first trial performed, patients 
received Ipilimumab after Docetaxel chemotherapy. Although the primary endpoint of OS was not 
reached (P=0.53), progression-free survival was increased. Further analyses showed Ipilimumab 
was more effective and did improve OS in patients with less advanced disease such as no visceral 
metastases (P = 0.0038). In the second trial, chemotherapy naive patients without visceral 
metastasis received Ipilimumab and while median progression-free survival was prolonged and PSA 
decrease was observed, OS was not improved. 
Although the clinical efficacy of Ipilimumab in mCRPC was disappointing, studies of tumours 
pre/post treatment showed an increase of VISTA and PD-L1 molecules on the surface of 
macrophages, suggesting new possible targets (Gao, et al. 2017).  
 
The first phase I trial assessing the efficacy of Nivolumab (anti PD-1) showed no objective response 
in mCRPC patients (Topalian, et al. 2012), which can be explained by the known weak PD-L1 
expression in human prostate tumours (Martin, et al. 2015). However, a phase II trial assessing 
Pembrolizumab (anti PD-1) in Enzatulamide-resistant mCRPC patients reported a drop of PSA value 
in 3 out of 10 patients, with 2 of them achieving a partial response (Graff, et al. 2016), corroborating 
the fact that PD-L1 expression increases in Enzatulamide resistant tumours (Bishop, et al. 2016). 
Indeed, further analysis demonstrated that the two responders had a PD-L1 positive biopsy and 
that one of them presented markers of microsatellite instability. In the phase I KEYNOTE-28 study 
assessing the effect of Pembrolizumab on advanced PCa patients with at least 1% of tumours 
expressing PD-L1, 13% of patients had a partial response and 39% had a stable disease (Hansen, et 
al. 2018). These encouraging results demonstrate the efficacy of anti PD-1 antibodies in selected 
PCa patients and lead to the phase II KEYNOTE-199 trial. This trial assessed Pembrolizumab in 
Docetaxel-refractory mCRPC patients and showed antitumor activity and disease control regardless 
of PD-L1 expression (De Bono, et al. 2018). 
Furthermore, the FDA-approval of Pembrolizumab in 2017 for the treatment of mismatch repair-
deficient or microsatellite-unstable cancers (Le, et al. 2017) will benefit a proportion of PCa patients 
(12%) (Pritchard, et al. 2014; Schweizer, et al. 2016). These patients have somatic mutations in 
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mismatch repair genes leading to microsatellite instability and therefore to hypermutated tumours 
(Pritchard, et al. 2014), which correlates with response to ICB (anti-CTLA4, anti-PD1, anti-PDL1) in 
several tumor types. 
Several anti PD-L1 antibodies are currently undergoing clinical trials in mCRPC. Although Avelumab 
(anti PD-L1) did not induce objective responses, 3 out of 18 mCRPC patients had a stable disease 
for at least 24 months (Fakhrejahani, et al. 2017). 
 
Thereafter, the combination of Ipilimumab and Nivolumab was tested in a phase II trial as it induced 
a synergistic effect in melanoma. mCRPC patients with ARV7+ tumours (constitutively active 
androgen-receptor splice variant 7) were selected, expecting these tumours would be enriched in 
DNA repair mutations and therefore more sensitive to ICB (Boudadi, et al. 2017). Results were 
encouraging and objectives responses were more common in DNA repair deficient tumours. 
 
Although ICB therapies have not been as successful as hoped in mCRPC patients, there have been 
some encouraging results which require further investigations and indicate that subsets of patients 
might respond to ICB. Patients should therefore be selected, by assessing the presence of mutations 
in mismatch repair genes as well as the expression of PD-L1 in tumours prior to therapy when 
considering blockade of the PD-1/PD-L1 axis. 
Nonetheless, ICB have since been extensively evaluated in combination with other therapies: 
hormonal therapy, chemotherapy, radiotherapy and therapeutic vaccines. Most of these trials are 
ongoing and results are not available yet but some are already completed. 
 
A phase I trial assessing the combination of Sipuleucel-T and low dose Ipilimumab was well 
tolerated and demonstrated an increase of PAP-specific Immunoglobulins in comparison to what is 
usually observed with Sipuleucel-T treatment alone (Scholz, et al. 2017). Median survival for the 9 
patients reached 4 years and although 3 patients died, the 6 remaining had a median PSA value of 
5.5, with one patient in durable remission (Ku, et al. 2018). 
Ipilimumab was also tested in combination with PSA-TRICOM vaccine in mCRPC patients. 58% of 
chemotherapy-naive patients had PSA declines with 6 of them having a drop of at least 50% (Madan, 
et al. 2012). This phase I trial reported a median OS of 2.63 years and identified immune cell subsets 
that correlated with longer OS (Jochems, et al. 2014). The lower proportion of PD-1+/TIM-3- CD4 
effector memory T-cells, higher proportion of PD-1-/TIM-3+ CD8+ T-cells and the higher proportion 
of CTLA- Tregs before immunotherapy correlated with longer OS. On the contrary, the increase of 




Finally, the combination of pTVG-HP DNA vaccine with Pembrolizumab is currently ongoing and 
preliminary results from this phase II trial showed PSA declines, decreased tumour volumes in 
several patients, including one partial response, and the presence of circulating Th1 PAP-specific T-
cells (McNeel, et al. 2017). This trial was based on a previous trial demonstrating anti-tumour 
responses when Pembrolizumab was given concurrently to the DNA vaccine and not sequentially 
(McNeel, et al. 2018). 
 
These trials demonstrate the safety and improved efficacy of therapeutic cancer vaccines in 
combination with ICB therapies, providing hope for the treatment of for mCRPC.
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Table 1:3: Completed selected clinical trials assessing ICB therapies targeting the CTLA-4 or PD-1/PD-L1 axis for the treatment of PCa 
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Table 1:4: Completed or ongoing selected clinical trials assessing therapeutic vaccines in combination with ICB therapies targeting the CTLA-4 or PD-1/PD-L1 axis for the 
treatment of PCa 








Median survival >4 years for 6 of 9 
patients 
 
1 durable remission 
 
Increased PAP-specific humoral 
response (versus Sipuleucel-T alone) 
 




























Anti-tumour activity observed 
 
1 partial response 
NCT02499835 






Oncolytic viruses exercise their efficacy by replicating within tumour cells, inducing their lysis and 
the release of tumour antigens thereby activating the innate immune system and promoting the 
priming and expansion of tumour-specific T-cells. 
The FDA-approval of Talimogene laherparepvec in 2015 for the treatment of advanced melanoma 
has confirmed the clinical benefit of these type of therapies (Conry, et al. 2018), which are now 
being developed for other cancer types. 
ProstAtak (aglatimagene besadenovec) is developed by Advantagene and is currently undergoing 
two clinical trials. This therapy consists of the intratumoral delivery of an inactivated herpetic virus 
containing the thymidine-kinase gene (adV-tk), followed by treatment with an anti-herpetic drug 
(Valacyclovir) (Rojas-Martinez, et al. 2013). 
An ongoing phase II trial is assessing the effect of ProstAtak as a stand-alone in patients with 
localised PCa undergoing active surveillance (NCT02768363), results are expected by September 
2020. 
ProstAtak is also currently being assessed in combination with radiotherapy in a phase III trial for 
patients with intermediate-high risk localised PCa (NCT01436968). Results are expected by 
December 2022. This trial is based on synergistic results observed during the phase II trial, 
demonstrating a reduced recurrence rate (Aguilar, et al. 2006). 
 
1.4.4.2.Anti-tumour antibodies 
Anti-tumour antibodies function by targeting tumour antigens that are highly expressed on tumour 
cells, leading to ADCC. In PCa, two antibodies have reached phase II clinical trial. 
J591 monoclonal antibody, targeting PSMA, assessed with low-dose IL-2 did not show encouraging 
results (Jeske, et al. 2007). However, J591 radiolabelled with lutetium-177, to facilitate the killing 
of prostate tumour cells, induced PSA decline in 60% of patients, one partial response and stable 
disease in 67% of patients with measurable disease (Tagawa, et al. 2013). 
Another strategy is to conjugate chemotherapeutic drugs to the antibody in order to deliver it 
directly to tumour cells. PSMA Antibody drug conjugate (ADC) delivers the chemotherapeutic agent 
MMAE (Monomethyl auristatin E) to PSMA-expressing cells. A phase II trial demonstrated anti-
tumour efficacy, PSA declines in 44% of patients, 61% of stable disease and 13% of partial responses 





1.4.4.3.Adoptive cellular Therapy (CAR T cells) 
This therapy consists in genetically engineering a patient’s own T-cells before reinfusion. 
Generation of Chimeric Antigen Receptor (CAR) T-cells, which target antigens via an antibody-
derived single chain variable fragment, rendering the T-cell MHC-independent, is the most 
promising approach. Targeting of CD19 in B-cell lymphomas using this technique was highly 
successful, with up to 71% of complete remissions and durable responses, leading to the FDA-
approval of 2 anti-CD19 CAR T-cell therapies (Comiskey, et al. 2018). 
In PCa, one CAR T-cell targeting PSMA is currently undergoing phase I clinical trial for metastatic 
PCa (NCT01140373) and demonstrated safety with increased levels of cytokines suggesting 
activation of the engineered T-cells (Slovin, et al. 2013). Another phase I trial, recently initiated, 
assesses CAR T-cells targeting the prostate stem cell antigen (PSCA) in mCRPC patients 
(NCT03873805).  
 
1.4.5.Immune effect of conventional therapies 
As immunotherapies developed in PCa aim at treating mCRPC, it is necessary to understand that 
these patients would have previously received conventional therapies that may have affected their 
immune system. Indeed, hormonal therapy, chemotherapy and radiotherapy have been shown to 
display immuno-modulatory properties. 
 
Hormonal therapy 
ADT demonstrated immuno-modulatory effects such as 1) reversing thymic involution (Sutherland, 
et al. 2005), 2) promoting the survival and differentiation of thymocytes into mature T lymphocytes 
(Dulos and Bagchus 2001; Roden, et al. 2004), 3) attenuating tolerance to prostatic antigens (Drake, 
et al. 2005) and 4) increasing the immune infiltration in prostate tumours (Mercader, et al. 2001). 
Roden et al. demonstrated that androgen ablation could enhance proliferation induced antigen-
specific stimulation and prostatic T-cell infiltration, while Drake et al. showed that vaccination could 
be potentiated following androgen ablation. 
Consecutive to ADT, human prostate tumours are enriched in both CD4+ and CD8+ T-cells and in 
APCs (Mercader, et al. 2001). Moreover, the T-cell response observed appeared to be oligo clonal. 
Gannon et al. also observed an increase of T-cells in prostate tumours following ADT treatment, 
however, the increase of macrophages reported correlated with a higher risk of disease progression 
(Gannon, et al. 2009). 
These findings led to trials assessing the combination of ADT with immunotherapies such as cancer 
vaccines in order to potentiate their effect.  
Primary results from a study suggested that Sipuleucel-T could be more efficacious if given after 
ADT (Antonarakis, et al. 2013), however, further assessment of this phase II trial showed that 
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patients benefited better from Sipuleucel-T when it was given prior to ADT, regarding vaccine-
specific induced humoral and cellular responses (Antonarakis, et al. 2017). Another study assessing 
the combination of PROSTVAC vaccine with ADT also suggested the benefit of vaccinating patients 
prior to ADT, as OS was improved (P=0.045) (Madan, et al. 2008). However, is it important to bear 
in mind that these studies were performed on small cohorts and therefore, more data is needed to 
determine whether vaccines are more efficacious when given before or after ADT. 
 
Chemotherapy 
A number of chemotherapy drugs have also been described as having immuno-modulatory effects, 
in particular by inducing immunogenic cell death, a type of cell death showed to stimulate the 
immune system by promoting the uptake and processing of tumour antigens by DCs and the antigen 
presentation to T-cells, resulting in an increased proportion of TILs (Wang, et al. 2018). 
Chemotherapy-induced cytotoxicity was proposed to induce antigen cascade, rendering more TAAs 
available to the immune system (Madan, et al. 2012). In the context of PCa, Docetaxel 
chemotherapy was reported to increase the production of pro-inflammatory cytokines (IFNγ and 
TNFα) by lymphocytes therefore increasing their cytotoxic functions (Grunberg, et al. 1998). These 
facts lead to numerous combinatorial trials of Docetaxel with immunotherapies. 
 
Radiation therapy 
Radiation can render tumour cells more sensitive to lymphocyte killing by upregulating the 
expression of 1) tumour antigens, 2) costimulatory molecules, such as CD80, 3) Fas molecules and 
4) MHC class-I molecules (Hodge, et al. 2012). Radiation was also reported to create a pro-
inflammatory microenvironment characterised by the presence of cytokines, chemokines and 
adhesion molecules enhancing the recruitment of T-cells (Friedman 2002). 
As expected, these findings also lead to combinatorial trials assessing the synergistic effect of 
radiotherapy and immunotherapy (Finkelstein, et al. 2015). 
 
Radium-223 was described as displaying immunomodulatory effects in vitro via increasing the 
expression of MHC class-I on PCa cell lines, thereby rendering them more susceptible to T-cell 
mediated lysis (Malamas, et al. 2016). 
 
These facts need to be considered when developing new strategies for the treatment of mCRPC. 
Indeed, although immunotherapy is extremely promising, it can be used not only in combination 
with other immunotherapies but with standard therapies that are already FDA-approved and have 




1.4.6.PAP as a target 
PAP is a 100 kDa glycoprotein composed of two subunits of about 50kDa each, acting as a tyrosine 
phosphatase (Muniyan, et al. 2013). Two forms have been described: intracellular and secreted in 
the seminal fluid. This protein is highly expressed in the prostate tissue, however, other tissues such 
as bladder, kidney, pancreas, cervix, testis, lung and ovary can also express low amounts of PAP at 
the mRNA level. 
PAP was discovered in the 1930s and was used as a diagnostic biomarker until the identification of 
PSA. Interestingly, its cellular form decreases as PCa progresses while its secretory form increases 
with disease progression. The cellular form is described as a tumour suppressor, with prostate 
tissue expressing low level of PAP being at higher risk of carcinogenesis. Indeed, several in vitro and 
in vivo studies with PCa cell lines showed that PAP expression inversely correlates with their growth 
rate and tumorigenicity.  
Apart from being involved in fertility, the role of PAP secretory form is less clear. 
Unlike PSA, PAP expression is androgen-independent. The decrease of cellular PAP induces a 
signalling cascade leading to the survival, proliferation and PSA production of PCa cells in an 
androgen-independent manner, allowing PCa cells to develop a castration-resistant phenotype 
(Muniyan, et al. 2013). 
PAP relatively restricted expression in prostate tissues makes it a good target for the treatment of 
prostate cancer. Moreover, PAP is expressed in 95% of primary prostate tumours (Graddis, et al. 
2011) and 11% of PCa patients have detectable circulating PAP-specific T helper cells (McNeel, et 
al. 2001). In addition, serum PAP was found to be increased in patients with bone metastases in 
comparison to those without metastases (Ahmann and Schifman 1987). Sipuleucel-T vaccine has 
validated the strategy of therapeutic cancer vaccines and of using PAP as a target for the treatment 
of PCa. Although it demonstrated clinical benefit by improving the OS of patients by 4 months, its 
limited efficacy illustrates the necessity of developing new therapeutic strategies.  
Its limited efficacy is due, in part, to the immunosuppressive environment of the tumour. Indeed, 
Fong et al.  demonstrated the expression of PD-1 on the majority of infiltrating T-cells as well as a 
small proportion of Tregs at the tumour interface in patients treated with Sipuleucel-T (Fong, et al. 
2014). 
 
Previous work conducted at the John van Geest Cancer Research Centre demonstrated that 
vaccination with a 15mer PAP-derived peptide, containing an HLA-A2 class-I restricted epitope 
within an HLA-DR1 class-II-restricted epitope, could induce PAP-specific T-cell responses. 
Furthermore, immunisation with this peptide sequence in a DNA vector format, the ImmunoBody®, 
generated higher avidity T-cell responses and reduced the tumour growth in established 
heterotopic TRAMP-C1 murine prostate cancer cell-derived tumours (Saif, et al. 2014). This 
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sequence was then elongated to 42 amino-acids long in order to increase the number of potential 
epitopes. The goal was to increase the HLA haplotypes that could present epitopes, thereby 
becoming applicable to a larger population of patients rather than only to HLA-A2+ patients. Longer 
peptides, rather than single epitopes, have been shown to induce stronger CD8+ T-cell reactivity in 
vivo (Bijker, et al. 2007) and were able to induce a more efficient and robust protective immune 
response. Moreover, long synthetic peptides were shown to be highly advantageous by allowing 
the incorporation of multiple epitopes allowing HLA typing-independent vaccine design (Melief 
2008).  
A change of amino-acid at position 116 was found to increase the immunogenicity of the previously 
reported 15mer, this was therefore retained in the elongated sequence. The mutated 42mer PAP-
derived peptide was shown to induce stronger PAP-specific T-cell responses towards MHC class-I 
and class-II epitopes than its WT counterpart which can be explained by its ability to improve the 
predicted MHC binding score to the epitopes assessed. 
This project aims to assess the efficacy of several adjuvant/delivery systems in eliciting strong PAP-
specific immune responses and the anti-tumour efficacy of the strongest vaccine strategy in tumour 
bearing animals.  
 
1.5. Aims of the study 
To assess the efficacy of the vaccine, two preclinical murine models were used: C57Bl/6 mice and 
HHDII/DR1 transgenic mice. In both models, the ability of wild type (WT) and mutated 42mer PAP-
peptide sequences to induce PAP-specific immune responses was compared using different delivery 
systems (peptide-based vaccines versus DNA vaccine). Following immunisation, in vitro 
experiments were performed on splenocytes to assess the vaccine-induced PAP-specific immune 
response as well as the capacity of lymphocytes to recognize and lyse PAP-expressing target cells. 
These results lead to the selection of the most immunogenic vaccine strategy.  
The final aim was to assess the anti-tumour efficacy of the selected vaccine strategy in heterotopic 
tumour models in both prophylactic and therapeutic settings. 
In parallel, the presence of circulating PAP-specific CTLs in the blood of PCa patients was measured 
to assess whether PCa patients have a pre-existing immune response towards PAP antigen, which 
differs from that of patients with benign disease. 
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Chapter 2: Materials and methods  
2.1 Materials  
2.1.1.Cell culture reagents  
 PROVIDER  
Media  
TexMACS  MACS Miltenyi Biotec 
RPMI 1640  SLS (Lonza)  
DMEM  SLS (Lonza)  
Opti-MEM®  Thermo Fisher Scientific  
CTL wash Immunospot 
Culture media supplements   
Fetal calf serum (FCS)  Fisher (GE Healthcare)  
Nu-Serum IV culture supplement Corning 
L-Glutamine  SLS (Lonza)  
D-glucose Sigma  
5α-dihydrotestosterone solution (DHT) Sigma 
HEPES  SLS (Lonza)  
Sodium Pyruvate  SLS (Lonza)  
Pen/strep antibiotic solution  SLS (Lonza)  
2-mercaptoethanol  Sigma  
Other culture reagents   
Benzonase Merck 
Dimethyl sulfoxide (DMSO)  Insight Biotechnology  
Dulbecco’s phosphate buffered saline (DPBS)  SLS (Lonza)  
Lipopolysaccharide (LPS)  Sigma  
Phosphate buffer saline (PBS)  BioWhittaker Europe  
Trypan Blue solution 0.4%  Sigma  
Trypsin/Versene  SLS (Lonza)  
EDTA 0.5M  Ambion  
Acetic acid  Fisher Scientific  
Anhydrous ethanol  Sigma  
Antibiotics  
Puromycin  Sigma  
Geneticin (G418) Sigma  
Hygromycin  Sigma  
Zeocin  Invitrogen  
Cytokines and peptides  
Murine interferon γ PeproTech 
Murine Interleukin 2 PeproTech 
Recombinant human IL-2 R&D Systems 
Recombinant human IL-15 R&D Systems 
Peptides  Genscript  
  
2.1.2.Chemical reagents   
 PROVIDER  
Agar  Bioline  
Ammonium Persulphate (APS)  Geneflow  
Ampicillin  Sigma  
Bovine serum albumin (BSA)  Merck  
Bromophenol blue  Arcos Organics  
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Butane  Fisher Scientific  
Calcium chloride (CaCl2)  Sigma  
Chromium-51  Biosciences  
Dextran sulphate  Sigma  
Double distilled water (ddH2O)  Barnstead, Nanopure  
Clarity Western ECL Substrate  Bio Rad  
Ethanol  Fisher Scientific  
Ethyl alcohol absolute  VWR chemicals  
Ethylenediaminetetraacetic acid (EDTA)  Sigma  
Gold microcarriers (1.0mm)  BioRad  
Glycerol  Sigma  
Glycine  Sigma  
Isopropanol  Sigma  
ISOTON sheath fluid  Beckman Coulter  
Lipofectamine 3000 Transfection Reagent  Invitrogen  
Liquid nitrogen  BOC  
Magnesium chloride (MgCl2)  Sigma  
Methanol  Fisher Scientific  
Paraformaldehyde  Arcos  
Phosphate Buffer Saline (PBS)  Bio Whittaker Europe  
Phosphate Buffer Saline (PBS) Tablets  Oxoid  
Polyvinyl pyrrolidone (PVP)  Sigma  
Protein Assay Dye Reagent Concentrate  Bio-Rad  
Protease Inhibitor Cocktail  Sigma  
Propidium iodide  Sigma  
Protogel (30% Acrylamide mix)  Geneflow  
Sodium azide (NaN3)  Sigma  
Sodium chloride (NaCl)  Calbiochem  
Sodium dodecyl sulphate (SDS)  Sigma  
Sodium hydroxide (NaOH)  Fisher Scientific  
Spermidine  Sigma  
Sucrose  Sigma  
2-methylbutane (isopentane)  Acro Organics  
TEMED  Sigma  
Triton-X-100  Sigma  
1M Tris-HCl  Invitrogen  
Trizma (Tris) base  Sigma  
Tryptone  Sigma  
Tween-20  Sigma  
Xylene  Fisher Scientific  
Yeast extract  Sigma  
  
2.1.3.Antibodies and Flow cytometry/Western blotting reagents 
 PROVIDER  
Flow cytometry antibodies Biolegend 
Dextramers Immudex 
soluble anti-CD28 Biolegend 
soluble anti-CD49d Biolegend 
Human FcR Blocking Reagent  Miltenyi Biotec  
Murine FcR Blocking Reagent  Biolegend 
LIVE/DEAD Fixable Yellow Dead Cell Reagent  Thermo Fisher Scientific  




Monensin/Golgi stop Biolegend/Sigma 
Rabbit anti-human PAP Cell Signalling  
Mouse anti-human β-actin  Sigma  
Anti-Rabbit IgG HRP-linked Ab  Cell Signalling  
Anti-Mouse IgG HRP-linked Ab  Cell Signalling  
Precision Plus Protein WesternC Standards  Bio Rad  
Precision Protein™ StrepTactin-HRP Conjugate  Bio Rad  
  
2.1.4. Reagent kits 
 PROVIDER  
Dynabeads Untouched mouse CD8+ T cell 
isolation  
Invitrogen  
CytoFix/CytoPerm kit Invitrogen 
PerFix-nc Kit Beckman Coulter 
Murine IFN γ cytokine ELISpot kit  Mabtech  
DAB Peroxidase (HRP) Substrate Kit (with Nickel), 
3,3’-diaminobenzidine  
Vector Laboratories  
OneComp eBeads Compensation Beads  Thermo Fisher Scientific  
Wizard plasmid DNA miniprep  Promega  
RNeasy Mini Kit (250)  QIAGEN  
QIAGEN QIAfilter Plasmid Midi  QIAGEN  
Taq Universal SYBR green supermix BIO-RAD 
  
2.1.5. Cell lines 
 PROVIDER  
TRAMP-C1 ATCC/PROVIDED BY Matteo Belone (Milan University) 
TRAMP-C2 ATCC 
T2 ATCC 
R-MAS Provided by Colin Brooks (University of Newcastle) 
LNCaP ATCC 
HEK-293T  ATCC  
B16/HHDII,DR1  Provided by Scancell  
  
2.1.6. Plasmids  
 PROVIDER  
pBUD CE4.1  Addgene  
pGL4.2/puro  Addgene  
pLKO.1 puro  Addgene  
Lentiviral Envelope and Packaging Plasmids Addgene  
Primers for qPCR Sigma 
  
2.1.7.Enzymes, buffers and gels  
 PROVIDER  
dNTPs Promega  
Oligo dT Promega  
KpnI Promega  
XhoI Promega  
AMV reverse transcriptase  Promega  
T4 DNA ligase  Promega  
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RNAse inhibitor  Promega  
All enzymes were used in combination with the buffers recommended and provided by the 
manufacturer.  
LB AGAR PLATE  FOR 500 ML  
NaCl  5 g  
Tryptone  5 g  
Yeast Extract  2.5 g  
Agar  7.5 g  
ddH2O  Up to 500 mL  
Autoclaved, cooled down to 50°C  
Ampicillin  100 mg  
Kanamycin  50mg  
Zeocin  40mg  
Poured on Petri dishes, left to solidify and stored at 4°C for up to a week.  
LB BROTH  FOR 500 ML  
NaCl  5 g  
Tryptone  5 g  
Yeast Extract  2.5 g  
Autoclaved, cooled down to 50°C  
Ampicillin  50 mg  
Stored at 4°C for up to a week  
TRIS-EDTA (TE) BUFFER  FOR 500 ML  
1 M Tris pH 8  5 mL  
0.5 M EDTA pH 8  1 mL  
ddH2O  Up to 500 mL  
TRIS-Acetate EDTA (TAE) BUFFER  FOR 50x  
1 M Tris base  242g  
Disodium EDTA  18.61g  
Glacial acetic acid  57.1mL  
ddH2O  Up to 1L  
Dilute to 1x using distilled water before use, store at 4°C  
4X SDS-PAGE LOADING BUFFER  FOR 10 ML  
1M Tris-HCl pH 6.8  2.4 mL  
Sodium dodecyl sulfate (SDS)  0.8 g  
Glycerol  4 mL  
DTT  0.5 mL  
Bromophenol blue  4 mg  
ddH2O  3.1 mL  
Aliquots were stored at -80°C.  
5% STACKING GEL  FOR 6 ML  
ddH2O  4.1 mL  
30% Acrylamide mix  1.0 mL  
1.0 M Tris (pH 6.8)  0.75 Ml  
10% SDS  0.06 mL  
10% ammonium persulfate  0.06 mL  
TEMED  0.006 mL  
10% RESOLVING GEL  FOR 20 ML  
H2O  6.6 mL  
30% Acrylamide mix  8.0 mL  
1.5 M Tris (pH 8.8)  5.0 mL  
10% SDS  0.2 mL  
10% ammonium persulfate  0.2 mL  
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TEMED  0.008 mL  
5X SDS RUNNING BUFFER  FOR 1 L  
Glycine  94 g  
Tris base  15.1 g  
10% SDS  50 mL  
ddH2O  Up to 1 L  
5X Running buffer was diluted with ddH2O to 1X working concentration prior use. Running buffer 
was stored at 4°C.  
TRANSFER BUFFER  FOR 2 L  
Glycine  5.8 g  
Tris base  11.6 g  
10% SDS  0.75 g  
Methanol  400 mL  
ddH2O  Up to 2 L  
Transfer buffer was stored at 4°C.  
10 X TRIS-BUFFERED SALINE (10 X TBS)  FOR 1 L  
Trizma base  24.2 g  
NaCl  80 g  
ddH2O  Up to 1 L  
TRIS-BUFFERED SALINE WITH TWEEN (TBST)  FOR 1 L  
10 X TBS  100 mL  
ddH2O  900 mL  
Laemilli buffer  Volume  
10% SDS (w/v) (4% final)  4mL  
Glycerol (20%)  2mL  
1M Tris-HCL (125mM)  1.2mL  
10% 2-mercaptoethanol  1mL  
Distilled water  0.8mL  
Buffers for tissue cultures  
Trypan Blue: White cell counting solution: 0.1% (v/v) solution of Trypan blue in PBS 0.6% (v/v) acetic 
acid in PBS  
Cell sorting media  Concentrations  
EMEM  -  
L-glutamine  1%  
EDTA  3 mM  
HEPES  25 mM  
Benzonase (95%)  3.513888889  
Pen/Strep  2%  
Complete T cell media  Concentrations  
RPMI 1640  -  
FCS  10%  
L-glutamine  1%  
Pen-Strep  2%  
HEPES  1%  
Fungizone  0.005%  
2-mercaptoethanol (to be freshly added)  50mM  
  
2.1.8. Laboratory plastics, glassware and sharps  
 PROVIDER  
Cell culture flasks (T25,T75,T175)  Sarstedt, UK  
Conical flasks (50 ml,100 ml)  Pyrex  
Cryovials  TPP  
55 
 
Eppendorf tubes (0.5 ml, 1.5 ml, 2 ml)  Sarstedt, UK  
ELISpot plates  Millipore  
FACS tubes  Tyco healthcare group  
Falcon tubes (50 ml, 15 ml)  Sarstedt, UK  
Filter tips (0.5-10µl, 2-20µl, 20-200µl, 200-
1000µl)  
Greiner bio-one/ Sarstedt  
Flat-bottom culture dishes (6, 24, 96-well)  Sarstedt, UK  
Glass coverslips  SLS  
Glass slides  SLS  
Micro tips (0.5-10µl, 20-200µl, 200-1000µl)  Sarstedt, UK  
Magnetic cell separators Mini MACS  Miltenyi Biotech  
Pasteur pipettes  Sarstedt, UK  
Petri dishes  Sarstedt, UK  
Pipettes (5mL, 10mL, 25mL)  Sarstedt, UK  
Nitrocellulose blotting membrane 0.22µm GILSON scientific  
Scalpels  SLS(Swann Morton)  
Multichannel pipette  Sartorius  
Syringes (10ml,20ml)  Becton Dickenson  
Tefzel tubing  BioRad  
Universal tubes (20ml)  Greiner  
Western blot filter paper  Schleicher-Schuell  
0.45 μm syringe filter  Sartorius  
0.22 μm syringe filter  Sartorius  
40 μm nylon strainer  Greiner  
70 μm nylon strainer  Greiner  
25mm Gauge needle  BD microlance  
 
2.1.9. Equipments 
 PROVIDER  
4°C refrigerators  Lec  
-20°C freezers  Lec  
-80°C freezers  Revco/ Sanyo  
96-well plate reader  Tecan  
Autoclave  Rodwell  
Bacterial cell orbital incubator 37°C  Stuart  
Bacterial cell culture plate incubator 37°C  Genlab  
Viral cell culture incubator 37°C, 5% CO2  IncuSafe  
Tissue culture incubator 37°C, 5% CO2  Sanyo, Binder  
Centrifuges  Sanyo, Eppendorf  
CCD camera - GBOX –western blot/gel imaging 
system  
Syngene  
Class II safety cabinets  Walker  
NucleoCounter® NC-250™ Chemometec 
FACS cell sorter  Beckman Coulter  
Flow cytometer (Gallios) Beckman Coulter  
Haemocytometers  SLS  
Heat blocks  Lab-Line  
Helios Gene gun  BioRad  
Light microscope  Nikon/Olympus  
Microcentrifuge  MSE  
Mo FloTM cell sorter  Beckman Coulter  
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Nanodrop 8000 Spectrophotometer  Thermo scientific  
NanoDrop ND UV-VIS Spectrophotometer 
version 3.2.1  
Thermo scientific  
ELISpot plate reader  Cellular Technology Limited CTL 
pH meters  Metler Toledo  
Pipettes and multichannel pipettes  Gilson, Star Labs, Eppendorf  
Plate rocker  VWR, Stuart  
Mixer/agitator  Intelli-mixer (ELMI)  
Microplate gamma scintillation counter  TopCount (Packard)  
Sonicator  VWR  
Top count scintillation counter  Packard  
Transfer tank  Bio Rad  
Tubing prep station  BioRad  
Ultracentrifuge Optima TLX  Beckman  
Ultrapure water dispenser  Barnstead  
Vacuum filtration unit  Sarstedt  
Vortex  Scientific industries  
Water baths  Clifton  
 
2.1.10.Softwares  
 PROVIDER  
ELISpot CTL software  CTL 
GraphPad Prism 7  Graph Pad software  




2.2.1.Preparation of target cell lines 
2.2.1.1.Cell culture 
2.2.1.1.1.Human cell lines 
LNCaP cells were obtained from the American Type Culture Collection (ATCC). These cells were 
grown in RPMI supplemented with 10% fetal calf serum (FCS), 1% L-glutamine, 1% HEPES and 0.20% 
glucose. LNCaP transfected with the HHDII plasmid were grown in 1mg/mL G418 and those 
transduced with the Lentiviral plasmid were grown in 1µg/mL puromycin. 
 
HEK293t cells were obtained from the ATCC. These cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% FCS and 1% L-glutamine. 
 
T2 cells were obtained from the ATCC. These cells were grown in RPMI, supplemented with 10% 




2.2.1.1.2.Murine cell lines 
B16F10 HHDII cells were a generous gift from Scancell. This cell line was knocked out for the murine 
MHC class I and II by Sigma using Zinc finger technology and then knocked in for the human DR1 
and a chimeric HHDII (HLA-A0201: human β2M, α1 and α2 but murine α3) by Scancell. These cells 
were grown in RPMI supplemented with 10% FCS, 500µg/ml G418 and 300µg/ml Hygromycin. 
B16-HHDII transduced cells to express the human PAP gene were grown with 1µg/mL puromycin. 
 
TRAMP C1 and Tramp C2 cells were obtained from the ATCC. These cells were grown in DMEM 
supplemented with 5% FCS, Insulin from bovine pancreas (10 mg/ml stock), and 5% Nu-Serum IV 
culture supplement and 3ng/mL 5α-dihydrotestosterone solution (DHT). 
TRAMP-C1 cells were also provided by Matteo Bellone (University of Milan), these cells were grown 
in DMEM with 10% FCS and 1% L-glutamine. 
TRAMP cells transduced with the Lentiviral plasmid were grown in 1µg/mL puromycin. 
 
R-MAS were a generous gift from Colin Brooks (University of Newcastle). These cells were grown in 
RPMI, supplemented with 10% FCS and 1% L-glutamine. 
 
2.2.1.1.3.Thawing, sub culturing and freezing of cell lines 
Cryovials of cells were taken from -80° freezers and thawed quickly in cell culture hood. 20mL of 
room temperature (RT) cell line required media was added to a 50mL Falcon tube, defrosted cells 
were transferred and pelleted by centrifugation at 350g for 5 minutes. Supernatant was discarded, 
pellet was resuspended in media and transferred into a T25 or T75 flask depending on the size of 
the pellet. Cells were incubated at 37°C 5% CO2. 
 
When 70%-90% confluency was reached, cells were sub cultured. 
For suspension cell lines (T2 and R-MAS), cells in culture media were transferred into a 50mL tubes 
and centrifuged at 350g for 5 minutes.  
For adherent cell lines, media was removed, cells were washed with sterile PBS and 1-2mL RT 
Trypsin/Versene was added onto the cells and incubated at 37°C until cells detached from the 
surface. 5-10mL of media was added onto the cells to neutralise the trypsin/Versene and the 
mixture was transferred into a 15 or 50mL Falcon tube and centrifuged at 350g for 5 minutes. 
Following centrifugation, supernatant was discarded and pellet was resuspended in fresh media. 
Cells were either re-seeded or counted for subsequent use. 
Cells to be frozen were resuspended in freezing media (90%FCS + 10% DMSO). Usually, 1/3 of a T75 





Cell line suspensions obtained as detailed in section 2.2.1.1.3 were counted using a 
Haemocytometer for sub culturing purposes. Haemocytometer was wiped with ethanol and a 
coverslip was placed at the centre. 10μL of cell suspensions was added to 90μL of trypan blue to 
obtain a 1:10 dilution. 10µL of the dilution was then added onto the edge of the coverslip and cells 
were counted in the 4 corners with 16 squares under the microscope. 
The number of cells per mL was calculated according to this formula:  
Concentration = (Total number of cells /number of squares counted) x 10 (dilution factor) x 104 
 
Cells obtained from animal tissues (spleens or tumours), from human PBMCs and cell lines for 
further use in assays (ELISpot, flow cytometry-based or cytotoxicity assays) were counted using the 
NucleoCounter to obtain more accurate cell concentrations and viability percentages. 
Cell suspensions were diluted as required to obtain cell concentrations within the range acceptable 
for the NucleoCounter (0.5-5x106 cells/mL). 50µL of the diluted suspension were mixed with 2.5μL 
of Solution 18 and added onto counting slides before insertion into the NucleoCounter for counting. 
The percentage of viability and cell concentration were obtained from automatic calculations by 
the software. 
  
2.2.1.2.Preparation of plasmids: cloning, gel electrophoresis, extraction of DNA from gel, plasmid 
bulk-up, sequencing 
2.2.1.2.1.HumanPAP knock in 
pLenti-puro plasmid was obtained from SIGMA in bacterial glycerol stock. The glycerol stock was 
bulked up in 100mL Laurie Broth media with 100µg/mL ampicillin and incubated overnight at 37°C 
with shaking at 200rpm. The plasmid was isolated using the QIAGEN Plasmid Midi Kit, according to 
manufacturer’s protocol and the concentration was measured on a Nanodrop instrument. 
The human PAP gene was cut out of pBud plasmid using KpnI and XhoI restriction enzymes, it was 
cut inserted into the pLenti-puro plasmid, the plasmid was then bulked up, extracted, run on a gel 
to confirm the size and sent to sequencing to confirm the sequence and the correct orientation of 





Figure 2.1: pLenti-puro/PAP plasmid map 
 
2.2.1.2.2.MurinePAP and humanPAP knock down 
MISSION shRNA plasmids were obtained from SIGMA in Bacterial Glycerol Stock. Two different 
plasmids were used, one to knock down the human PAP gene and one to knock down the murine 
PAP gene. The glycerol stock was bulked up in 100mL Laurie Broth media with 100µg/mL ampicillin 
and incubate overnight at 37°C with shaking at 200rpm. The plasmid was isolated using either the 
QIAGEN Plasmid Midi Kit or the Wizard® Plus SV Minipreps DNA Purification System, according to 
manufacturer’s protocol and the concentration was measured on a Nanodrop instrument. Plasmids 





Figure 2.2: pLKO.1-puro plasmid map 
 
2.2.1.3.Lentiviral transduction 
2.2.1.3.1.Transfection of packaging cells  
HEK293t cells were used as packaging cells to produce viral particles. On day 1, cells were 
transfected at 50-60% confluency using the lipofectamine 3000 kit by mixing 20µL of Lipofectamine 
3000 reagent in 500µL OPTIMEM with 12µL of P3000 reagent in 500µL OPTIMEM and 8µg of 
plasmid of interest, 6µg of packaging plasmid and 2µg of envelope plasmid. After 30 minutes of 
incubation at RT, 1mL of the mix was added per T25 flask.  
 
2.2.1.3.2.Virus Collection  
Media was changed on day 2, fraction 1 was collected on day 3 and fraction 2 on day 4. Both 






Target cells at 70% confluency (LNCaP for the humanPAP knock down; TRAMP-C1 and TRAMP-C2 
for the murinePAP knock down) were transduced by adding the virus-containing fractions to the 
media. The antibiotic for selection of successfully transduced cells, puromycin, was added 24 to 48 
hours later at 1µg/mL. The optimal puromycin concentration was previously determined by 
applying various concentrations and selecting the lowest able to kill 100% of cells within 2 to 4 days. 
 
2.2.1.4.RNA extraction, cDNAs synthesis and RT-PCR 
2.2.1.4.1.RNA extraction 
Total RNA was extracted from 1-5.10^6 cell pellets (stored at -20°C) using the RNeasy mini 
extraction kit, according to manufacturer’s protocol and the concentration was measured on a 
Nanodrop instrument. The RNA was stored immediately at -20°C until cDNA synthesis. 
 
2.2.1.4.2.cDNA synthesis 
Two µg of RNA in nuclease free water (final volume 9µL) and 1µL of oligo dT were heated at 70°C 
for 5 minutes. A mix containing 5µL of RT buffer, 1µL of Reverse Transcriptase enzyme, 0.7µL of 
RNasin, 1µL of dNTP’s and 7.3µL of nuclease free water was then added to the reaction and 




The RT PCR reaction was performed in a final volume of 13µL by mixing 1µL of cDNA, 6.25µL of Taq 
Universal SYBR green supermix, 0.5µL of forward and reverse primer (10pM) and 4.75µL of nuclease 
free water. The relative expression was measured using the 2-^Ct method with one or two 
housekeeping genes. 
 
Table 2.1: Real-Time PCR conditions 
Cycle Cycle Point 
Hold Hold @ 95°C, 5min 0s 
Cycling (35 repeats) Step 1: Hold @ 95°C, 10s 
Step 2: Hold @ 58°C, 15s 
Step 3: Hold @ 72°C, 20s, acquiring to Cycling A 
Melt Ramp from 58°C to 95°C 
Hold for 90s on the 1st step 
Hold for 5s on next steps,Melt A 
 
Table 2.2: Real-Time PCR primers sequences 
Gene Forward primer Reverse primer 
hHPRT TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT 
hPAP GAGAAGGGGGAGTACTTTG CTGTTTGTGGTCATACACTC 
mHPRT TGCTCGAGATGTCATGAAGG TATGTCCCCCGTTGACTGAT 
mGAPDH ACACATTGGGGGTAGGAACA AACTTTGGCATTGTGGAAGG 




2.2.1.5.Western Blotting for hPAP 
2.2.1.5.1.Sample preparation 
PAP protein being secreted, the supernatant of cells in culture was used as a sample instead of cell 
lysates. B16-HHDII cells were cultured overnight in a confluent T75 flasks with 3mL of media, 
allowing to just cover the cells to concentrate the protein. 80µL of the supernatant mixed 1:2 with 
2X Laemmli buffer was then loaded per well of 1mm, 5-well comb. 
 
2.2.1.5.2.SDS-page and transfer 
The gel was run at 100V through the 5% stacking gel and at 130V through the 10% resolving gel for 
2 to 3 hours. Proteins were then transferred onto a nitrocellulose membrane for 60 minutes at 
100V by wet transfer. 
 
2.2.1.5.3.Immunoprobing 
Membranes were stained with Ponceau to ensure the transfer of proteins onto the membrane. The 
membrane was blocked with 5% skimmed milk powder in TBST for 1hr at RT under constant 
agitation, washed 5 times for 5 minutes in TBS- 5% tween-20 at RT and then incubated overnight at 
4°C with 1:1000 rabbit anti-humanPAP primary antibody in 5% skimmed milk powder in TBS- 5% 
tween-20. After 5 washes for 5 minutes in TBS- 5% tween-20 at RT, the membrane was incubated 
with 1:1000 secondary anti-rabbit antibody in 5% skimmed milk powder in TBS- 5% tween-20 for 
1hr at RT. After 5 washes for 5 minutes in TBS- 5% tween-20 at RT, the revelation was performed 
using ECL chemi-luminescence kit. 
 
2.2.1.6.Peptide binding assay for T2 and R-MAS cells 
R-MAS or T2 cells were incubated at 26°C overnight to increase the number MHC class-I molecules 
at the surface of cells. 1 million of cells were incubated for 1 hour (R-MAS cells) or overnight (T2 
cells) in 1mL of media containing different concentrations of peptide of interest. Two 9-mer 
peptides were used: ILL for T2 cells (HLA-A2) and ISI for R-MAS (H2-Db). Six concentrations were 
tested: 0; 1; 2; 10; 50 and 100µg/mL. Cells were washed in their respective media, counted and 0.5 
million were stained with 0.5µL of live dead violet and 1µL of FITC anti- H2-Kb-Db antibody or 2.5µL 
of APC anti-HLA-A2 antibody. After washing in PBS and resuspension in Isoton, cells were acquired 
on a Gallios flow cytometer. Results were analysed on Kaluza software. 
 
2.2.1.7.Interferon γ treatment 
Murine cell lines (TRAMP-C1 and TRAMP-C2) at 70% confluency were treated with murine IFNγ 
respectively. Six concentrations were tested: 0; 0.1; 1; 2; 5 and 10 ng/mL. After 24 hours of 
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treatment, cells were harvested, counted and 0.5 million were stained with 0.5µL of live dead violet, 
1µL of FITC anti- H2-Kb-Db antibody and 1µL of PE anti-murine PD-L1 antibody. After washing in PBS 
and resuspension in 300µL Isoton, cells were acquired on a Gallios flow cytometer. Results were 
analysed on Kaluza software. 
 
2.2.2.Optimisation of the vaccination and assessment of the anti-tumour efficacy of the 
vaccine 
Pre-clinical studies were approved by the Home Office under the Animals (Scientific Procedures) 
Act under two Project Licences (PPL): 
1. 40/3563 valid until the 5th December 2016 
2. PB26CF602, granted on the 28th of November 2016 and valid until the 28th of November 
2021. 
 
2.2.2.1.Mouse models: HHDII/DR1 and C57Bl/6 mice 
Humanized HHDII/DR1 males were bred at Nottingham Trent University animal facility in 
accordance with the Home Office Codes of Practice for the Housing and Care of Animals. These 
animals are HLA-A2.1/HLA-DR1- transgenic C57Bl/6 mice. C57Bl/6 mice were purchased from 
Charles River. Both were used between 7 to 18 weeks old at the start of treatment. 
 
2.2.2.2.Peptides, adjuvants: CpG and CAF09; and ImmunoBody DNA vaccine for Immunisation 
2.2.2.2.1.Peptides 
Peptides were purchased from GeneScript (USA), resuspended at 10mg/mL in 100% DMSO and 
stored at -80°C.  
 






 1 YIRSTDVDRTLMSAMTNLAALFPPEGISIWNPRLLWQPIPVH 42 WT 
 1 YIRSTDVDRTLMSLMTNLAALFPPEGISIWNPRLLWQPIPVH 42 1 mutation 
WT 1 YIRSTDVDRTLMSAMTNLAALFPPEGVSIWNPILLWQPIPVH  42 2 mutations 
1 mutation 1 YIRSTDVDRTLMSLMTNLAALFPPEGVSIWNPILLWQPIPVH  42 3 mutations 
 
2.2.2.2.2.Adjuvants 
CpG ODN nucleotide was purchased from Eurofins. CAF09 adjuvant is a liposomal cationic adjuvant 
developed to generate CD8+ T-cell responses and was a generous gift from Dennis Christensen 




2.2.2.2.3.ImmunoBody DNA vaccines 
ImmunoBody DNA vaccines were a generous gift from Lindy Durrant (Scancel, Nottingham). The 
plasmids encoding for the ImmunoBody were bulked up and isolated as described in 2.2.1.2 using 
law salt Laurie Broth media and 40µg/mL of zeocin antibiotic. 
 
ImmunoBody DNA vaccines were administered to mice using DNA bullets. The preparation 
consisted in coating expression vectors encoding the IB-PAP42mer onto 1μm gold particles. 200μl 
of 0.05M spermidine was mixed to 16.6mg of gold microcarriers, then, 36μg of DNA was added to 
this mixture. Following 5 seconds of sonication, 200μl of CaCl2 (1M) were added dropwise to the 
mix. For it to precipitate, the mixture was incubated at RT for 10 minutes. The suspension was then 
washed twice in absolute Ethanol and resuspended in 2ml of PVP solution (0.025mg/ml). After 
sonication, the solution was loaded into the tubing (Tefzel) and allowed to settle for 10min using a 
tubing preparation station (Bio-Rad). Following the removal of ethanol using a syringe, the tube 
was dried using 0.3L/min flowing Nitrogen. Once dried, the tubing was cut using a guillotine. DNA 
bullets were stored at 4°C until use. 
 
2.2.2.3.Immunisation procedures 




Immunisation using peptide and CpG adjuvant were prepared by mixing 50µg CpG and 30µg of 
PAP42mer peptide in a final volume of 100µL of PBS. The solution was administered by 
intramuscular injection at the base of the tail (50µL each side of the base of tail). 
Immunisation using peptide and CAF09 adjuvant were prepared by mixing 100µL of CAF09 and 30µg 
of PAP42mer peptide in a final volume of 200µL of PBS containing 9% sucrose. The solution was 
administered by intraperitoneal injection. 
Immunisation using ImmunoBody DNA vaccines were performed by firing one bullet containing 1µg 
of DNA using a Helios gene gun (Bio-Rad). 
 
2.2.2.4.Tumour implantation 
Cells were harvested as described in section 2.2.1.1.3, counted as described in section 2.2.1.1.4 
using the NucleoCounter for accuracy and prepared in either serum free media or in sterile PBS at 
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the required concentration: 3x106 cells/mL for B16-HHDII-PAP cells and 50x106 cells/mL for TRAMP-
C1 cells. 100µL of the cell suspension was then injected subcutaneously per animal. 
 
2.2.2.5.Processing of tissue samples 
2.2.2.5.1.Isolation of splenocytes 
Spleens from immunized mice were harvested and placed in a tube containing T-cell media. Each 
spleen was placed into a sterile petri dish containing 10ml T-cell media and flushed with another 
10ml of media using a syringe. The cell suspension was centrifuged at 300g for 10min and re-
suspended in 5ml of T-cell media. Cells were then counted using the cell counter NucleoCounter as 
in 2.2.1.1.4. 
 
2.2.2.5.2.Isolation of tumour cells 
Tumours were harvested from animals upon reaching the maximum tumour volume and placed in 
a tube containing T-cell media. In order to obtain single cell suspensions for flow cytometry assays, 
tumours were put in a petri dish containing 10mL of T-cell media (50μg/mL of DNase I and 0.1u/mL 
of collagenase IV) and cut into small pieces using scalpels. The tissue mixture was transferred into 
a 50mL Falcon tube and setup to gently swirl for 30 minutes (B16 tumours) or 1-2hrs (TRAMP-C1 
tumours) at 37°C to help cell dissociation. The mixture was then mashed using the back of a 10mL 
syringe against a 70μm cell strainer. Another 10mL of T-cell media was used to rinse the cell strainer. 
The 20mL mixture was then centrifuged at 400g for 5 minutes and resuspended in 2mL (B16 
tumours) or 5mL (TRAMP-C1 tumours). 100-200μL of cell suspension was taken into a FACS tube 
and washed with 2mL of PBS at 400g for 5 minutes before staining with antibodies. 
 
2.2.2.6.IFNg ELISPOT assays 
The number of IFNγ releasing PAP-specific T-cells was measured using a murine IFNγ Elispot assay. 
96-well filtration plates were activated by adding 50μl/well of 70% Ethanol and washed 5 times 
with deionised H2O at 200μl/well. Plates were then coated with 50μl of coating antibody (AN18) 
diluted 1:1000 in sterile PBS and incubated overnight at 4°C. The following day, plates were washed 
4 times with sterile PBS and incubated with 100μL/well of T-cell media for 30 minutes at 37°C. After 
removal of the T-cell media, 0.5x10^6 splenocytes/well were plated in a final volume of 100μL/well. 
Cells were stimulated with MHC class-I and class-II peptides (see tables 3.2 and 3.3) at 1μg/mL and 
10μg/mL respectively in 100μL/well so that the final volume in each well was 200μL/well. Cells with 
T-cell media alone were used as a negative control. After 48hours of incubation at 37°C, plates were 
washed 5 times with 200μL/well of PBS+0.05% Tween20. 50μL/well of the biotinylated-detection-
antibody (R4-6A2) diluted 1:100 in PBS was added for 2 hours at RT followed by 5 washes again. 
Then, 50μL/well of streptavidin-AP (AP-conjugate substrate system) diluted 1:100 in PBS was added 
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for 1hour and 30 minutes at RT. Finally, plates were washed 6 times and the development solution, 
prepared according to manufacturer’s instruction, was added followed by a 10 to 30 minutes 
incubation in the dark. Once the spots were visible, the reaction was stopped by washing the plates 
under running tap water. Plates were left to dry overnight. The number of spots were quantified 
using an Elispot plate reader.  
 
2.2.2.7.Immunophenotyping of splenocytes and TILs 
Multi-color flow cytometry was used to assess the expression of activation and exhaustion markers 
on the surface of T-cells as well as for assessing the presence memory T-cells. 
1x106 of fresh splenocytes were washed in 2mL PBS by centrifugation at 400g for 5 minutes and 
incubated for 10-15 minutes with 1µL of anti-CD16/CD32 antibody to block their FcR (1µg/tube) for 
15 minutes at 4°C. Cells were then incubated with surface antibodies for 30 minutes at 4° in the 
dark, washed in 2mL PBS by centrifugation at 400g for 5 minutes and resuspended in 300µL isoton. 
Cells were finally acquired on a Gallios flow cytometer and results were analysed on Kaluza software. 
 
Table 2.4: List of flow cytometry antibodies for exhaustion and memory panel 
 Common Memory panel Exhaustion panel 
 Antibody 
Quantity µg 
/ Volume µl 
Antibody 
Quantity µg / 
Volume µl 
Antibody 




CD62L  0.25µg / 0.5µL GITR (CD357) 1µg / 2µL 
PE FL2 
 
OX-40 (CD134) 0.25µg/1.25µL 
PE-efluor610 FL3 CTLA-4 (CD152) 0.5µg/2.5µL 
PerCp-Cy5.5 FL4 LAG-3 (CD223) 0.5µg/2.5µL 
PE-Cy7 FL5 Tim-3 (CD366) 0.5µg/2.5µL 





  APC-Cy7 FL8 CD8 0.5µg/2.5µL 
BV421 FL9 CD45 0.2µg/1µL 
FL10 Live dead 0.5µL 
 
Intracellular flow cytometry was used to assess the peptide-specific cytokine release, proliferation 
and degranulation of T-cells by performing Intracellular Cytokine staining (ICS). 1x10^6 fresh 
splenocytes/well were seeded in 100µl in a 96-wel plate. Three wells/mice were prepared, one 
containing 100µl of media (negative control), one containing 100µl of class-I peptide (1µg/ml final 
concentration) in T-cell media and one containing 100µL of class-I peptide (1µg/ml) and class-I 
peptide (10µg/ml) in T-cell media. Cells were incubated with anti-CD28 and anti-CD49d antibodies 
(1µg/mL) for co-stimulation, for 1 hour at 37°C. Brefeldin A (5µg/ml) and monensin (2µM) were 
added to stop the Golgi transport and cells were left at 37°C for a further 5 hours. The plate was 
then kept at 4°C overnight until staining the following day. Splenocytes were transferred into FACS 
tubes, washed with 3mL of PBS and resuspended in 50µL FCS. The Fc Receptor was further blocked 
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using 1µL of anti-CD16/CD32 antibody (1µg/tube) for 15 minutes at 4°C. Surface antibodies were 
added and incubated for 15 to 30 minutes at 4°C in the dark. 
The PerFix-nc Kit (no centrifuge assay kit) was used to fix and permeabilize cells. Cells were fixed 
with 25µL of fixative agent R1 for 15minutes at 4°C in the dark and permeabilized with 300µl of 
permeabilizing reagent R2. Intracellular antibodies were added and incubated for 15 to 30 minutes 
at 4°C in the dark. 
Cells were washed with 3mL of 1X R3, re-suspend in 250-300µl of 1X R3 and acquired on a Gallios 
flow cytometer. Results were analysed on Kaluza software. 
The protocol was provided by our collaborator Dennis Christensen (Statens Institut, Copenhagen) 
who had showed that overnight incubation of splenocytes did not affect the cytokine expression. 
 
Table 2.5: List of flow cytometry antibodies for ICS staining 
 Antibody Fluorochrome/FL Quantity µg / Volume µl 
Surface Abs 
CD107a FITC FL1 1.5µg / 3µl 
CD4 Alexa-fluor700 FL7 0.25µg / 0.5µl 
CD8 APC-Cy7 FL8 0.5µg / 2.5µl 
CD45 BV421 FL9 0.2µg / 1µl 
Live dead FL10 0.5µl 
Intra-cellular 
Abs 
TNF-a PE FL2 0.25µg / 1.25µL 
Ki67 PE-efluor610 FL3 0.125µg / 0.3µl 
IL-2 PerCp-Cy5.5 FL4 0.6µg / 3µl 
IFNg PE-Cy7 FL5 0.6µg / 3µl 
Granzyme B APC FL6 0.5µg / 2.5µl 
 
2.2.2.8.In vitro stimulation and killing assays 
2.2.2.8.1.Generation of LPs-blast 
Splenocytes were stimulated in vitro for 6 days to then assess their capacity to kill relevant target 
cells. LPS-blast were generated to be used as APCs to re-stimulate vaccine-specific T-cells in vitro. 
Spleens from naive mice were treated with LPS (25µg/mL) and Dextran sulphate (7µg/mL) for 48 
hours at 37°C. Splenocytes were then washed, treated with mitomycin C (1µg/1x106 splenocytes) 
for 20 minutes at 37°C, washed in T-cell media 4 times and then incubated for 1hr 15 minutes at 
37°C with a cocktail of class I peptides at 1 μg/ml (ILL for HHDII/DR1 mice experiments and ISI and 
SIW for C57Bl/6 mice experiments). Cells were washed, counted and diluted in T-cell media for 
future use. 
 
2.2.2.8.2.In vitro stimulation of splenocytes 
30x10^6 splenocytes from each immunised mouse was seeded in T-cell media into 24 well plates 
at a concentration of 5x106/2mL (6 wells/mice). Cells were grown 6 days at 37°C in media containing 
50U/mL of mIL-2, 2mM of β-mercaptoethanol and LPS-blasts at a 1:10 ratio (1 LPS-blast for 10 




2.2.2.8.3.51Cr killing assays 
Stimulated splenocytes were harvested, counted and seeded in 100µL in 96-well plate (round-
bottom) according to the effector:target ratio. Four different effector:target ratios were used: 
100:1 (500,000:5,000), 50:1 (250,000:5,000), 25:1 (125,000:5,000), 12.5:1 (62,500:5,000).  Target 
cells were harvested, counted and 2x106 cells were labelled with 1.85 MBq of 51Cr. Cells were 
incubated for 1hr at 37°C in a water bath followed by 4 washes with specific-cell lines media. For R-
MAS and T2 cells, cells were incubated for 1hr at 37°C with class I peptides at 1 μg/ml (ILL for 
HHDII/DR1 mice experiments and ISI or SIW for C57Bl/6 mice experiments). Cells were then washed 
1 more time, counted, diluted in specific-cell lines media and seeded at 5x103 cells/well in 100µL 
into the 96-well plates containing effector cells. Following 4 hours of incubation at 37°C, 50µL of 
the supernatant of each well was transferred to Luma plates. Plates were left to dry overnight and 
were read on the Top Count machine. Target cells alone with media were used as negative control 
(spontaneous release) and target cells with media and 10µL of 10% SDS were used as positive 
control (maximum release). Cytotoxicity was calculated according to the following formula: 
 
 (Experimental release – spontaneous release)   x 100 =   % of Cytotoxicity 
   (Maximum release – spontaneous release) 
 
2.2.2.8.4.Negative selection of CD8+ T-cells 
CD8+ T-cells were isolated from total splenocytes following 6 days of in vitro stimulation with 
class-I epitopes using the Dynabeads Untouched mouse CD8+ T cell isolation. Manufacturer’s 
protocol was followed. 
 
2.2.2.8.5.Flow-cytometry-based cytotoxicity assay 
Target cells (LNCaP cell line) were harvested as described in 2.2.1.1.3 and 1x106 cells was labelled 
with PK26 fluorescent dye. Manufacturer’s protocol was followed. Briefly, cells were washed in 
serum-free media at 350g for 5 minutes and supernatant was discarded in order to leave no more 
than 25µL of residual media on the pellet. Cells were resuspended gently with the diluent C 
provided, by pipetting several times to ensure single cell suspension. A 2X working solution of 
PKH26 dye (4µM) in diluent C was prepared by mixing 0.8µL of the 1mM stock solution of PK26 dye 
with 200µL of diluent C. The 200µL cell solution was then added rapidly to the 2X working dye 
solution to obtain a 2µM final concentration and mixed by pipetting several times. Cells were 
incubated with the dye for 2-5 minutes and the reaction was stopped by adding an equal volume 
(400µL) of FCS. Cells were centrifuged at 350g for 5 minutes and then washed three times with 
complete media. Cell were then counted using the NucleoCounter as in 2.2.1.1.4. 
69 
 
Labelled-target cells and splenocytes were seeded in FACS tubes according to the effector:target 
ratio and co-incubated for 3 hours. Three different effector:target ratios were used: 20:1 
(400,000:20,000), 10:1 (200,000:20,000), 5:1 (10,000:20,000). 
At the end of the incubation, cells were washed in PBS and stained with 1µL per tube of LIVE/DEAD 
Fixable Yellow Dead Cell Reagent (in 100µLof PBS) for 20-30 minutes in the dark. Cells were then 
topped up with 300µL of Isoton and acquired on a Gallios flow cytometer. Results were analysed 
on Kaluza software. 
Target cells alone were used to determine the spontaneous percentage of dead target cells. 
Cytotoxicity was calculated according to the following formula: 
 
 (% dead target cells - % spontaneous dead target cells) x 100 =   % of Cytotoxicity 




Ethical approval for using Human clinical material: 
1. Ethical approval for the collection of peripheral blood and the analysis of peripheral blood 
mononuclear cells (PBMCs) from prostate cancer patients was provided under EoSRES ref 
no: 14/ES/1014 
Whole blood sample from patients with prostate cancer were taken and provided by Dr Masood 
Khan (Leicester Hospital). 
2. Ethical approval for the collection of peripheral blood and the analysis of peripheral blood 
mononuclear cells (PBMCs) from healthy donors has been provided under application 
number 435 
 
2.2.3.1.Isolation of PBMCs 
PBMCs were isolated from whole blood using Leucosep tubes. Firstly, 15mL of Lymphocyte 
Separation Medium (LSM) was added per leucosep tube and a quick centrifugation was performed 
to pass the LSM through the membrane. 30mL of blood diluted in PBS at a 1:1 ratio was then added 
to the leucosep tubes and centrifuged at 800g for 20 minutes at RT with brakes off. The layer of 
PBMCs was then collected by pouring the cell suspension into a Falcon tube. The tube was topped 
up with PBS up to 50mL and centrifuged at RT at 800g for 10 minutes. This washing step was 
repeated one more time, the pellet was resuspended in 2mL of FCS and cells were counted with 
the NucleoCounter as described in 2.2.1.1.4. 




2.2.3.2.Freezing of PBMCs 
PBMCs were frozen as described in 2.2.1.1.3 at 10X106 cells/mL. Cells were firstly frozen at -80°C 
for at least 24hrs and then transferred to a liquid nitrogen tank for long-term preservation. 
 
2.2.3.3.Expansion protocol 
Cryopreserved PBMCs were thawed out in a prewarmed CTL thaw solution (RPMI with 10% CTL 
thaw solution and 0.02% benzonase) and then centrifuged at 400g for 10 minutes. The PBMCs were 
resuspended in 10mL TexMACS media and incubated 37°C, 5% CO2 for 2hrs. The cells were then 
centrifuged at 300g for 10 minutes and counted using the NucleoCounter as described in 2.2.1.1.4. 
PBMCs were prepared at 2x106 cells/ml in TexMACS media and 2x106 cells were seeded per well in 
a 24-well plate (number of wells per patient depended on the number of PBMCs recovered). 
PBMCs of each patient were stimulated with 3 different conditions: 1) hPAP42mer mutated peptide, 
2) ILL 9mer peptide and 3) a mix of EBV, CMV and FLuA class-I peptides. The peptides mixes were 
prepared in TexMACS media: ILL peptide at 1µg/ml, hPAP42mer mutated peptide at 10µg/ml and 
CMV/EBV/FluA cocktail at 2µg/ml for each peptide. PBMCs were then incubated at 37°C, 5% CO2. 
Following four days of culture, IL-2 and IL-15 were added to each well at 10IU/ml and 10ng/ml 
respectively. One further mL of TEXMACS media was added per well and PBMCs were incubated 
for a further six days at 37°C, 5% CO2. 
On Day 10, PBMCs were transferred into Falcon tubes, each well was gently rinsed with pre-warmed 
TexMACS media and the cell suspension was centrifuged at 300g for 10 minutes. PBMCs were 
resuspended in TexMACS media with 10IU/mL of IL-2, re-seeded in the 24-well plate an incubated 
for a further 2 days. 
On day 12, cells were washed as described above, counted with the NucleoCounter and used as 
required for Dextramer staining and cytotoxicity assays. 
 
2.2.3.4.Dextramer staining 
1x106 cells were transferred into FACS tubes and washed with PBS by centrifugation at 400g for 5 
minutes. Cells were then resuspended in 90µL PBS and 10µL FcR blocking agent was added for 10 
minutes at 4°C in the dark. 10μl of control dextramer, ILL dextramer or CMV dextramer was added 
to the appropriate tubes and incubated for 10 minutes at 4°C in the dark. CD8, CD3 and CD19 
antibodies were added to each tube and incubated for 30 minutes at 4°C in the dark. Cells were 
then washed in PBS by centrifugation at 400g for 5 minutes, resuspended in 300μl isoton and 
acquired on a Gallios flow cytometer. Results were analysed on Kaluza software. 
 
Table 2.6: List of flow cytometry antibodies for dextramer staining 
Antibody Provider Volume (µL) 
Dextramers Immudex 10 
CD8 APC/Fire750 Biolegend 2.5 
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CD3 PE/Dazzle594 Biolegend 2.5 
CD19 Brilliant violet 421 Biolegend 2.5 
Live dead yellow Invitrogen 0.5 
 
2.2.3.5.Cytotoxicity assays 
Cytotoxicity assays were performed as described section 2.2.2.8.5 using PBMCs instead of 




Statistical analysis for all experiments were performed using GraphPad Prism 7 software. p-values 
were calculated using either Student’s t-test with two-tailed distribution or Two-way/one-way 




Chapter 3: Optimisation of the vaccination strategy to enhance the 
immunogenicity of the PAP42mer vaccine 
3.1. Introduction 
The main challenge when developing therapeutic cancer vaccines is choosing the right antigen. PAP 
protein as an appropriate target antigen when developing a therapeutic vaccine against PCa was 
discussed in the introduction. In brief, PAP expression is mainly restricted to the prostate, with 
some expression in other tissues, but at a much lesser magnitude than its expression within 
prostate tissues (Graddis, et al. 2011). The secretory form of PAP is overexpressed during PCa (Kong 
and Byun 2013). Finally, the strongest argument for using PAP as a target for the development of a 
vaccine against PCa is the FDA-approval of Sipuleucel-T in 2010 for the treatment of mCRPC patients. 
It confirmed the pertinence and safety of targeting PAP for the treatment of PCa. 
Besides the choice of the antigen being crucial when developing a vaccine, the choice of the delivery 
system used also is, as it affects its capacity to generate an effective immune response. The 
different types of vaccine delivery systems can be divided into 4 categories: tumour cell vaccines, 
DC vaccines, protein/peptide-based cancer vaccines and DNA/RNA-based vaccines (Guo, et al. 
2013). This study focuses strictly on peptide-based cancer vaccines and DNA vaccines. Regarding 
peptide-based vaccines, the other parameter to consider, other than the choice of the target, is the 
choice of the immunostimulatory adjuvant. This study focuses on two adjuvants that induce an 
innate immune response by stimulating APCs: CpG and CAF09, a poly I:C like synthetic molecule. 
Although no peptide-based vaccine for the treatment of cancer has yet shown sufficient efficacy to 
be FDA-approved, many phase I and II clinical trials are ongoing in many different type of cancers, 
including PCa, using either short TAA-derived peptides or synthetic long peptides (Bezu, et al. 2018).  
 
CpG Synthetic oligonucleotides (ODN) target TLR9 (Toll like receptor 9), which are expressed by 
plasmacytoid DCs and B cells (Scheiermann, et al. 2014). The resulting innate immune response is 
characterised by the production of Th1 and pro-inflammatory cytokines. Numerous clinical trials 
have evaluated the use of CpG ODN as a vaccine adjuvant and showed that it could improve antigen 
presentation and generate vaccine-specific cellular responses. 
CAF09 is a poly I:C like synthetic molecule that binds to TLR-3 receptors expressed by myeloid DCs 
and macrophages. Its binding induces the production of pro-inflammatory cytokines and 
chemokines (Korsholm, et al. 2014). CAF09 has been used in preclinical studies and is now 
undergoing phase I clinical with a Bcl-Xl peptide for the treatment of PCa patients with lymph node 
metastases (NCT03412786). 
 
DNA vaccines have also confirmed their efficacy in cancer. Indeed, evaluation of a DNA vaccine 
targeting PAP has been discussed in section 1.4.2.2. 
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The DNA vaccine assessed in this study, ImmunoBody®, has two mechanisms of action: direct 
presentation by transfection of APCs and cross-presentation by uptake via the Fc Receptor 
(Metheringham, et al. 2009). The SCIB1 cancer vaccine uses the ImmunoBody® technology to target 
two antigens (TRP2 and gp100) and has been assessed in a phase I/II clinical trial for the treatment 
of melanoma (Patel, et al. 2018). The study showed that the DNA vaccine was well tolerated and 
induced T-cell responses in patients. 
 
Previously published data have demonstrated that a 15 amino-acid sequence, PAP 114-128 HLA-
DR1 peptide, containing the PAP115-123 HLA-A2 peptide, could elicit peptide-specific T cell 
responses after immunisation into transgenic HHDII/DR1 humanised mice. Higher avidity T cell 
responses in C57Bl/6 and HHDII/DR1 mice were generated by incorporating this sequence into the 
backbone of the ImmunoBody® DNA vaccine. Moreover, the DNA vaccine could produce an anti-
tumour response against pre-established TRAMP C1 murine prostate cancer cell-derived tumours 
(Saif, et al. 2014). 
The elongation of this 15mer peptide to a 42 amino acids sequence and the introduction of a point 
mutation increased the number of potential class-I and II epitopes and the immunogenicity of the 
peptide, rendering it foreign in order to break tolerance against PAP. The improved predicted 
peptide-MHC binding score towards several epitopes is shown Table 3.2.  
 
The aim of this chapter is to evaluate the immunogenicity of the wild-type vs mutated PAP42mer 
vaccine and the effect of the different adjuvants (CpG, CAF09 and ImmunoBody®). This was 
assessed in two mouse models. It is important to point that the sequence of the PAP42mer peptide 
is different between human and mouse, in that there are two amino acids that differ between the 
2 sequences, as shown in Table 3.1. 
 
The C57Bl/6 model allowed to determine if the vaccine was sufficiently immunogenic to induce an 
effective immune response against PAP and therefore to break tolerance against PAP protein, as 
this self-antigen is expressed in normal prostate tissue. The HHDII/DR1 humanized model allowed 
the evaluation of the vaccine in an HLA-A2/ DLA-DR1 context, which is relevant and translatable to 
the human setting. Firstly, the vaccine approach was optimised by incorporating mutations in the 
PAP42mer sequence and assessing the effect of these mutations on the immunogenicity of the 
vaccine. The PAP-specific immune response elicited after vaccinating the animals with the mutated 
peptides or their WT counterpart was compared. Secondly, the PAP-specific immune response 
elicited when using the selected sequence in combination with different delivery systems: two 
peptide-based vaccines and a DNA-based vaccine (ImmunoBody®) was also assessed. 
These results permitted us to select the vaccine strategy capable of inducing the most effective 
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3.2.1. Effect of introducing mutations in the human and murine PAP42mer peptide sequences 
on the immunogenicity of peptide-based vaccines 
The first approach to increase the immunogenicity of the vaccine was to introduce at least one 
mutation in the 42 amino acids sequence. 
 
3.2.1.1.Human PAP42mer sequences and epitope repertoire 
The immunogenicity of both the WT and the mutated humanPAP42mer peptides were assessed 
using CpG adjuvant by vaccinating HHDII/DR1 mice, as described in 2.2.2.3. Seven days after the 
last immunisation, spleens of the animals were harvested to isolate the splenocytes and assess their 
ability to specifically recognize human PAP-derived peptides based on the IFNγ ELISpot assay. The 
HLA-A2 class-I and HLA-DR1 class-II peptides assessed, as determined by the SYFPEITHI 
algorithm/website, are listed in Table 3.2, along with their binding score. The amino acid affected 













 1 YIRSTDVDRTLMSAMTNLAALFPPEGISIWNPRLLWQPIPVH 42 WT 
 1 YIRSTDVDRTLMSLMTNLAALFPPEGISIWNPRLLWQPIPVH 42  
WT 1 YIRSTDVDRTLMSAMTNLAALFPPEGVSIWNPILLWQPIPVH  42 2 mutations 
1 mutation 1 YIRSTDVDRTLMSLMTNLAALFPPEGVSIWNPILLWQPIPVH  42 3 mutations 
Table 3.2: List of HLA-A2 class-I and HLA-DR1 class-II peptides derived from the hPAP42mer sequence 
HHDII/DR1 
mice 









9mer 24 30 
ILLWQPIPV 9mer 24 24 





15mer 25 25 
MSAMTNLAALFPPEG 15mer 33 33 
PEGVSIWNPILLWQP 15mer 25 25 
VSIWNPILLWQPIPV 15mer 25 25 
DRTLMSAMTNLAALF 15mer 22 30 
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Immunisation with the WT hPAP42mer peptide induced IFNγ-secreting T-cells following stimulation 
with all hPAP-derived peptides, except for SAM 9mer and MSA 15mer (figure 3.1 A). The ILL 9mer 
class-I peptide and VSI 15mer and DRT 15mer class-II peptides induced the highest number of IFNγ-
secreting T-cells. Immunisation with the mutated form of the hPAP42mer peptide increased the 
number of IFNγ-secreting T-cells following stimulation with all 8 PAP-derived peptides tested, 
although not all increases were of statistical significance. Stimulation with the ILL 9mer elicited a 
statistically significant increase in IFNγ-secreting and was shown to be the strongest class-I epitope, 
regardless of the PAP42mer peptide used for the immunisation, despite not having the highest HLA-
A2 binding score. Indeed, this epitope was previously identified as an HLA-A2.1-restricted epitope 
for which specific CD8+ T-cells were present in PBMCs from PCa patients and from healthy blood 
donors (Olson, et al. 2010). VSI 15mer, DRT 15mer and PEG 15mer were the 3 class-II epitopes 
shown to induce the highest number of IFNγ-secreting T-cells, regardless of the PAP42mer peptide 
used for the immunisation. 
 
The functional avidity of the TCR is defined by the T-cell responsiveness to a peptide and depends, 
in part, on its affinity for a peptide. T-cells having a high functional avidity are able to respond to 
low quantities of peptides (Viganò, et al. 2012) and are essential for establishing an effective anti-
tumour immune response (Durrant, et al. 2010). Moreover, there is a direct link between the 
binding affinity and the immunogenicity of a potential cytotoxic T-cell epitope (Sette, et al. 1994). 
Following the identification of ILL 9mer peptide as the strongest class-I epitope, the functional 
avidity of T-cells for the ILL 9mer class-I epitope was assessed. For this, an IFNγ ELISpot assay was 
performed using decreasing concentrations of the ILL 9mer peptide to stimulate the splenocytes. 
The vaccination strategy using the mutated peptide was able to induce ILL-specific T-cells with 
higher functional avidity than when immunising using the WT peptide (Figure 3.1 B). Indeed, the 
half maximal effective concentration (EC50) of ILL peptide was 10 times lower: WT= 0.01267µg/ml 
and Mut = 0.00105µg/ml (Figure 3.1 B bottom). Moreover, a concentration 1000 times lower of ILL 
9mer peptide than the 1µg/mL usually used (0.001µg/mL) was able to induce the same number of 





Figure 3.1: Assessment of the hPAP 42mer WT or mutated peptides with CpG adjuvant vaccination on the 
overall response against several hPAP-derived class I and class II epitopes and on the avidity to ILL class-I 
epitope. HHDII/DR1 mice were immunised on days 1, 15 and 29 with either hPAP 42mer WT or mutated 
peptide with CpG adjuvant. Seven days after the last immunisation, splenocytes were isolated from spleens 
and an in vitro IFNγ ELISpot assay was performed. Splenocytes were stimulated with (A) hPAP-derived class I 
and class II peptides or (B) decreasing concentrations of ILL 9mer peptide, for 48 hours at 37°C. Immunisation 
with the mutated hPAP42mer peptide induced higher numbers of peptide-specific IFNγ releasing T-cells and 
induced T-cells with a higher functional avidity for ILL 9mer peptide than immunisation with the WT 
hPAP42mer peptide. Bars represent the mean number of spots and the error bars represent the SD. Sigmoidal 
curve representing the functional avidity of ILL 9mer peptide (B, bottom). Two independent experiments 
performed (n= 6-7 mice per test group). A significant difference in the induction of peptide-specific IFNγ 
releasing T-cells between immunisation groups was determined using a two-way ANOVA comparison test. 
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3.2.1.2.Murine PAP42mer sequences and epitope repertoire 
The immunogenicities of the WT and 2 different mutated murine PAP42mer peptides in 
combination with the CAF09 adjuvant were assessed by vaccinating C57Bl/6 mice using a similar 
approach to that used for the HHDII/DR1 model. The CAF09 adjuvant was selected following a brief 
pilot study demonstrating that CpG adjuvant was too weak to observe differences between the 
different mPAP42er peptides to be assessed. The 2 mutated peptides consist of the WT hPAP42mer 
peptide and the mutated hPAP42mer peptide, which contain 2 and 3 mutations, respectively, in 
comparison to the WT mPAP42mer sequence. In this model, the ability of splenocytes to specifically 
recognize murine PAP-derived peptides was assessed using IFNγ ELISpot assay. The H2-Kb and H2-
Db class-I and H2-IAb class-II epitopes assessed, determined by the SYFPEITHI algorithm/website, 
are listed in Table 3.3, along with their binding score.  
 
Table 3.3: List of H2-Kb and H2-Db class-I and H2-IAb class-II peptides derived from the mPAP42mer sequence 
C57Bl/6 
mice 











SAMTNLAAL H2-Db 9mer 28 28 26 
SIWNPRLL H2-Kb 8mer 13 13 13 
GISIWNPRL H2-Db 9mer 10 8 8 
ISIWNPRLL H2-Db 9mer 25 26 26 
Class-II 
peptides 
ISIWNPRLLWQPIPV H2-IAb 15mer N/A N/A N/A 
PEGISIWNPRLLWQP H2-IAb 15mer N/A N/A N/A 
 
Immunisation with the WT mPAP42mer peptide did not induce IFNγ-releasing T-cells following 
stimulation with the mPAP-derived peptides. However, immunisation with either the 2 or the 3 
mutations mPAP42mer peptides was able to induce IFNγ-releasing T-cells following stimulation 
with all 3 class-I (ISI 9mer, GIS 9mer and SIW 8mer) and 2 class-II (ISI 15mer and PEG 15mer) 
epitopes (figure 3.2 A). The ISI9mer peptide has previously been reported as being an immunogenic 
H2-Db epitope, inducing lysis of peptide-pulsed RMA-S cells (Spies, et al. 2012). There was no 
significant difference between the 2 or the 3 mutations mPAP42mer peptides. Although exhibiting 
the highest binding score (28), the SAM 9mer peptide did not induce IFNγ-releasing T-cells, neither 
did the MSAM 15mer (data not shown). 
 
On the basis of these results and due to its high binding score (25) ISI 9mer was further assessed. 
The functional avidity of T-cells towards this epitope was compared following vaccination of 
C57Bl/6 mice with each of the three murine PAP42mer peptides and CAF09 adjuvant. For this assay, 
mice were pooled per group due to practical reasons. Immunisation using both the 2 and the 3 
mutations peptides induced T-cells having a higher avidity towards the two peptides. Indeed, 
immunising mice with both the 2 and 3 mutations peptides induced a high number of ISI-specific 
78 
 
IFNγ-releasing T-cells following in vitro stimulation with low peptide concentrations, in comparison 
to immunising mice with the WT peptide (Figure 3.2 B). In the group of mice immunised with the 
mutated peptides, a concentration 1000 times lower of ISI 9mer peptide than the 1µg/mL usually 
used (0.001µg/mL) was able to induce the same number of ISI-specific IFNγ-releasing T-cells. ISI was 





Figure 3.2: Assessment of the mPAP 42mer WT or mutated peptides with CAF09 adjuvant vaccination on 
the overall response against several mPAP-derived class I and class II epitopes and on the avidity to ISI 
class-I epitope. C57Bl/6 mice were immunised on days 1, 15 and 29 with either mPAP 42mer WT, 1 mutation 
or 2 mutations peptides with CAF09 adjuvant. Seven days after the last immunisation, splenocytes were 
isolated from spleens and an in vitro IFNγ ELISpot assay was performed. Splenocytes were stimulated with (A) 
mPAP-derived class I and class II peptides or (B) decreasing concentrations of ISI 9mer peptide, for 48 hours 
at 37°C to measure the immune response induced. Immunisation with both 2 mutations and 3 mutations 
mPAP42mer peptides induced high numbers of peptide-specific IFNγ releasing T-cells and higher avidity T-
cells while immunisation with the WT mPAP42mer peptide did not induce any. Bars represent the mean 
number of spots and the error bars represent the SD. Sigmoidal curve representing the functional avidity of 
ISI class-I epitope (B bottom). Two to three independent experiments performed (n= 6 to 9 mice per test 
group). A significant difference in the induction of peptide-specific IFN-secreting T-cells between 
immunisation groups was determined using a two-way ANOVA comparison test. 
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3.2.2.Effect of different adjuvants and delivery system on the immunogenicity of the 
PAP42mer vaccine: peptide + CpG versus peptide + CAF09 versus the ImmunoBody®-PAP 
DNA vaccine 
Following the determination of the most immunogenic PAP42mer peptide in both mouse models, 
the second approach to enhance the immunogenicity of the vaccine was by using different delivery 
systems. As described in the introduction of this chapter, 3 different vaccines were compared in 
each mouse model: two peptides + adjuvant-based vaccines and one DNA vaccine. 
 
3.2.2.1.HHDII/DR1 model 
3.2.2.1.1.Effect on the overall response against class-I and class-II epitopes 
The human PAP42mer mutated peptide was shown to be more immunogenic than its WT 
counterpart (Figure 3.1). These results were obtained using the CpG adjuvant. A new adjuvant was 
assessed, CAF09, and a DNA vaccine, the ImmunoBody®. The DNA sequence coding for the human 
mutated PAP 42mer peptide sequence was inserted into the Complementarity determining regions 
(CDR) region of the ImmunoBody®. The immunogenicity of each delivery system was compared by 
vaccination of HHDII/DR1 mice, as described previously, followed by an IFNγ ELISpot assay. 
Vaccination using CAF09 adjuvant induced significantly (p<0.0001) higher numbers of IFNγ-
secreting T-cells following stimulation with ILL 9mer peptide and VSIW 15mer peptide in 
comparison with CpG adjuvant and the ImmunoBody® DNA vaccine (Figure 3.3 A). As expected, 
immunisation with CpG adjuvant induced IFNγ-secreting T-cells, although the response to some 
hPAP-derived peptides was not as high as previously obtained in experiments reported in Figure 
3.1 A. On the other hand, the ImmunoBody® DNA vaccine did not induce IFNγ-secreting T-cells. 
These results showed that CAF09 is a strong adjuvant and that the CAF09-based vaccine induces 
the strongest PAP-specific immune response in this model, out of the 3 vaccine strategies tested. 
The functional avidity of T-cells for the ILL 9mer class-I peptide was compared following vaccination 
with the humanPAP42mer peptide with either CpG or CAF09 adjuvant and followed by an IFNγ 
ELISpot assay (Figure 3.3 B). This assay was not performed with the ImmunoBody® DNA vaccine, as 
it did not induce IFNγ-secreting T-cells following stimulation with the ILL 9mer peptide. CAF09 
adjuvant was able to induce higher number of ILL-specific T-cells down to 0.01µg/mL of peptide, 
but at lower peptide concentrations, the induction of ILL-specific T-cells was only detected in the 
CpG adjuvant group (Figure 3.3 B). Indeed, the half maximal effective concentration (EC50) of ILL 
peptide was 9 times lower for the CpG adjuvant group: CpG = 0.00105µg/ml, CAF09 = 0.00937µg/ml 




Figure 3.3: Effect of the hPAP 42 peptide mutated form with CpG, CAF09 adjuvant or in the ImmunoBody® 
DNA vaccine on the overall response against class I and class II epitopes and on the avidity to ILL class-I 
epitope. HHDII/DR1 mice were immunised on days 1, 15 and 29 with either the CpG, the CAF09 or the 
ImmunoBody®-based mutated hPAP 42mer vaccine. 7 days after the last immunisation, splenocytes were 
isolated from spleens and an in vitro IFNγ ELISpot assay was performed. Splenocytes were stimulated with (A) 
hPAP-derived class I and class II peptides or (B) decreasing concentrations of ILL 9mer peptide, for 48 hours 
at 37°C. Immunisation with the CAF09-based vaccine induced higher numbers of peptide-specific IFNγ-
secreting T-cells than immunisation with other vaccines. Immunisation with CpG adjuvant induced T-cells 
with a higher functional avidity for ILL 9mer peptide than immunisation with the CAF09 adjuvant. Bars 
represent the mean number of spots and the error bars represent the SD. Sigmoidal curve representing the 
functional avidity of ILL 9mer peptide (B right). (A) 4 to 6 independent experiments performed (n= 13 to 20 
mice per test group) and (B) 1 to 2 independent experiments (n= 3 to 6 mice per test group). A significant 
difference in the induction of peptide-specific IFNγ releasing T-cells between immunisation groups was 
determined using a two-way ANOVA comparison test. 
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3.2.2.1.2.Immunophenotyping of CD8+ T-cells 
To assess the effect of the vaccine on T-cell subsets, the phenotype of splenocytes from vaccinated 
mice was investigated using flow cytometry. The gating strategy used is presented in Figure 3.4. 
The effect of the 3 different vaccines were compared with each other and with a baseline: naïve, 
non-vaccinated mice. Splenocytes were stained with antibodies to assess the proportion of T-cell 
subsets, the presence of memory T-cells and the presence of activation and inhibitory markers on 
T-cells. To determine the T-cells responsible for the IFNγ production, splenocytes were also 
stimulated in vitro with ILL 9mer alone or with VSIW 15mer peptides for 6 hours and then assessed 
by flow cytometry for the expression of cytokines, degranulation markers and for proliferation. 
Indeed, the secretion of IFNγ in response to VSIW 15mer peptide could be actually directed against 
the ILL9mer epitope after processing of the 15mer by APCs during the 48hrs of culture period. 
 
 
Figure 3.4: Gating strategy used for flow cytometry analysis. 
 
Percentages of CD4+ and CD8+ T-cells within the T-cell compartment were measured. Both CAF09 
and ImmunoBody® based vaccines induced an increase in the proportion of CD8+ T-cells (Figure 3.5 
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A). The CAF09-based vaccine induced approximately a 2-fold increase in comparison to the baseline 
and to the CpG-based vaccine (p<0.0005). The ImmunoBody®-based vaccine induced a lesser 
increase in comparison to the baseline and the CpG-based vaccine. Surprisingly, the CpG-based 
vaccine did not increase the proportion of CD8+ T-cells. As expected, any increase in the proportion 
of CD8+ cells was accompanied by a proportional decrease in the proportion of CD4+ T-cells (Figure 
3.5 A). 
 
CD4+ and CD8+ T cells can be categorized into different effector, memory and naïve phenotypes 
based on their expression of defined markers. Naïve T-cells are CD44lowCD62L+, central memory T-
cells are CD44highCD62L+, and the effector and/or effector memory CD4+ and CD8+ T-cells are 
CD44highCD62Lneg (Sckisel, et al. 2017). 
The percentage of CD4+ memory T-cells was not affected by the vaccination (Figure 3.5 B). On the 
other hand, the proportion of CD8+ effector/effector memory T-cells was significantly increased (3-
fold change) in the CAF09-based vaccine group in comparison to all other groups (p<0.0005), 
reaching an average of 60% of CD8+ T-cells exhibiting a memory phenotype (Figure 3.5 B). There 
was no increased proportion of central memory T-cells (data not shown). 
 
The expression of activation and inhibitory markers on CD4+ and CD8+ T-cells was then assessed. 
The expression of GITR and OX40 activation markers and of CTLA-4, LAG-3 and Tim-3 inhibitory 
markers in CD4+ nor in CD8+ T-cells was not significantly affected by vaccination (Figure 3.5 C). The 
expression of PD-1 inhibitory marker by CD4+ T-cells was modestly increased by the CAF09-based 
vaccine and the ImmunoBody®-based vaccine in comparison to the baseline. However, the 
increased PD-1 expression by CD8+ T cells was only observed in the CAF09-based vaccine group 




Figure 3.5: Effect of different delivery systems on the induction of a memory response and the expression 
of activation and inhibitory markers following immunisation with the hPAP42mer mutated sequence. 
HHDII/DR1 mice were immunised on days 1, 15 and 29 with either the CpG-based, the CAF09-based or the 
ImmunoBody®-based mutated hPAP 42mer vaccine. Seven days after the last immunisation, splenocytes 
were isolated from spleens, incubated with a murine FcR block and then stained with surface antibodies for 
flow cytometry analysis indicating (A) proportion of CD4+ and CD8+ T-cells, (B) proportion of memory T-cells 
and (C) proportion of T-cells expressing activating and inhibitory markers. The CAF09-based vaccine induced 
an increase of the proportion of CD8+ T-cells, an increase of the proportion of CD8+ memory T-cells and the 
expression of PD-1 on both CD4+ and CD8+ T-cells. Bars represent the mean percentage of positive cells and 
the error bars represent the SD. Two to three independent experiments performed (n= 6 to 9 mice per test 
group). A significant difference in the proportion of positive cells between immunisation groups was 




The functionality of splenocytes was then assessed following 6 hours of in vitro stimulation with 
relevant peptides, either ILL 9mer alone or with VSI 15mer. 
The proliferation of T-cells was measured based on the expression of Ki67, which has been shown 
to be a maker of antigen-specific in vitro lymphoproliferation (Soares, et al. 2010). Both stimulating 
conditions induced the proliferation of CD8+ T-cells, with up to 7% of CD8+ T-cells being Ki67+ in the 
CAF09-based vaccine group (Figure 3.6 A). This result correlates with the higher percentage of CD8+ 
T-cells within the T-cell compartment (Figure 3.6 A). The proliferation of CD4+ T-cells was not 
affected (data not shown).  
 
Then, the cytokine secreting capacity of T-cells was assessed. As revealed using the IFNγ ELISpot 
assay, the response of splenocytes from the CAF09 immunised mice to ILL and VSI peptides was 
greater than that of splenocytes from other groups, with only CD8+ T-cells, among T-cells, being 
responsible for the IFNγ secretion (Figure 3.6 B), as CD4+ T-cells did not secrete cytokines (data not 
shown). Interestingly, IFNγ and TNFα were strictly co-secreted by the same CD8+ T-cells. IL-2 was 
also secreted upon stimulation in the CAF09-based vaccine group, by a subset of IFNγ/TNFα-
releasing CD8+ T-cells. The addition of VSI 15mer peptide to ILL9mer peptide induced a non-
significant increase in the proliferation and cytokine secreting capacities of CD8+ T-cells. CD4+ T-
cells did not secrete cytokines upon peptide stimulation (data not shown). 
 
Finally, the capacity of CD8+ T-cells to release cytolytic granules was measured based on the 
expression of CD107a and Granzyme B proteins. CD107a molecule was described as a marker of 
degranulation, its surface expression correlates with the loss of intracellular perforin and with the 
production of IFNγ following activation with a peptide (Betts, et al. 2003).  Betts et al. showed that 
CD8+ T cells expressing CD107a mediated cytolytic activity in an antigen-specific manner. 
The CAF09-based vaccine induced a significant increase in the expression of CD107a degranulation 
marker expression upon in vitro peptide stimulation while no difference was observed for the 
expression of Granzyme B (Figure 3.6 C). Regardless of the stimulating conditions, the proportion 
of CD8+ T-cells expressing Granzyme B was the greatest for the CAF09-based vaccine group. As 
suggested by Tietze et al. Granzyme B can be released by non-antigen-specific CD8+ T-cells (Tietze, 
et al. 2012). The presence of CD8+ T-cells co-expressing CD107a and Granzyme B was only observed 
for the CAF09-based vaccine group (Figure 3.6 D). Overall, 15% to 20% of total CD8+ T-cells were 
expressing CD107a and/or Granzyme B in the CAF09-vaccine based group, versus up to 7% in other 
groups. The same analysis was made when focusing on CD8+ T-cells secreting IFNγ and TNFα (Figure 
3.6 E). For the CAF09-based vaccine group, the majority of cytokine-secreting CD8+ T-cells were 
either CD107a+ or Granzyme B+, or co-expressed both. Therefore, it appears that vaccine-induced 
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Figure 3.6: Effect of different delivery systems with the hPAP 42 mutated sequence on the functional 
capacities of CD8+ T-cells following class-I and class-II peptides stimulation. HHDII/DR1 mice were 
immunised on days 1, 15 and 29 with either the CpG, the CAF09 or the ImmunoBody®-based mutated hPAP 
42mer vaccine. 7 days after the last immunisation, splenocytes were isolated from spleens, stimulated with 
either ILL 9mer alone or with VSI 15mer for 6 hours at 37°C. Splenocytes were then incubated with a murine 
FcR block, stained with surface Abs, fixed and permeabilized and stained with intracellular Abs for flow 
cytometry analysis indicating (A) proliferation (B) cytokines secretion (C) degranulation markers single 
expression or (D) double expression and (E) co-expression of degranulation markers within secreting cells. 
The CAF09-based vaccine induced the proliferation, the cytokines secretion and the degranulation of CD8+ T-
cells upon stimulation. Bars represent the mean percentage of positive cells and the error bars represent the 
SD. 1 to 3 independent experiments performed (n= 3 to 9 mice per test group). A significant difference in the 






3.2.2.2.1.Effect on the overall response against class-I and class-II epitopes 
The murine PAP42mer 2 and 3 mutations peptides were shown to be more immunogenic than the 
WT peptide (Figure 3.2). The capacity of different delivery systems to further increase the 
immunogenicity of the mutated PAP sequence were compared, as was undertaken for the HHII/DR1 
mice: CpG or CAF09 adjuvant and the ImmunoBody® DNA vaccine were assessed. The DNA 
sequences coding for the murine PAP42mer 2 or 3 mutations peptides were incorporated into the 
CDR regions of the ImmunoBody® vaccine sequence. The immunogenicity of each delivery system 
was compared by vaccination of C57Bl/6 mice followed by IFNγ ELISpot assay. Both the CAF09-
based vaccine and the ImmunoBody® DNA vaccine were able to induce higher numbers of IFNγ-
secreting T-cells following stimulation with three class-I (ISI 9mer, GSI 9mer and SIW 8mer) and two 
class-II (ISI 15mer and PEG 15mer) epitopes (Figure 3.7 A) in comparison to CpG adjuvant, which 
did not induce any IFNγ-secreting T-cells. The mPAP42mer 2 mutations sequence, either in the 
CAF09-based vaccine or in the ImmunoBody®-based vaccine, induced the highest number of IFNγ-
secreting T-cells upon stimulation with mPAP-derived peptides, although this difference was not of 
statistical significance. 
 
The functional avidity of T-cells for both the ISI 9mer and the SIW 8mer epitopes were compared 
following vaccination with either the 2 or the 3 mutations murine PAP42mer peptides with CAF09 
or in the ImmunoBody® DNA vaccine, followed by an IFNγ ELISpot assay. For this assay, mice were 
again pooled per group for practical reasons. All vaccination strategies were able to induce high 
affinity ISI-specific IFNγ releasing T-cells, as even the lowest concentration was able to induce ISI-
specific IFNγ releasing T-cells (Figure 3.7 B). On the other hand, except for the 2 mutations peptide-
based vaccine administered with the CAF09 adjuvant, there was no high affinity SIW-specific T-cells 
generated as there was no SIW-specific IFNγ releasing T-cells at low peptide concentrations. Based 
on these results, the 2 mutations sequence in combination with either CAF09 adjuvant or in the 




Figure 3.7: Effect of the mPAP 42 peptide mutated forms with CpG, CAF09 adjuvant or in the ImmunoBody® 
DNA vaccine on the overall response against class I and class II epitopes and on the avidity to ISI and SIW 
class-I epitopes. C57Bl/6 mice were immunised on days 1, 15 and 29 with either the CpG-based, the CAF09-
based or the ImmunoBody®-based mutated mPAP 42mer vaccine. Seven days after the last immunisation, 
splenocytes were isolated from spleens and an in vitro IFNγ ELISpot assay was performed. Splenocytes were 
stimulated with (A) mPAP-derived class I and class II peptides or (B) decreasing concentrations of ISI or SIW 
peptides, for 48 hours at 37°C. Immunisation with both CAF09-based and ImmunoBody®-based vaccine 
induced high numbers of peptide-specific IFNγ releasing T-cells and high functional avidity for ISI peptide, 
whereas the CpG-based vaccine did not induce IFNγ-releasing T-cells. Bars represent the mean number of 
spots and the error bars represent the SD. Sigmoidal curve representing the functional avidity of ISI and SIW 
peptide (B right). (A) two to seven independent experiments performed (n= 6 to 24 mice per test group) and 
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(B) two independent experiments. A significant difference in the induction of peptide-specific IFNγ releasing 
T-cells between immunisation groups was determined using a two-way ANOVA comparison test. 
 
3.2.2.2.2.Immunophenotyping of CD8+ T-cells 
The effect of the vaccine strategies on T-cell subsets was assessed in this model as described for 
the HHDII/DR1 model. To determine the T-cells responsible for the IFNγ production, splenocytes 
were stimulated in vitro with either class-I peptides alone (ISI 9mer and SIW) or with class-II 
peptides (ISI 15mer and PEG) for 6 hours. Indeed, the same hypothesis can be made regarding the 
secretion of IFNγ in response to 15mer peptides, which could be directed against 9mer peptides 
after processing by APCs during the culture period. 
 
CAF09 and ImmunoBody®-based vaccines both induced a modest increase in the proportion of CD8+ 
T-cells (Figure 3.8 A). The proportion of CD4+ memory T-cells did not change, however, the 
proportion of CD8+ effector/effector memory T-cells was slightly increased in both the CAF09-based 
vaccine and the ImmunoBody®-based vaccine groups in comparison to the baseline, reaching an 
average of 10-12% of CD8+ T-cells exhibiting an effector memory phenotype (Figure 3.8 B). 
 
As was found in the HHDII/DR1 model, only the expression of the inhibitory PD-1 molecule was 
affected by the vaccines. Its expression was increased on CD4+ and in CD8+ T-cells in the CAF09-
based vaccine group in comparison to the baseline and to the ImmunoBody®-based vaccine group, 




Figure 3.8: Effect of different delivery systems with the mPAP42mer mutated sequence on the induction of 
a memory response and the expression of activation and inhibitory markers. C57Bl/6 mice were immunised 
on days 1, 15 and 29 with either the CAF09-based or the ImmunoBody®-based mutated mPAP 42mer vaccine. 
Seven days after the last immunisation, splenocytes were isolated from spleens, incubated with a murine FcR 
block and then stained with surface antibodies for flow cytometry analysis indicating (A) proportion of CD4+ 
and CD8+ T-cells, (B) proportion of memory T-cells and (C) proportion of T-cells expressing activating and 
inhibitory markers. Both vaccines induced an increase of the proportion of CD8+ T-cells and an increase of the 
proportion of CD8+ memory T-cells, but only the CAF09-based vaccine increased the expression of PD-1 on 
CD4+ and CD8+ T-cells. Bars represent the mean percentage of positive cells and the error bars represent the 
SD. Two to three independent experiments performed (n= 6 to 9 mice per test group). A significant difference 





The functionality of the splenocytes was then assessed following 6 hours of in vitro stimulation with 
ISI 9mer/SIW 8mer +/- ISI 15mer/PEG 15mer. Both stimulating conditions induced the proliferation 
of CD8+ T-cells with up to 1.8% of CD8+ T-cells expressing Ki67 in the ImmunoBody®-based vaccine 
group (Figure 3.9 A). The proliferation of CD4+ T-cells was not affected (data not shown). 
 
As was showed in the IFNγ ELISpot assay, splenocytes from both vaccine groups were able to 
produce class-I-specific IFNγ-releasing T-cells. Results showed that only CD8+ T-cells were 
responsible for the IFNγ secretion (Figure 3.9 B). In this model too, IFNγ and TNFα were strictly co-
secreted by the same CD8+ T-cells. IL-2 was also secreted upon stimulation, in both vaccine groups, 
by a subset of IFNγ/TNFα-secreting CD8+ T-cells. The increase in IL-2 secretion was only significant 
when class-II peptides were added to class-I peptides for the stimulation. The addition of class-II 
peptides to the class-I peptides induced a non-significant increase of proliferative and secreting 
capacities of CD8+ T-cells. CD4+ T-cells did not secrete cytokines upon stimulation (data not shown). 
 
Considering the degranulation capacities of CD8+ T-cells, both vaccines induced an increase of 
CD107a degranulation marker expression upon stimulation (non-significant for the ImmunoBody® 
group) (Figure 3.9 C). Regardless of the stimulating conditions, CD8+ T-cells from the CAF09-based 
vaccine group exhibited a higher proportion of Granzyme B+ CD8+ T-cells. The presence of CD8+ T-
cells co-expressing CD107a and Granzyme B was observed in both vaccine groups, in a very small 
proportion (less than 0.5% of CD8+ T-cells) (Figure 3.9 D). Overall, 3-5% of CD8+ T-cells were 
expressing either CD107a or Granzyme B or both in vaccine groups, versus up to 1% for the baseline.  
Unlike what was observed in the HHDII/DR1 model, CD8+ secreting T-cells (IFNγ and TNFα) 




Figure 3.9: Effect of different delivery systems with the mPAP 42 mutated sequence on the functional 
capacities of CD8+ T-cells following class-I and class-II peptides stimulation. C57Bl/6 mice were immunised 
on days 1, 15 and 29 with either the CAF09 or the ImmunoBody®-based mutated mPAP 42mer vaccine. 7 days 
after the last immunisation, splenocytes were isolated from spleens, stimulated with either ISI 9mer + SIW 
8mer alone or with ISI 15mer + PEG 15mer for 6 hours at 37°C. Splenocytes were then incubated with a 
murine FcR block, stained with surface antibodies, fixed and permeabilized and then stained with intracellular 
antibodies for flow cytometry analysis indicating (A) proliferation (B) cytokines secretion (C) degranulation 
markers single expression or (D) double expression and (E) co-expression of degranulation markers within 
secreting cells. Both vaccines induced the cytokines secretion and the degranulation of CD8+ T-cells but only 
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the ImmunoBody®-based vaccine induced the proliferation of CD8+ T-cells upon stimulation. Bars represent 
the mean percentage of positive cells and the error bars represent the SD. 1 to 3 independent experiments 
performed (n= 3 to 9 mice per test group). A significant difference in the proportion of positive cells between 
immunisation groups was determined using a two-way ANOVA comparison test. 
 
3.3. Discussion 
This study focussed on the use of PAP protein as a target for the development of a therapeutic 
vaccine against prostate cancer. PAP protein is an attractive target for prostate cancer vaccines due 
to its relative specific expression within the prostate and its disease-dependant overexpression. 
Moreover, the FDA-approval of Provenge vaccine in 2010 has demonstrated the rationale for using 
PAP as a target for cancer vaccines in prostate cancer. 
 
The first goal of this study was to optimise our vaccine, in order to identify the most immunogenic 
vaccine strategy capable of inducing PAP-specific T cell responses that were identified with the 
SYFPEITHI database. In the two mouse models tested, the findings demonstrate the higher capacity 
of mutated 42mer PAP-derived peptides to induce a PAP-specific immune response. Higher number 
of IFNγ-releasing T cells was obtained following stimulation with short class-I and long class-II WT 
peptides and the functional avidity to short peptides was also improved.  
 
In the humanized model, the ILL 9mer and the VSIW 15mer peptides induced the highest number 
of IFNγ-releasing T cells. The ILL 9mer particularly has been reported to induce anti-tumour 
immunity in vitro, through killing of HLA-A2.1+ LNCaP cells and of peptide-pulsed T2 cells by peptide-
primed PBMCs, and in vivo, in the HHDII mice, making it a good vaccine candidate for 
immunotherapy of prostate cancer (Machlenkin, et al. 2005). The murine and human PAP proteins 
are only 81% identical, the ILL9mer murine homologue has 1AA difference: 
ILLLWQPIPVRLLWQPIPV, keeping the anchor motifs at positions 2 and 9 (Rammensee, et al. 1993). 
It is therefore possible that the ILL9mer induces cytotoxic T lymphocytes reactive against 
xenoantigenic determinants, as has been suggested by Machlenkin et al. (Machlenkin, et al. 2005). 
Indeed, considering that HHDII/DR1 humanized mice naturally express the murine PAP protein, 
immunisation using the hPAP42mer mutated peptide is an immunisation with a peptide containing 
3 mutations (two between murine and human PAP42mer sequence, plus the additional mutation). 
Therefore, CD8+ T-cells are recognizing a foreign antigen during vaccination. The ELISpot assay is 
performed with hPAP42mer-derived short sequences, human and foreign sequences. Although the 
assay proves that the vaccination induced ILL-specific CD8+ T-cells, the intensity of the response is 
probably overestimated due to the ‘foreignness’ of ILL 9mer. 
 
In the C57Bl/6 model, 2 short peptides: SIW 8mer and ISI 9mer and 2 long peptides: ISI 15mer and 




In both models, class-I and class-II peptides displaying the highest SYFPEITHI binding score did not 
induce the highest number of IFNg releasing T-cells, thereby illustrating the limitations of the 
algorithm. Indeed, in the HHDII/DR1 model, ILL, the strongest HLA-A2 epitope has a score of 24 but 
induced a greater number of peptide-specific releasing T-cells than SAM and ALF which have scores 
of 24 and 27 respectively. As for the C57Bl/6 model, ISI which has the highest binding score, 25, was 
as immunogenic as SIW, with a binding score of only 13. GIS was less immunogenic, which correlates 
with its lower binding score: 10. However, the functional avidity assay demonstrated the much 
higher functional avidity of T-cells for ISI peptide, which correlates with its higher binding score. 
 
The absence of IFNγ release following stimulation with SAM 9mer and MSAM 15mer in the two 
models was unexpected as these two peptides have previously been described as immunogenic 
(Saif, et al. 2014). This could be explained by a differential processing of the 42mer peptide in 
comparison to the 15mer peptide, not in favour of the SAM 9mer and MSAM 15mer peptides, as 
well as the potential binding competition between ILL and SAM in some way advantaging ILL. 
 
In both models, the short peptide sequences (8 to 9mer) were part of the 15AA long peptides 
sequences. Since the ELISpot assay was developed 48hrs after the stimulation it is possible that 
15AA long peptides were processed by APCs and cut into 8-9mer long peptides and therefore that 
the IFNγ secretion observed in response to the long 15mer peptides stimulation was due to CD8+ 
and not CD4+ T-cells. To answer this question, in vitro stimulation with short and long peptides 
followed by intra-cellular flow cytometry staining was performed. The results showed that CD8+ T-
cells only were responsible for the secretion of IFNγ, suggesting that the vaccine induces a class-I 
response only. The lack of cytokine secretion by CD4+ T-cells was unexpected. However, the 
addition of long 15mer peptides did increase the intensity of the CD8+ T-cell response (cytokines 
secretion and proliferation). In particular, IL-2 secretion by CD8+ T-cells was increased in the 
presence of class-II epitopes during the stimulation, suggesting a potential helper role for CD4+ T-
cells, however this was not investigated further. 
 
Interestingly, although the mutation in the hPAP42mer sequence does not directly affect the 
ILL9mer and the VSIW15mer sequences, it appears to affect their immunogenicity. On the other 
hand, the mutations in the mPAP42mer sequences directly affect ISI9mer, SIW8mer, PEGI15mer 
and ISI15mer sequences and their immunogenicity, with the T-cells generated still able to recognise 




The other aspect of the study was to determine whether different adjuvants or delivery systems 
could improve the immunogenicity of the PAP42mer vaccine. CAF09 adjuvant was identified as a 
stronger adjuvant than CpG in the two models studied. The ImmunoBody® DNA vaccine was able 
to improve the immunogenicity of the vaccine in only one of the two mouse model tested, 
demonstrating that the efficacy of an adjuvant/delivery system depends on the antigen of interest 
and in the model in which it is tested. 
 
Overall, the immune response in the HDDII/DR1 model was stronger than that obtained with the 
C57Bl/6 model, probably due to the foreignness of the hPAP42mer peptide. The proportion of CD8+ 
T-cells displaying a memory phenotype was higher in the HHDII/DR1 mice as was the proportion of 
proliferating, secreting and degranulating CD8+ T-cells. The two-models differed in their 
quantitative response, but not in their qualitative response. Indeed, the pattern of cytokines 
produced was identical: co-secretion of IFNγ and TNFα by CD8+ T-cells, and for a subset of these 
cells, co-secretion of IL-2 as well. The pattern of degranulation was also identical, CD107a 
expression was affected by the presence of antigen whereas that of granzyme B was not.  
 
The only major difference between the two models was the incapacity of the ImmunoBody®-based 
vaccine to elicit a PAP-specific immune response in the HHDII/DR1 model. This result is surprising 
considering that the incorporation of the PAP15mer sequence into the ImmunoBody® DNA vaccine 
increased the immunogenicity and anti-tumour response of the vaccine (Saif, et al. 2014). Moreover, 
the ImmunoBody® was previously described as a strong delivery system capable of inducing high 
frequency helper and cytolytic responses capable of anti-tumour activity (Durrant, et al. 2010). A 
possibile explanation was that the PAP42mer sequence is too long, as incorporating such a long 
sequence had never been assessed before (maximum was 30AA). However, the ImmunoBody®-
derived vaccine was able to induce a strong immune response in the C57Bl/6. 
 
The CAF09-based vaccine induced PD-1 expression in both models in CD4+ and CD8+ T-cells. The 
ImmunoBody®-based vaccine also induced the expression of PD-1 on T-cells, albeit to a much lesser 
extent. The expression of PD-1 on T-cells has different implications. Its expression is the evidence 
that the TCR of T-cells has been activated (Simon and Labarriere 2017). In the absence of the antigen, 
PD-1 expression will decrease, however, in the case of persisting antigen stimulation, PD-1 
expression is maintained as this inhibitory receptor has for role to maintain the peripheral immune 
tolerance and to limit auto-immunity. Although PD-1 has been described as a marker of dysfunction 
/ exhaustion for T-cells, it is now accepted that its expression on its own is not sufficient to conclude 
on the exhausted status of T-cells. The co-expression of various other inhibitory markers has to be 
present. PD-1 expression has been linked to the presence of tumour-reactive CD8+ T-cells (Inozume, 
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et al. 2010) (Gros, et al. 2014) and of high avidity CD8+ T-cells (Simon, et al. 2015; Gros, et al. 2016). 
Its expression level is related to the strength of TCR signalling, therefore to the functional avidity of 
peptide specific T-cells. As suggested by Simon et al. (Simon, et al. 2015) and correlating with the 
results obtained in our study, the expression of PD-1 seems to be a marker of efficient CD8+ T-cells. 
The presence of “exhausted” T-cells will be assessed in the next chapters when assessing the anti-
tumour activity of T-cells, both in vitro and in vivo. Indeed, in the case of exhaustion of T-cells, their 
unability to secrete cytokines and to degranulate cytotoxic molecules upon PAP recognition on the 
surface of tumour cells would be deleterious to the anti-tumour activity of the vaccine. If this is 
observed, combining the vaccine with an anti-PD1 antibody might be necessary, as suggested by 
Rekoske et al. (Rekoske, et al. 2015). 
 
Nonetheless, the fact that the CAF09-based vaccine was able to induce the expression of CD107a 
and granzyme B by CD8+ T-cells suggests that CD8+ T-cells from that vaccine group would have a 
better capacity of lysing tumour cells. 
 
Previous studies have described a population of memory T-cells that can proliferate and exhibit 
effector functions in response to cytokines during viral and bacterial infections, without TCR 
engagement (Tough, et al. 1998) (Dhanji, et al. 2004) (Ehl, et al. 1997). TLR agonists, CpG and Poly 
I:C, have also been shown to induce the proliferation of these CD8+ CD44high T-cells (Sprent, et al. 
2000). These antigen-nonspecific CD44high T-cells, described as the main cell type expanding 
following stimulatory immunotherapies, express NKG2D, release granzyme B and are induced 
following cytokine exposure (Tietze, et al. 2012). Further studies demonstrated a correlation 
between PD-1 expression and CD62Llow expression (corresponding to an effector/effector memory 
phenotype) (Sckisel, et al. 2017). Moreover, the elevated PD-1 expression on effector/effector 
memory cells was also observed in patients undergoing systemic high-dose IL-2 therapy. Although, 
this was found to be true for CD4+ T-cells mainly and in the peripheral organs, these results correlate 
with our findings regarding CD8+ splenocytes. Indeed, within the CD8+ T-cells from CAF09-vaccine 
immunised mice, approximately 60% displayed an effector/effector memory phenotype (20% for 
naïve mice), about 50% expressed PD-1 (20% for naïve mice) and about 10% expressed Granzyme 
B without antigen stimulation (2% for naïve mice). These findings suggest that the effector/effector 
memory cells could express PD-1 and that a small proportion of these cells might have cytotoxic 
capacities by releasing Granzyme B, although it could not be verified. Assessing the expression of 
NKG2D would be of interest to compare our findings with those of others and determine if the 
CAF09-based vaccine induces antigen non-specific CD8+ memory T cells with non-MHC restricted 
cytotoxic capacities. The induction of these cells would be of advantage when assessing the anti-
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tumour effect of the vaccine, as tumour cells have the capacity to downregulate both MHC and 
tumour antigen expression in order to avoid recognition by CD8+ T cells (Dunn, et al. 2002). 
 
In conclusion, these results demonstrated the relevance of using a mutated peptide sequence in a 
vaccine in order to render it more immunogenic. The capacity of splenocytes from immunised 
animals to recognize WT-derived epitopes was therefore increased. Moreover, the different 
vaccine strategies tested have highlighted the importance of choosing the optimal delivery system 
in order to maximise the immunogenic potential of a vaccine. It is important to note that the 
optimal delivery system can differ depending on the peptide sequence length and on the mouse 
model used. We have shown that a strong vaccine strategy can induce a PAP-specific immune 
response, and generate functional PAP-specific CD8+ T-cells capable of cytokine secretion and of 
degranulation of cytotoxic granules. In the next part of the study, the anti-tumour capacity of 
splenocytes from animals immunised with the optimised vaccine strategy was assessed in vitro. 





Chapter 4: Generation of relevant murine and human target cells and 
assessment of the anti-tumour capacity of the PAP42mer vaccine in 
vitro 
4.1. Introduction 
As detailed in the introduction, cytotoxic T lymphocytes (CTLs) are essential for long-term anti-
tumour response. Indeed, tumours highly infiltrated in CTLs are more responsive to 
immunotherapy (Farhood, et al. 2019). The proliferation of intratumoral CTLs correlates with the 
reduction of tumour size (Tumeh, et al. 2014). The TCR of primed CD8+ T-cells recognises antigenic 
peptides presented by MHC class-I molecules on the surface of tumour cells. Upon TCR engagement, 
activated CTLs secrete IFNγ and TNFα to promote cytotoxicity and induce direct cytotoxicity by two 
main pathways: the perforin/granzyme pathway and the death ligand pathway (section 1.3.4.1). 
In the previous chapter, immunization with CAF09 adjuvant, which has previously been reported to 
elicit cytotoxic CD8+ T-cells (Korsholm, et al. 2014), was demonstrated to induce ILL-specific CD8+ T-
cells capable of cytokine secretion and of degranulation of cytotoxic granules. 
 
The aim of the studies presented in this chapter was to assess the efficacy of the selected vaccine 
strategies in generating CTLs capable of killing cancer cells in a PAP-specific manner in vitro. To this 
end, murine and human cancer cell lines were selected and modified to render them suitable 
targets. The first step was to assess the endogenous MHC class-I expression as well as the 
endogenous PAP expression. Secondly, to induce both the expression of the relevant MHC class-I 
molecule (human HLA-A2 or murine H2-KbDb) and either the murine or the human PAP protein. 
Following the generation of relevant target cells, the next step was to assess the capacity of vaccine-
induced T-cells to lyse these target cells. Class-I peptide specific CD8+ T-cells which would then be 
able to recognize and lyse target cells, were expanded in vitro prior to proceeding with the 
cytotoxicity assay. Two different cytotoxicity assays were used: the 51Cr release assay and a flow 
cytometry-based cytotoxicity assay. 
These results allowed the selection of the vaccine strategy best capable of inducing PAP-specific 









4.2.1. Generation of relevant target cells and tumour models 
In order to assess the anti-tumour efficacy of the vaccine in the C57Bl/6 mouse model and in the 
HHDII/DR1 humanised mouse model, six cell lines were selected: three murine, two human and 
one humanized murine cell line. The tables below summarize the different target cells used and the 
changes required to assess the PAP-specific cytotoxicity. 
 
Table 4.1: MHC class-I and PAP expression in murine cell lines 
Murine cell lines 
  TRAMP-C1 TRAMP-C2 RMAS 
MHC class-I 
Endogenous expression Low H2-Kb-Db Low H2-Kb-Db H2-Kb-Db 
Adaptation needed IFNγ treatment IFNγ treatment 
Optimisation of 
peptide-binding 
PAP expression Endogenous expression Murine PAP Murine PAP None 








Table 4.2: MHC class-I and PAP expression in human cell lines 
 
4.2.1.1.TRAMP-C1 and TRAMP-C2 murine cell lines 
The TRAMP-C1 and the TRAMP-C2 prostatic murine cancer cell lines are derived from the 
Transgenic Adenocarcinoma Mouse Prostate (TRAMP) mouse model (Foster, et al. 1997). TRAMP 
males develop histological prostatic intraepithelial neoplasia (PIN) by 8 to 12 weeks of age that 
progresses to adenocarcinoma with distant metastases by 24-30 weeks of age. Three cell lines were 
established from the heterogeneous tumour of a 32-week old TRAMP mouse: TRAMP-C1, TRAMP-
C2 and TRAMP-C3. Only TRAMP-C1 and TRAMP-C2 cell lines are tumorigenic when implanted into 
syngeneic C57Bl/6 animals (Foster, et al. 1997). All three cell lines are epithelial of origin. In this 
chapter, TRAMP-C1 and TRAMP-C2 cells were considered as target cells for in vitro killing. 
 
 
Human(ized) cell lines 
  B16 HHDII LNCaP T2 
MHC class-I 
Endogenous expression Chimeric HLA-A2 HLA-A2 HLA-A2 






PAP expression Endogenous expression None Human PAP None 










4.2.1.1.1.Assessing MHC class-I expression 
TRAMP-C2 cells have been described as having low MHC class-I molecules expression on their 
surface (Martini, et al. 2010). MHC class-I expression is required for class-I epitope presentation to 
CD8+ T-cells, as a consequence of which, H2-Kb-Db expression on TRAMP-C1 and TRAMP-C2 cells 
was assessed by flow cytometry.  The analysis indicated that there was no endogenous H2-Kb-Db 
expression (Figure 4.1A). Although IFNγ can induce MHC class-I expression and promote tumour-
specific immune responses in TRAMP-C2-derived tumours (Martini, et al. 2010), IFNγ has also been 
shown to induce PD-L1 expression, an inhibitory molecule that binds to the PD-1 receptor expressed 
on T-cells thereby impairing the anti-tumour immunity (Abiko, et al. 2015). TRAMP-C1/C2 cells were 
treated with various concentrations of murine IFNγ for 24 hours and the (co-)expression of H2-Kb-
Db and of PD-L1 was measured by flow cytometry (Figure 4.1B and C). A concentration as low as 
0.1ng/mL increased the percentage of H2-Kb-Db positive cells up to 49% (~25% on average), 
however, ~66% of these cells also co-expressed PD-L1 (Figure 4.1B). A concentration of 1ng/mL 
resulted in 51% and 47% of H2-Kb-Db positive TRAMP-C1 and TRAMP-C2 cells, respectively, with 
almost 100% of these cells also expressing PD-L1. A concentration of 2ng/mL or higher only slightly 
increased the percentage of H2-Kb-Db positive cells. 
 
PD-L1 was expressed on ~20% of TRAMP cells without IFNγ treatment (Figure 4.1 B). 0.1ng/mL of 
IFNγ induced PD-L1 expression in 50% of TRAMP cells and concentrations of 1ng/mL and over 
induced PD-L1 expression in 95% of TRAMP-C1 cells (Figure 4.1B).  
 
The intensity of expression (Median Fluorescence Intensity, MFI) of H2-Kb-Db and PD-L1 on TRAMP 
cells was also determined (Figure 4.1C). A concentration of 2ng/mL of IFNγ and over induced the 
highest H2-Kb-Db MFI value (Figure 4.1C left), with 5ng/mL being required to induce maximal 
expression of PD-L1 MFI (Figure 4.1C right). 
 
Considering these results, 1ng/mL of IFNγ was selected as the optimal concentration for pre-
treating TRAMP cells prior in vitro killing assays. Although this concentration was shown to induce 
the expression of PD-L1 in most TRAMP cells, it induced the expression of H2-Kb-Db molecules on 
50% of TRAMP cells while 0.1ng/mL only induced the expression of MHC class-I molecules on 25% 
of TRAMP cells. This compromise was based on prioritising the expression of MHC class-I expression, 




Figure  4.1: MHC class-I expression in TRAMP-C1 and TRAMP-C2 murine cancer cell lines (A) Histogram of 
H2Kb Db expression in TRAMP-C1 and TRAMP-C2 cells. (B) Effect of 24 hours mIFNγ treatment on the (co-) 
expression of MHC class-I H2Kb Db and PD-L1 molecules in TRAMP-C1 and TRAMP-C2 cells. (C) Expression by 






4.2.1.1.2.Assessing endogenous mPAP expression and knock down of mPAP 
TRAMP-C1 and TRAMP-C2 cell lines have been described as endogenously expressing PAP mRNA 
(Grossmann, et al. 2001). A qPCR for the murine PAP gene confirmed its expression within both 
TRAMP cell lines, with a higher mPAP expression in TRAMP-C2 cells (Figure 4.2 A). 
In order to assess the role of mPAP expression in the killing of TRAMP cells by vaccine-induced CTLs, 
the mPAP gene was knocked down in TRAMP-C1 and TRAMP-C2 cell lines. The lentiviral 
transduction method was used (described in 2.2.1.3). mRNA from successfully transduced cells 
(selected in 1µg/mL of puromycin) was extracted to assess the expression of the mPAP gene. In 
both cell lines, there was a decrease in the mPAP expression in comparison to the empty vector 
control transduced cells (Figure 4.2 B). TRAMP-C1 knock down cells expressed 18% of the empty 
vector transfected counterpart, whereas TRAMP-C2 knock down cells expressed 47% of the empty 
vector transfected counterpart. In order to decrease the percentage of mPAP expression in the 
knock down cells, clones from single cells were selected. Empty vector transfected clones with the 
highest mPAP expression and shRNA knock down clones with the lowest mPAP expression were 
selected (Figure 4.2 C): TRAMP-C1 empty vector control clone 5, TRAMP-C1 shRNA clone 4, TRAMP-
C2 empty vector clone 2 and TRAMP-C2 shRNa clone 3. These selected clones were used for 
subsequent in vitro killing assays. 
The choice of clones could not be based on the protein expression of mPAP because none of the 




Figure 4.2: Endogenous mPAP expression and knock down of mPAP in TRAMP-C1 and TRAMP-C2 murine 
cancer cell lines. (A) Relative endogenous expression of mPAP. (B) Relative expression of the murine PAP 
gene following knock down with shRNA, before cloning (HPRT and GAPH normalisation) and (C) after cloning 
(HPRT normalisation). N=1 for each experiment. 
 
4.2.1.2.LNCaP human cell line 
The LNCaP cell line was isolated from a lymph node biopsy from a 50-year-old Caucasian male 
diagnosed with metastatic prostate carcinoma in 1977 (Horoszewicz, et al. 1980). The morphology, 
preservation of functional properties and conservation of tumorigenicity in athymic nude mice 
confirmed the human prostatic cancer tissue origin of LNCaP cells (Horoszewicz, et al. 1983). LNCaP 
cells were shown to be positive for the androgen receptor and for the oestrogen receptor. 
Moreover, their production of PAP and PSA was demonstrated in vitro as well as in vivo in tumours 
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and in the plasma of tumour-bearing animals (Horoszewicz, et al. 1983). The plasma level of PAP 
was found to increase with the size of the tumours. 
 
4.2.1.2.1.Assessment of MHC class-I expression 
The LNCaP cell line has been described as being HLA-A*0201 positive, although the HLA-A2 
expression level was low and did not increase in response to IFN-gamma stimulation (Carlsson, et 
al. 2007). Olson et al. found similar results and used HLA-A2 transfected LNCaP as targets in 
cytotoxicity assays (Oslon, et al. 2010). However, when assessing the expression of HLA-A2 in the 
LNCaP cell line by flow cytometry, cells were positive (Figure 4.3 A). Thus, there was no need to 
increase the HLA-A2 expression of LNCaP cells in order to use them as target cells for future 
cytotoxicity experiments. 
 
On the other hand, in order to use LNCaP cells as target cells for splenocytes from vaccinated 
HHDII/DR1 mice, cells were transfected to express a chimeric HLA-A2 gene, called HHD. The HHD 
molecule contains the HLA-A2.1 α1 and α2 domains, the H-2Db α3 domain and the human β2 
microglobulin. The presence of the H-2Db α3 domain has been shown to facilitate the interaction 
with mouse CD8 molecules, thereby improving the CTL responses, as HHD-transfected cells are 
more efficiently recognized than cells transfected with the human HLA-A2.1 molecule (Pascolo, et 
al. 1997). The selection of successfully transfected cells was solely based on antibiotic selection 
(1mg/mL of G418) because the expression of the chimeric HLA-A2 cannot be distinguished from 
that of the wild-type HLA-A2 molecules. Hereafter, these cells will be called LNCaP HHDII cells. 
 
4.2.1.2.2.Assessment of endogenous hPAP expression and knock down of hPAP 
As stated earlier (section 4.2.1.2), LNCaP cells have been described as expressing PAP. Its expression 
was confirmed RT-PCR in comparison with HEK293t cells which are known to be PAP negative 
(Figure 4.3 B). In order to assess the role of human PAP expression in their sensitivity to killing by 
vaccine-induced CTLs, the humanPAP gene was knocked down in both the LNCaP WT and the LNCaP 
HHDII cell lines. The lentiviral transduction method was used and mRNA from successfully 
transduced cells (selected in 1µg/mL of puromycin) was extracted to assess the expression of the 
hPAP gene. In both cell lines, there was a decrease in the hPAP expression in comparison to the 
empty vector control transduced cells (Figure 4.3 C): 100 to 16% for LNCaP WT cells and 100 to 7% 
for LNCaP HHDII cells. These cells were not cloned due to their sensitivity and the difficulty to 




Figure 4.3: MHC class-I expression and endogenous hPAP expression and knock down of hPAP in LNCaP 
human cancer cell line. (A) Histogram of HLA-A2 expression. (B) Relative endogenous expression of hPAP. (C) 




4.2.1.3.B16F10 humanised murine cell line 
B16F10 are melanoma cells derived from C57Bl/6 mice and were engineered by Scancell Limited to 
express the chimeric HLA-A2 and HLA-DR1 molecules, as described in 2.2.1.1.1. Although melanoma 
cells, these are the only available cell line that can be used to establish tumours in the HHDII/DR1 
mice and therefore are being used as “proof of concept” in this study. Expression of the chimeric 
HLA-A2 and the HLA-DR1 molecules was confirmed by flow cytometry by a colleague by measuring 
the expression of the human β-2microglobulin and of the HLA-DR1 proteins (data not shown). As 
these cells do not express PAP protein, the hPAP gene was knocked-in to enable them to be used 
as target cells for the in vitro cytotoxicity assays and in vivo tumour studies. For this, the cell line 
was subjected to lentiviral transduction with both fraction 1 and 2 collected as described in 2.2.1.3.2. 
mRNA from the successfully transduced cells (selected in 1µg/mL of puromycin) was extracted to 
assess the expression of the hPAP gene by RT-PCR. Cells infected with both fractions showed a 
strong hPAP expression in comparison to the empty vector control transduced cells (Figure 4.4 A). 
Fraction 1, displaying an earlier Ct value, has a stronger expression of the hPAP gene. The expression 
was confirmed at the protein level by Western Blotting of supernatants from B16F10 cells, as PAP 
protein is mainly secreted (Figure 4.4 B). Indeed, the hPAP protein could not be detected from cell 
lysates (data not shown). 
 
Clones from single cells were grown from both the empty vector control and the fraction 1 
transduced cells. Six clones were expanded for each and the hPAP expression was assessed at the 
mRNA level. The clone number 5 displayed the highest hPAP expression (Figure 4.4 C). The 
expression was confirmed at the protein level by Western Blotting (Figure 4.4 D). B16F10 PAP clone 




Figure 4.4: Knock in of hPAP in B16F10 humanized murine cancer cell line. (A) Relative expression of the 
human PAP gene following knock in in B16F10 cell line. (B) Protein expression of the human PAP from 
supernatants following knock in in B16F10 cell line. (C) Relative expression of the human PAP following knock 
in in B16 cell line and cloning. (D) Protein expression of the human PAP in B16-HHDII-PAP+ clone 5 cells. N=1 
for each experiment. 
 
4.2.1.4.R-MAS and T2 cells 
T2 and R-MAS cells are deficient for TAP, and therefore cannot process and present any internal 
peptides which are TAP-dependant (Anderson, et al. 1993). As a consequence, any empty MHC 
class-I/beta2 microglobulin (beta2m) molecules reaching the surface of the cells are quickly 
disassembled and recycled. However, an exogenous peptide with sufficient binding affinity for the 
MHC-Class-I molecule can stabilise the MHC class-I/beta2m complex. The stable 
MHC/beta2m/peptide complex can then be indirectly detected by staining for MHC-Class-I 
molecules. The total number of MHC Class-I molecules on the surface of the cells reflects the 
number of peptides bound. T2 and R-MAS cells can be pulsed with short (class-I) peptides, so that 
the epitopes can be presented at the surface of HLA-A2 (T2) or H-2KbDb (R-MAS) MHC class-I 





4.2.1.4.1.Effect of overnight incubation of R-MAS and T2 cells at 26°C 
Incubation of R-MAS and T2 cells at 26°C increases the intensity of MHC class-I expression 
(Ljunggren, et al. 1990). This was confirmed by comparing the effect of overnight incubation of TAP-
deficient cells at 37° and at 26°C followed by a flow cytometry staining with anti-MHC class-I 
antibodies (HLA-A2 for T2 cells, H-2Kb-Db for R-MAS cells). In both cell lines, the expression of MHC 
class-I molecules increased by overnight incubation at 26°C (figure 4.5 A). 
 
4.2.1.4.2.T2 and R-MAS peptide binding assay 
The lowest concentration of short peptides necessary to obtain the highest number of 
peptide/MHC class-I stable complexes at the surface of R-MAS and T2 cells was determined by 
performing MHC peptide binding assays. Peptide binding assays were performed on cells which had 
been incubated overnight at 26°C. The assay was performed with ISI 9mer peptide for R-MAS H2-
Kb-Db+ cells and with ILL 9mer peptide for T2 HLA-A2+ cells. In both cases, 50µg/mL was found to be 
the concentration needed to reach a plateau in the MFI of MHC class-I molecules (Figure 4.5 B). 
 
Figure 4.5: Enhancement of T2 and R-MAS cell lines as class-I peptide presenting target cells. (A) Effect of 
overnight incubation at 26°C on MHC class-I expression of R-MAS and T2 cells. (B) Effect of increasing quantity 
of 9mer peptides on MHC class-I expression in R-MAS and T2 cells. N=1 for each experiment. 
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4.2.2. Capacity of vaccine induced T-cells to kill relevant target cells 
Following the generation of relevant target cells, the next step was to assess the capacity of vaccine-
induced T-cells to kill these target cells. To expand vaccine-specific T-cells, splenocytes were 
stimulated in vitro with either mitomycin treated LPS-blast cells previously pulsed with class-I 
peptides or with class-I peptides directly. The use of syngeneic LPS-irradiated blasts has been shown 
to induce the stimulation of T-cells and to generate effector cytotoxic and helper cells (Bjorklund, 
et al. 1986). The goal was to expend class-I peptide specific CD8+ T-cells which would then be able 
to recognize and kill target cells. Because total splenocytes were used for the cytotoxicity assays, 
the proportion of T-cells, CD4+ and CD8+ T-cells was assessed by flow cytometry (Figure 4.6 A). In 
the C57Bl/6 model, the proportion of CD8+ T-cells within total T-cells in vaccinated mice was ~70-
80% (Figure 4.6 A left), which was similar to the proportion of CD8+ T-cells in splenocytes from naïve 
mice. The proportion of CD8+ T-cells in the CAF09-based vaccine group was greater than that in the 
ImmunoBody®-based vaccine group. 
On the other hand, the increased proportion of CD8+ T-cells and decreased proportion of CD4+ T-
cells within the total T-cell population was vaccine-specific in the HHDII/DR1 model (Figure 4.6 A 
right). The proportion of CD8+ T-cells in the CAF09-based vaccine group was significantly higher than 
that in naïve and in other vaccinated groups. The CpG-based and the ImmunoBody®-based vaccines 
induced a non-significant increase in the proportion of CD8+ T-cells. 
Given the fact that CD8+ T-cells were shown to be activated by the vaccines in both models in 
Chapter 3, their expression of activating and inhibitory markers was determined. In the C57Bl/6 
model, both vaccines induced a significant increase of PD-1 expression and a non-significant 
increase in the proportion of PD-1/Tim3+ cells (Figure 4.6 B top graph). Other markers were not 
affected in a vaccine-specific manner, but GITR, LAG-3 and Tim-3 were increased in all groups in 
comparison to their expression before class-I epitope stimulation (Figure 3.5C and 3.8C versus 
Figure 4.6B). In the HHDII/DR1 model, the proportion of PD-1/Tim3+ cells was significantly increased 
in the CAF09-vaccine group (~90% of cells) and in the CpG-vaccine group (~60% of cells). GITR, LAG-
3 and Tim-3 were also increased in all groups, although there was a slight decrease of GITR in the 
CA09-vaccine group and a slight increase of OX40 in the CpG-vaccine group. Overall, the CAF09-
based vaccine induced the highest proportion of CD8+ T-cells and of PD-1/Tim3+ CD8+ T-cells in both 
models. 
 
The use of mitomycin-C treated peptide-pulsed LPS blasts or of class-I peptides alone to stimulate 
splenocytes did not change the number or the phenotype of T-cells, neither did it change the 




Figure 4.6: Effect of different vaccines on the proportion of CD4+ and CD8+ T-cells and on the phenotype of 
CD8+ T-cells following 6 days of in vitro stimulation in both mouse models. C57Bl/6 mice or HHDII/DR1 mice 
were immunised on days 1, 15 and 29 with either the CpG-based, the CAF09-based or the ImmunoBody®-
based PAP 42mer vaccine. Seven days after the last immunisation, splenocytes were isolated from spleens 
and incubated with either pulsed LPS-blast cells or class-I peptides alone. Six days later, splenocytes were 
incubated with a murine FcR block and then stained with surface antibodies for flow cytometry analysis 
indicating (A) proportion of CD4+ and CD8+ T-cells, (B) proportion of CD8+ T-cells expressing activating and 
inhibitory markers. The CAF09-based vaccine induced an increase of the proportion of CD8+ T-cells, and an 
increase in the proportion of PD-1 +/- Tim3+ CD8+ T-cells. Bars represent the mean percentage of positive 
cells and the error bars represent the SD. Results are representative of two to three independent experiments 
(n= 6 to 9 mice per test group). A significant difference between immunisation groups was determined using 





4.2.2.1.1.Killing of ILL peptide-pulsed T2 cells  
The ability of splenocytes from mice vaccinated with the hPAP42mer mutated vaccines to lyse 
relevant target cells was assessed in vitro by performing a 51Cr release assay. To assess the capacity 
of splenocytes to specifically recognise the ILL 9mer epitope presented by an HLA-A2-expressing 
target cell, T2 cells previously pulsed with the ILL9mer peptide were used (Figure 4.7 A). Splenocytes 
from the CpG-vaccine immunised group and from the CAF09-vaccine immunised group were able 
to specifically lyse ILL-pulsed T2 cells, with a greater percentage of cytotoxicity against T2 ILL cells 
for the CAF09-vaccine group. There was no ILL-specific killing in the ImmunoBody®-vaccine nor in 
the naïve group. The proportion of CD8+ T-cells co-expressing PD-1, LAG-3 and Tim-3 correlated 
positively with the capacity of splenocytes to recognize and lyse ILL-pulsed T2 cells (Figure 4.7 B). 
 
4.2.2.1.2.Killing of B16-HHDII-PAP+ cells 
Similarly, the cytotoxic capacity of splenocytes from mice vaccinated with the hPAP42mer mutated 
vaccines against B16-HHDII-PAP+ cells was assessed (Figure 4.7 C). Although the cytotoxicity 
observed was not PAP-specific, the cytotoxic capacity of splenocytes from both the CAF09 and the 




Figure 4.7: Cytotoxic capacity of splenocytes from vaccinated HHDII/DR1 mice against T2 cells -/+ ILL 
peptide and against B16-HHDII cells -/+ hPAP. HHDII/DR1 mice were immunised on days 1, 15 and 29 with 
either the CpG-based, the CAF09-based or the ImmunoBody®-based hPAP 42mer mutated vaccine. Seven 
days after the last immunisation, splenocytes were isolated from spleens and incubated with either pulsed 
LPS-blast cells or class-I peptides alone. Six days later, splenocytes were co-incubated with 51Cr labelled target 
cells for an incubation of 4hrs to overnight, at the end of which the radioactivity was measured to determine 
the percentage of cytotoxicity. (A) Percentage of cytotoxicity against T2 cells pulsed or not with ILL9mer 
peptide and (B) correlation between the percentage of CD8+ T-cells co-expressing PD-1, Tim-3 and LAG-3 and 
the percentage of cytotoxicity against T2-ILL cells at 100:1 ratio. (C) Percentage of cytotoxicity against B16 
cells -/+ hPAP. The CAF09 and the CpG-based vaccines induced ILL-specific killing against T2 cells. No PAP-
specific killing was observed against B16 cells. Dots represent the mean percentage of cytotoxicity and the 
error bars represent the SD. Results are representative of two to three independent experiments. A 





4.2.2.1.3.Killing of LNCaP HHDII cells 
The next step was to assess the capacity of vaccine-induced T-cells to lyse LNCaP cells naturally 
expressing the hPAP protein and transfected with the chimeric HLA-A2 molecule. This was firstly 
performed using a 51Cr release assay, however, results were inconclusive, both after 4 hours and 
after overnight incubation (data not shown). LNCaP cells are highly sensitive and the spontaneous 
cell death was high. It was therefore decided to perform a flow cytometry-based assay, which 
allows the direct detection of target cell death on an individual cell basis, therefore allowing a 
shorter time of co-incubation (3 hours). The cytotoxic activity of total splenocytes was assessed at 
similar effector cell : target cell ratios (minus the 100:1 ratio). No PAP-specific killing (Figure 4.8A 
upper graph) and no vaccine-specific killing (Figure 4.8A lower graph) was detected. The cytotoxicity 
effect of isolated CD8+ T-cells was measured at lower ratios: 5:1, 10:1 and 20:1. No significant PAP-
specific killing (Figure 4.8 B upper graph) and no vaccine-specific killing (Figure 4.8B lower graph) 
was observed, although cells from the CpG-vaccine and the CAF09-vaccine groups induced a higher 




Figure 4.8: Killing of LNCaP HHDII -/+ hPAP cells by splenocytes from vaccinated HHDII/DR1 mice. 
HHDII/DR1 mice were immunised on days 1, 15 and 29 with either the CAF09-based or the CpG-based hPAP 
42mer 1 mutation vaccine. Seven days after the last immunisation, splenocytes were isolated from spleens 
and incubated with either pulsed LPS-blast cells or class-I peptides alone. Six days later, splenocytes were co-
incubated with PK26 fluorescent dye-labelled target cells for 3hrs, at the end of which the cytotoxicity of 
PK26+ cells was measured by flow cytometry. Percentage of cytotoxicity against LNCaP HHDII cells -/+ hPAP 
was measured when co-incubated with (A) total splenocytes or (B) isolated CD8+ T-cells. None of the vaccines 
induced PAP-specific killing. Dots represent the mean percentage of cytotoxicity and the error bars represent 
the SD. Results are representative of one experiment. A significant difference between immunisation groups 





4.2.2.2.1.Killing of R-MAS cells pulsed with ISI and SIW peptides 
The ability of splenocytes from mice vaccinated with the mPAP42mer 2 mutations vaccines to lyse 
relevant target cells was assessed in vitro using the 51Cr release assay. To assess the capacity of 
splenocytes to specifically recognise ISI9mer and SIW8mer epitopes presented by H2-Kb-Db-
expressing target cell, RMAS cells were previously pulsed with each epitope (Figure 4.9). To confirm 
the most immunogenic mPAP42mer peptide to be used in the vaccine, the experiment was 
performed with splenocytes from animals immunised with either the WT, the 2 mutations or the 3 
mutations mPAP42mer peptide with CAF09 adjuvant (Figure 4.9 A). As concluded in Chapter 3, the 
mPAP42mer 2 mutation peptide was the most immunogenic with significant specific killing 
achieved for all ratios with both peptide (ISI and SIW) in that group. The 3 mutations peptide also 
induced ISI and SIW peptides specific killing, but to a lesser extent and not in the case of the 100:1 
ratio. Despite displaying a lowest binding score and being recognised by lower avidity T-cells than 
ISI9mer (section 3.2.2.2.1), RMAS cells pulsed with the SIW8mer peptide induced a higher 
percentage of cytotoxicity than those pulsed with the ISI9mer peptide. 
 
The same experiment was performed to compare the cytotoxicity induced by the mPAP42mer 2 
mutations CAF09 or ImmunoBody®-vaccine approaches (Figure 4.9 B). Splenocytes from the CAF09-
vaccine group were able to induce ISI and SIW specific cytotoxicity down to an effector: target cell 
ratios of 12.5:1. However, the difference with the unpulsed RMAS cells was not as high as previously 
(Figure 4.9 A middle graph) as there is more variability due to the higher experimental (n) number. 
Splenocytes from the ImmunoBody®-vaccine group were able to induce ISI specific killing at the 
12.5:1 ratio, but there was no SIW specific killing (Figure 4.9 B right). 
 
To assess vaccine-specific induced killing, the percentage of RMAS ISI and RMAS SIW cytotoxicity 
induced by vaccines was compared with that induced using splenocytes from naïve mice (Figure 4.9 
C). In the case of ISI9mer epitope, only cells from the ImmunoBody®-vaccine group induced a 
significantly higher percentage of killing at ratios 12.5:1 and 50:1. In the case of SIW8mer epitope, 
both CAF09 and ImmunoBody® vaccines induced a significantly higher percentage of cytotoxicity at 
all ratios (except for ImmunoBody® group at 12.5:1 ratio). Overall, the SIW8mer epitope appears 




Figure 4.9: Killing of R-MAS cells pulsed with ISI / SIW peptides by splenocytes from vaccinated C57Bl/6 
mice. C57Bl/6 mice were immunised on days 1, 15 and 29 with either the CAF09-based or the ImmunoBody®-
based mPAP 42mer 2 mutations vaccine. Seven days after the last immunisation, splenocytes were isolated 
from spleens and incubated with either pulsed LPS-blast cells or class-I peptides alone. Six days later, 
splenocytes were co-incubated with 51Cr labelled target cells for 4hrs, at the end of which the radioactivity 
was measured to determine the percentage of cytotoxicity. Percentage of cytotoxicity against RMAS cells un-
pulsed or pulsed with ISI9mer or SIW8mer was measured according to (A) the mPAP42mer peptide sequence 
used for vaccination, (B) the delivery system and (C) in comparison to splenocytes from naive mice. The 2 
mutation mPAP42mer peptide induced more ISI and SIW-specific killing than other peptides. The CAF09-
based vaccine induced ISI and SIW-specific killing against RMAS cells. Dots represent the mean percentage of 
cytotoxicity and the error bars represent the SD. Results are representative of one to six independent 





4.2.2.2.2.Killing of TRAMP-C1 and TRAMP-C2 cell lines 
The same experiment was performed with TRAMP-C1 and TRAMP-C2 cell lines as target cells, 
naturally expressing the mPAP. The cells knocked down for the mPAP gene were used as controls 
to assess the PAP-specificity of the cytotoxicity. 
 
As mentioned in section 4.2.1.1.1, the effect of IFNγ pre-treatment of TRAMP cells on their 
susceptibility to be killed in vitro was assessed. To this end, the capacity of splenocytes from mice 
immunised with either the CAF09 or the ImmunoBody®-based vaccine to kill TRAMP-C1 cells was 
tested. Regardless of the vaccine used, IFNγ pre-treatment of TRAMP-C1 cells lead to a higher 
percentage of cytotoxicity (Figure 4.10 A). Without IFNγ pre-treatment, splenocytes from the 
ImmunoBody®-vaccine group induced more killing, whereas with IFNγ pre-treatment, splenocytes 
from the CAF09-vaccine group induced a higher percentage of cytotoxicity. 
The observation that IFNγ pre-treatment of TRAMP-C1 renders them more susceptible to killing by 
splenocytes can be explained by the induction of immunoproteasome (Tanaka et Kasahara, 1998) 
in TRAMP-C1 cells which renders them more immunogenic through the presentation of different 
epitopes by MHC class-I molecules. 
 
To understand if the cytotoxicity observed was PAP-specific, the same experiment was performed 
using both the WT and the mPAP knocked down TRAMP-C1 cells. PAP-specific killing was observed 
in the CAF09-vaccine group at ratios 50:1 and 100:1, whereas it was only observed at the ratio 100:1 
in the ImmunoBody®-vaccine group (Figure 4.10 B). Surprisingly, the PAP-specific killing was almost 
exclusively observed when cells had not been pre-treated with IFNγ. These results led us to perform 




Figure 4.10: Optimisation of killing assay using TRAMP-C1 cells -/+ mPAP and -/+ IFNg pretreatment, with 
splenocytes from vaccinated C57Bl/6 mice. C57Bl/6 mice were immunised on days 1, 15 and 29 with either 
the CAF09-based or the ImmunoBody®-based mPAP 42mer 2 mutations vaccine. Seven days after the last 
immunisation, splenocytes were isolated from spleens and incubated with either pulsed LPS-blast cells or 
class-I peptides alone. Six days later, splenocytes were co-incubated with 51Cr labelled target cells for an 
overnight incubation, at the end of which the radioactivity was measured to determine the percentage of 
cytotoxicity. Percentage of cytotoxicity against TRAMP-C1 cells was measured according to (A) IFNγ pre-
treatment and (B) PAP-specific killing. IFNγ pre-treatment increased the percentage of cytotoxicity. The 
CAF09-based vaccine induced PAP-specific killing against TRAMP-C1 cells without IFNγ pre-treatment. Dots 
represent the mean percentage of cytotoxicity and the error bars represent the SD. Results are representative 
of one to three independent experiments. A significant difference between immunisation groups was 




To determine if the PAP-specific TRAMP-C1 killing observed was due to the vaccine itself, the killing 
assay was also performed with splenocytes from unvaccinated naïve mice. Splenocytes from all 
three groups induced a higher percentage of cytotoxicity against the WT TRAMP-C1 cells in 
comparison to their knocked down counterpart (Figure 4.11 A), albeit non-significantly in the case 
of the ImmunoBody®-vaccine group. The same experiment performed on TRAMP-C2 cells 
demonstrated that only splenocytes from the CAF09-vaccine group lysed these cells in a PAP-
specific manner (Figure 4.11 B). However, there was a non-significant increase in the percentage of 
cytotoxicity against the WT TRAMP-C2 cells in the ImmunoBody®-vaccine group. Finally, the 
percentage of cytotoxicity against the WT TRAMP cells between the three groups was compared. 
There was no vaccine-specific killing against TRAMP-C1 cells, whereas in the case of TRAMP-C2 cells, 
the CAF09-vaccine induced a significantly higher percentage of cytotoxicity than the 




Figure 4.11: Killing of TRAMP-C1 and 
TRAMP-C2 cells -/+ mPAP by splenocytes 
from vaccinated C57Bl/6 mice. C57Bl/6 
mice were immunised on days 1, 15 and 29 
with either the CAF09-based or the 
ImmunoBody®-based mPAP 42mer 2 
mutations vaccine. Seven days after the last 
immunisation, splenocytes were isolated 
from spleens and incubated with either 
pulsed LPS-blast cells or class-I peptides 
alone. Six days later, splenocytes were co-
incubated with 51Cr labelled target cells for 
an overnight incubation, at the end of which 
the radioactivity was measured to 
determine the percentage of cytotoxicity. 
(A) Percentage of cytotoxicity against 
TRAMP-C1 cells (A) and (B) TRAMP-C2 cells 
according to mPAP expression. (C) 
Percentage of cytotoxicity against WT 
TRAMP-C1 cells or WT TRAMP-C2 cells 
according to the vaccination. Both the 
CAF09-based vaccine and no vaccination 
were sufficient to induce PAP-specific killing 
against TRAMP-C1 cells. Only the CAF09-
based vaccine induced PAP-specific killing 
against TRAMP-C2 cells. Dots represent the 
mean percentage of cytotoxicity and the 
error bars represent the SD. Results are 
representative of one to three independent 
experiments. A significant difference 
between immunisation groups was 





The aim of this part of the project was to select the vaccine strategies inducing the strongest 
cytotoxicity against target cells in a PAP-specific manner. To achieve this, suitable target cells were 
prepared. The expression of MHC class-I molecules matching those of the mouse model was 
assessed qualitatively and quantitatively and modified when required. The expression of either the 
mPAP or the hPAP gene was assessed and modified through genetic modifications as per required. 
 
Prior to performing cytotoxicity assays, total splenocytes were enriched in class-I peptide specific 
CD8+ T-cells by 6 days of in vitro stimulation in the presence of class-I peptides and of IL-2. IL-2 
cytokine has been shown to control the proliferation and differentiation of T-cells (Ross, et al. 2018) 
and to promote the expansion of CD8+ CTLs (Ross, et al. 2016). Although the peptide-specificity of 
CD8+ T-cells was not assessed, their proportion and phenotype were. The in vitro stimulation led to 
an overall increase of CD8+ T-cells in both models, in comparison to their proportion in freshly 
isolated splenocytes. However, this increase was only vaccine-induced in the HHDII/DR1 model, in 
which the percentage of CD8+ T-cells within T-cells in naive mice went from 6% (freshly isolated 
splenocytes) to 29% (after 6 days in vitro stimulation), whereas it went from 15% to 78% in the case 
of cells from CAF09-vaccine immunised mice. In the C57Bl/6 model, the proportion of CD8+ T-cells 
in naïve mice went from 37% to 76%, from 43% to 78% in CAF09-vaccine immunised mice and from 
42% to 74% for ImmunoBody®-vaccine immunised mice, reaching approximately the same 
proportion after 6 days of stimulation. These results suggest that the presence of IL-2 in the culture 
had a major role in inducing the proliferation of CD8+ T-cells. Indeed, IL-2 has been shown to induce 
the proliferation of CD8+ T-cells in an antigen-independent manner (Wong, et al. 2001; Wong, et al. 
2004). An overall increase in the proportion of CD44highCD62Lneg effector memory CD8+ T-cells was 
observed after the in vitro expansion, in all groups (data not shown), reinforcing the fact that the 
IL-2 induced an antigen-independent proliferation of CD8+ T-cells. However, the proportion was 
higher in the vaccinated groups (mainly CAF09-based vaccine in the HHDII/DR1 model), suggesting 
a clonal expansion and differentiation of ILL-specific CD8+ T-cells. These results correlate with the 
hypothesis made in the previous chapter, that the CAF09-based vaccine induces antigen-
nonspecific CD8+ memory T cells with non-MHC restricted cytotoxic capacities. Dhanji et al. 
described a subset of IL-2-activated CD8+ CD44high cells displaying significant levels of activating NK 
receptors (2B4 and NKG2D) that are capable of specifically killing syngeneic tumour cells in a 
NKG2D-dependant manner (Dhanji, et al. 2003). These cells expressed receptors of both the innate 
and the adaptive immune system. Therefore, it would have been of interest to assess by flow 





Regarding the phenotype of expanded CD8+ T-cells, the main difference observed between the 
groups in both models was the induction of PD-1 expression. As discussed in the previous chapter 
(Section 3.3), the meaning of PD-1 expression is controversial, being described as an activation 
marker and as a marker of dysfunction/exhaustion. However, its co-expression with other inhibitory 
markers such as LAG-3 and Tim-3 is a sign of exhaustion (He, et al. 2019). In the HHDII/DR1 model, 
PD-1 was co-expressed with Tim-3 and LAG-3: 64% for CpG group and 87% for CAF09 group. In the 
C57Bl/6 group, only 27% of CD8+ T-cells exhibited this exhausted phenotype in the CAF09 group 
and 25% in the ImmunoBody® group, with some CD8+ T-cells expressing PD-1 on its own. Unlike 
others (Wang, et al. 2019), we did not observe the expression of CTLA-4 molecule. 
It would have been of interest to assess the expression of exhaustion markers after resting of T-
cells, to determine if the exhausted phenotype observed is reversible or permanent. 
 
These results suggest that the CAF09-vaccine in the HHDII/DR1 model mainly induces CD8+ T-cells 
displaying an exhausted phenotype. Exhausted T-cells are commonly described as dysfunctional T-
cells having lost their proliferative potential, their capacity to secrete cytokines, their memory 
phenotype, their cytotoxic capacities and expressing inhibitory receptors (Wherry, et al. 2015) 
(Maimela, et al. 2019). Tim-3 in particular has been described as a negative regulator of CD8+ T-cell 
induced cytotoxicity in the context of HIV infection, despite the fact that Tim-3-expressing CD8+ T-
cells still contained high levels of perforin (Sakhdari, et al. 2012). Others have shown that 
“exhausted” T-cells from patients with Chronic Lymphoid Leukaemia (CLL) retained their ability to 
secrete cytokines (Riches, et al. 2013). On the other hand, in the context hepatocellular carcinoma, 
“exhausted” T-cells displayed lower secretory capacities (Wang, et al. 2019). 
 
The present findings show that vaccine-induced CD8+ T-cells co-expressing inhibitory markers 
displayed a memory phenotype and were capable of cytotoxicity in an antigen-dependant manner, 
although cytotoxicity assays were performed on total splenocytes (except for LNCaP killing). The 
proliferative and secretory functions of CD8+ T-cells upon ILL recognition were not studied. 
 
As stated above, splenocytes from the CAF09-vaccine group lysed ILL-presenting cells in a highly 
specific manner, far better than splenocytes from CpG-vaccinated mice, whereas splenocytes from 
naïve or ImmunoBody®-vaccinated mice did not induce any cytotoxicity. The positive correlation 
between the presence of exhausted CD8+ T-cells and the cytotoxicity against T2-ILL cells 
demonstrate the cytotoxic capacities of vaccine-induced CD8+ T-cells. Taken together, these results 
suggest that CD8+ T-cells are responsible for the cytotoxicity observed and confirm the findings 
presented in the last chapter demonstrating that the CAF09-vaccine induced CD8+ T-cells express 




Although lysis of B16 cells observed was not influenced by the expression of the hPAP protein, the 
cytotoxicity appeared to be enhanced by vaccination. The CpG-vaccine induced almost no 
cytotoxicity, whereas the ImmunoBody®-vaccine and the CAF09-vaccine induced similar levels of 
cytotoxicity. The cytotoxicity of cells from non-immunised animals would be required to confirm 
this. 
 
As discussed earlier, the CAF09-based vaccine might induce antigen non-specific CD8+ memory T 
cells displaying non-MHC restricted cytotoxic capacities. Although this could be responsible for the 
killing of B16 cells -/+ hPAP, it does not explain the induction of cytotoxicity against B16 cells in the 
ImmunoBody®-vaccine group. These results suggest the possibility that ILL epitope is not presented 
at the surface of B16-HHDII-PAP cells. Considering that these cells do not naturally express PAP, its 
processing might be different and lead to different epitopes being presented, epitopes that are not 
contained in the 42mer sequences and therefore that T-cells from vaccinated animals have not yet 
encountered. 
 
One can also hypothesise that the cytotoxicity observed is due to another cell type, for example NK 
cells. These cells do not induce cytotoxicity in an antigen-dependant manner (Topham, et al. 2009) 
and their proliferation is also induced by IL-2 (Sharma, et al. 2018). However, their presence within 
splenocytes was not assessed following the in vitro stimulation. 
 
The cytotoxicity of LNCaP cells was neither PAP- nor vaccine-dependant. The isolation of CD8+ T-
cells reduced the percentage of cytotoxicity suggesting that cells other than CD8+ T-cells were 
responsible for the killing when performed with total splenocytes. In that context, results observed 
suggest that the toxicity might be vaccine-dependant although there was no significant difference. 
Olson et al. (Olson, et al. 2010) demonstrated that ILL epitope is not a naturally processed epitope 
specific for PAP and that ILL-specific CTLs cannot lyse LNCaP cells in an HLA-A2 restricted manner. 
However, Machlenkin et al. showed that ILL-specific CTLs could kill LNCaP cells and concluded that 
ILL was naturally processed and presented by LNCaP cells (Machlenkin, et al. 2005). Unlike for B16 
cells, PAP protein is naturally expressed in LNCaP cells, however we cannot conclude with our 
results if the ILL epitope is presented at their surface. It is important to remember that these LNCaP 
cells express the HLA-A2 and the chimeric HLA-A2 molecules. 
 
The absence of significant differences between the killing of two LNCap cell types (PAP+ and PAPlow) 
could be explained by the fact that the cells were ‘knocked down’ rather than ‘knocked out’ for PAP 
and therefore still express PAP. The qPCR data showed there is still 6.65% of PAP mRNA in 
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comparison to the cells transfected with the empty vector plasmid. Therefore, the expression at 
the protein level could be high enough for a similar number of ILL-HLA-A2 complexes to be 
presented at their surface. A knockout of PAP within LNCaP cells would answer this question and 
an HLA-A2 blocking antibody would be needed to conclude if the lysis was HLA-A2 restricted. 
 
In the C57Bl/6 model, both vaccine strategies induced class-I peptide-specific killing, but the CAF09-
vaccine induced a higher peptide-specific killing with both ISI9mer and SIW8mer peptides. Similarly, 
the CAF09-vaccine induced the highest percentage of PAP-specific killing of TRAMP-C1 and TRAMP-
C2 cells in comparison to the ImmunoBody®-vaccine or to the “no vaccine” control. These results 
corroborate findings from the last chapter demonstrating that CAF09-vaccine induced a higher 
percentage of CD8+ T-cells expressing both CD107a and Granzyme B, in comparison to the 
ImmunoBody®-vaccine. 
 
One can therefore hypothesize that in this model, the CAF09-vaccine induces CD8+ T-cells with 
higher cytotoxic capacities, whereas the ImmunoBody®-vaccine induces CD8+ T-cells with higher 
capacity to proliferate and secrete cytokines. It would be worth assessing what would happen if 
one was to immunise mice first with ImmunoBody®-based vaccine and then boost with CAF09-
based vaccine. 
As for the LNCaP cells, TRAMP cells were only knocked down for the mPAP gene. This need to be 
taken into consideration as the TRAMP-PAPlow cells could still present some class-I epitopes-MHC 
class-I complexes on their surface and be recognized and lysed specifically. 
 
TRAMP-C1 and TRAMP-C2 cells, do not express naturally detectable H2-KbDb MHC class-I molecules 
on their surface, which limits the capacity of CD8+ T-cell's TCR to bind to peptide-loaded MHC class-
I molecules and to induce cytotoxicity in these cells. IFNγ pre-treatment of TRAMP cells increased 
the number of H2-KbDb MHC class-I molecules on their surface which increased the cytotoxicity of 
these cells, despite the concomitant expression of PD-L1 molecule. However, these conditions did 
not demonstrate PAP-specific killing. 
 
The fact that cytotoxicity against TRAMP cells could be observed without IFNγ pre-treatment 
suggests that CD8+ T-cells secreted IFNγ during the overnight co-culture of TRAMP-cells and 
splenocytes, leading to the upregulation of H2-KbDb MHC class-I molecules. Indeed, in the previous 
chapter, CD8+ T-cells were shown to secrete IFNγ within 6 hours of class-I peptide stimulation, and 
although it was not quantified, the level of IFNγ secreted might be sufficient. In order to confirm 
this, the level of MHC class-I expression on TRAMP cells should have been assessed after in vitro co-
culture with splenocytes. 
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One can hypothesize that ISI9mer and SIW8mer epitopes are presented by TRAMP-C1 and TRAMP-
C2 cells and that there are more epitope/MHC-complexes present at the surface of TRAMP-C2 cells, 
as these cells express higher levels of PAP mRNA than TRAMP-C1 cells. This could explain the 
observed PAP-specific and vaccine-specific lysis against TRAMP-C2 but not TRAMP-C1 cells. 
 
ISI-specific CTLs capable of killing ISI-pulsed RMAS cells as well as TRAMP-C1 have been described 
by Spies et. al (Spies, et al. 2012), In these studies, a PAP-based DNA vaccine could induce ISI-CTLs 
capable of IFNγ secretion and detectable by pentamers, and had the capacity to induce the 
regression of TRAMP-C1 tumours and to inhibit the growth of spontaneous tumours in TRAMP mice. 
 
It has been reported that the knockdown of PAP expression allows androgen-sensitive prostate 
cancer cells to develop the castration-resistant phenotype having the capacity to proliferate under 
an androgen-reduced condition (Muniyan, et al. 2013). Hence, PAP has a major role in the growth 
of prostate cancer cells. Although we did not observe differences in the proliferation of WT versus 
knock down cells (LNCaP, TRAMP-C1 and TRAMP-C2 cells), this should be taken into consideration. 
 
In conclusion, these results demonstrated that the vaccine was able to induce the PAP-specific lysis 
of target cells in vitro. The mPAP42mer and the hPAP42mer CAF09-based vaccines induced 
splenocytes capable of recognising PAP42mer-derived class-I epitopes presented by T2 and RMAS 
cells, respectively. Moreover, these splenocytes were also able to recognise and kill TRAMP-C1 and 
TRAMP-C2 cells in a PAP-specific manner. On the other hand, the mPAP42mer ImmunoBody®-
based vaccine induced splenocytes much weaker in term of cytotoxicity. These results, together 
with the results obtained from the previous chapter, justified the assessment of the CAF09-based 
vaccine in the HHDII/DR1 tumour model and with both the CAF09 and the ImmunoBody®-based 
vaccine in the C57Bl/6 tumour model. In the next chapter, the effect of the vaccines on the in vivo 




Chapter 5: Assessment of the anti-tumour capacity of the PAP42mer 
vaccine in vivo 
5.1. Introduction 
The fact that a vaccine is capable of inducing a strong PAP-specific immune response in non-tumour 
bearing animals does not necessarily mean that the same proportion of PAP-specific T-cells can be 
induced in tumour-bearing animals and that the vaccine can elicit protective anti-tumour immunity. 
Indeed, even if cells migrate to the TME, they might face immuno-suppressive mechanisms that 
would render them non-functional/exhausted, incapable of recognizing their cognate antigen or 
incapable of initiating CTL functions when they do. 
 
The prostate cancer TME has been described as predominantly immunosuppressive. Indeed, an 
abundance of TGF-β in PCa tumours has been reported and shown to inhibit NK cell-mediated 
cytotoxicity (Pasero, et al. 2016). Moreover, overexpression of TGF-β in comparison to benign 
prostates correlates with Gleason scores ≥7 of poor prognosis (Reis, et al. 2011) and metastatic 
stages (Adler, et al. 1999). The presence of Tregs (Miller, et al. 2006), Th17 cells (Sfanos, et al. 2008), 
MDSCs (Garcia, et al. 2014) and of PD-L1/PD-L2-expressing DCs (Bishop, et al. 2015) has been 
observed in tumours from patients with prostate cancer. The dysfunction of T-cells has also widely 
been described in prostate cancer (Ness, et al. 2014; Sfanos, et al. 2009; Ebelt, et al. 2008) as has a 
linkage between the presence of TILs and poor prognosis (Ness, et al. 2014; Leclerc, et al. 2016). 
These facts illustrate the main challenge when developing a cancer vaccine for PCa: inducing an 
immune response sufficiently strong to outperform the immunosuppressive mechanisms put in 
place in the TME. 
Murine tumour models are therefore essential to assess the anti-tumour efficacy of a cancer 
vaccine. The anti-tumour efficacy can be assessed in two different setting: prophylactic or 
therapeutic. Although prophylactic studies can determine if a vaccine can elicit vaccine-specific T-
cells capable of recognising and lysing tumour cells in vivo and prevent tumour growth, they do not 
mimic the clinical situation of patients presenting established tumours. 
On the contrary, although more challenging, therapeutic models better mimic the clinical situation 
of cancer patients. Two situations could indicate an efficient anti-tumour response, either the 
slowing down of tumour growth or the regression of tumours. However, the most crucial outcome 
when performing these studies is survival. Assessing the TILs present in tumours helps 





In the previous chapters, both ImmunoBody® and CAF09 PAP-derived vaccine strategies were 
shown to induce functional PAP-specific CD8+ T-cells and PAP-specific killing of target cells. The aim 
of the work presented in this chapter was to develop tumour models in which the anti-tumour 
efficacy of selected vaccine strategies could be assessed. Moreover, the vaccine-specific immune 
response was evaluated by studying the presence and the phenotype of T-cells from the spleen as 
well as TILs. 
Two established tumour models were chosen for the C57Bl/6 mouse model - implantation of 
tumorigenic TRAMP-C1 or TRAMP-C2 cells. The HHDII/DR1 model involved the implantation of the 
engineered B16 cells (humanised and expressing hPAP). In each model, the anti-tumour efficacy of 
the most potent vaccine strategies, identified in the previous chapter, were assessed both in the 
prophylactic and therapeutic settings. Findings from these studies provide insight into whether the 
PAP42mer vaccine can slow down or eradicate PAP-expressing tumours. This information is crucial 
for understanding whether the vaccine has therapeutic and translational potential for patients with 
prostate cancer. 
Tumour studies were conducted according to the Home Office regulations. The endpoint was based 
on the tumour size and animals were culled when tumours reached the maximum size permitted 
under the Home Office PPL Licence (1.2cm mean diameter for prophylactic studies and 1.5cm mean 
diameter for therapeutic studies). Besides tumour growth, the effect of each vaccine strategies on 





5.2.1. B16F10 model in HHDII/DR1 mice 
The first step to establish the B16-HHDII-PAP tumour model was to assess the number of cells 
required to obtain tumour growth in 100% of mice. Injecting 0.25x106 cells per animal resulted in 
13% of animals not developing tumours while doubling this number (0.5x106 cells/animal) led to an 
overly rapid tumour growth which would allow insufficient time to assess the anti-tumour efficacy 
of the vaccine (data not shown). The optimal number was found to be 0.3x106 cells per animal and 
was used for subsequent experiments. 
 
5.2.1.1.Prophylactic setting 
The anti-tumour efficacy of the hPAP42mer mutated peptide vaccine was firstly assessed in a 
prophylactic setting (Figure 5.1). For this, animals were immunised three times according to the 
immunisation protocol shown Figure 5.1 A and challenged a week later with 0.3x106 B16-HHDII-
PAP+ cells per mouse. The first group of animals did not receive any immunisation to assess the 
effect of the CAF09 adjuvant on its own. The effect of the CAF09 vaccine (CAF09 adjuvant with the 
hPAP42mer mutated peptide) on tumour growth was compared to that in a group which was not 
immunised and the group receiving CAF09 alone. All animals ultimately had to be culled due to 
tumour size. The tumour growth showed that animals developed tumours between day 11 and day 
25, regardless of the group (Figure 5.1 A). One animal from the CAF09 alone group (6%) and 3 
animals from the CAF09 vaccine group (16%) developed tumours after day 25. However, once 
tumours were measurable, the growth rate was similar. There was a non-significant increased 
survival of 3 days in the CAF09 alone treated group in comparison to the control group (figure 5.1 
B). The survival of the CAF09 vaccine treated group was prolonged by 10 days in comparison to the 
control group and by 7 days in the CAF09 alone group, although none of the two were significant. 





Figure 5.1: Effect of the hPAP 42 mutated sequence with CAF09 adjuvant on B16-HHDII-PAP+ tumour 
growth in a prophylactic setting in HHDII/DR1 mice. HHDII/DR1 mice were immunised on days 1, 15 and 29 
with the CAF09 adjuvant alone or with the CAF09-based hPAP 42mer mutated vaccine. Seven days after the 
last immunisation, 0.3x106 B16-HHDII-PAP+ cells were implanted into the right flank of animals and tumour 
growth followed. (A) Individual tumour growth monitored by callipers measurements and (B) Kaplan-Meier 
curve of OS. The CAF09 vaccine prolonged the survival of animals in comparison to control groups, although 




When tumours reached the maximum size permitted under the Home Office PPL Licence, spleens 
and tumours were taken to study the status and function of CD4+ and of CD8+ T-cells. As 
demonstrated Chapter 3, the CAF09 vaccine induced a CD8+ T-cell driven immune response (Figure 
5.2). CD4+ T-cells were not affected by the vaccine (data not shown). The vaccine induced an 
increase in the proportion of CD8+ T-cells within the peripheral T-cell compartment and an increase 
of effector memory CD8+ T-cells (Figure 5.2 A). Although immunisation also induced high levels of 
PD-1 expression on CD8+ T-cells (Figure 5.2 B), it had no effect on the expression of other inhibitory 
markers. A proportion of CD8+ T-cells secreted IL-2, IFNγ and TNFα and degranulated (CD107a) in 
response to ILL peptide stimulation (Figure 5.2 C). Increased expression of Granzyme B by CD8+ T-





Figure 5.2: Effect of the hPAP42mer mutated CAF09-based vaccine on the phenotype of splenocytes from 
HHDII/DR1 mice bearing B16-HHDII-PAP+ tumours in a prophylactic setting. HHDII/DR1 mice were 
immunised on days 1, 15 and 29 with the CAF09 adjuvant alone or with the CAF09-based hPAP 42mer 
mutated vaccine. Seven days after the last immunisation, 0.3x106 B16-HHDII-PAP+ cells were implanted into 
the right flank of animals and tumour growth followed. Once the tumour size limit was reached, spleens were 
taken, dissociated, incubated with a murine FcR block and then stained with surface antibodies for flow 
cytometry analysis indicating (A) proportion of CD8+ T-cells and proportion of effector memory CD8+ T-cells, 
(B) proportion of CD8+ T-cells expressing activating and inhibitory markers or (C) proportion of CD8+ T-cells 
secreting cytokines and degranulating after ILL stimulation for 6 hours. The CAF09 vaccine induced a CD8+ T-
cell driven immune response with cytokines secretion and degranulation of CD8+ T-cells upon stimulation. 
Bars represent the mean percentage of positive cells and the error bars represent the SD. Two to three 
independent experiments performed (n= 9 to 15 mice per test group). A significant difference in the 





To understand if the vaccine was responsible for the delay observed, the status and function of TILs 
was studied. The results observed were different from those observed in splenic CD8+ T-cells. A 
higher proportion of CD8+ T-cells was found in the tumour (approximately 40% on average), 
inversing the CD4/CD8 ratio: the proportion of CD8+ T-cells was higher than that of CD4+ T-cells. 
Moreover, the proportion of CD8+ T-cells was increased in the CAF09 vaccine group, although this 
difference was not of statistical significance (Figure 5.3 A). CD8+ TILs from the CAF09 vaccine group 
displayed a slightly less exhausted phenotype, in that a lower proportion of cells expressed LAG-3, 
Tim-3 and PD-1 at high levels (Figure 5.3 B). Inversely, there were more PD-1low CD8+ T-cells in the 
CAF09 vaccine group. Unexpectedly, expression of the activation markers GITR and OX-40 was also 
slightly decreased in the CAF09-vaccine group. There was an increase in the proportion of CD8+ T-
cells secreting IFNγ and TNFα, particularly in 2 mice, but no IL-2 secretion (Figure 5.3 C). A higher 
proportion of CD8+ T-cells expressed CD107a in response to ILL in comparison to the control group, 
but there was no increase of Granzyme B expression. Overall, there were less cytokines-secreting 





Figure 5.3: Effect of the hPAP42mer mutated CAF09-based vaccine on the phenotype of tumour infiltrating 
lymphocytes in B16-HHDII-PAP+ tumours in HHDII/DR1 in a prophylactic setting. HHDII/DR1 mice were 
immunised on days 1, 15 and 29 with the CAF09 adjuvant alone or with the CAF09-based hPAP 42mer 
mutated vaccine. Seven days after the last immunisation, 0.3x106 B16-HHDII-PAP+ cells were implanted into 
the right flank of animals and tumour growth followed. Once the tumour size limit was reached, tumours 
were taken, dissociated, incubated with a murine FcR block and then stained with surface antibodies for flow 
cytometry analysis indicating (A) proportion of CD4+ and CD8+ T-cells and proportion of effector memory CD8+ 
T-cells, (B) proportion of CD8+ T-cells expressing activating and inhibitory markers or (C) proportion of CD8+ 
T-cells secreting cytokines and degranulating after ILL stimulation for 6 hours. The CAF09 vaccine induced a 
CD8+ T-cell driven immune response with cytokine secretion and degranulation of CD8+ T-cells upon 
stimulation. Bars represent the mean percentage of positive cells and the error bars represent the SD. Two 
to three independent experiments performed (n= 9 to 15 mice per test group). A significant difference in the 





Considering the unclear effect of the CAF09 vaccine on the growth of B16-HHDII-PAP+ tumours in a 
prophylactic setting and the large proportion of CD8+ T-cells expressing PD-1 in the spleen and in 
the tumour, its effect was assessed in a therapeutic setting in combination with an anti-PD-1 
antibody. Treatment started at day 4 post tumour implantation, before tumours were palpable, 
due to the rapid and aggressive phenotype of the B16 tumour model. 
Tumour growth showed that animals developed tumours between day 14 and day 18, regardless 
of the group (Figure 5.4 A). One animal from the CAF09 alone + anti-PD-1 antibody group and 1 
animal from the CAF09 vaccine group developed tumours after day 31. The growth rate was similar 
in all test groups. There was no significant difference in survival between any groups (Figure 5.4 B). 
However, in comparison to the control group (CAF09 alone and isotype control) the anti-PD1 
antibody increased the survival of 8 days, the vaccine alone of 11 days and the combination of the 
two increased the survival of 4 days. There was no combinatorial effect of the vaccine with the anti-
PD-1 antibody. 
 
The proportion of CD8+ T-cells within the spleen and the tumour was assessed, but no difference 
was observed between the groups (Figure 5.4 C). Also, due to technical difficulties, the flow 





Figure 5.4: Effect of the hPAP42mer mutated CAF09-based vaccine in combination with an anti PD-1 
antibody on tumour growth and immune responses in HHDII/DR1 bearing B16-HHDII-PAP+ tumours in a 
therapeutic setting. HHDII/DR1 mice were injected with 0.3x106 B16-HHDII-PAP+ cells into their right flank, 
then immunised on days 4, 8, 12 and 18 with the CAF09 adjuvant alone or with the CAF09-based hPAP 42mer 
mutated vaccine and with the isotype control or with anti-PD-1 antibody while the tumour growth was 
followed. (A) Individual tumour growth monitored by calliper measurements, (B) Kaplan -Meier curve of OS 
and (C) proportion of splenic CD8+ T-cells and of CD8+ TILs at the time of culling of each an-Meier curve of 
OS and (C) proportion of splenic CD8+ T-cells and of CD8+ TILs at the time of culling of each animal. The CAF09 
vaccine alone and the anti-PD1 antibody alone prolonged the survival of animals in comparison to other 




5.2.2. TRAMP-C1 and TRAMP-C2 tumour model in C57Bl/6 mice 
5.2.2.1.TRAMP-C1 and TRAMP-C2 tumour model establishment 
Several issues were encountered when establishing both the TRAMP-C1 and the TRAMP-C2 tumour 
models. TRAMP-C1 cells were obtained from a collaborator (Matteo Bellone). These cells were 
isolated from TRAMP-C1 tumours and grown in culture to render them more tumorigenic and to 
facilitate tumour implantations. The number of cells needed to obtain tumour growth in 100% of 
mice was assessed. Three concentrations were tested: 1, 2 and 5x106 cells per animal, with 5x106 
cells being found to be the optimal number of cells required. Although not 100% of mice developed 
tumours, this cell number was used for subsequent experiments. However, after a short time, cells 
ceased developing tumours. Thus, TRAMP-C1 and TRAMP-C2 cells were obtained from the ATCC. 
Both cell lines were transfected with the Luciferase2 gene to follow the tumour growth with more 
accuracy, as well as to potentially develop an orthotopic model by injecting the TRAMP cells directly 
into the prostate of C57Bl/6 males. The expression of the LUC2 gene was confirmed (data not 
shown). However, tumour implantation with 5x106 cells per animal did not result in tumour 
development. Animals were imaged a day after tumour implantation and the signal was followed 
weekly. The Luciferin signal decreased from the tumour implantation until becoming undetectable 
(data not shown). This can be explained by the immunogenicity of the Luciferase2 protein, inducing 
an immune reponse against that foreign antigen and resulting in tumour rejection. 
 
Various parameters were modified to increase the tumorigenicity of TRAMP cells: cells were 
implanted 1) into old (immuno-depressed) animals, 2) into immuno-suppressed NOD/SCID mice 
and 3) with 10 and 50% Matrigel™ to facilitate the attachment of the cells. 
Nonetheless, all these attempts were unsuccessful. Therefore, our collaborator (Matteo Bellone) 
kindly gave us TRAMP-C1 cells which had been obtained from TRAMP-C1 tumours, grown in culture 
and then implanted back into C57Bl/6 animals multiple times. Tumours were obtained from these 
cells and cells were isolated from these tumours, grown in culture and stored for future use. 
Unfortunately, the TRAMP-C2 tumour model could never be established, restricting our tumour 
studies to the TRAMP-C1 tumour model. 
 
5.2.2.2.Therapeutic setting 
A first pilot study assessed the anti-tumour effect of mPAP42mer vaccines against established 
TRAMP-C1 tumours.  Treatment started when 33% of animals had tumours measurable by callipers 
(4 out of 12 animals), on day 17 post tumour implantation. Mice that did not receive any treatment 
were used as a control for the CAF09-based vaccine and for the ImmunoBody®-based vaccine. The 
tumour growth rate was similar in all groups (Figure 5.5 A). One animal in the CAF09 vaccine group 
started developing a tumour at day 46 post tumour-implantation and exhibited a slower growth 
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rate. Its survival was prolonged by 29 days in comparison to the last animal of the control group 
(day 48 versus day 77) and by 27 days in comparison to the last animal of the ImmunoBody® vaccine 
group (day 50 versus day 77) (Figure 5.5 B). 
 
Although there was no statistically significant difference between groups, 25% (1 out of 4 animals) 
of the animals immunised with the CAF09 vaccine had a tumour growth delay and therefore an 
increased survival, while none responded to the ImmunoBody® vaccine. The proportion of splenic 
CD8+ T-cells was unchanged between groups, neither was the proportion of CD8+ TILs. However, 
the proportions of CD8+ T-cells in the CAF09 vaccine treated animal which had a delay in tumour 
growth was also unchanged. Moreover, splenic CD8+ T-cells and CD8+ TILs from this animal did not 
secrete cytokines or degranulate in response to ISI9mer and SIW8mer peptides stimulation in vitro 
(data not shown). These results suggest that the vaccine was not responsible for the tumour growth 
delay; however, the delay in tumour growth might be explained by an incorrect subcutaneous 
injection of tumour cells at the day of tumour implantation or by the heteregenous tumour growth 





Figure 5.5: Pilot study: effect of the mPAP42mer mutated CAF09 and ImmunoBody®-based vaccines on 
tumour growth and immune parameters in C57Bl/6 mice bearing TRAMP-C1 tumours in a therapeutic 
setting. C57Bl/6 mice were injected with 5x106 TRAMP-C1 cells into their right flank, immunised on days 17, 
24, 31 and 38 with the CAF09-based or the ImmunoBody®-based mPAP 42mer mutated vaccine while the 
tumour growth was followed. (A) Individual tumour growth monitored by callipers measurements, (B) Kaplan-
Meier curve of OS and (C) proportion of splenic CD8+ T-cells and of CD8+ TILs at the time of culling of each 
animal. The CAF09 vaccine prolonged the survival of one animal in comparison to other groups, but no 




The immunisation regimen was slightly modified in order to leave a similar prime-boost gap as the 
one when assessing the vaccine in Chapter 3, by treating animals every 14 days. Due to the length 
of this regimen, it was decided that animals would only receive prime and boost immunisations. 
However, when the experiment was performed, there was no tumour growth in any group (data 
not shown). The next experiment was conducted using the frozen cells from untreated tumours 
from another study. This experiment contained two extra groups. A group of mice immunised with 
the CAF09 adjuvant alone, to assess the effect of the adjuvant alone and to be used as a control 
group for the CAF09 vaccine group and another group of mice receiving only a prime of the CAF09 
vaccine, as it was suggested that booster immunisations might be detrimental in the therapeutic 
setting (Ricupito, et al. 2013).  
 
Due to a faster tumour growth rate observed, animals received the ‘prime’ immunisation 8 days 
post tumour-implantation instead of 17 days in the case of the pilot study. Nonetheless, none of 
the treatment strategies induced a delay in the tumour growth (Figure 5.6 A). Tumours appeared 
between day 7 and day 45, regardless of the treatment received. As a result, none of the vaccine 
induced a prolonged survival (Figure 5.5 B). The proportions of splenic CD8+ T-cells and of CD8+ TILs 




Figure 5.6: Effect of the mPAP42mer mutated CAF09 and ImmunoBody®-based vaccines on tumour growth 
and immune parameters in C57Bl/6 mice bearing TRAMP-C1 tumours in a therapeutic setting. C57Bl/6 mice 
were injected with 5x106 TRAMP-C1 cells into their right flank, immunised on days 8 and 22 with the CAF09 
adjuvant alone, the CAF09-based or the ImmunoBody®-based mPAP 42mer mutated vaccine while the 
tumour growth was followed. (A) Individual tumour growth monitored by callipers measurements, (B) Kaplan-
Meier curve of OS and (C) proportion of splenic CD8+ T-cells and of CD8+ TILs at the time of culling of each 







In parallel to the therapeutic study, a prophylactic study was performed to understand if any of the 
vaccines could prevent the growth of TRAMP-C1 tumours. Animals were immunised three times 
according to the immunisation regimen shown in Figure 5.7 A and challenged a week later with 
TRAMP-C1 cells. Animals developed tumours between days 7 and 33 regardless of the group (Figure 
5.7A). None of the treatments induced a change in the tumour growth rate. However, the 2 animals 
left in the study on day 42, were not culled due to tumour size: one from the CAF09 alone group 
and one from the CAF09 vaccine group. The animal from the CAF09 alone group had a tumour of 
56mm2. The animal from the CAF09 vaccine group had no measurable tumour and no raised area. 
We can extrapolate that even if this animal developed a tumour, it would have survived a minimum 
of an extra two weeks. We therefore cannot make any conclusions about the effect of the CAF09 
vaccine on the growth of TRAMP-C1 tumours, however, this experiment suggests that 20% (1 out 
of 5 animals) of the animals responded to the CAF09 vaccine, whereas none responded to the 
ImmunoBody® vaccine. 
However, the effect of the vaccine on T-cells was not investigated in this study, therefore, the delay 
in tumour growth might be explained by an incorrect subcutaneous injection of tumour cells at the 
day of tumour implantation or by the heteregenous tumour growth pattern observed with TRAMP-





Figure 5.7: Effect of the mPAP42mer mutated CAF09 and ImmunoBody®-based vaccines on tumour growth 
in C57Bl/6 mice bearing TRAMP-C1 tumours in a prophylactic setting. C57Bl/6 mice were immunised on 
days 1, 15 and 29 with the CAF09 adjuvant alone, the CAF09-based or the ImmunoBody®-based mPAP 42mer 
mutated vaccine. Six days after the last immunisation, 5x106 TRAMP-C1 cells were injected into their right 
flank, while the tumour growth was followed. (A) Individual tumour growth monitored by callipers 
measurements, and (B) Kaplan-Meier curve of OS. The CAF09 vaccine induced 20% of tumour-free animals at 





Results obtained in the previous chapters demonstrated that the vaccines used induced a CD8+ T-
cell immune response. Moreover, the vaccine-induced CD8+ T-cells displayed characteristics of CTLs, 
as well as the ability to kill target cells in a PAP-specific manner. 
However, the in vivo anti-tumour effect of the vaccines in the prophylactic and therapeutic settings 
in both mouse models used did not reflect these. 
 
In the HHDII/DR1 mouse model, the B16-HHDII-PAP tumour model was used to assess the efficacy 
of the hPAP/CAF09-based vaccine. The prophylactic study led to a delay of tumour growth in 16% 
of the animals with a small survival increase despite no effect on the growth rate of the tumour. 
The analysis of splenic T-cells and TILs showed that the vaccine induced a PAP-specific immune 
response weaker than in non-tumour bearing vaccinated animals (Chapter 3). The proportion of 
CD8+ T-cells, of memory CD8+ T-cells and of ILL-specific CD8+ T-cells was diminished. Indeed, a 
smaller proportion of CD8+ T-cells had the capacity to proliferate (data not shown), to secrete 
cytokines and to degranulate in response to ILL stimulation. Interestingly though, the proportion of 
PD-1-expressing CD8+ T-cells was not increased and no other inhibitory marker was expressed. 
 
In the tumour, there were more CD8+ TILs than CD4+ TILs, which could explain the lower proportion 
than expected of splenic CD8+ T-cells. The majority of CD8+ TILs displayed an “exhausted” 
phenotype, as characterised by the co-expression of PD-1, Tim-3, LAG-3, but no CTLA-4. The vaccine 
increased the proportion of PD-1low CD8+ TILs and decreased the proportion of exhausted CD8+ TILs. 
CD4+ T-cells has a similar phenotype, co-expressing all inhibitory markers apart from CTLA-4, with 
no differences between groups (data not shown). ILL-specific CD8+ T-cells secreting IFNγ and TNFα 
were detected at a lower frequency than in the spleen. Interestingly, the animal that survived the 
longest had CD8+ TILs displaying an “exhausted” phenotype: high GITR, higher PD-1+Tim3+, and 
fewer PD-1low. Despite the exhausted phenotype, their functional capacity was retained as these 
cells displayed the highest percentage of IFNγ/TNFα secreting CD8+ T-cells. 
 
Although results from the previous chapter suggested that ILL epitope is not presented by B16 cells, 
the CAF09-based vaccine induced splenocytes capable of lysing B16 cells, which could be explained 
by the presence of NK cells. The low proportion of ILL-specific CTLs at the tumour site suggests that 
ILL epitope is indeed not presented by B16 cells, otherwise these cells would have been recruited 
in higher number at the tumour site. Yet, the observation that the longest survival correlated with 
the highest proportion of IFNγ/TNFα secreting CD8+ T-cells in response to ILL suggests the opposite. 
However, this could be a random event as it was observed in one animal only. It is possible that the 
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delay in tumour growth observed is due to the cytokine secretion of CD8+ T-cells activating other 
cell types, such as NK cells, responsible for the anti-tumour response observed.  
The activation of NK cells following vaccination has been described and depends on myeloid 
accessory cell‐derived cytokines such as IL‐12, IL‐18 and type I interferons (Wagstaffe, et al. 2018). 
In particular, the activation of APC by the use of adjuvants was found to enhance and sustain NK 
cell activity, thereafter, contributing to T cell recruitment and memory cell formation. In particular, 
a subset of cytokine-induced memory-like (CIML) NK cells characterised by enhanced IFNγ 
production and cytotoxicity have been described to be induced by IL-2 secreting CD4+ T-cells 
(Fehniger, et al. 2003; Goodier, et al. 2016) and myeloid cell‐derived IL‐12 and type I interferons. 
Although the enhanced NK immune response following vaccination has mainly been described in 
the context of infectious disease (Blohmke, et al. 2017; Darboe, et al. 2017) and in a CD4+ T-cells-
dependant manner (Horowitz, et al. 2010; Jost, et al. 2014), CIML NK cells have been shown to 
exhibit enhanced responses against myeloid leukaemia in a pre-clinical mouse model and in a first-
in-human phase 1 clinical trial (Romee, et al. 2016). Administration of poly ICLC adjuvant on its own 
was shown to activate DCs and NK cells (Martins, et al. 2014). Although IL-2 secretion by CD4+ T-
cells following vaccination was not demonstrated, IL-2 secretion by CD8+ T-cells was observed and 
could have led to NK activation. 
 
Despite the unclear effect of the CAF09-based vaccine in preventing the growth of B16-HHDII-PAP 
tumours, the anti-tumour efficacy of the vaccine against established B16 tumour was assessed. 
Considering the results obtained in the prophylactic setting, an anti-PD-1 antibody was used in 
combination with the vaccine. No anti-tumour effect was observed. One animal treated with the 
anti-PD1 alone and one treated with the vaccine alone had a prolonged survival due to tumour 
developing more than 10 days later. However, one can argue about the role of the treatments in 
tumour growth delay since the treatment started before the observation of measurable tumours. 
Moreover, two animals in the prophylactic study who did not receive treatment developed tumours 
after day 20 post tumour implantation. Another important point to take into consideration is that 
the treatment schedule was different, with a 4 days gap in between immunisation instead of two 
weeks, due to the aggressiveness of the B16 tumour model. However, this immunisation schedule 
is not as efficient in inducing a PAP-specific immune response (data not shown). Although the 
immunophenotyping of T-cells was not performed, this was confirmed by the absence of increased 
proportion of splenic CD8+ T-cells in the therapeutic study. 
 
The presence of established tumours has been shown to suppress the clonal expansion of CD8+ T-
cells in vivo, following vaccination in comparison to tumour-free animals (Oizumi, et al. 2008). 
Schreiber et al. described a potential mechanism by which tumours escape immunosurveillance by 
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preventing the clonal expansion of tumour-specific CTLs without inducing anergy (Schreiber, et al. 
2009). This mechanism can explain the reduction of the vaccine-induced immune response 
observed in our model. These results demonstrate the difficulty of breaking tolerance in tumour-
bearing animals in comparison to tumour-free animals. 
 
The same observations can be made about the TRAMP-C1 therapeutic studies. In the pilot study, 
the therapeutic treatment started at day 17 post tumour implantation, when only 33% of animals 
had developed tumours. One can again question the effect of the vaccine on the tumour growth 
delay observed in one animal. Moreover, immunisations were one week apart instead of two. The 
PAP-specific immune response induced using this treatment schedule was not assessed. The 
unchanged proportion of splenic and TIL CD8+ T-cells suggest that the schedule was not optimal for 
mounting a vaccine-induced PAP-specific immune response. 
 
In the other therapeutic study performed with faster growing TRAMP-C1 cells, no effect was 
observed on the tumour growth nor on the proportion of splenic and TIL CD8+ T-cells in vaccinated 
animals. No conclusion can be drawn out of the prophylactic study, although it appears that one 
animal responded to the CAF09 vaccine. 
 
Overall, the CAF09 vaccine delayed tumour growth in 20-25% of animals in 2/3 of the experiments 
whereas the ImmunoBody® vaccine had no anti-tumour effects. A higher number of animals per 
group is required to be able to reach a definite conclusion on the anti-tumour effect of the CAF09 
vaccine. 
 
Although others have shown that PAP-specific vaccines could break tolerance and induce anti-
tumour responses against TRAMP-C1 tumour (Silva, et al. 2015; Spies, et al. 2012), treatment 
started at day 2 and day 6-8 post tumour implantation respectively. Cytotoxicity assay results 
(Chapter 4) showed PAP-specific killing against TRAMP-C1 and TRAMP-C2 cells, but vaccine-specific 
killing only against TRAMP-C2 cells. This could be explained by the fact that TRAMP-C2 express 5 
times more PAP mRNA than TRAMP-C1 cells (Figure 4.2 A). The TRAMP-C2 tumour model would 
therefore have been a better choice, but could not be established. 
 
Established tumours induce immunosuppression and tolerance (Mapara, et al. 2004). As mentioned 
in the context of B16 tumours, TRAMP-C1 tumours may have had a deleterious impact on the 
induction of a strong PAP-specific immune response. The presence of PAP-specific CD8+ CTL should 




As mentioned earlier, the induction of a CD4+ helper T-cell response was not demonstrated by the 
vaccine strategies studied here. However, CD4+ T-cells are required for inducing CD8+ CTL responses 
(Bennet, et al. 1998). In particular, the induction of CD8+ memory T-cells is dependent on CD4+ T-
cells (Janssen, et al. 2003). CD4+ T-cells have also been described as capable of displaying cytotoxic 
activity against established tumours (Quezada, et al. 2010). For these reasons, tumour-specific T 
helper epitopes should be included in the design of epitope-based vaccines (Ossendorp, et al. 1998). 
 
As concluded by Melief “Therapeutic cancer vaccines cannot be expected to act as a monotherapy” 
(Melief, et al. 2015). The CAF09-based vaccine will need to be assessed in combination with other 
immuno-modulatory drugs to compensate for the immunosuppression induced by TRAMP-C1 
tumours. 
 
To conclude, despite a vaccine strategy inducing PAP-specific CD8+ CTLs, the anti-tumour response 
elicited was too weak to prevent the tumour growth or to observe regression of established 
tumours. These results can be explained for several reasons. Firstly, the treatment scheduling was 
not optimal. Secondly, another immuno-modulatory treatment is likely to be required to counteract 
the immunosuppression induced by the tumour. Lastly, the tumour models used might not be the 
most adequate. 
In the final part of this study, the relevance of this work for patients with prostate cancer was 
studied using PBMCs from patients with prostate cancer and healthy individuals. The presence of 
ILL-specific T-cells and their capacity to lyse ILL-presenting and PAP-expressing human prostatic 




Chapter 6: Assessing the presence of PAP-specific immune responses 
in healthy individuals and patients with prostate cancer 
6.1. Introduction 
PAP protein is naturally expressed by the prostate and is therefore not foreign to the immune 
system of patients with prostate cancer. The expression of both PAP variants, cellular and secreted 
has been observed in mouse (Quintero, et al. 2007) and human thymus (Kong and Byun 2013), 
meaning that T-cells with high avidity TCRs towards PAP epitopes would have been eliminated 
when undergoing negative selection by the process of central tolerance. This mechanism is 
necessary to protect organs, such as the prostate, from auto-immune responses. Peripheral 
tolerance mechanisms further regulate auto-reactive T-cells that might have escaped central 
tolerance. These mechanisms include suppression of T cells by 1) expression of checkpoints (PD-1, 
Tim-3, LAG-3,…), 2) immuno-suppressive cells (Treg cells, MDSCs), 3) immunosuppressive cytokines 
and enzymes (TGF-β, IL-10, IDO), 4) poor T cell infiltration in tumours and 5) improper inflammation 
(Melief, et al. 2015). 
 
Voutsas et al. demonstrated that high pre-existing immunity in patients with prostate cancer 
towards the native HER-2 peptide, AE36, correlated with longer PFS following vaccination with a 
HER-2/neu hybrid peptide in a phase I clinical trial (Voutsas, et al. 2016). 
We can therefore assume that the efficacy of a prostate cancer vaccine targeting PAP is likely to be 
higher if the patient has pre-existing PAP-specific T-cells that could be boosted by the vaccine, or 
pre-existing naïve T-cells that express TCRs recognizing PAP-derived epitopes and could be primed 
by DCs after vaccination. However, although the presence of PAP-specific T-cells can be detected, 
proving the existence of naïve T-cell expressing PAP peptide-specific TCRs is much more difficult 
due to their low frequency. 
 
The presence of circulating PAP-specific T-cells in patients with prostate cancer has previously been 
reported and generating insight into this might constitute a valuable tool to predict the potential 
efficacy of a PAP vaccine. 
The presence of PAP-specific T-cells has been particularly evaluated in HLA-A2+ individuals given 
their high frequency in the population. HLA-A2 is a large and diverse allele family as it is composed 
of 31 alleles, and is common in all ethnicities (Ellis, et al. 2000). Ellis et al. reported HLA-A2 
frequencies in 5 US ethnic groups: Caucasian (49.6%), African-American (34.6%), Asian/Pacific 
Islander (36%), Hispanic (46.9%) and Native Americans (49.7%), with an average of 47.6% of all 
individuals tested (82,979) being HLA-A2+. Moreover, a Swedish study has demonstrated a higher 
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HLA-A2 frequency in patients with prostate cancer (69%) than in healthy individuals (58%), thereby 
suggesting the negative prognostic correlation with HLA-A2 (Masucci, et al. 2006). 
 
Studies have demonstrated the presence of PAP-specific T-cells that could secrete IFNγ in response 
to in vitro stimulation with PAP-derived peptides and/or lyse peptide pulsed T2 cells in healthy 
individuals (Peshwa, et al. 1998) and in patients with prostate cancer (Olson, et al. 2010). Several 
epitopes were identified, one of which was PAP 135-143 (ILL), for which specific T-cells were found 
in 40% of patients with prostate cancer (6 of 15) (Olson, et al. 2010). In that study, ILL-specific cells 
were shown to lyse ILL-pulsed T2 cells, but not LNCaP cells. However, these findings were distinct 
to those of Machlenkin et al. who had previously demonstrated that LNCaP cells were lysed by ILL-
specific T-cells from patients with prostate cancer in an HLA-A2 specific manner (Machlenkin, et al. 
2005). 
 
Although the presence of PAP-specific CTLs is relevant given their involvement in tumour cell 
cytotoxicity, the presence and function of PAP-specific CD4+ helper T-cells is of interest given their 
role in promoting CTL responses and inducing long-term memory CD8+ T-cells. 
McNeel et al. observed PAP-specific T-cells with a Th1 phenotype (as characterised by proliferation 
and IFNγ secretion in response to PAP whole protein stimulation) in 11% of patients with prostate 
cancer (McNeel, et al. 2001) and later identified two MHC class-II epitopes (15AA) that were capable 
of inducing PAP-specific proliferation in patients with prostate cancer (McNeel, et al. 2001). 
Klyushnenkova et al. then identified two PAP-derived HLA-DRB1*1501-restricted T-cell epitopes of 
20AA (PAP (133-152) and PAP (173-192)) capable of stimulating CD4+ T-cells in healthy individuals 
and patients with prostate cancer (Klyushnenkova, et al. 2007). Johnson et al. subsequently 
identified four HLA-DRB1*0101 epitopes of 15AA (PAP (161-175), PAP (181-195), PAP (191-205), 
and PAP (351-365)) in HLA-A2.01/HLA-DRB1*0101 transgenic mice, along with one epitope which 
could elicit specific T-cells following immunisation with the pTVG-HP DNA vaccine (Johnson and 
McNeel 2012). Although this study does not refer to naturally occurring PAP-specific CD4+ helper T-
cells, it reinforces the findings of Klyushnenkova et al. that MHC class-II PAP-derived epitopes can 
be present in patients with prostate cancer. 
 
The aim of the studies presented in this chapter was to compare the presence and functionality of 
ILL-specific CTLs in the blood of HLA-A2+ patients with prostate cancer and HLA-A2+ healthy 
individuals. 
Responsiveness was assessed following a 12-day protocol to expand the potential ILL-specific CTLs 
within the PBMC compartment of each individual. Two stimulating conditions were employed: 




Firstly, the pre-existence of ILL-specific CTLs was measured by dextramer-based flow cytometric 
analysis. Dextramers were shown to be better at assessing the presence of antigen-specific T-cells 
than tetramers for several reasons: brighter staining, stronger binding for TCR-pMHC complexes of 
low affinity and enhanced sensitivity (Dolton, et al. 2014). Then, the capacity of PBMCs to recognize 




PBMCs were obtained from three HLA-A2+ groups:  
 Healthy individuals: 40+ years old males (3 individuals); 
 Men with benign disease: males with benign prostate tumours (5 individuals); 
 Patients with prostate cancer (16 individuals). 
Samples from patients with prostate cancer and men with benign disease were obtained from 
Leicester Hospital. 
 
Clinical information available included: 
 Presence of Lower Urinary Tract Symptoms (LUTS) 
 Serum PSA concentration and PSA density 
 Two different type of biopsy information: TRUS and TPTPB, which was shown to improve 
diagnostic accuracy in men with elevated PSA and previous negative TRUS biopsies (Nafie, 
et al. 2014) 
 Gleason score, TNM pathological stage and D’Amico classification. 
 
Regarding patients LE097 to LE113, only pathology information from the TRUS biopsy was available, 
whereas the TRUS pathology + TPTP pathology was available for LE309 to LE325 patients.
151 
 
Table 6.1: Clinical information for patients with prostate cancer
















LE097 75 Benign YES 11 0.22 N/A   - N/A - 
LE100 68 Benign YES 0.25 0.01 N/A   - T2 - 
LE103 65 Benign YES 12 0.10 N/A   - Benign - 
LE112 60  Benign NO  5.7  0.14  N/A   - N/A - 
LE312 67 Benign NO 12 0.13 N/A   - N/A  - 
LE317 73 Cancer YES 11 0.16 N/A 3+3 6 T1c Low 
LE098 74 Cancer NO 8.3 0.18 3+3   6   Intermediate 
LE101 51 Cancer YES 4.2 0.16 3+4   7 Benign Intermediate 
LE111 83 Cancer YES 11 0.11       Flat Intermediate 
LE319 69 Cancer YES 7.2 15.00 N/A 3+4 7 T1c Intermediate 
LE320 71 Cancer NO 7.5 0.18 N/A 3+4 7 T1c Intermediate 
LE322 71 Cancer NO 21 0.16 N/A 3+3 6 T1c Intermediate 
LE102 74 Cancer YES 75 2.72 4+5   9 T3 High 
LE104 78 Cancer YES 82 2.68 5+5   10 T4 High 
LE105 80 Cancer YES 40 1.90 5+4   9 T3 High 
LE109 65 Cancer YES 31 1.53 4+5   9 T2 High 
LE113  79 Cancer NO  29  1  4+5    9 T2  High 
LE309 56 Cancer YES 10 0.19 N/A 4+3 7 T2 High 
LE311 64 Cancer YES 47 1.09 4+3 Mets 7 Bone metastasis High 
LE313 76 Cancer YES 66 0.05 Neg 4+5 9 T1c High 
LE325 75 Cancer NO 21 0.18 N/A 3+5 8 T1c High 
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Samples from patients LE097, 101, 102, 103, 104, 105, 111, 112 and 113 (9 patients) and one 
healthy control were processed and analysed by Dr Stéphanie McArdle and Holly Nicholls (Masters 
student). These experiments were performed in 2017 and the dextramer data obtained pooled with 
the data generated by myself (LE309 to LE325 patients). 
 
Due to the number of PBMCs available after expansion protocol, not all assays could be performed 
on all samples, and this limitation needs to be considered when interpreting results. 
 
6.2.2.Validation of the method for expanding antigen-specific CD8+ T-cells from PBMCs 
In order to validate the 12-day expansion protocol (see Figure 6.1), PBMCs of patients LE309 to 
LE325 were stimulated with a cocktail of 3 HLA-A2 class-I viral epitopes: Influenza A virus (FLuA), 
Epstein-Barr virus (EBV) and Cytomegalovirus (CMV). IL-2 and IL-15 cytokines were used as they 
have been shown to promote the expansion of antigen-specific CD8+ T-cells (Montes, et al. 2005). 
The high frequency of these viruses means that most individuals of the population would have 
encountered at least one of these viruses during their life. FLuA, which causes the common Flu, 
affects 20% of the population every year (Klein, et al. 2016), EBV herpes virus infects more than 90% 
of adults (Lünemann, et al. 2008) and CMV infects between 60 to 70% of the adult population in 
developed countries and almost 100% of adults in emerging countries (Gupta and Shorman 2019). 
These were therefore used as positive controls to assess the presence of antigen specific T-cells by 





Figure 6.1: Workflow of the protocol for the expansion of antigen-specific CD8+ T-cells from PBMCs. 
 
Given their cost, the assessment of antigen-specific cells by dextramer analysis was only performed 
for the CMV epitope. Others have previously confirmed the accuracy of fluorescently-labelled TCR-
specific dextramers for quantifying CMV antigen-specific T-cells in blood samples (Tario, et al. 2015). 
To this end, CMV-specific dextramer fluorescence of CD8+ T-cells was determined according to the 
gating strategy showed Figure 6.2A. 
 
One of two healthy individuals and 4 of 8 patients with prostate cancer exhibited CMV-specific CTLs 
(Figure 6.2B), which is just below the 60 to 70% of positive individuals previously reported (Gupta 
and Shorman 2019). To evaluate the enrichment in CMV-specific T-cells after 12 days of culture, 
the proportion of circulating versus in vitro expanded CMV-specific T-cells was compared for one 
patient. 0.06% of dextramer positive cells were detected on day 0, whereas 1.92% was observed 
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on day 12, thereby demonstrating the capacity of the protocol to expand antigen-specific CD8+ T-
cells (data not shown). 
 
The healthy individual and two of the patients had between 1.92 and 4.52% of CMV-specific CTLs. 
The other two patients had a surprisingly high percentage of CMV-specific T-cells of 34.8 and 
56.11%. However, these represent the proportion of CMV-specific T-cells within total CD8+ T-cells 
after in vitro expansion and not the proportion of circulating CMV-specific CTLs. We can speculate 
that these two patients had an ongoing CMV infection. 
Results from dextramer analysis are summarized in Table 6.2 below. 
 
Table 6.2: Positive cells for dextramer negative control and dextramer CMV (red= patients exhibiting 
CMV-specific CTLs) 
Individual % Dextramer negative CTRL % Dextramer CMV 
Healthy 1 0.13 1.92 
Healthy 2 0.05 0.09 
LE309 0.01 0 
LE311 0.04 4.52 
LE313 0 3.39 
LE317 0.01 34.84 
LE319 0.02 0.04 
LE320 0.03 0.01 
LE322 0.02 0.03 





Figure 6.2: Gating strategy and results for CMV dextramer analysis. Cryopreserved PBMCs from HLA-
A2+ healthy individuals and patients with prostate cancer were cultured for 12 days in the presence of 
IL-2, IL-15 and an HLA-A2-restricted CMV epitope. At the end of the stimulation, PBMCs were incubated 
with a human FcR block and then stained with surface antibodies and the CMV dextramer. (A) 
Represents the gating strategy used and (B) represents the proportion of dextramer positive cells within 
CD8+ T-cells. CMV-specific CTLs were detected in 5 of 10 individuals.  
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Subsequently, expanded virus-specific CTLs were tested for their capacity to recognise and lyse 
epitope-pulsed T2 cells. The gating strategy used to analyse results is shown Figure 6.3A. Gating of 
PKH26+ target cells was purposely stringent in order to avoid contamination of PBMCs. 
 
Evidently, this experiment was not only relevant for CMV dextramer+ patients as PBMCs had been 
stimulated with the cocktail of viral epitopes. Three conditions were compared, PBMCs were co-
incubated with either T2 cells, T2 cells pulsed with all three epitopes used for the expansion or T2 
cells pulsed with the CMV epitope only. This last condition was used for only four patients (LE317, 
319, 322 and 325). Table 6.3 summarizes the assays that were performed. 
 





T2- T2 cocktail T2 CMV 
1:1 5:1 1:1 5:1 1:1 5:1 
Healthy 3                 
LE309                 
LE311                 
LE312                 
LE313                 
LE317                 
LE319                 
LE320                 
LE322                 
LE325                 
 
On average, cytotoxicity towards peptide-pulsed T2 cells was higher than that towards un-pulsed 
T2 cells (Figure 6.3B top). As expected, PBMCs from CMV dextramer+ patients induced cytotoxicity 
against both CMV-pulsed and cocktail pulsed-T2 cells (Figure 6.3.B bottom right), whereas PBMCs 
from CMV dextramer- patients only induced cytotoxicity against cocktail pulsed-T2 cells (Figure 
6.3.B bottom left). These results suggest that CMV dextramer- patients probably had encountered 
EBV and/or FluA, and if dextramer analysis for CTLs specific for these epitopes was performed, 
EBV/FluA-specific CTLs would have been found.  
 
For LE325, which had 56.11% of CMV dextramer+ CD8+ T-cells, the killing of CMV peptide- and 
cocktail pulsed-T2 cells was similar (60.02% versus 54.17%, respectively), thereby suggesting that 
LE325 did not have FluA or EBV CTLs. These results also suggest the possibility that CMV epitope 
had a higher affinity for HLA-A2 molecules at the surface of T2 cells, although this was not tested. 
If this was the case, results assessing the capacity of PBMCs to lyse FluA or EBV-pulsed T2 cells 
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would not be optimal and the assay should have been performed with single epitope-pulsed T2 
cells. Nonetheless, dextramer analysis and cytotoxicity assays performed on viral epitope-specific 
CTLs demonstrated the efficacy of each technique and the correlation between the presence of 
epitope-specific CD8+ T-cells and the capability of these cells to lyse specifically epitope-pulsed 
target cells. 
 
Although planned, the secretory function and the activated status of CD4+ and CD8+ T-cells could 
not be assessed due to the shortage of PBMCs. Despite the 30-fold increase in CMV-specific CTLs 
observed, the recovery of PBMCs following 12 days of in vitro culture was consistently reduced by 




Figure 6.3: Gating strategy for cytotoxicity assay analysis and cytotoxicity against CMV-presenting T2 
cells. Cryopreserved PBMCs from HLA-A2+ healthy individuals and patients with prostate cancer were 
cultured for 12 days in the presence of IL-2, IL-15 and an HLA-A2-restricted CMV epitope. At the end of 
the stimulation, PBMCs were co-incubated with PKH26 stained target cells for 3 hours, at the end of 
which cells were stained with LIVE/DEAD™ Yellow Dead Cell Stain to measure the percentage of dead 
target cells. (A) Gating strategy used and (B) percentage of cytotoxicity against PK26+ (target) cells. 
PBMCs from patients with CMV-specific CTLs induced CMV-specific cytotoxicity. Bars represent the 
mean percentage of positive cells and the error bars represent the SD (n= 1 to 8 patients). Differences 




6.2.3.Presence of HLA-A2 ILL-specific CD8+ T-cells 
The presence of ILL-restricted HLA-A2 CD8+ T-cells was assessed using the dextramer technology. 
Two stimulating conditions were compared to expand the ILL-specific CTLs population: stimulation 
with the ILL 9mer epitope or with the human PAP42mer mutated peptide. Neither stimulation 
influenced the proportion of CD8+ T-cells within the CD3+ T-cell population (Figure 6.4A). Moreover, 
the proportion of CD8+ T-cells in healthy individuals, men with benign disease and patients with 
prostate cancer were similar (Figure 6.4A). 
 
Following ILL stimulation, ILL-specific CTLs were detected in patients with prostate cancer (Figure 
6.4B). Of the 16 patients with prostate cancer, 6 had ILL-specific CTLs, ranging from 0.29 to 1.6% 
with only one patient having a percentage higher than 1%. Although, a small cohort, 37.5% of 
patients with prostate cancer had detectable circulating ILL-specific CTLs, whereas only one 
individual (out of 5 tested i.e 20%) with benign disease exhibited ILL-specific CTLs (0.92%). 
 
Following stimulation with the PAP42mut peptide, ILL-specific CTLs were also detected in patients 
with prostate cancer (Figure 6.4B), however, the proportion was systematically lower than when 
PBMCs where stimulated with the ILL9mer (Figure 6.4B). Moreover, for LE109, 111 and 312, only 
ILL stimulation could induce ILL-specific CTLs.  We can conclude that 4 of 15 (26.7%) patients with 
prostate cancer and 1 of 5 (20%) individuals with benign disease had detectable ILL-specific CTLs 
after stimulation with the hPAP42mut peptide. 
None of the 3 healthy individuals tested had detectable ILL-specific CTLs, although the cohort is too 
small to conclude. 
 
In conclusion, stimulation with the ILL 9mer peptide is more efficient than stimulation with the 
whole PAP42mut peptide to expand the pre-existing population of circulating ILL-specific CTLs from 




Table 6.4: Positive cells for dextramer negative control and dextramer ILL (red= patients exhibiting 
ILL-specific CTLs) 




% Dextramer ILL 
% Dextramer 
negative CTRL 
% Dextramer ILL 
Healthy 1 0.1 0.12 0.09 0.11 
Healthy 2 0.02 0.02 0.02 0.02 
Healthy 3 0.03 0.06 0.03 0.07 
LE097 0.18 0.1 0.16 0.2 
LE098 0.1 0.11 0.09 0.12 
LE100 0.14 0.14 0.09 0.15 
LE101 0.04 0.37 0.01 0.39 
LE102 0.05 0.29   
LE103 0.12 0.19 0.01 0.48 
LE104 0.02 0.8 0.08 0.3 
LE105 0.03 1.6 0.08 1.09 
LE109 0.1 0.42 0.12 0.17 
LE111 0.13 0.46 0.18 0.21 
LE112 0.11 0.26 0.11 0.13 
LE113 0.11 0.23 0.11 0.31 
LE309 0 0 0.01 0.01 
LE311 0 0.01 0 0.03 
LE312 0.01 0.92 0.03 0.01 
LE313 0 0 0 0 
LE317 0.01 0.02 0 0.01 
LE319 0.06 0.04 0.03 0.09 
LE320 0.01 0.01 0.02 0.04 
LE322 0.05 0.04 0.03 0.03 





Figure 6.4: Presence of ILL-specific CD8+ T-cells within the blood of patients with prostate cancer. 
Cryopreserved PBMCs from HLA-A2+ healthy individuals, individuals with benign disease and patients 
with prostate cancer were cultured for 12 days in the presence of IL-2, IL-15 and either the HLA-A2-
restricted ILL epitope or the hPAP42mer mutated peptide. At the end of the stimulation, PBMCs were 
incubated with a human FcR block and then stained with surface antibodies and the ILL dextramer. (A) 
proportion of CD8+ T-cells within total T-cells, (B) proportion of ILL dextramer positive cells within CD8+ 
T-cells following ILL peptide or hPAP42mut peptide stimulation (normalised on dextramer control). 
There was no difference in the proportion of CD8+ T-cells among groups. ILL-specific CTLs were detected 
following ILL stimulation (benign disease: 1/5, prostate cancer: 6/16) and after hPAP42mut peptide 





6.2.4.Cytotoxic function of PBMCs against ILL-presenting cells and the human prostatic cell 
line LNCaP 
The capacity of PBMCs to recognize and lyse target cells in a PAP-dependant manner was assessed 
by performing cytotoxicity assays, as detailed in Section 6.2.2. Firstly, cytotoxicity against ILL-pulsed 
T2 cells was measured to assess the correlation between the presence of ILL-specific CTLs and the 
lysis of ILL-pulsed cells. Due to shortage of PBMCs, the assay could only be performed on PBMCs 
from individuals who did not have ILL-specific CTLs detectable with the dextramer, therefore, no 
ILL-specific killing was observed regardless of the stimulating condition (Figure 6.5A, B and C). 
 
The LNcaP cell line was shown in Chapter 4 to be HLA-A2+ and to express the hPAP (Figure 4.3). 
‘Knocking out’ the hPAP gene reduced PAP expression by 84%, relative to LNCaP WT cells (Figure 
4.3) and these cells (LNCaP PAPlow) were used to evaluate the capacity of PBMCs to lyse LNCaP cells 
in a PAP-specific manner. To further test the presence of ILL-specific CTLs, LNCaP WT cells were also 
pulsed with the ILL 9mer peptide prior to performing cytotoxicity assays. 
 
Results demonstrated a slight, but non-significant higher cytotoxicity against LNCaP WT cells than 
against LNCaP PAPlow for both stimulating conditions (Figure 6.6B), with cytotoxicity against LNCaP 
cells being higher after PAP42mut peptide stimulation (Figure 6.6C). However, the only significant 
difference between the 2 stimulating conditions was observed for ILL-pulsed LNCaP WT target cells. 
This result is surprising as no ILL-specific CTLs were detected in these patients. These results suggest 
the possibility that these patients have PAP-specific CTLs for epitope(s) other than ILL, that are 
contained within the hPAP42mer sequence and that these were expanded during the 12 days in 
vitro culture. There is also the possibility that because the method used was initially developed for 
expanding CTLs of higher frequencies, such as those against viruses, it might not be optimal for 





Figure 6.5: Cytotoxicity of PBMCs from patients with prostate cancer against ILL-presenting T2 
cells. Cryopreserved PBMCs from HLA-A2+ patients with prostate cancer were cultured for 12 days in 
the presence of IL-2, IL-15 and either the HLA-A2-restricted ILL epitope or the hPAP42mer mutated 
peptide. At the end of the stimulation, PBMCs were co-incubated with PKH26 stained target cells for 3 
hours, at the end of which cells were stained with LIVE/DEAD™ Yellow Dead Cell Stain to measure the 
percentage of dead target cells. Percentage of cytotoxicity against PK26+ (target) cells was compared 
per patient (A) between T2 unpulsed and pulsed cells (B) and between stimulating condition (C). No 
ILL-specific lysis was observed. Bars represent the mean percentage of positive cells and the error bars 
represent the SD (n= 3 to 7 patients). Differences in the cytotoxicity between groups were determined 





Figure 6.6: Cytotoxicity of PBMCs from patients with prostate cancer the human prostatic cell line 
LNCaP. Cryopreserved PBMCs from HLA-A2+ patients with prostate cancer were cultured for 12 days in 
the presence of IL-2, IL-15 and either the HLA-A2-restricted ILL epitope or the hPAP42mer mutated 
peptide. At the end of the stimulation, PBMCs were co-incubated with PKH26 stained target cells for 3 
hours, at the end of which cells were stained with LIVE/DEAD™ Yellow Dead Cell Stain to measure the 
percentage of dead target cells. Percentage of cytotoxicity against PK26+ (target) cells was compared 
per patient (A) between LNCaP shRNA, WT and WT ILL cells (B) and between stimulating condition (C). 
No significant PAP-specific lysis was observed. PAP42mut peptide stimulated PBMCs induced higher 
percentage of cytotoxicity against LNCaP cells. Bars represent the mean percentage of positive cells and 
the error bars represent the SD (n= 2 to 6 patients). Differences in the cytotoxicity between groups were 
determined using a two-way ANOVA comparison test.
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T2 cells LNCaP cells 
T2- T2 ILL shRNA WT WT ILL 
1:1 5:1 1:1 5:1 1:1 5:1 1:1 5:1 1:1 5:1 
Healthy 2 
ILL             
PAP42mut             
Healthy 3 
ILL             
PAP42mut             
LE309 
ILL             
PAP42mut             
LE311 
ILL             
PAP42mut             
LE312 
ILL             
PAP42mut             
LE313 
ILL             
PAP42mut             
LE317 
ILL             
PAP42mut             
LE319 
ILL             
PAP42mut             
LE320 
ILL             
PAP42mut             
LE322 
ILL             
PAP42mut             
LE325 
ILL             




Results presented in this chapter illustrate the heterogeneity of each individual’s immune system. 
Evidently, the incapacity or capacity of patients with prostate cancer to develop an ILL-specific 
immune response depends on diversity in central and peripheral tolerance mechanisms which can 
vary between individuals. The expression of peripheral tissue antigens in the thymus varies among 
individuals, suggesting that the level of expression of a specific antigen determines the 
susceptibility to autoimmunity against that antigen (Takase, et al. 2005). Although PAP has been 
shown to be expressed in the thymus (Kong and Byun 2013), no investigation has assessed the 
differential expression of this protein among individuals. Based on the study by Takase et al., one 
can speculate that PAP expression in thymic cells varies among individuals (Takase, et al. 2005), 
providing a possible explanation for the disparity in circulating ILL-specific T-cells in patients with 
prostate cancer. 
 
Stimulation with the PAP42mut was less efficient at inducing ILL-specific CTLs, which could be due 
to the length of the peptide. Indeed, although 9mer epitopes can bind directly to MHC class-I 
molecules and be presented to T-cells, longer peptides such as the hPAP42mut peptide are required 
to be taken up and processed by APCs in order for these cells to break down the peptide into class-
I and class-II epitopes that can be presented to T-cells (Melief 2008). Although monocytes and B 
cells present in PBMCs can act as APCs, they are not as efficient at stimulating antigen-experienced 
T cells as DCs. The in vitro generation of DCs would have allowed a more efficient processing of the 
hPAP42mut peptide and possibility not only improve the generation of ILL-specific CTLs, but also 
allow for other/additional peptide(s) to be presented. 
 
Johnson et al. demonstrated that 80% of patients with prostate cancer had PAP-specific IFNγ-
releasing T-cells (Johnson, et al. 2017). Although this percentage is much higher than 37.5%, the 
current study was highly restrictive and only assessed the presence of CTLs specific to a single HLA-
A2 epitope, in a few patients. The study of other HLA-A2 epitopes contained within the hPAP42mer 
sequence would be of interest. Indeed, the higher cytotoxicity induced against LNCaP cells following 
stimulation with the hPAP42mut peptide suggests the presence of PAP-specific CTLs other than ILL-
specific CTLs. 
 
The aim of this study assumed that patients with prostate cancer exhibiting pre-existing PAP-
specific immunity, in particular of ILL-specific CTLs, which were highly increased following 
vaccination with the CAF09-based vaccine in Chapter 3, would respond better to immunisation with 
this new and patented mutated-PAP derived 42mer peptide vaccine. 
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However, whether pre-existing immunity towards a class-I epitope can predict an improved OS in 
vaccinated patients is not clear. Voutsas et al., assessed a therapeutic peptide-based vaccine 
targeting the oncogene HER-2 in a phase I clinical trial for the treatment of patients with prostate 
cancer (Voutsas, et al. 2016). Pre-existence of reactivity to 2 PSA-derived epitopes at high 
frequencies was detected and a further enhancement was observed after vaccination. However, 
while pre-existing immunity towards the HLA-A24 restricted epitope correlated with longer PFS, 
high pre-existing and vaccine-induced immunity towards the HLA-A2 restricted epitope showed a 
trend towards a shorter PFS. 
 
In the context of pTVG-HP PAP DNA vaccine, two predictive parameters of the development of 
vaccine-induced PAP-specific effector responses have been described. Johnson et al. investigated 
baseline immune parameters that were predictive of the establishment of a PAP-specific immune 
response following vaccination with the pTVG-HP PAP DNA vaccine (Johnson, et al. 2017). Although 
T-cell responses towards HLA-restricted epitopes was not assessed, cytokine secretion following 
PAP stimulation was. Both responders and non-responders exhibited PAP-specific Th1 responses 
before vaccination, however non-responders displayed a higher PAP-specific secretion of IL-10 
(p=0.09) which was secreted by both CD4+ and CD8+ T-cells. It therefore appears that pre-existing 
regulatory-type antigen-specific T-cell immunity is a negative predictive parameter of 
responsiveness to a PAP DNA vaccine. These results suggest that vaccination should be combined 
with anti-IL-10 treatment. 
Another potential negative predictive marker for the development of PAP-specific immunity after 
vaccination is the presence PAP-specific CD8+ regulatory T-cells expressing CTLA-4 and secreting IL-
35 (Olson, et al. 2012). The presence of these cells was detected in 33% (7/21) of patients with 
prostate cancer before vaccination and it has been suggested that they inhibit the detection of PAP-
specific effector responses after vaccination. Unlike IL-10 or TGF-β blockade, CTLA-4 and IL-35 
blockade could reverse their suppressive phenotype. However, none of these studies correlated 
the presence of these negative predictive markers with OS. 
 
Other than assessing the presence of antigen-specific T-cells prior to vaccination, Farsaci et al. have 
calculated a “peripheral immunoscore” that can predict the OS benefit of prostate cancer before 
receiving PROSTVAC vaccine, which is characterised by the presence of specific immune cell subsets 
prior vaccination, (Farsaci, et al. 2016).  High frequencies of PD-1+ and CTLA-4+ CD4+ T-cells and of 
differentiated CD8+ T-cells and low frequencies of Treg cells and differentiated CD4+ T-cells were 
shown to correlate with improved OS following combination of GVAX vaccine with Ippilimumab 
(Santegoets, et al. 2013). Moreover, high frequencies of MDSCs pre-treatment were associated 
with shorter OS (Santegoets, et al. 2014). These studies demonstrate the feasibility and utility of 
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determining pre-vaccine immune subsets that can predict the efficacy of a therapeutic prostate 
cancer vaccine and enable the selection of individuals that are most likely to benefit from it. 
In conclusion, 37.5% of the patients with prostate cancer evaluated had circulating ILL-specific T-
cells. Moreover, PBMCs from most patients were able to lyse the LNCaP prostatic cancer cell line. 
Although it was not significant, cytotoxicity towards LNCaP was lower in LNCaP PAPlow cells, 
suggesting that cytotoxicity was driven by recognition of PAP epitopes. However, this study was 
conducted on only 16 patients. Moreover, control groups (healthy individuals and individuals with 
benign disease) were too small to assess if the proportion of individuals with circulating ILL-specific 
CTLs is higher in patients.  Further studies are required to assess not only the presence, but also the 
functionality of ILL-specific CTLs. PBMCs from additional patients would allow the cytotoxic function 
of ILL-CTLs to be assessed. Additionally, as suggested by studies mentioned above, it is essential to 




Chapter 7: Discussion 
Prostate cancer is a slow evolving disease, however, for patients who become resistant to 
androgen-deprivation therapy, there is currently no curative treatment. The five therapies currently 
FDA-approved for mCRPC only improve the OS of patients by few months, testifying of the need for 
developing new therapies. 
Despite the breakthrough in immunotherapeutic treatments for cancer in the last decade, only one 
of the therapies for mCRPC is an immunotherapy: Provenge vaccine. 
The limitations of Provenge vaccine include 1) its limited efficacy (improved OS of 4.1 months) 2) 
its autologous aspect, requiring PBMCs from each patient to be taken prior to reinfusion and 3) its 
cost, in order to isolate and cultivate CD54+ DCs in the presence of the PAP/GM-CSF fusion protein 
per patient. 
The current study focused on a vaccine more restrictive in terms of potential PAP-derived epitope 
CTLs that can be elicited, as it encompasses 42AA of the PAP protein, while Provenge covers the 
whole PAP protein (354AA). However, this vaccine would be non-invasive and its production easier 
and less costly.  
 
The rationale behind the current study was therefore to develop a PAP-derived vaccine for the 
treatment of mCRPC. 
This study demonstrated the ability of our vaccine to 1) elicit HLA-A2 restricted CTLs with secretory 
and cytolytic functions in a humanized mouse model, 2) break tolerance towards PAP in the C57Bl/6 
mouse model by eliciting mPAP-specific CTLs with secretory and cytolytic functions and 3) the pre-
existence of HLA-A2 restricted CTLs in PCa. 
 
7.1. Optimisation of the vaccine strategy 
The study began with the optimisation of the vaccine strategy. Two parameters of the vaccine were 
altered: the sequence of the PAP42mer peptide and the vehicle/adjuvant used. 
The alteration of the PAP sequence was based on a previously characterised 15AA sequence, PAP 
114-128 (MSAM), validated as an immunogenic HLA-DR1 peptide, containing the PAP115-123 HLA-
A2 peptide (SAM) (Saif, et al. 2013). A mutation was introduced to increase the predicting binding 
affinity of SAM class-I epitope to HLA-A*02:01, according to the SYFPEITHI algorithm, which was 
confirmed by IFNγ ELISpot assays (data not shown). The 15mer was subsequently elongated to a 
42mer sequence to include several class-I and class-II epitopes. 
However, elongating the sequence to 42AA lead to the loss of SAM-specific IFNγ release and the 
preeminence of ILL class-I epitope (PAP135-143). Although this peptide was not affected by the 
mutation, its immunogenicity increased following immunisation with the mutated PAP42mer. 
Regarding the C57Bl/6 model, all class-I epitopes with an improved IFNγ response following 
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immunisation with mutated mPAP42mer peptides (2 or 3 mutations sequences), were altered by 
the mutation. In both models, the functional avidity towards immunogenic epitopes was improved 
by immunising with mutated PAP42mer peptides. Therefore, immunisation with a mutated 
sequence improved the CTL response towards WT epitopes following in vitro stimulation, whether 
these epitopes were altered or not by the mutation. 
This phenomenon has not been studied well but was described by other groups as a mean to 
overcome tolerance towards self-antigens. In melanoma, DNA vaccines targeting two mouse 
antigens (gp100 and tyrosinase) demonstrated safety and immunogenicity in phase I clinical trials 
(Yuan, et al. 2009) (Wolchok, et al. 2007). Moreover, peptide analogues to a NY-ESO-1 epitope were 
more efficient than the wild-type peptide in expanding NY-ESO-1-specific CTLs from melanoma 
patients PBMCs (Chen, et al. 2000). 
One phase I clinical trial assessed the capacity of a dendritic cell-based xenoantigen vaccine to break 
tolerance towards PAP (Fong, et al. 2001). All 21 PCa patients developed Th1 T-cell responses 
towards the murine PAP and 11 out of 21 towards the human PAP. Moreover, 6 of these patients 
had a stable disease. 
These examples demonstrate the feasibility in human clinical trials of vaccines using modified 
antigens capable of breaking tolerance towards self-antigens. 
 
The second parameter modified was the delivery system. Two peptide-based strategies and one 
DNA vaccine were tested. CpG adjuvant was able to induce PAP responses in the HHDII/DR1 model 
but could not break tolerance in the C57B/6 model. The ImmunoBody® DNA vaccine could elicit 
strong immune responses in the C57Bl/6 model but none in the HHDII/DR1 model. The CAF09 
adjuvant, however, was able to induce strong PAP-specific immune responses in both mouse 
models. 
It should be noted that the route of administration was different for each vaccine strategies, 
rendering the results obtained not directly comparable. The CpG vaccine was injected via 
intramuscular route while the CAF09 vaccine and the ImmunoBody® vaccine were administered as 
per recommended by collaborators providing these vaccines (intraperitoneal route for CAF09 and 
via a gold coated bullet fired with a gene gun for the ImmunoBody®). 
The intraperitoneal route aims at targeting the mucosal lymphatic system and was shown to induce 
stronger splenic CD8+ T-cell response in comparison to intramuscular or subcutaneous 
administration in the context of the CAF09 vaccine (Schimdt. et al, 2016). However, it does not 
translate to human subjects as the intramuscular route is generally used. It would have been of 
interest to compare the CpG and CAF09 vaccines using the same route of administration, both 




7.2. Characterisation of the vaccine-induced immune response 
Subsequent to the optimisation of the vaccination strategy, selected optimal vaccine strategies 
were further assessed. Beyond the IFNγ release response, the phenotype and function of vaccine-
induced T-cells was evaluated. 
Overall, the immune response observed in both mouse models was defined by a CD8-driven 
immune response characterised by 1) an increased functional avidity towards class-I epitopes, 2) 
induction of PD-1 expression on both CD4+ and CD8+ T-cells, 3) induction of effector memory but 
not central memory CD8+ T-cells, 4) cytokine release, proliferation (Ki67) and degranulation 
(CD107a and granzyme B) by CD8+ T-cells following 6hrs of class-I epitope(s) stimulation, 5) 
induction of an exhausted phenotype on CD8+ T-cells (co-expression of PD-1, TIM-3 and LAG-3) 
following 6 days stimulation with class-I epitopes and 6) epitope and/or PAP-specific cytotoxicity. 
 
As mentioned in section 1.3.4.1, the functional avidity relates to the overall clonal T-cell response 
towards its antigen and usually correlates with TCR affinity and avidity, both of which are crucial in 
the context of TAAs such as PAP. High avidity T-cells are highly cytotoxic (Dutoit, et al. 2001) (Pudney, 
et al. 2010) and T-cells with high TCR affinity are required for efficient tumour eradication as they 
allow efficient antigen cross-presentation and cytokines secretion by CTLs (Engels, et al. 2013). 
Moreover, PD-1 expression defines CTLs clonotypes of high avidity (Simon, et al. 2015). Altogether, 
these data suggest the highly cytotoxic potential of vaccine-elicited CTLs in this study. 
 
The goal of vaccination is to produce a long-term immunological memory response which, in the 
case of cancer, can contribute to tumour eradication and prevent relapse. Our vaccine strategy 
generated effector memory CD8+ T-cells. In fact, the CD44highCD62Lneg/low population could be 
effector and/or effector memory cells. Considering that the vaccine-induced immune response was 
found to be CD8 driven, it is not surprising that no memory CD4+ T-cells response was elicited. 
However, the lack of central memory T-cells (CD44highCD62L+) could be deleterious as these cells 
are less differentiated than effector memory cells, persist longer in vivo and have a higher 
proliferative potential conferring a more efficient capacity to generate protective immunity 
(Wherry, et al. 2003). Seaman et al. suggested that in the case of vaccines inducing CTLs responses, 
central memory rather than effector memory T-cell responses were essential as effector memory 
T-cells were unable to expand efficiently in vivo following a secondary antigen exposure (Seaman, 
et al. 2004). Recently, the indispensable role of tissue resident memory T-cells in mediating anti-
cancer immunity was illustrated. These long-lived memory T-cells, that do not recirculate once 
established in tissue, were shown to enhance the efficacy of a cancer vaccine in a preclinical model 
(Nizard, et al. 2017). Moreover, the study demonstrated a correlation between the number of tissue 
resident memory T-cells and the improved survival of patients in lung cancer, suggesting the 
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importance of designing vaccine strategies eliciting tissue resident memory T-cells. In the current 
study, the presence of these cells following vaccination was not assessed but would be of interest. 
The lack of central memory T-cells could be due to the timing. Indeed, Roberts et al. suggested that 
there is a progressive loss of effector memory T cell pools over time, and a subsequent 
establishment of a stable pool of central memory T cells (Roberts, et al. 2005). The presence of 
effector memory T-cells versus central memory T-cells could therefore be followed over time 
following vaccination (e.g. at months 1, 6, 12, and 20 after vaccination, as performed by Roberts et 
al.). 
 
The functional capacity of vaccine-elicited CD8+ T-cells following short stimulation (6 hours) with 
class-I epitopes was assessed and revealed the presence of ILL (HHDII/DR1 model) or ISI/SIW 
(C57Bl/6 model)-specific CTLs with secretory, proliferative and cytotoxic functions. A small 
proportion of secretory CTLs released IFNγ, TNFα and IL-2 while the rest released IFNγ and TNFα. 
The release of Granzyme B and perforin molecules constitutes the main cytolytic TCR-triggered 
pathway. However, only the release of Granzyme B was assessed in CTLs. Granzyme B has been 
shown to function in a perforin-independent manner, entering target cells by endocytosis. 
Granzyme B expression was vaccine-dependant but was not altered by ILL stimulation, while 
CD107a expression was vaccine and ILL stimulation-dependant. CD107a is a marker of 
degranulation and was shown to correlate with the loss of intracellular perforin (Betts, et al. 2003). 
The fact that CD107a expression did not correlate with Granzyme B release suggests that CD107a 
expression correlated with the release of perforin or of other cytotoxic molecules, such as other 
Granzymes molecules, although this was not assessed. It would also have been of interest to assess 
the death ligands pathways by measuring the expression of TRAIL and FAS-ligand on CTLs. 
 
To confirm the cytolytic potential of vaccine-elicited CTLs, cytotoxicity assays were performed 
following 6 days of stimulation in the presence of class-I epitopes and IL-2. In both mouse models, 
the proportion of CD8+ T-cells exhibiting an exhausted phenotype (co-expression of PD-1, Tim-3 and 
LAG-3) was increased in splenocytes from vaccinated mice. Class-I epitope specific lysis was 
confirmed, although it was performed on total splenocytes. Performing cytotoxicity assays on 
isolated CD8+ T-cells would have been advantageous to confirm that CTLs were responsible for the 
lysis observed. Moreover, it would enable to remove potential immunosuppressive cells that could 
dampen the cytolytic activity of CTLs, such as Tregs, whose development and expansion is 
promoted by IL-2 (Nelson 2004). 
 
In regard to PAP-specific cytotoxicity, results were disparate between mouse models. 
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In the HHDII/DR1 model, the hPAP-specific lysis could not be confirmed. No hPAP-specific 
cytotoxicity was observed when using total splenocytes with B16 cells or LNCaP cells. However, 
when performing the assay with isolated CD8+ T-cells, there was a slight increased cytotoxicity 
against LNCaP WT cells in comparison to LNCaP-PAPlow cells (still expressing 7% of hPAP mRNA) in 
the CpG and CAF09-vaccine groups. It should be noted that LNCaP cells express less hPAP protein 
than B16-HHDII-PAP+ cells (data not shown). 
B16-HHDII -/+ hPAP provided a perfect model to assess the hPAP-specific cytotoxicity, however, 
results suggest that these cells might not present ILL-HLA-A2 complexes at their surface. 
Cytotoxicity assays were performed following 6 days of in vitro stimulation in the presence of the 
HLA-A2 restricted epitope ILL. Therefore, only ILL-specific CTLs were expected to be expanded, 
although it was not verified. As a result, potential CTLs specific for other epitopes, induced by 
vaccination with the hPAP42mer mutated peptide would not have been expanded. If B16-HHDII-
PAP+ cells presented at their surface these epitopes, they would not have been recognized. To 
answer this question, the hPAP42mer mutated peptide should be used for in vitro stimulation of 
splenocytes. 
Several factors might have induced a different processing of the hPAP protein in B16-HHDII-PAP+ 
cells. Firstly, the expression of PAP was induced via transfection of the gene encoding for the human 
PAP rather than naturally expressed as in LNCaP cells. Secondly, B16-HHDII cells express chimeric 
and not WT HLA-A2 molecules. The consequence of chimeric HHDII molecules expression by B16 
cells could have been investigated by exogenous loading of ILL synthetic peptide onto these cells. 
Finally, murine cells probably have a different machinery for processing proteins. All these factors 
might have led to a different pool of epitopes being produced in B16-HHDII-PAP+ cells. Peptide-
elution followed by mass-spectrometry analysis could have answered this question. 
 
In the C57Bl/6 model, the CAF09-based vaccine induced mPAP-specific lysis of TRAMP-C1 and 
TRAMP-C2 cells. However, the cytotoxicity was only vaccine-specific against TRAMP-C2 cells. The in 
vitro expansion of epitope-specific CTLs might have induced ISI or SIW-specific CTLs from 
splenocytes from naive animals. However, it is unlikely considering that TRAMP-C2 cells naturally 
express 5 times more mPAP mRNA than TRAMP-C1, suggesting that mPAP protein expression is 
higher in TRAMP-C2 cells. If PAP-derived CTLs had been induced from naive animals, they would 
have lysed TRAMP-C2 cells more efficiently than TRAMP-C1 cells. 
 
One major criticism that can be made against the methods used to assess the cytotoxicity towards 
PCa cell lines is that both techniques (Cr51 release assay and flow cytometry-based assay) 
constrained target cells being in suspension. However, all cell lines used: B16, LNCaP, TRAMP-C1 
and TRAMP-C2 cells, are adherent cells. In the future, alternative cytotoxicity assays allowing the 
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use of adherent cells could be used. For example, the Xcelligence real time monitoring system 
measures the electrical impedance at the bottom of plates providing information on adherent cells 
including viability, cell numbers and morphology. 
 
Optimal vaccination strategies should induce not only CD8 but also CD4 antigen-specific immune 
responses in order to optimise the magnitude and quality of the CD8+ immune response. In 
particular, CD4+ T-cells provide help signals to CD8+ T-cells via DCs during the priming phase (Borst, 
et al. 2018) and have a major role in generating CD8+ T-cells memory cells (Laidlaw, et al. 2016). 
Moreover, the help provided by CD4+ T-cells was shown to rescue exhausted CD8+ T-cells, allowing 
them to regain functional capacities such as cytokines secretion and proliferation, in the context of 
chronic viral infection (Aubert et al. 2011). Recently, CD4+ T-cell help was shown to improve the CTL 
response by increasing the expression of cytotoxic effector molecules and decreasing the 
expression of inhibitory receptors (Ahrends, et al. 2017).  
The 15mer PAP-derived peptide previously described contained both class-I and a class-II restricted 
epitopes. In this study, the PAP42mer peptide was predicted to contain several class-I and class-II 
restricted epitopes in order to generate CD4 and CD8 PAP-specific T-cells. 
However, in spite of CAF09 adjuvant being described as inducing CD4+ T-cell responses, especially 
Th1 and Th17 immune responses (Pedersen, et al. 2018), no cytokine release and no memory 
response was detected by CD4+ T-cells in this study. 
The possibility that the CAF09 vaccine (in both models) and the ImmunoBody® DNA vaccine (in the 
C57Bl/6 model only) induced a CD4 helper immune response was suggested in section 3.3 due to 
higher IL-2 secretion by CD8+ T-cells when the stimulation was in the presence of 15mer epitopes, 
although it was not confirmed. The lack of helper immune response in our study might explain the 
absence of central memory CD8+ T-cells.  
 
Circulating neoantigen-specific CD8+ T-cells expressing PD-1 in melanoma patients (Gros, et al. 2016) 
were proposed to be primed in the absence of help (Borst, et al. 2018) as CTLs primed with CD4 
help downregulated PD-1 (Ahrends, et al. 2017). This theory provides another argument supporting 
the absence of a CD4 helper response in the current study as CD8+ T-cells from vaccinated animals 
upregulated PD-1. 
Borst et al. also suggest that the inclusion of helper epitopes in therapeutic vaccines design does 
not ensure the delivery of the help signal as these epitopes require to reach specific DC subtypes 
(Borst, et al. 2018). 
Studies suggested the use of CD27 and CD40 agonist antibodies in order to mimic help to provide 
co-stimulatory signals to CD8+ T-cells (Ahrends, et al. 2016; Vonderheide, et al. 2013), this could be 




The possibility that our vaccine induces antigen non-specific CD8 T-cells was mentioned in section 
3.3. This theory was supported by the fact that others described antigen non-specific CD8+ T-cells 
with an effector/effector memory phenotype (CD44high, CD62Llow) expressing PD-1, releasing 
Granzyme B and displaying cytotoxic functions without TCR engagement, that could proliferate 
following cytokines stimulation and could be induced by TLR agonists such as CpG and Poly I:C. In 
our model, CAF09 adjuvant could therefore induce these cells. 
CD8+ T-cells with some of these features were describes both in preclinical models and in humans 
following high dose IL-2 therapy. 
Tietze et al. described the antigen-independent expansion of memory CD8+ T-cells capable of 
antigen-specific tumour cell killing through TCRs with upregulation of PD-1 and CD25, as well as the 
presence of cytokine-induced memory CD8+ T-cells expressing NKG2D, Granzyme B, with an 
NKG2D-dependant anti-tumour effect. TCR-transgenic mice bearing non-antigen expressing 
tumours still benefited from the immunotherapy treatment. Their results demonstrated the innate 
and adaptive capacities of memory CD8+ T-cells depending on the stimuli (Tietze, et al. 2012). 
Another study described CD8+ T-cells with a memory phenotype capable of both MHC-restricted 
and non-MHC-restricted cytotoxicity (Dhanji, et al. 2004). 
These cells might have an advantage against immunosuppressive mechanisms such as antigen loss 
and down-regulation of MHC class-I molecules and it would therefore be of interest to perform 
further experiments to evaluate their presence in our model. 
 
7.3. In vivo tumour studies 
The next stage of the study was naturally to test the cytotoxic capacities of vaccine-induced PAP-
specific CTLs in vivo against PAP-expressing tumours. 
The B16-HHDII-PAP+ cell line was used to establish a tumour model allowing to assess the anti-
tumour efficacy of the hPAP42mer mutated vaccine (with CAF09 adjuvant). Although no PAP-
specific lysis of B16-HHDII cells was observed in vitro, both CAF09 and ImmunoBody®-based vaccine 
induced higher percentage of cytotoxicity towards B16-HHDII cells than the CpG-based vaccine. 
In a prophylactic setting, the CAF09 vaccine induced a slight delay in tumour growth and therefore 
prolonged survival, while the ImmunoBody® vaccine had no effect (data not shown). The 
immunophenotyping of splenocytes and TILs confirmed that the CAF09 vaccine induced ILL-specific 
CTLs, which mainly remained in the spleen with a small proportion migrating to the tumour site. 
TILs in vaccinated animals displayed a less exhausted phenotype which could explain the anti-
tumour effect observed. However, the therapeutic experiment with or without an anti-PD-1 
antibody did not show any anti-tumour effect. These results confirmed that ILL epitope might not 
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be presented at the surface of B16-HHDII-PAP+ cells and therefore was not the correct model to use 
to assess the anti-tumour efficacy of the vaccine. 
One point to consider is that hPAP expression was assessed in B16-HHDII-PAP+ cells prior tumour 
implantation but hPAP expression was not assessed in tumours. 
A more suitable tumour model would consist in establishing LNCaP/HHDII tumours into NOD/SCID 
immuno-deficient animals which would receive isolated T-cells from immunised HHDII/DR1 animals 
by adoptive transfer. However, this could not be performed due to the complexity, duration and 
cost of this type of experiment. 
 
The anti-tumour efficacy of the mPAP42mer mutated vaccines (both CAF09 and ImmunoBody®-
based vaccines) were evaluated against TRAMP-C1 tumours.  
TRAMP-C2 cells were believed to be a more suitable cell line to establish a tumour model as these 
cells express 5 times more mPAP mRNA than TRAMP-C1 cells, however, they were not enough 
tumorigenic to generate tumours. We can hypothesize that the higher PAP expression renders 
these cells more immunogenic. This hypothesis could have been investigated by assessing the 
presence of ISI of SIW-specific CTLs in the animals, following tumour rejection, and by rechallenging 
with TRAMP-C1 tumour cells and looking for protection. 
The results of these experiments showed that with the exception of one animal in the first 
therapeutic pilot study, no treated animals experienced tumour growth delay with either 
mPAP42mer mutated vaccines in prophylactic or therapeutic settings. The presence of PAP-specific 
CTLs and the phenotype of splenocytes and TILs were not assessed in these TRAMP-C1 studies, 
therefore, we cannot speculate on the presentation of ISI or SIW epitopes at the surface of TRAMP-
C1 cells. However, an ongoing study demonstrated that similarly to the B16 tumour model, animals 
treated with the CAF09 vaccine display less exhausted TILs (data not shown). 
 
These results demonstrate that the CAF09 vaccine can decrease the exhaustion of CTLs at the 
tumour site. Nevertheless, tumour cells employ numerous immunosuppressive mechanisms that 
can counteract an efficient vaccine strategy. For example, the presence of MDSCs within the tumour, 
as well as in other lymphoid compartments (spleen, tumour draining lymph node), in the blood and 
the bone marrow was observed in the ongoing TRAMP-C1 study (data not shown). This information 
provides one possible immunosuppressive mechanism adopted by TRAMP-C1 tumours that could 
be targeted to improve the anti-tumour efficacy of the CAF09 vaccine. Assessing the presence of 
other immuno-suppressive cells in the TME such as Tregs or TAMs would be of interest as well. 
Indeed, it was suggested that multiple vaccinations can induce Tregs, therefore dampening the anti-




One interesting observation worth noting is the fact that in vitro, the CAF09 vaccine induced CTLs 
exhibiting an exhausted phenotype, which had retained their cytotoxic functions as their presence 
correlated strongly with high cytotoxicity towards ILL-pulsed T2 cells. On the other hand, in vivo, 
animals treated with the CAF09 vaccine displayed a smaller proportion of exhausted CD8+ TILs. 
However, in the prophylactic B16 study, the animal with the longest survival displayed exhausted 
CD8+ TILs (high proportion of PD-1+/Tim3+ and small proportion of PD-1low) and CD8+ TILS with the 
highest percentage of IFNγ/TNFα secretion. These results suggest that in vivo as well, the exhausted 
phenotype correlates with functional CTLs. The meaning of co-expression of markers such as PD-1, 
Tim-3 and LAG-3 should be further studied. Other makers such as 4-1BB or CD38 could further 
distinguish between non-functional and functional CTLs. Indeed, one study reported that co-
expression of LAG-3 and 4-1BB on CTLs characterised dysfunctional antigen-specific CD8+ TILs 
deficient in IL-2 and TNFα production but retaining the expression of IFNγ, in vitro (Williams, et al. 
2017). Another study described the presence of circulating PSA-specific CD8+ T-cells in healthy 
individuals and in PCa patients, with cells from PCa patients expressing higher levels of Tim-3 and 
CD38, suggesting exhaustion, although their function was not assessed (Japp, et al. 2015). 
 
The lack of CD4+ T-cells helper response could play a major role in the weak anti-tumour effect of 
the CAF09 vaccine. As discussed above, CD4 helper T-cells are essential for an optimal CD8 response. 
In the case of antigen persistence, the generation of a CD8 memory response cannot be achieved 
and CD8+ T-cells are ultimately eliminated (Bevan 2004). The ability of CD4+ T-cells to promote the 
survival of CTLs in that case is unclear. 
 
Accessing tumours samples from PCa patients is difficult, impeding the possibility to compare the 
phenotype of TILs induced in preclinical experiments from this study with the phenotype of TILs in 
PCa patients. However, although the data available in the literature is limited, some studies have 
assessed TILs from patients with PCa prior immunotherapy. 
Fong et al. compared the tumour infiltrate of prostate tumours before and after Sipuleucel-T 
treatment and observed a 3-fold increase in infiltrating CD4+ and CD8+ T-cells at the tumour 
interface, which was not observed in the control group (Fong, et al. 2014). Most of infiltrating T-
cells expressed PD-1 and Ki67, but these were the only surface markers assessed which are not 
sufficient to determine whether T-cells have an exhausted phenotype. No information was 
available on the correlation between increased expression of PD-1+ CD8+ TILs following Sipuleucel-
T treatment and survival of patients. 
Sfanos et al. demonstrated that CD8+ TILs from PCa patients were oligo-clonal and PD-1+, but did 
not assess their function (Sfanos et al. 2009). 
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In melanoma, PD-1/Tim-3/LAG-3-expressing CD8+ TILs were described as autologous tumour-
reactive CTLs, and were capable of secreting IFNγ and lysing tumour cells in vitro following IL-2 
expansion, suggesting that the dysfunction of “exhausted” T-cells can be reversed (Gros, et al. 2014). 
Another study assessing TILs from melanoma cancer patients determined that PD-1-expressing 
CD8+ T-cells were tumour specific, however, these cells exhibit impaired effector functions as 
shown by a reduced IFNγ secretion (Ahmadzadeh, et al. 2009). Expression of PD-1 on CD8+ TILs from 
melanoma determined clones of low functional avidity and in vitro PD-1 blockade could select high 
avidity T-cell clonotypes (Simon, et al. 2015). 
TILs from gastric cancer patients co-expressing PD-1 and Tim-3 or Tim-3 alone also exhibited 
impaired functions characterised by a decreased secretion of IFNγ, TNF-α and IL-2 (Lu, et al. 2017). 
 
These results indicate that antigen persistence in tumour induce PD-1-expression on tumour-
specific T-cells. Moreover, 20% of TRAMP-C1 and TRAMP-C2 cells express a basal level of PD-L1 
which increases to almost 100% in the presence of IFNγ as showed in figure 4.1. Even though it 
might be reversible in vitro, T-cells require blockade of the PD-1/PD-L1/L2 axis to be functional in 
vivo. The efficacy of the vaccine in the TRAMP-C1 model should therefore be considered in 
combination with an anti-PD-1 antibody. 
 
7.4. Pre-existence of PAP-specific immunity in PCa patients 
The assumption that a pre-existing immunity towards a tumour antigen can be enhanced by 
immunisation with a vaccine targeting that specific antigen seems evident. 
Considering that CTLs specific for ILL9mer HLA-A*02:01-restricted epitope were previously 
described in HLA-A*02:01+ healthy individuals and PCa patients (Machlenkin, et al. 2005) and that 
the hPAP42mer mutated peptide vaccine with CAF09 adjuvant can elicit functional ILL-specific CTLs 
in HHDII/DR1 mice, dextramer technology was used to assess the presence of ILL-specific CD8+ T-
cells in PCa patients. 
In a cohort of 16 patients, 37.5% had detectable circulating ILL-specific CTLs. 1 out of 5 individuals 
with benign tumours and none of the 3 healthy individuals had detectable ILL-specific CTLs. The 
number of healthy individuals and benign tumour bearing individuals was too low to conclude if 
patients with PCa do have an increased proportion of circulating ILL-specific CTLs in their blood. 
Nonetheless, our results demonstrate the existence of a pre-existing immunity towards ILL epitope 
in PCa patients, which might be boosted with a vaccine targeting PAP. It would be of interest to 
assess the proportion of ILL-specific CTLs in PCa patients prior to and after vaccination with 
Provenge or with the pTVG-HP DNA vaccine as these two vaccines target the PAP protein. 
Preliminary results from ongoing experiments confirmed the specificity of vaccine-elicited CD8+ T-
cells towards ILL epitope in the HHDII/DR1 model that can be detected by the same dextramer used 
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in human studies, further reinforcing the potential of the CAF09-based vaccine for patients with 
prostate cancer. 
 
As discussed in section 6.3, the correlation between pre-existing immunity prior vaccination and 
improved OS or PFS post vaccination has not been demonstrated in a sufficient number of studies 
in order to conclude. 
A study assessing a vaccine in myeloid malignancies compared the percentage of HLA-A2-restricted 
epitope tetramer+ CTLs before and after vaccination (Qazilbash, et al. 2017). Out of 66 patients, 85% 
had pre-existing antigen-specific CTLs, independently of disease type and status. 53% of patients 
had at least a 2-fold increase in the percentage of tetramer+ CTLs. However, there was no 
association between the percentage of antigen-specific CTL prior and after vaccination. 
Interestingly, they demonstrated that TCR avidity of epitope-specific CTLs increased following 
vaccination and that the increase was higher in clinical responders. 
This study demonstrates that not only the percentage of epitope-specific CTLs is of importance but 
also the quality of these CTLs. 
The study mentioned above by Japp et al. demonstrated that PSA-CTLs from PCa patients expressed 
higher levels of Tim-3 and CD38 that those from healthy individuals, suggesting that these cells 
were exhausted, and reinforces the requirement for estimating the quality of antigen-specific CTLs 
(Japp, et al. 2015). 
 
It would therefore be of interest to further assess the phenotype and function of ILL-CTLs by 
evaluating their TCR avidity, their “exhausted” phenotype (PD-1, CTLA-4, Tim-3, …) , their cytokines 
secretory pattern (IFNγ, TNFα, IL-2) and the presence of ILL-specific Tregs (secretion of IL-10). 
Moreover, although, the capacity of ILL-CTLs to lyse ILL-pulsed T2 cells and LNCaP cells could not 
be performed in the current study, assessing the cytolytic capacity of ILL-CTLs cells is essential and 
should be performed in the future. 
 
Hadaschik et al. found a correlation between the proportion of ILL-CTLs (characterised as ILL-
specific IFNγ-secreting CTLs) and the stage of the disease, with a higher proportion of mCRPC 
patients displaying ILL-CTLs in comparison to low, intermediate or high risk PCa patients (Hadaschik, 
et al. 2012). In the current study, no correlation was found between the presence of circulating ILL-
CTLs and the stage of the disease (low, intermediate or high risk) (data not shown), although only 
one patient out of 16 was known to have metastasis. 
The study by Hadaschik et al. also determined that removal of Tregs in the culture highly increased 
the number of ILL-specific IFNγ-secreting T-cells. 
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Another study demonstrated that in vitro blockade of PD-L1 with a monoclonal antibody could 
enhance the frequency of activated antigen-specific CTLs and induced a switch from Th2 to Th1 
cytokines (Grenga, et al. 2016). These two studies suggest that immuno-suppressive cells present 
in the blood can dampen the antigen-specific response to an antigen in vitro, therefore 
underestimating the full potential of antigen-specific CTLs. This observation reinforces the fact that 
cancer vaccines require to be combined with other immunotherapies than can counteract 
mechanisms of peripheral tolerance employed by the tumour. 
 
The most important question to render this study more relevant to PCa patients is “is ILL epitope 
presented by HLA-A2 molecules at the surface of prostate tumours of HLA-A2+ patients?” Indeed, 
ILL-presenting tumour cells could have been deleted during immunoediting, via antigen loss variant. 
Ostroumov et al. suggests that epitopes with high affinity for MHC class-I molecules have 
undergone high selection pressure during the phase of immunoediting (Ostroumov, et al. 2018). 
Moreover, CTLs with high TCR affinity towards their epitope probably generated escape variants by 
the tumour. It has been proposed that low to medium avidity polyclonal rather than high avidity 
monoclonal immune responses could provide better anti-tumour responses (Ostroumov, et al. 
2018). 
 
Besides boosting a pre-existent PAP-specific immune response, the current vaccine strategy could 
induce antigen spreading and generating immune responses against other PAP epitopes or against 
other prostate specific antigens such as PSA or PSMA. 
 
7.5. Conclusion and future work 
The development of new immunotherapies for the treatment of cancer constitutes a major 
challenge. Most preclinical studies are never translated into human studies. The few, most 
successful, tested in clinical trials, do not achieve the same level of anti-tumour response in cancer 
patients. This is partly due to the heterogeneity of cancer patients, whereas preclinical studies are 
performed on few mouse models with identical genetic background. Therefore, there is no 
possibility to predict the success of a preclinical treatment once translated in human clinical trials. 
 
This study demonstrated the therapeutic potential of a newly developed vaccine targeting PAP 
antigen for the treatment of PCa. 
This research lead to the development of an immunogenic vaccine strategy targeting 42AA of the 
PAP protein optimised by rendering its sequence more foreign and by selecting a strong adjuvant. 
Two mouse models allowed to demonstrate both the potential translation of this work for human 
HLA-A2+ patients and the capacity of the PAP vaccine to break tolerance towards a self-antigen. In 
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both models, selected vaccine strategies induced strong PAP-specific CD8 responses. The CAF09 + 
peptide-based vaccine rather than the ImmunoBody® DNA vaccine was shown to induce highly 
cytotoxic antigen-specific CTLs in vitro, capable of lysing target cells in a PAP-specific manner. 
Regarding the in vivo anti-tumour effect of the PAP vaccine, further studies are required to conclude. 
In the HHDII/DR1 model, the B16 tumour model was not adequate to assess the efficacy of the 
hPAP42mer mutated peptide + CAF09 adjuvant vaccine. 
In the C57Bl/6 model, the mPAP42mer mutated vaccine did not induce sufficient anti-tumour 
immunity to break tolerance in the presence of a tumour. Results obtained strongly suggest the 
necessity of combining the vaccine with other immunomodulatory treatments such as 
immunotherapies or conventional therapies as these were shown to impact the immune system. 
Although ICB have had a limited efficacy in PCa patients so far, they have shown some effects in 
subsets of patients as well as in combination with therapeutic vaccines. Until now, studies have 
concentrated mainly on anti CTLA-4 and anti PD-1/PD-L1 monoclonal antibodies, yet, there is an 
abundance of ICB antibodies with a therapeutic potential for PCa patients. For example, LAG-3 and 
TIM-3 molecules were co-expressed with PD-1 on T-cells in our model and could be targeted. The 
expression of VISTA molecule was not assessed but could a potential target as it was shown to be 
increased following Ipilimumab treatment in PCa patients (Gao, et al. 2017). 
MDSCs might also be a suitable target to improve the vaccine efficacy as these cells were found in 
TRAMP-C1 tumours (data not shown), have been observed in the blood of PCa patients (Idorn, et 
al. 2014), with an increased proportion in patients with visceral metastases (Autio, et al. 2015) and 
their blockade was shown to sensitize PCa patients to ICB therapies (Lu, et al. 2017). 
 
In order to render this work more relevant to the pathophysiology of PCa, an ongoing collaboration 
is assessing the anti-tumour efficacy of the mPAP42mer mutated peptide with the CAF09 adjuvant 
vaccine against spontaneous prostate tumours in TRAMP mice. These tumours grow spontaneously 
and slowly in the prostates of mice which will make these results highly informative. 
 
Finally, the potential of the hPAP42mer mutated vaccine to elicit PAP-specific responses in PCa 
patients was reinforced by the fact that 37.5% of the 16 PCa patients tested had pre-existing 
circulating ILL-specific CTLs. However, the questions of whether or not ILL epitope is a naturally 
processed epitope specific for PAP and if ILL-specific CTLs can lyse prostate tumour cells remain 
unanswered. Our findings neither corroborate Machlenkin et al. findings that ILL-CTLs could lyse 
LNCaP cells (Machlenkin, et al. 2005) nor contradict Olson et al. observations that ILL-CTLs from 
prostate cancer patients could not lyse prostate cancer cells (Olson, et al. 2015). Further studies are 





Abel, A.M., Yang, C., Thakar, M.S. and Malarkannan, S., 2018. Natural Killer Cells: Development, 
Maturation, and Clinical Utilization. Frontiers in Immunology, 9, 1869.  
Abiko, K., Matsumura, N., Hamanishi, J., Horikawa, N., Murakami, R., Yamaguchi, K., Yoshioka, Y., 
Baba, T., Konishi, I. and Mandai, M., 2015. IFN-gamma from lymphocytes induces PD-L1 expression 
and promotes progression of ovarian cancer. British Journal of Cancer, 112 (9), 1501-1509.  
Adler, H.L., McCurdy, M.A., Kattan, M.W., Timme, T.L., Scardino, P.T. and Thompson, T.C., 1999. 
Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with 
metastatic prostatic carcinoma. The Journal of Urology, 161 (1), 182-187.  
Agaugue, S., Carosella, E.D. and Rouas-Freiss, N., 2011. Role of HLA-G in tumor escape through 
expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus 
Th1/Th17. Blood, 117 (26), 7021-7031.  
Aguilar, L.K., Teh, B., Mai, W., Caillouet, J., Ayala, G., Aguilar-Cordova, E. and Butler, E., 2006. Five 
year follow up of a phase II study of cytotoxic immunotherapy combined with radiation in newly 
diagnosed prostate cancer. Jco, 24 (18), 4635-4635.  
Ahmadzadeh, M., Johnson, L.A., Heemskerk, B., Wunderlich, J.R., Dudley, M.E., White, D.E. and 
Rosenberg, S.A., 2009. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels 
of PD-1 and are functionally impaired. Blood, 114 (8), 1537-1544.  
Ahmann, F.R., and Schifman, R.B., 1987. Prospective comparison between serum monoclonal 
prostate specific antigen and acid phosphatase measurements in metastatic prostatic cancer. The 
Journal of Urology, 137 (3), 431-434.  
Ahrends, T., Babala, N., Xiao, Y., Yagita, H., van Eenennaam, H. and Borst, J., 2016. CD27 Agonism 
Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination. Cancer 
Research, 76 (10), 2921-2931.  
Ahrends, T., Spanjaard, A., Pilzecker, B., Babala, N., Bovens, A., Xiao, Y., Jacobs, H. and Borst, J., 
2017. CD4(+) T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor 
Downregulation and Increased Tissue Invasiveness. Immunity, 47 (5), 848-861.e5.  
Albini, A., Bruno, A., Noonan, D.M. and Mortara, L., 2018. Contribution to Tumor Angiogenesis From 
Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy. 
Frontiers in Immunology, 9, 527.  
Ammirante, M., Luo, J.L., Grivennikov, S., Nedospasov, S. and Karin, M., 2010. B-cell-derived 
lymphotoxin promotes castration-resistant prostate cancer. Nature, 464 (7286), 302-305.  
Anderson, K.S., Alexander, J., Wei, M. and Cresswell, P., 1993. Intracellular transport of class I MHC 
molecules in antigen processing mutant cell lines. Journal of Immunology (Baltimore, Md.: 1950), 
151 (7), 3407-3419.  
Antonarakis, E.S., Kibel, A.S., Yu, E.Y., Karsh, L.I., Elfiky, A., Shore, N.D., Vogelzang, N.J., Corman, 
J.M., Millard, F.E., Maher, J.C., Chang, N.N., DeVries, T., Sheikh, N.A., Drake, C.G. and STAND 
Investigators, 2017. Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with 
Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial. Clinical 
183 
 
Cancer Research: An Official Journal of the American Association for Cancer Research, 23 (10), 2451-
2459.  
Antonarakis, E.S., Small, E.J., Petrylak, D.P., AUID, Q.D., Kibel, A.S., Chang, N.N., Dearstyne, E., 
Harmon, M., Campogan, D., Haynes, H., Vu, T., Sheikh, N.A. and Drake, C.G., Antigen-Specific CD8 
Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate 
Cancer and Association with Overall Survival.  
Antonarakis, E.S., Kibel, A.S., Adams, G., Karsh, L.I., Elfiky, A., Shore, N.D., Vogelzang, N.J., Corman, 
J.M., Tyler, R.C., McCoy, C., Wang, Y., Sheikh, N.A. and Drake, C.G., 2013. A randomized phase II 
study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in 
biochemically recurrent prostate cancer (BRPC): Immune results. Jco, 31 (15), 5016-5016.  
Arstila, T.P., Casrouge, A., Baron, V., Even, J., Kanellopoulos, J. and Kourilsky, P., 1999. A direct 
estimate of the human alphabeta T cell receptor diversity. Science (New York, N.Y.), 286 (5441), 
958-961.  
Aubert, R.D., Kamphorst, A.O., Sarkar, S., Vezys, V., Ha, S.J., Barber, D.L., Ye, L., Sharpe, A.H., 
Freeman, G.J. and Ahmed, R., 2011. Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells 
during chronic viral infection. Proceedings of the National Academy of Sciences of the United States 
of America, 108 (52), 21182-21187.  
Autio, K.A., Wong, P., Rabinowitz, A., Yuan, J., Slavin, L.M., Brennan, R., DerSarkissian, M., Mu, Z., 
Scher, H.I. and Lesokhin, A.M., 2015. Presence of myeloid-derived suppressor cells (MDSC) in 
patients with metastatic castration-sensitive and castration-resistant prostate cancer. Jco, 33 (7), 
222-222.  
Bahl, A., Oudard, S., Tombal, B., Ozguroglu, M., Hansen, S., Kocak, I., Gravis, G., Devin, J., Shen, L., 
de Bono, J.S., Sartor, A.O. and TROPIC Investigators, 2013. Impact of cabazitaxel on 2-year survival 
and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer 
treated in the TROPIC trial. Annals of Oncology: Official Journal of the European Society for Medical 
Oncology, 24 (9), 2402-2408.  
Baitsch, L., Baumgaertner, P., Devevre, E., Raghav, S.K., Legat, A., Barba, L., Wieckowski, S., 
Bouzourene, H., Deplancke, B., Romero, P., Rufer, N. and Speiser, D.E., 2011. Exhaustion of tumor-
specific CD8 (+) T cells in metastases from melanoma patients. The Journal of Clinical Investigation, 
121 (6), 2350-2360.  
Balkwill, F., 2009. Tumour necrosis factor and cancer. Nature Reviews.Cancer, 9 (5), 361-371.  
Becker, J.T., Olson, B.M., Johnson, L.E., Davies, J.G., Dunphy, E.J. and McNeel, D.G., 2010. DNA 
vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients 
with recurrent prostate cancer. Journal of Immunotherapy (Hagerstown, Md.: 1997), 33 (6), 639-
647.  
Beer, T.M., Kwon, E.D., Drake, C.G., Fizazi, K., Logothetis, C., Gravis, G., Ganju, V., Polikoff, J., Saad, 
F., Humanski, P., Piulats, J.M., Gonzalez Mella, P., Ng, S.S., Jaeger, D., Parnis, F.X., Franke, F.A., 
Puente, J., Carvajal, R., Sengelov, L., McHenry, M.B., Varma, A., van den Eertwegh, A.J. and Gerritsen, 
W., 2017. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic 
or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant 
Prostate Cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical 
Oncology, 35 (1), 40-47.  
184 
 
Bennett, S.R., Carbone, F.R., Karamalis, F., Flavell, R.A., Miller, J.F. and Heath, W.R., 1998. Help for 
cytotoxic-T-cell responses is mediated by CD40 signalling. Nature, 393 (6684), 478-480.  
Berthold, D.R., Pond, G.R., Soban, F., de Wit, R., Eisenberger, M. and Tannock, I.F., 2008. Docetaxel 
plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival 
in the TAX 327 study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical 
Oncology, 26 (2), 242-245.  
Bertrand, F., Montfort, A., Marcheteau, E., Imbert, C., Gilhodes, J., Filleron, T., Rochaix, P., Andrieu-
Abadie, N., Levade, T., Meyer, N., Colacios, C. and Segui, B., 2017. TNFalpha blockade overcomes 
resistance to anti-PD-1 in experimental melanoma. Nature Communications, 8 (1), 2256-017-
02358-7.  
Betts, M.R., Brenchley, J.M., Price, D.A., De Rosa, S.C., Douek, D.C., Roederer, M. and Koup, R.A., 
2003. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay 
for degranulation. Journal of Immunological Methods, 281 (1-2), 65-78.  
Bevan, M.J., 2004. Helping the CD8 (+) T-cell response. Nature Reviews.Immunology, 4 (8), 595-602.  
Bezu, L., Kepp, O., Cerrato, G., Pol, J., Fucikova, J., Spisek, R., Zitvogel, L., Kroemer, G. and Galluzzi, 
L., 2018. Trial watch: Peptide-based vaccines in anticancer therapy. Oncoimmunology, 7 (12), 
e1511506.  
Bhat, P., Leggatt, G., Waterhouse, N. and Frazer, I.H., 2017. Interferon-gamma derived from 
cytotoxic lymphocytes directly enhances their motility and cytotoxicity. Cell Death & Disease, 8 (6), 
e2836.  
Bijker, M.S., van den Eeden, S.J., Franken, K.L., Melief, C.J., Offringa, R. and van der Burg, S.H., 2007. 
CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing 
CTL response, whereas long peptides induce sustained CTL reactivity. Journal of Immunology 
(Baltimore, Md.: 1950), 179 (8), 5033-5040.  
Bishop, J.L., Sio, A., Angeles, A., Roberts, M.E., Azad, A.A., Chi, K.N. and Zoubeidi, A., 2015. PD-L1 is 
highly expressed in Enzalutamide resistant prostate cancer. Oncotarget, 6 (1), 234-242.  
Bjorklund, M., Beretta, A., Coutinho, A. and Gullberg, M., 1986. Effector functions and specificities 
of normal murine T cells stimulated by syngeneic blasts. European Journal of Immunology, 16 (5), 
471-477.  
Blohmke, C.J., Hill, J., Darton, T.C., Carvalho-Burger, M., Eustace, A., Jones, C., Schreiber, F., Goodier, 
M.R., Dougan, G., Nakaya, H.I. and Pollard, A.J., 2017. Induction of Cell Cycle and NK Cell Responses 
by Live-Attenuated Oral Vaccines against Typhoid Fever. Frontiers in Immunology, 8, 1276.  
Blum, J.S., Wearsch, P.A. and Cresswell, P., 2013. Pathways of antigen processing. Annual Review of 
Immunology, 31, 443-473.  
Borley, N., and Feneley, M.R., 2009. Prostate cancer: diagnosis and staging. Asian Journal of 
Andrology, 11 (1), 74-80.  
Borst, J., Ahrends, T., Babala, N., Melief, C.J.M. and Kastenmuller, W., 2018. CD4 (+) T cell help in 
cancer immunology and immunotherapy. Nature Reviews.Immunology, 18 (10), 635-647.  
Boudadi, K., Suzman, D.L., Luber, B., Wang, H., Silberstein, J., Sullivan, R., Dowling, D., Harb, R., 
Nirschl, T., Dittamore, R.V., Carducci, M.A., Eisenberger, M.A., Haffner, M., Meeker, A., Eshleman, 
185 
 
J.R., Luo, J., Drake, C.G. and Antonarakis, E.S., 2017. Phase 2 biomarker-driven study of ipilimumab 
plus nivolumab (Ipi/Nivo) for ARV7-positive metastatic castrate-resistant prostate cancer (mCRPC). 
Jco, 35 (15), 5035-5035.  
Brandt, A., Sundquist, J. and Hemminki, K., 2012. Risk for incident and fatal prostate cancer in men 
with a family history of any incident and fatal cancer. Annals of Oncology: Official Journal of the 
European Society for Medical Oncology, 23 (1), 251-256.  
Braumuller, H., Wieder, T., Brenner, E., Assmann, S., Hahn, M., Alkhaled, M., Schilbach, K., Essmann, 
F., Kneilling, M., Griessinger, C., Ranta, F., Ullrich, S., Mocikat, R., Braungart, K., Mehra, T., 
Fehrenbacher, B., Berdel, J., Niessner, H., Meier, F., van den Broek, M., Haring, H.U., Handgretinger, 
R., Quintanilla-Martinez, L., Fend, F., Pesic, M., Bauer, J., Zender, L., Schaller, M., Schulze-Osthoff, 
K. and Rocken, M., 2013. T-helper-1-cell cytokines drive cancer into senescence. Nature, 494 (7437), 
361-365.  
Brentville, V.A., Metheringham, R.L., Gunn, B. and Durrant, L.G., 2012. High avidity cytotoxic T 
lymphocytes can be selected into the memory pool but they are exquisitely sensitive to functional 
impairment. PloS One, 7 (7), e41112.  
Budhwani M, Mazzieri R, Dolcetti R. Plasticity of Type I Interferon-Mediated Responses in Cancer 
Therapy: From Anti-tumor Immunity to Resistance. Front Oncol. 2018 Aug 21;8:322. 
Burnet, F.M., 1970. The concept of immunological surveillance. Progress in Experimental Tumor 
Research, 13, 1-27.  
Buyyounouski, M.K., Choyke, P.L., McKenney, J.K., Sartor, O., Sandler, H.M., Amin, M.B., Kattan, 
M.W. and Lin, D.W., 2017. Prostate cancer - major changes in the American Joint Committee on 
Cancer eighth edition cancer staging manual. CA: A Cancer Journal for Clinicians, 67 (3), 245-253.  
Calcinotto, A., Spataro, C., Zagato, E., Di Mitri, D., Gil, V., Crespo, M., De Bernardis, G., Losa, M., 
Mirenda, M., Pasquini, E., Rinaldi, A., Sumanasuriya, S., Lambros, M.B., Neeb, A., Luciano, R., Bravi, 
C.A., Nava-Rodrigues, D., Dolling, D., Prayer-Galetti, T., Ferreira, A., Briganti, A., Esposito, A., Barry, 
S., Yuan, W., Sharp, A., de Bono, J. and Alimonti, A., 2018. IL-23 secreted by myeloid cells drives 
castration-resistant prostate cancer. Nature, 559 (7714), 363-369.  
Carlsson, B., Forsberg, O., Bengtsson, M., Totterman, T.H. and Essand, M., 2007. Characterization 
of human prostate and breast cancer cell lines for experimental T cell-based immunotherapy. The 
Prostate, 67 (4), 389-395.  
Caza, T., and Landas, S., 2015. Functional and Phenotypic Plasticity of CD4 (+) T Cell Subsets. BioMed 
Research International, 2015, 521957.  
Chaplin, D.D., 2010. Overview of the immune response. The Journal of Allergy and Clinical 
Immunology, 125 (2 Suppl 2), S3-23.  
Chen, D.S., and Mellman, I., 2017. Elements of cancer immunity and the cancer-immune set point. 
Nature, 541 (7637), 321-330.  
Chen, J.L., Dunbar, P.R., Gileadi, U., Jager, E., Gnjatic, S., Nagata, Y., Stockert, E., Panicali, D.L., Chen, 
Y.T., Knuth, A., Old, L.J. and Cerundolo, V., 2000. Identification of NY-ESO-1 peptide analogues 
capable of improved stimulation of tumor-reactive CTL. Journal of Immunology (Baltimore, Md.: 
1950), 165 (2), 948-955.  
186 
 
Chen, L., and Flies, D.B., 2013. Molecular mechanisms of T cell co-stimulation and co-inhibition. 
Nature Reviews.Immunology, 13 (4), 227-242.  
Chen, N., and Zhou, Q., 2016. The evolving Gleason grading system. Chinese Journal of Cancer 
Research = Chung-Kuo Yen Cheng Yen Chiu, 28 (1), 58-64.  
Cheon H, Borden EC, Stark GR. Interferons and their stimulated genes in the tumor 
microenvironment. Semin Oncol. (2014) 41:156–73. 10.1053/j.seminoncol.2014.02.002 
Comiskey, M.C., Dallos, M.C. and Drake, C.G., 2018. Immunotherapy in Prostate Cancer: Teaching 
an Old Dog New Tricks. Current Oncology Reports, 20 (9), 75-018-0712-z.  
Condotta, S.A., and Richer, M.J., 2017. The immune battlefield: The impact of inflammatory 
cytokines on CD8+ T-cell immunity. PLoS Pathogens, 13 (10), e1006618.  
Conry, R.M., Westbrook, B., McKee, S. and Norwood, T.G., 2018. Talimogene laherparepvec: First 
in class oncolytic virotherapy. Human Vaccines & Immunotherapeutics, 14 (4), 839-846.  
D'Amico, A.V., Whittington, R., Malkowicz, S.B., Fondurulia, J., Chen, M.H., Kaplan, I., Beard, C.J., 
Tomaszewski, J.E., Renshaw, A.A., Wein, A. and Coleman, C.N., 1999. Pretreatment nomogram for 
prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation 
therapy for clinically localized prostate cancer. Journal of Clinical Oncology: Official Journal of the 
American Society of Clinical Oncology, 17 (1), 168-172.  
Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I, Caviglia JM, Khiabanian H, 
Adeyemi A, Bataller R, Lefkowitch JH, Bower M, Friedman R, Sartor RB, Rabadan R, Schwabe RF. 
Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell. 
2012;21:504–516. 
Darboe, A., Danso, E., Clarke, E., Umesi, A., Touray, E., Wegmuller, R., Moore, S.E., Riley, E.M. and 
Goodier, M.R., 2017. Enhancement of cytokine-driven NK cell IFN-gamma production after 
vaccination of HCMV infected Africans. European Journal of Immunology, 47 (6), 1040-1050.  
Davidsson, S., Ohlson, A.L., Andersson, S.O., Fall, K., Meisner, A., Fiorentino, M., Andren, O. and 
Rider, J.R., 2013. CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3 (+) regulatory T cells with 
respect to lethal prostate cancer. Modern Pathology: An Official Journal of the United States and 
Canadian Academy of Pathology, Inc, 26 (3), 448-455.  
De Angelis, R., Sant, M., Coleman, M.P., Francisci, S., Baili, P., Pierannunzio, D., Trama, A., Visser, O., 
Brenner, H., Ardanaz, E., Bielska-Lasota, M., Engholm, G., Nennecke, A., Siesling, S., Berrino, F., 
Capocaccia, R. and EUROCARE-5 Working Group, 2014. Cancer survival in Europe 1999-2007 by 
country and age: results of EUROCARE--5-a population-based study. The Lancet.Oncology, 15 (1), 
23-34.  
De Bono, J.S., Goh, J.C.H., Ojamaa, K., Piulats Rodriguez, J.M., Drake, C.G., Hoimes, C.J., Wu, H., 
Poehlein, C.H. and Antonarakis, E.S., 2018. KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-
refractory metastatic castration-resistant prostate cancer (mCRPC). Jco, 36 (15), 5007-5007.  
de Jong, E.C., Smits, H.H. and Kapsenberg, M.L., 2005. Dendritic cell-mediated T cell polarization. 
Springer Seminars in Immunopathology, 26 (3), 289-307.  
De Maeseneer, D.J., Van Praet, C., Lumen, N. and Rottey, S., 2015. Battling resistance mechanisms 
in antihormonal prostate cancer treatment: Novel agents and combinations. Urologic Oncology, 33 
(7), 310-321.  
187 
 
Derre, L., Corvaisier, M., Charreau, B., Moreau, A., Godefroy, E., Moreau-Aubry, A., Jotereau, F. and 
Gervois, N., 2006. Expression and release of HLA-E by melanoma cells and melanocytes: potential 
impact on the response of cytotoxic effector cells. Journal of Immunology (Baltimore, Md.: 1950), 
177 (5), 3100-3107.  
Descotes, J.L., 2019. Diagnosis of prostate cancer. Asian Journal of Urology, 6 (2), 129-136.  
Dhanji, S., and Teh, H.S., 2003. IL-2-activated CD8+CD44high cells express both adaptive and innate 
immune system receptors and demonstrate specificity for syngeneic tumor cells. Journal of 
Immunology (Baltimore, Md.: 1950), 171 (7), 3442-3450.  
Dhanji, S., Teh, S.J., Oble, D., Priatel, J.J. and Teh, H.S., 2004. Self-reactive memory-phenotype CD8 
T cells exhibit both MHC-restricted and non-MHC-restricted cytotoxicity: a role for the T-cell 
receptor and natural killer cell receptors. Blood, 104 (7), 2116-2123.  
Dokka, S., Shi, X., Leonard, S., Wang, L., Castranova, V. and Rojanasakul, Y., 2001. Interleukin-10-
mediated inhibition of free radical generation in macrophages. American Journal of Physiology.Lung 
Cellular and Molecular Physiology, 280 (6), L1196-202.  
Dolton, G., Lissina, A., Skowera, A., Ladell, K., Tungatt, K., Jones, E., Kronenberg-Versteeg, D., 
Akpovwa, H., Pentier, J.M., Holland, C.J., Godkin, A.J., Cole, D.K., Neller, M.A., Miles, J.J., Price, D.A., 
Peakman, M. and Sewell, A.K., 2014. Comparison of peptide-major histocompatibility complex 
tetramers and dextramers for the identification of antigen-specific T cells. Clinical and Experimental 
Immunology, 177 (1), 47-63.  
Dong, H., Strome, S.E., Salomao, D.R., Tamura, H., Hirano, F., Flies, D.B., Roche, P.C., Lu, J., Zhu, G., 
Tamada, K., Lennon, V.A., Celis, E. and Chen, L., 2002. Tumor-associated B7-H1 promotes T-cell 
apoptosis: a potential mechanism of immune evasion. Nature Medicine, 8 (8), 793-800.  
Dulos, G.J., and Bagchus, W.M., 2001. Androgens indirectly accelerate thymocyte apoptosis. 
International Immunopharmacology, 1 (2), 321-328.  
Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J. and Schreiber, R.D., 2002. Cancer immunoediting: from 
immunosurveillance to tumor escape. Nature Immunology, 3 (11), 991-998.  
Durrant, L.G., Pudney, V., Spendlove, I. and Metheringham, R.L., 2010. Vaccines as early therapeutic 
interventions for cancer therapy: neutralising the immunosuppressive tumour environment and 
increasing T cell avidity may lead to improved responses. Expert Opinion on Biological Therapy, 10 
(5), 735-748.  
Dutoit, V., Rubio-Godoy, V., Dietrich, P.Y., Quiqueres, A.L., Schnuriger, V., Rimoldi, D., Lienard, D., 
Speiser, D., Guillaume, P., Batard, P., Cerottini, J.C., Romero, P. and Valmori, D., 2001. 
Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T 
lymphocytes show superior antitumor activity. Cancer Research, 61 (15), 5850-5856.  
Ebelt, K., Babaryka, G., Figel, A.M., Pohla, H., Buchner, A., Stief, C.G., Eisenmenger, W., Kirchner, T., 
Schendel, D.J. and Noessner, E., 2008. Dominance of CD4+ lymphocytic infiltrates with disturbed 
effector cell characteristics in the tumor microenvironment of prostate carcinoma. The Prostate, 68 
(1), 1-10.  
Ehl, S., Hombach, J., Aichele, P., Hengartner, H. and Zinkernagel, R.M., 1997. Bystander activation 
of cytotoxic T cells: studies on the mechanism and evaluation of in vivo significance in a transgenic 
mouse model. The Journal of Experimental Medicine, 185 (7), 1241-1251.  
188 
 
Ehrlich P. Ueber den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd. 1909;5:273–
290. 
Eickhoff, S., Brewitz, A., Gerner, M.Y., Klauschen, F., Komander, K., Hemmi, H., Garbi, N., Kaisho, T., 
Germain, R.N. and Kastenmuller, W., 2015. Robust Anti-viral Immunity Requires Multiple Distinct T 
Cell-Dendritic Cell Interactions. Cell, 162 (6), 1322-1337.  
Ellis, J.M., Henson, V., Slack, R., Ng, J., Hartzman, R.J. and Katovich Hurley, C., 2000. Frequencies of 
HLA-A2 alleles in five U.S. population groups. Predominance Of A*02011 and identification of HLA-
A*0231. Human Immunology, 61 (3), 334-340.  
Engels, B., Engelhard, V.H., Sidney, J., Sette, A., Binder, D.C., Liu, R.B., Kranz, D.M., Meredith, S.C., 
Rowley, D.A. and Schreiber, H., 2013. Relapse or eradication of cancer is predicted by peptide-major 
histocompatibility complex affinity. Cancer Cell, 23 (4), 516-526.  
Etzioni, R., Gulati, R., Falcon, S. and Penson, D.F., 2008. Impact of PSA screening on the incidence of 
advanced stage prostate cancer in the United States: a surveillance modeling approach. Medical 
Decision Making: An International Journal of the Society for Medical Decision Making, 28 (3), 323-
331.  
Fakhrejahani, F., Madan, R.A., Dahut, W.L., Karzai, F., Cordes, L.M., Schlom, J. and Gulley, J.L., 2017. 
Avelumab in metastatic castration-resistant prostate cancer (mCRPC). Jco, 35 (6), 159-159.  
Farhood, B., Najafi, M. and Mortezaee, K., 2019. CD8 (+) cytotoxic T lymphocytes in cancer 
immunotherapy: A review. Journal of Cellular Physiology, 234 (6), 8509-8521.  
Farsaci, B., Donahue, R.N., Grenga, I., Lepone, L.M., Kim, P.S., Dempsey, B., Siebert, J.C., Ibrahim, 
N.K., Madan, R.A., Heery, C.R., Gulley, J.L. and Schlom, J., 2016. Analyses of Pretherapy Peripheral 
Immunoscore and Response to Vaccine Therapy. Cancer Immunology Research, 4 (9), 755-765.  
Favier, B., Lemaoult, J., Lesport, E. and Carosella, E.D., 2010. ILT2/HLA-G interaction impairs NK-cell 
functions through the inhibition of the late but not the early events of the NK-cell activating synapse. 
FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 
24 (3), 689-699.  
Feau, S., Garcia, Z., Arens, R., Yagita, H., Borst, J. and Schoenberger, S.P., 2012. The CD4 (+) T-cell 
help signal is transmitted from APC to CD8 (+) T-cells via CD27-CD70 interactions. Nature 
Communications, 3, 948.  
Fehniger, T.A., Cooper, M.A., Nuovo, G.J., Cella, M., Facchetti, F., Colonna, M. and Caligiuri, M.A., 
2003. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-
derived IL-2: a potential new link between adaptive and innate immunity. Blood, 101 (8), 3052-3057.  
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D. 
and Bray, F., 2015. Cancer incidence and mortality worldwide: sources, methods and major patterns 
in GLOBOCAN 2012. International Journal of Cancer, 136 (5), E359-86.  
Fiorentino, D.F., Zlotnik, A., Mosmann, T.R., Howard, M. and O'Garra, A., 1991. IL-10 inhibits 
cytokine production by activated macrophages. Journal of Immunology (Baltimore, Md.: 1950), 147 
(11), 3815-3822.  
Fizazi, K., Scher, H.I., Molina, A., Logothetis, C.J., Chi, K.N., Jones, R.J., Staffurth, J.N., North, S., 
Vogelzang, N.J., Saad, F., Mainwaring, P., Harland, S., Goodman, O.B.,Jr, Sternberg, C.N., Li, J.H., 
Kheoh, T., Haqq, C.M., de Bono, J.S. and COU-AA-301 Investigators, 2012. Abiraterone acetate for 
189 
 
treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the 
COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. The Lancet.Oncology, 13 
(10), 983-992.  
Fong, L., Brockstedt, D., Benike, C., Breen, J.K., Strang, G., Ruegg, C.L. and Engleman, E.G., 2001. 
Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. Journal of 
Immunology (Baltimore, Md.: 1950), 167 (12), 7150-7156.  
Fong, L., Carroll, P., Weinberg, V., Chan, S., Lewis, J., Corman, J., Amling, C.L., Stephenson, R.A., 
Simko, J., Sheikh, N.A., Sims, R.B., Frohlich, M.W. and Small, E.J., 2014. Activated lymphocyte 
recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized 
prostate cancer. Journal of the National Cancer Institute, 106 (11), 10.1093/jnci/dju268. Print 2014 
Nov.  
Foster, B.A., Gingrich, J.R., Kwon, E.D., Madias, C. and Greenberg, N.M., 1997. Characterization of 
prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate 
(TRAMP) model. Cancer Research, 57 (16), 3325-3330.  
Fridman, W.H., Zitvogel, L., Sautes-Fridman, C. and Kroemer, G., 2017. The immune contexture in 
cancer prognosis and treatment. Nature Reviews.Clinical Oncology, 14 (12), 717-734.  
Friedman, E.J., 2002. Immune modulation by ionizing radiation and its implications for cancer 
immunotherapy. Current Pharmaceutical Design, 8 (19), 1765-1780.  
Gabrilovich, D.I., Chen, H.L., Girgis, K.R., Cunningham, H.T., Meny, G.M., Nadaf, S., Kavanaugh, D. 
and Carbone, D.P., 1996. Production of vascular endothelial growth factor by human tumors inhibits 
the functional maturation of dendritic cells. Nature Medicine, 2 (10), 1096-1103.  
Galletti, G., Leach, B.I., Lam, L. and Tagawa, S.T., 2017. Mechanisms of resistance to systemic 
therapy in metastatic castration-resistant prostate cancer. Cancer Treatment Reviews, 57, 16-27.  
Galluzzi, L., Vacchelli, E., Bravo-San Pedro, J.M., Buque, A., Senovilla, L., Baracco, E.E., Bloy, N., 
Castoldi, F., Abastado, J.P., Agostinis, P., Apte, R.N., Aranda, F., Ayyoub, M., Beckhove, P., Blay, J.Y., 
Bracci, L., Caignard, A., Castelli, C., Cavallo, F., Celis, E., Cerundolo, V., Clayton, A., Colombo, M.P., 
Coussens, L., Dhodapkar, M.V., Eggermont, A.M., Fearon, D.T., Fridman, W.H., Fucikova, J., 
Gabrilovich, D.I., Galon, J., Garg, A., Ghiringhelli, F., Giaccone, G., Gilboa, E., Gnjatic, S., Hoos, A., 
Hosmalin, A., Jager, D., Kalinski, P., Karre, K., Kepp, O., Kiessling, R., Kirkwood, J.M., Klein, E., Knuth, 
A., Lewis, C.E., Liblau, R., Lotze, M.T., Lugli, E., Mach, J.P., Mattei, F., Mavilio, D., Melero, I., Melief, 
C.J., Mittendorf, E.A., Moretta, L., Odunsi, A., Okada, H., Palucka, A.K., Peter, M.E., Pienta, K.J., 
Porgador, A., Prendergast, G.C., Rabinovich, G.A., Restifo, N.P., Rizvi, N., Sautes-Fridman, C., 
Schreiber, H., Seliger, B., Shiku, H., Silva-Santos, B., Smyth, M.J., Speiser, D.E., Spisek, R., Srivastava, 
P.K., Talmadge, J.E., Tartour, E., Van Der Burg, S.H., Van Den Eynde, B.J., Vile, R., Wagner, H., Weber, 
J.S., Whiteside, T.L., Wolchok, J.D., Zitvogel, L., Zou, W. and Kroemer, G., 2014. Classification of 
current anticancer immunotherapies. Oncotarget, 5 (24), 12472-12508.  
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pages, C., Tosolini, M., 
Camus, M., Berger, A., Wind, P., Zinzindohoue, F., Bruneval, P., Cugnenc, P.H., Trajanoski, Z., 
Fridman, W.H. and Pages, F., 2006. Type, density, and location of immune cells within human 
colorectal tumors predict clinical outcome. Science (New York, N.Y.), 313 (5795), 1960-1964.  
Gannon, P.O., Poisson, A.O., Delvoye, N., Lapointe, R., Mes-Masson, A.M. and Saad, F., 2009. 
Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate 
cancer patients. Journal of Immunological Methods, 348 (1-2), 9-17.  
190 
 
Gao, J., Ward, J.F., Pettaway, C.A., Shi, L.Z., Subudhi, S.K., Vence, L.M., Zhao, H., Chen, J., Chen, H., 
Efstathiou, E., Troncoso, P., Allison, J.P., Logothetis, C.J., Wistuba, I.I., Sepulveda, M.A., Sun, J., 
Wargo, J., Blando, J. and Sharma, P., 2017. VISTA is an inhibitory immune checkpoint that is 
increased after ipilimumab therapy in patients with prostate cancer. Nature Medicine, 23 (5), 551-
555.  
Garcia, A.J., Ruscetti, M., Arenzana, T.L., Tran, L.M., Bianci-Frias, D., Sybert, E., Priceman, S.J., Wu, 
L., Nelson, P.S., Smale, S.T. and Wu, H., 2014. Pten null prostate epithelium promotes localized 
myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and 
progression. Molecular and Cellular Biology, 34 (11), 2017-2028.  
Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C.M., Quigley, M.F., Almeida, J.R., Gostick, E., Yu, Z., 
Carpenito, C., Wang, E., Douek, D.C., Price, D.A., June, C.H., Marincola, F.M., Roederer, M. and 
Restifo, N.P., 2011. A human memory T cell subset with stem cell-like properties. Nature Medicine, 
17 (10), 1290-1297.  
Gaudino, S.J., and Kumar, P., 2019. Cross-Talk Between Antigen Presenting Cells and T Cells Impacts 
Intestinal Homeostasis, Bacterial Infections, and Tumorigenesis. Frontiers in Immunology, 10, 360.  
Gebhardt, T., Wakim, L.M., Eidsmo, L., Reading, P.C., Heath, W.R. and Carbone, F.R., 2009. Memory 
T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes 
simplex virus. Nature Immunology, 10 (5), 524-530.  
Gleason, D.F., and Mellinger, G.T., 1974. Prediction of prognosis for prostatic adenocarcinoma by 
combined histological grading and clinical staging. The Journal of Urology, 111 (1), 58-64.  
Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R.M., Barregard, 
L., Bhutta, Z.A., Brenner, H., Dicker, D.J., Chimed-Orchir, O., Dandona, R., Dandona, L., Fleming, T., 
Forouzanfar, M.H., Hancock, J., Hay, R.J., Hunter-Merrill, R., Huynh, C., Hosgood, H.D., Johnson, C.O., 
Jonas, J.B., Khubchandani, J., Kumar, G.A., Kutz, M., Lan, Q., Larson, H.J., Liang, X., Lim, S.S., Lopez, 
A.D., MacIntyre, M.F., Marczak, L., Marquez, N., Mokdad, A.H., Pinho, C., Pourmalek, F., Salomon, 
J.A., Sanabria, J.R., Sandar, L., Sartorius, B., Schwartz, S.M., Shackelford, K.A., Shibuya, K., Stanaway, 
J., Steiner, C., Sun, J., Takahashi, K., Vollset, S.E., Vos, T., Wagner, J.A., Wang, H., Westerman, R., 
Zeeb, H., Zoeckler, L., Abd-Allah, F., Ahmed, M.B., Alabed, S., Alam, N.K., Aldhahri, S.F., Alem, G., 
Alemayohu, M.A., Ali, R., Al-Raddadi, R., Amare, A., Amoako, Y., Artaman, A., Asayesh, H., Atnafu, 
N., Awasthi, A., Saleem, H.B., Barac, A., Bedi, N., Bensenor, I., Berhane, A., Bernabe, E., Betsu, B., 
Binagwaho, A., Boneya, D., Campos-Nonato, I., Castaneda-Orjuela, C., Catala-Lopez, F., Chiang, P., 
Chibueze, C., Chitheer, A., Choi, J.Y., Cowie, B., Damtew, S., das Neves, J., Dey, S., Dharmaratne, S., 
Dhillon, P., Ding, E., Driscoll, T., Ekwueme, D., Endries, A.Y., Farvid, M., Farzadfar, F., Fernandes, J., 
Fischer, F., G/Hiwot, T.T., Gebru, A., Gopalani, S., Hailu, A., Horino, M., Horita, N., Husseini, A., 
Huybrechts, I., Inoue, M., Islami, F., Jakovljevic, M., James, S., Javanbakht, M., Jee, S.H., Kasaeian, 
A., Kedir, M.S., Khader, Y.S., Khang, Y.H., Kim, D., Leigh, J., Linn, S., Lunevicius, R., El Razek, H.M.A., 
Malekzadeh, R., Malta, D.C., Marcenes, W., Markos, D., Melaku, Y.A., Meles, K.G., Mendoza, W., 
Mengiste, D.T., Meretoja, T.J., Miller, T.R., Mohammad, K.A., Mohammadi, A., Mohammed, S., 
Moradi-Lakeh, M., Nagel, G., Nand, D., Le Nguyen, Q., Nolte, S., Ogbo, F.A., Oladimeji, K.E., Oren, E., 
Pa, M., Park, E.K., Pereira, D.M., Plass, D., Qorbani, M., Radfar, A., Rafay, A., Rahman, M., Rana, S.M., 
Soreide, K., Satpathy, M., Sawhney, M., Sepanlou, S.G., Shaikh, M.A., She, J., Shiue, I., Shore, H.R., 
Shrime, M.G., So, S., Soneji, S., Stathopoulou, V., Stroumpoulis, K., Sufiyan, M.B., Sykes, B.L., 
Tabares-Seisdedos, R., Tadese, F., Tedla, B.A., Tessema, G.A., Thakur, J.S., Tran, B.X., Ukwaja, K.N., 
Uzochukwu, B.S.C., Vlassov, V.V., Weiderpass, E., Wubshet Terefe, M., Yebyo, H.G., Yimam, H.H., 
Yonemoto, N., Younis, M.Z., Yu, C., Zaidi, Z., Zaki, M.E.S., Zenebe, Z.M., Murray, C.J.L. and Naghavi, 
M., 2017. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived 
With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic 
Analysis for the Global Burden of Disease Study. JAMA Oncology, 3 (4), 524-548.  
191 
 
Goding, S.R., Wilson, K.A., Xie, Y., Harris, K.M., Baxi, A., Akpinarli, A., Fulton, A., Tamada, K., Strome, 
S.E. and Antony, P.A., 2013. Restoring immune function of tumor-specific CD4+ T cells during 
recurrence of melanoma. Journal of Immunology (Baltimore, Md.: 1950), 190 (9), 4899-4909.  
Gok Yavuz, B., Gunaydin, G., Gedik, M.E., Kosemehmetoglu, K., Karakoc, D., Ozgur, F. and Guc, D., 
2019. Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and 
inducing immunosuppressive PD-1(+) TAMs. Scientific Reports, 9 (1), 3172-019-39553-z.  
Golubovskaya, V., and Wu, L., 2016. Different Subsets of T Cells, Memory, Effector Functions, and 
CAR-T Immunotherapy. Cancers, 8 (3), 10.3390/cancers8030036.  
Goodier, M.R., Rodriguez-Galan, A., Lusa, C., Nielsen, C.M., Darboe, A., Moldoveanu, A.L., White, 
M.J., Behrens, R. and Riley, E.M., 2016. Influenza Vaccination Generates Cytokine-Induced Memory-
like NK Cells: Impact of Human Cytomegalovirus Infection. Journal of Immunology (Baltimore, Md.: 
1950), 197 (1), 313-325.  
Gosselaar, C., Roobol, M.J., Roemeling, S. and Schroder, F.H., 2008. The role of the digital rectal 
examination in subsequent screening visits in the European randomized study of screening for 
prostate cancer (ERSPC), Rotterdam. European Urology, 54 (3), 581-588.  
Graddis, T.J., McMahan, C.J., Tamman, J., Page, K.J. and Trager, J.B., 2011. Prostatic acid 
phosphatase expression in human tissues. International Journal of Clinical and Experimental 
Pathology, 4 (3), 295-306.  
Graff, J.N., Alumkal, J.J., Drake, C.G., Thomas, G.V., Redmond, W.L., Farhad, M., Cetnar, J.P., Ey, F.S., 
Bergan, R.C., Slottke, R. and Beer, T.M., 2016. Early evidence of anti-PD-1 activity in enzalutamide-
resistant prostate cancer. Oncotarget, 7 (33), 52810-52817.  
Grenga, I., Donahue, R.N., Lepone, L.M., Richards, J. and Schlom, J., 2016. A fully human IgG1 anti-
PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses. Clinical & Translational 
Immunology, 5 (5), e83.  
Gros, A., Parkhurst, M.R., Tran, E., Pasetto, A., Robbins, P.F., Ilyas, S., Prickett, T.D., Gartner, J.J., 
Crystal, J.S., Roberts, I.M., Trebska-McGowan, K., Wunderlich, J.R., Yang, J.C. and Rosenberg, S.A., 
2016. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of 
melanoma patients. Nature Medicine, 22 (4), 433-438.  
Gros, A., Robbins, P.F., Yao, X., Li, Y.F., Turcotte, S., Tran, E., Wunderlich, J.R., Mixon, A., Farid, S., 
Dudley, M.E., Hanada, K., Almeida, J.R., Darko, S., Douek, D.C., Yang, J.C. and Rosenberg, S.A., 2014. 
PD-1 identifies the patient-specific CD8 (+) tumor-reactive repertoire infiltrating human tumors. 
The Journal of Clinical Investigation, 124 (5), 2246-2259.  
Grossmann, M.E., Wood, M. and Celis, E., 2001. Expression, specificity and immunotherapy 
potential of prostate-associated genes in murine cell lines. World Journal of Urology, 19 (5), 365-
370.  
Grunberg, E., Eckert, K. and Maurer, H.R., 1998. Docetaxel treatment of HT-29 colon carcinoma cells 
reinforces the adhesion and immunocytotoxicity of peripheral blood lymphocytes in vitro. 
International Journal of Oncology, 12 (4), 957-963.  
GuhaThakurta, D., Sheikh, N.A., Fan, L.Q., Kandadi, H., Meagher, T.C., Hall, S.J., Kantoff, P.W., 
Higano, C.S., Small, E.J., Gardner, T.A., Bailey, K., Vu, T., DeVries, T., Whitmore, J.B., Frohlich, M.W., 
Trager, J.B. and Drake, C.G., 2015. Humoral Immune Response against Nontargeted Tumor Antigens 
after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome. Clinical 
192 
 
Cancer Research: An Official Journal of the American Association for Cancer Research, 21 (16), 3619-
3630.  
Gulley, J.L., FAU, M.R., FAU, T.K., Jochems C FAU - Marte, Jennifer,L., FAU, M.J., Farsaci B FAU - 
Tucker, Jo,A., FAU, T.J., FAU, H.J., FAU, L.D., FAU, S.S., FAU, H.C. and Schlom, J., Immune impact 
induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.  
Gulley, J.L., Giacchino, J.L., Breitmeyer, J.B., Franzusoff, A.J., Panicali, D., Schlom, J. and Kantoff, 
P.W., 2015. Prospect: A randomized double-blind phase 3 efficacy study of PROSTVAC-VF 
immunotherapy in men with asymptomatic/minimally symptomatic metastatic castration-resistant 
prostate cancer. Jco, 33 (15), TPS5081-TPS5081.  
Guo, C., Manjili, M.H., Subjeck, J.R., Sarkar, D., Fisher, P.B. and Wang, X.Y., 2013. Therapeutic cancer 
vaccines: past, present, and future. Advances in Cancer Research, 119, 421-475.  
Gupta, M., and Shorman, M., 2019. Cytomegalovirus. In: Cytomegalovirus. StatPearls. Treasure 
Island (FL): StatPearls Publishing LLC, 2019.  
Hadaschik, B., Su, Y., Huter, E., Ge, Y., Hohenfellner, M. and Beckhove, P., 2012. Antigen specific T-
cell responses against tumor antigens are controlled by regulatory T cells in patients with prostate 
cancer. The Journal of Urology, 187 (4), 1458-1465.  
Haiman, C.A., Chen, G.K., Blot, W.J., Strom, S.S., Berndt, S.I., Kittles, R.A., Rybicki, B.A., Isaacs, W.B., 
Ingles, S.A., Stanford, J.L., Diver, W.R., Witte, J.S., Chanock, S.J., Kolb, S., Signorello, L.B., Yamamura, 
Y., Neslund-Dudas, C., Thun, M.J., Murphy, A., Casey, G., Sheng, X., Wan, P., Pooler, L.C., Monroe, 
K.R., Waters, K.M., Le Marchand, L., Kolonel, L.N., Stram, D.O. and Henderson, B.E., 2011. 
Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. PLoS 
Genetics, 7 (5), e1001387.  
Hansen, A.R., Massard, C., Ott, P.A., Haas, N.B., Lopez, J.S., Ejadi, S., Wallmark, J.M., Keam, B., 
Delord, J.P., Aggarwal, R., Gould, M., Yang, P., Keefe, S.M. and Piha-Paul, S.A., 2018. Pembrolizumab 
for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Annals of Oncology: 
Official Journal of the European Society for Medical Oncology, 29 (8), 1807-1813.  
Harari, A., Cellerai, C., Bellutti Enders, F., Kostler, J., Codarri, L., Tapia, G., Boyman, O., Castro, E., 
Gaudieri, S., James, I., John, M., Wagner, R., Mallal, S. and Pantaleo, G., 2007. Skewed association 
of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype. Proceedings of the 
National Academy of Sciences of the United States of America, 104 (41), 16233-16238.  
Hassanipour-Azgomi, S., Mohammadian-Hafshejani, A., Ghoncheh, M., Towhidi, F., Jamehshorani, 
S. and Salehiniya, H., 2016. Incidence and mortality of prostate cancer and their relationship with 
the Human Development Index worldwide. Prostate International, 4 (3), 118-124.  
Hayakawa, Y., Takeda, K., Yagita, H., Smyth, M.J., Van Kaer, L., Okumura, K. and Saiki, I., 2002. IFN-
gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-
galactosylceramide. Blood, 100 (5), 1728-1733.  
He, Q.F., Xu, Y., Li, J., Huang, Z.M., Li, X.H. and Wang, X., 2019. CD8+ T-cell exhaustion in cancer: 
mechanisms and new area for cancer immunotherapy. Briefings in Functional Genomics, 18 (2), 99-
106.  
Hemminki, K., and Czene, K., 2002. Attributable risks of familial cancer from the Family-Cancer 
Database. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American 
193 
 
Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 11 
(12), 1638-1644.  
Hinz, S., Trauzold, A., Boenicke, L., Sandberg, C., Beckmann, S., Bayer, E., Walczak, H., Kalthoff, H. 
and Ungefroren, H., 2000. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and 
TRAIL-receptor-mediated apoptosis. Oncogene, 19 (48), 5477-5486.  
Hodge, J.W., Ardiani, A., Farsaci, B., Kwilas, A.R. and Gameiro, S.R., 2012. The tipping point for 
combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule 
inhibitors. Seminars in Oncology, 39 (3), 323-339.  
Hodge, K.K., McNeal, J.E., Terris, M.K. and Stamey, T.A., 1989. Random systematic versus directed 
ultrasound guided transrectal core biopsies of the prostate. The Journal of Urology, 142 (1), 71-4; 
discussion 74-5.  
Hoffmann, T.J., Van Den Eeden, S.K., Sakoda, L.C., Jorgenson, E., Habel, L.A., Graff, R.E., Passarelli, 
M.N., Cario, C.L., Emami, N.C., Chao, C.R., Ghai, N.R., Shan, J., Ranatunga, D.K., Quesenberry, C.P., 
Aaronson, D., Presti, J., Wang, Z., Berndt, S.I., Chanock, S.J., McDonnell, S.K., French, A.J., Schaid, 
D.J., Thibodeau, S.N., Li, Q., Freedman, M.L., Penney, K.L., Mucci, L.A., Haiman, C.A., Henderson, 
B.E., Seminara, D., Kvale, M.N., Kwok, P.Y., Schaefer, C., Risch, N. and Witte, J.S., 2015. A large 
multiethnic genome-wide association study of prostate cancer identifies novel risk variants and 
substantial ethnic differences. Cancer Discovery, 5 (8), 878-891.  
Hor, J.L., Whitney, P.G., Zaid, A., Brooks, A.G., Heath, W.R. and Mueller, S.N., 2015. 
Spatiotemporally Distinct Interactions with Dendritic Cell Subsets Facilitates CD4+ and CD8+ T Cell 
Activation to Localized Viral Infection. Immunity, 43 (3), 554-565.  
Horoszewicz, J.S., Leong, S.S., Chu, T.M., Wajsman, Z.L., Friedman, M., Papsidero, L., Kim, U., Chai, 
L.S., Kakati, S., Arya, S.K. and Sandberg, A.A., 1980. The LNCaP cell line--a new model for studies on 
human prostatic carcinoma. Progress in Clinical and Biological Research, 37, 115-132.  
Horoszewicz, J.S., Leong, S.S., Kawinski, E., Karr, J.P., Rosenthal, H., Chu, T.M., Mirand, E.A. and 
Murphy, G.P., 1983. LNCaP model of human prostatic carcinoma. Cancer Research, 43 (4), 1809-
1818.  
Horowitz, A., Behrens, R.H., Okell, L., Fooks, A.R. and Riley, E.M., 2010. NK cells as effectors of 
acquired immune responses: effector CD4+ T cell-dependent activation of NK cells following 
vaccination. Journal of Immunology (Baltimore, Md.: 1950), 185 (5), 2808-2818.  
Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, 
Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 
1975-2013, National Cancer Institute. Bethesda, MD, 
https://seer.cancer.gov/archive/csr/1975_2013/, based on November 2015 SEER data submission, 
posted to the SEER web site, April 2016 
Humphrey, P.A., 2004. Gleason grading and prognostic factors in carcinoma of the prostate. Modern 
Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc, 17 (3), 
292-306.  
Huse, M., 2009. The T-cell-receptor signaling network. Journal of Cell Science, 122 (Pt 9), 1269-1273.  
Idorn, M., Kollgaard, T., Kongsted, P., Sengelov, L. and Thor Straten, P., 2014. Correlation between 
frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative 
194 
 
prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer 
Immunology, Immunotherapy: CII, 63 (11), 1177-1187.  
Inozume, T., Hanada, K., Wang, Q.J., Ahmadzadeh, M., Wunderlich, J.R., Rosenberg, S.A. and Yang, 
J.C., 2010. Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-
reactive T cells. Journal of Immunotherapy (Hagerstown, Md.: 1997), 33 (9), 956-964.  
Janeway CA Jr, Travers P, Walport M, et al. Immunobiology: The Immune System in Health and 
Disease. 5th edition. New York: Garland Science; 2001. 
Janicki, C.N., Jenkinson, S.R., Williams, N.A. and Morgan, D.J., 2008. Loss of CTL function among 
high-avidity tumor-specific CD8+ T cells following tumor infiltration. Cancer Research, 68 (8), 2993-
3000.  
Janssen, E.M., Droin, N.M., Lemmens, E.E., Pinkoski, M.J., Bensinger, S.J., Ehst, B.D., Griffith, T.S., 
Green, D.R. and Schoenberger, S.P., 2005. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-
mediated activation-induced cell death. Nature, 434 (7029), 88-93.  
Janssen, E.M., Lemmens, E.E., Wolfe, T., Christen, U., von Herrath, M.G. and Schoenberger, S.P., 
2003. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. 
Nature, 421 (6925), 852-856.  
Japp, A.S., Kursunel, M.A., Meier, S., Malzer, J.N., Li, X., Rahman, N.A., Jekabsons, W., Krause, H., 
Magheli, A., Klopf, C., Thiel, A. and Frentsch, M., 2015. Dysfunction of PSA-specific CD8+ T cells in 
prostate cancer patients correlates with CD38 and Tim-3 expression. Cancer Immunology, 
Immunotherapy: CII, 64 (11), 1487-1494.  
Jeske, S.J., Milowsky, M.I., Smith, C.R., Smith, K.A., Bander, N.H. and Nanus, D.M., 2007. Phase II 
trial of the anti-prostate specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 plus 
low-dose interleukin-2 (IL-2) in patients (pts) with recurrent prostate cancer (PC). Jco, 25 (18), 
15558-15558.  
Jiang, T., Zhou, C. and Ren, S., 2016. Role of IL-2 in cancer immunotherapy. Oncoimmunology, 5 (6), 
e1163462.  
Jochems, C., Tucker, J.A., Tsang, K.Y., Madan, R.A., Dahut, W.L., Liewehr, D.J., Steinberg, S.M., Gulley, 
J.L. and Schlom, J., 2014. A combination trial of vaccine plus ipilimumab in metastatic castration-
resistant prostate cancer patients: immune correlates. Cancer Immunology, Immunotherapy: CII, 
63 (4), 407-418.  
Johnson, L.E., and McNeel, D.G., 2012. Identification of prostatic acid phosphatase (PAP) specific 
HLA-DR1-restricted T-cell epitopes. The Prostate, 72 (7), 730-740.  
Johnson, L.E., Olson, B.M. and McNeel, D.G., 2017. Pretreatment antigen-specific immunity and 
regulation - association with subsequent immune response to anti-tumor DNA vaccination. Journal 
for Immunotherapy of Cancer, 5 (1), 56-017-0260-3.  
Josefowicz, S.Z., Lu, L.F. and Rudensky, A.Y., 2012. Regulatory T cells: mechanisms of differentiation 
and function. Annual Review of Immunology, 30, 531-564.  
Jost, S., Tomezsko, P.J., Rands, K., Toth, I., Lichterfeld, M., Gandhi, R.T. and Altfeld, M., 2014. CD4+ 
T-cell help enhances NK cell function following therapeutic HIV-1 vaccination. Journal of Virology, 
88 (15), 8349-8354.  
195 
 
Kantoff, P.W., Higano, C.S., Shore, N.D., Berger, E.R., Small, E.J., Penson, D.F., Redfern, C.H., Ferrari, 
A.C., Dreicer, R., Sims, R.B., Xu, Y., Frohlich, M.W., Schellhammer, P.F. and IMPACT Study 
Investigators, 2010. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. The New 
England Journal of Medicine, 363 (5), 411-422.  
Kantoff, P.W., Schuetz, T.J., Blumenstein, B.A., Glode, L.M., Bilhartz, D.L., Wyand, M., Manson, K., 
Panicali, D.L., Laus, R., Schlom, J., Dahut, W.L., Arlen, P.M., Gulley, J.L. and Godfrey, W.R., 2010. 
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted 
immunotherapy in metastatic castration-resistant prostate cancer. Journal of Clinical Oncology: 
Official Journal of the American Society of Clinical Oncology, 28 (7), 1099-1105.  
Kaur, H.B., Guedes, L.B., Lu, J., Maldonado, L., Reitz, L., Barber, J.R., De Marzo, A.M., Tosoian, J.J., 
Tomlins, S.A., Schaeffer, E.M., Joshu, C.E., Sfanos, K.S. and Lotan, T.L., 2018. Association of tumor-
infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate 
cancer. Modern Pathology: An Official Journal of the United States and Canadian Academy of 
Pathology, Inc, 31 (10), 1539-1552.  
Khan, K.A., and Kerbel, R.S., 2018. Improving immunotherapy outcomes with anti-angiogenic 
treatments and vice versa. Nature Reviews.Clinical Oncology, 15 (5), 310-324.  
Kim, H.J., and Cantor, H., 2014. CD4 T-cell subsets and tumor immunity: the helpful and the not-so-
helpful. Cancer Immunology Research, 2 (2), 91-98.  
Kiniwa, Y., Miyahara, Y., Wang, H.Y., Peng, W., Peng, G., Wheeler, T.M., Thompson, T.C., Old, L.J. 
and Wang, R.F., 2007. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate 
cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer 
Research, 13 (23), 6947-6958.  
Kirby, M., Hirst, C. and Crawford, E.D., 2011. Characterising the castration-resistant prostate cancer 
population: a systematic review. International Journal of Clinical Practice, 65 (11), 1180-1192.  
Klein, E.Y., Monteforte, B., Gupta, A., Jiang, W., May, L., Hsieh, Y.H. and Dugas, A., 2016. The 
frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. Influenza 
and Other Respiratory Viruses, 10 (5), 394-403.  
Klyushnenkova, E.N., Kouiavskaia, D.V., Kodak, J.A., Vandenbark, A.A. and Alexander, R.B., 2007. 
Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase. 
The Prostate, 67 (10), 1019-1028.  
Koch, U., and Radtke, F., 2011. Mechanisms of T cell development and transformation. Annual 
Review of Cell and Developmental Biology, 27, 539-562.  
Kolonel, L.N., Altshuler, D. and Henderson, B.E., 2004. The multiethnic cohort study: exploring genes, 
lifestyle and cancer risk. Nature Reviews.Cancer, 4 (7), 519-527.  
Kong, H.Y., and Byun, J., 2013. Emerging roles of human prostatic Acid phosphatase. Biomolecules 
& Therapeutics, 21 (1), 10-20.  
Korsholm, K.S., Hansen, J., Karlsen, K., Filskov, J., Mikkelsen, M., Lindenstrom, T., Schmidt, S.T., 
Andersen, P. and Christensen, D., 2014. Induction of CD8+ T-cell responses against subunit antigens 
by the novel cationic liposomal CAF09 adjuvant. Vaccine, 32 (31), 3927-3935.  
196 
 
Ku, J., Wilenius, K., Larsen, C., De Guzman, K., Yoshinaga, S., Turner, J.S., Lam, R.Y. and Scholz, M.C., 
2018. Survival after sipuleucel-T (SIP-T) and low-dose ipilimumab (IPI) in men with metastatic, 
progressive, castrate-resistant prostate cancer (M-CRPC). Jco, 36 (6), 368-368.  
Kumar, B.V., Connors, T.J. and Farber, D.L., 2018. Human T Cell Development, Localization, and 
Function throughout Life. Immunity, 48 (2), 202-213.  
Kvale, R., Moller, B., Wahlqvist, R., Fossa, S.D., Berner, A., Busch, C., Kyrdalen, A.E., Svindland, A., 
Viset, T. and Halvorsen, O.J., 2009. Concordance between Gleason scores of needle biopsies and 
radical prostatectomy specimens: a population-based study. BJU International, 103 (12), 1647-1654.  
Kwon, E.D., Drake, C.G., Scher, H.I., Fizazi, K., Bossi, A., van den Eertwegh, A.J., Krainer, M., Houede, 
N., Santos, R., Mahammedi, H., Ng, S., Maio, M., Franke, F.A., Sundar, S., Agarwal, N., Bergman, 
A.M., Ciuleanu, T.E., Korbenfeld, E., Sengelov, L., Hansen, S., Logothetis, C., Beer, T.M., McHenry, 
M.B., Gagnier, P., Liu, D., Gerritsen, W.R. and CA184-043 Investigators, 2014. Ipilimumab versus 
placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had 
progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, 
phase 3 trial. The Lancet.Oncology, 15 (7), 700-712.  
Kyewski, B., and Klein, L., 2006. A central role for central tolerance. Annual Review of Immunology, 
24, 571-606.  
L.H. Sobin, C.W., 2002. TNM Classification of Malignant Tumours. 6th edition ed. 2002: Wiley-Liss.  
Labadie, B.W., Bao, R. and Luke, J.J., 2019. Reimagining IDO Pathway Inhibition in Cancer 
Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis. 
Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 25 (5), 
1462-1471.  
LaCelle, M.G., Jensen, S.M. and Fox, B.A., 2009. Partial CD4 depletion reduces regulatory T cells 
induced by multiple vaccinations and restores therapeutic efficacy. Clinical Cancer Research: An 
Official Journal of the American Association for Cancer Research, 15 (22), 6881-6890.  
Laidlaw, B.J., Craft, J.E. and Kaech, S.M., 2016. The multifaceted role of CD4 (+) T cells in CD8 (+) T 
cell memory. Nature Reviews.Immunology, 16 (2), 102-111.  
Le, D.T., Durham, J.N., Smith, K.N., Wang, H., Bartlett, B.R., Aulakh, L.K., Lu, S., Kemberling, H., Wilt, 
C., Luber, B.S., Wong, F., Azad, N.S., Rucki, A.A., Laheru, D., Donehower, R., Zaheer, A., Fisher, G.A., 
Crocenzi, T.S., Lee, J.J., Greten, T.F., Duffy, A.G., Ciombor, K.K., Eyring, A.D., Lam, B.H., Joe, A., Kang, 
S.P., Holdhoff, M., Danilova, L., Cope, L., Meyer, C., Zhou, S., Goldberg, R.M., Armstrong, D.K., Bever, 
K.M., Fader, A.N., Taube, J., Housseau, F., Spetzler, D., Xiao, N., Pardoll, D.M., Papadopoulos, N., 
Kinzler, K.W., Eshleman, J.R., Vogelstein, B., Anders, R.A. and Diaz, L.A.,Jr, 2017. Mismatch repair 
deficiency predicts response of solid tumors to PD-1 blockade. Science (New York, N.Y.), 357 (6349), 
409-413.  
Leclerc, B.G., Charlebois, R., Chouinard, G., Allard, B., Pommey, S., Saad, F. and Stagg, J., 2016. CD73 
Expression Is an Independent Prognostic Factor in Prostate Cancer. Clinical Cancer Research: An 
Official Journal of the American Association for Cancer Research, 22 (1), 158-166.  
Li, H., Fan, X. and Houghton, J., 2007. Tumor microenvironment: the role of the tumor stroma in 
cancer. Journal of Cellular Biochemistry, 101 (4), 805-815.  
197 
 
Lim, T.S., Goh, J.K., Mortellaro, A., Lim, C.T., Hammerling, G.J. and Ricciardi-Castagnoli, P., 2012. 
CD80 and CD86 differentially regulate mechanical interactions of T-cells with antigen-presenting 
dendritic cells and B-cells. PloS One, 7 (9), e45185.  
Liu, F.T., and Rabinovich, G.A., 2005. Galectins as modulators of tumour progression. Nature 
Reviews.Cancer, 5 (1), 29-41.  
Liu, Y., Saeter, T., Vlatkovic, L., Servoll, E., Waaler, G., Axcrona, U., Giercksky, K.E., Nesland, J.M., 
Suo, Z.H. and Axcrona, K., 2013. Dendritic and lymphocytic cell infiltration in prostate carcinoma. 
Histology and Histopathology, 28 (12), 1621-1628.  
Ljunggren, H.G., Stam, N.J., Ohlen, C., Neefjes, J.J., Hoglund, P., Heemels, M.T., Bastin, J., 
Schumacher, T.N., Townsend, A. and Karre, K., 1990. Empty MHC class I molecules come out in the 
cold. Nature, 346 (6283), 476-480.  
Loeb, S., Bjurlin, M.A., Nicholson, J., Tammela, T.L., Penson, D.F., Carter, H.B., Carroll, P. and Etzioni, 
R., 2014. Overdiagnosis and overtreatment of prostate cancer. European Urology, 65 (6), 1046-1055.  
Loeb, S., Folkvaljon, Y., Bratt, O., Robinson, D. and Stattin, P., 2019. Defining Intermediate Risk 
Prostate Cancer Suitable for Active Surveillance. The Journal of Urology, 201 (2), 292-299.  
Lorente, D., Mateo, J., Perez-Lopez, R., de Bono, J.S. and Attard, G., 2015. Sequencing of agents in 
castration-resistant prostate cancer. The Lancet.Oncology, 16 (6), e279-92.  
Lu, X., Horner, J.W., Paul, E., Shang, X., Troncoso, P., Deng, P., Jiang, S., Chang, Q., Spring, D.J., 
Sharma, P., Zebala, J.A., Maeda, D.Y., Wang, Y.A. and DePinho, R.A., 2017. Effective combinatorial 
immunotherapy for castration-resistant prostate cancer. Nature, 543 (7647), 728-732.  
Lu, X., Yang, L., Yao, D., Wu, X., Li, J., Liu, X., Deng, L., Huang, C., Wang, Y., Li, D. and Liu, J., 2017. 
Tumor antigen-specific CD8 (+) T cells are negatively regulated by PD-1 and Tim-3 in human gastric 
cancer. Cellular Immunology, 313, 43-51.  
Lucia, M.S., Darke, A.K., Goodman, P.J., La Rosa, F.G., Parnes, H.L., Ford, L.G., Coltman, C.A.,Jr and 
Thompson, I.M., 2008. Pathologic characteristics of cancers detected in The Prostate Cancer 
Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer 
Prevention Research (Philadelphia, Pa.), 1 (3), 167-173.  
Lundholm, M., Hagglof, C., Wikberg, M.L., Stattin, P., Egevad, L., Bergh, A., Wikstrom, P., Palmqvist, 
R. and Edin, S., 2015. Secreted Factors from Colorectal and Prostate Cancer Cells Skew the Immune 
Response in Opposite Directions. Scientific Reports, 5, 15651.  
Lunemann, J.D., Frey, O., Eidner, T., Baier, M., Roberts, S., Sashihara, J., Volkmer, R., Cohen, J.I., 
Hein, G., Kamradt, T. and Munz, C., 2008. Increased frequency of EBV-specific effector memory 
CD8+ T cells correlates with higher viral load in rheumatoid arthritis. Journal of Immunology 
(Baltimore, Md.: 1950), 181 (2), 991-1000.  
Luo, J.L., Tan, W., Ricono, J.M., Korchynskyi, O., Zhang, M., Gonias, S.L., Cheresh, D.A. and Karin, M., 
2007. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing 
Maspin. Nature, 446 (7136), 690-694.  
Machlenkin, A., Paz, A., Bar Haim, E., Goldberger, O., Finkel, E., Tirosh, B., Volovitz, I., Vadai, E., 
Lugassy, G., Cytron, S., Lemonnier, F., Tzehoval, E. and Eisenbach, L., 2005. Human CTL epitopes 
prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates 
for prostate cancer immunotherapy. Cancer Research, 65 (14), 6435-6442.  
198 
 
Madan, R.A., Gulley, J.L., Schlom, J., Steinberg, S.M., Liewehr, D.J., Dahut, W.L. and Arlen, P.M., 
2008. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer 
treated with vaccine, nilutamide, and combination therapy. Clinical Cancer Research: An Official 
Journal of the American Association for Cancer Research, 14 (14), 4526-4531.  
Madan, R.A., Mohebtash, M., Arlen, P.M., Vergati, M., Rauckhorst, M., Steinberg, S.M., Tsang, K.Y., 
Poole, D.J., Parnes, H.L., Wright, J.J., Dahut, W.L., Schlom, J. and Gulley, J.L., 2012. Ipilimumab and 
a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate 
cancer: a phase 1 dose-escalation trial. The Lancet.Oncology, 13 (5), 501-508.  
Maimela, N.R., Liu, S. and Zhang, Y., 2018. Fates of CD8+ T cells in Tumor Microenvironment. 
Computational and Structural Biotechnology Journal, 17, 1-13.  
Malamas, A.S., Gameiro, S.R., Knudson, K.M. and Hodge, J.W., 2016. Sublethal exposure to alpha 
radiation (223Ra dichloride) enhances various carcinomas' sensitivity to lysis by antigen-specific 
cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation. Oncotarget, 7 
(52), 86937-86947.  
Mapara, M.Y., and Sykes, M., 2004. Tolerance and cancer: mechanisms of tumor evasion and 
strategies for breaking tolerance. Journal of Clinical Oncology: Official Journal of the American 
Society of Clinical Oncology, 22 (6), 1136-1151.  
Mariathasan, S., Turley, S.J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel, E.E.,III, Koeppen, 
H., Astarita, J.L., Cubas, R., Jhunjhunwala, S., Banchereau, R., Yang, Y., Guan, Y., Chalouni, C., Ziai, J., 
Senbabaoglu, Y., Santoro, S., Sheinson, D., Hung, J., Giltnane, J.M., Pierce, A.A., Mesh, K., Lianoglou, 
S., Riegler, J., Carano, R.A.D., Eriksson, P., Hoglund, M., Somarriba, L., Halligan, D.L., van der Heijden, 
M.S., Loriot, Y., Rosenberg, J.E., Fong, L., Mellman, I., Chen, D.S., Green, M., Derleth, C., Fine, G.D., 
Hegde, P.S., Bourgon, R. and Powles, T., 2018. TGFbeta attenuates tumour response to PD-L1 
blockade by contributing to exclusion of T cells. Nature, 554 (7693), 544-548.  
Marincola, F.M., Jaffee, E.M., Hicklin, D.J. and Ferrone, S., 2000. Escape of human solid tumors from 
T-cell recognition: molecular mechanisms and functional significance. Advances in Immunology, 74, 
181-273.  
Martin, A.M., Nirschl, T.R., Nirschl, C.J., Francica, B.J., Kochel, C.M., van Bokhoven, A., Meeker, A.K., 
Lucia, M.S., Anders, R.A., DeMarzo, A.M. and Drake, C.G., 2015. Paucity of PD-L1 expression in 
prostate cancer: innate and adaptive immune resistance. Prostate Cancer and Prostatic Diseases, 
18 (4), 325-332.  
Martinez-Lostao, L., Anel, A. and Pardo, J., 2015. How Do Cytotoxic Lymphocytes Kill Cancer Cells? 
Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 21 
(22), 5047-5056.  
Martini, M., Testi, M.G., Pasetto, M., Picchio, M.C., Innamorati, G., Mazzocco, M., Ugel, S., Cingarlini, 
S., Bronte, V., Zanovello, P., Krampera, M., Mosna, F., Cestari, T., Riviera, A.P., Brutti, N., Barbieri, 
O., Matera, L., Tridente, G., Colombatti, M. and Sartoris, S., 2010. IFN-gamma-mediated 
upmodulation of MHC class I expression activates tumor-specific immune response in a mouse 
model of prostate cancer. Vaccine, 28 (20), 3548-3557.  
Martins, K.A., Steffens, J.T., van Tongeren, S.A., Wells, J.B., Bergeron, A.A., Dickson, S.P., Dye, J.M., 
Salazar, A.M. and Bavari, S., 2014. Toll-like receptor agonist augments virus-like particle-mediated 
protection from Ebola virus with transient immune activation. PloS One, 9 (2), e89735.  
199 
 
Massari, F., Ciccarese, C., Calio, A., Munari, E., Cima, L., Porcaro, A.B., Novella, G., Artibani, W., Sava, 
T., Eccher, A., Ghimenton, C., Bertoldo, F., Scarpa, A., Sperandio, N., Porta, C., Bronte, V., Chilosi, 
M., Bogina, G., Zamboni, G., Tortora, G., Samaratunga, H., Martignoni, G. and Brunelli, M., 2016. 
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant 
Prostate Adenocarcinoma: An Exploratory Analysis. Targeted Oncology, 11 (3), 345-351.  
Masucci, G.V., Andersson, E., Egevad, L., Kälkner, K., Harmenberg, U., Ryberg, M., Nilsson, S. and 
Pisa, P., 2006. High frequency of human leucocyte antigen (HLA) A2 and HLA-B7, -B44, -B15 and -
DRB1–4 haplotypes in Swedish prostate cancer patients. Jco, 24 (18), 14543-14543.  
McNeal, J.E., 1988. Normal histology of the prostate. The American Journal of Surgical Pathology, 
12 (8), 619-633.  
McNeel, D.G., Bander, N.H., Beer, T.M., Drake, C.G., Fong, L., Harrelson, S., Kantoff, P.W., Madan, 
R.A., Oh, W.K., Peace, D.J., Petrylak, D.P., Porterfield, H., Sartor, O., Shore, N.D., Slovin, S.F., Stein, 
M.N., Vieweg, J. and Gulley, J.L., 2016. The Society for Immunotherapy of Cancer consensus 
statement on immunotherapy for the treatment of prostate carcinoma. Journal for Immunotherapy 
of Cancer, 4, 92-016-0198-x. eCollection 2016.  
McNeel, D.G., Becker, J.T., Eickhoff, J.C., Johnson, L.E., Bradley, E., Pohlkamp, I., Staab, M.J., Liu, G., 
Wilding, G. and Olson, B.M., 2014. Real-time immune monitoring to guide plasmid DNA vaccination 
schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer. 
Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 20 
(14), 3692-3704.  
McNeel, D.G., Dunphy, E.J., Davies, J.G., Frye, T.P., Johnson, L.E., Staab, M.J., Horvath, D.L., Straus, 
J., Alberti, D., Marnocha, R., Liu, G., Eickhoff, J.C. and Wilding, G., 2009. Safety and immunological 
efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate 
cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 27 
(25), 4047-4054.  
McNeel, D.G., Eickhoff, J.C., Wargowski, E., Zahm, C., Staab, M.J., Straus, J. and Liu, G., 2018. 
Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in 
patients with metastatic, castration-resistant prostate cancer. Oncotarget, 9 (39), 25586-25596.  
McNeel, D.G., Gardner, T.A., Higano, C.S., Kantoff, P.W., Small, E.J., Wener, M.H., Sims, R.B., DeVries, 
T., Sheikh, N.A. and Dreicer, R., 2014. A transient increase in eosinophils is associated with 
prolonged survival in men with metastatic castration-resistant prostate cancer who receive 
sipuleucel-T. Cancer Immunology Research, 2 (10), 988-999.  
McNeel, D.G., Nguyen, L.D. and Disis, M.L., 2001. Identification of T helper epitopes from prostatic 
acid phosphatase. Cancer Research, 61 (13), 5161-5167.  
McNeel, D.G., Nguyen, L.D., Ellis, W.J., Higano, C.S., Lange, P.H. and Disis, M.L., 2001. Naturally 
occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in 
patients with prostate cancer. The Prostate, 47 (3), 222-229.  
McNeel, D.G., Eickhoff, J.C., Jeraj, R., Staab, M.J., Straus, J., Rekoske, B. and Liu, G., 2017. DNA 
vaccine with pembrolizumab to elicit antitumor responses in patients with metastatic, castration-
resistant prostate cancer (mCRPC). Jco, 35 (7), 168-168.  
Mehta, A.K., Gracias, D.T. and Croft, M., 2018. TNF activity and T cells. Cytokine, 101, 14-18.  
200 
 
Melero, I., Gaudernack, G., Gerritsen, W., Huber, C., Parmiani, G., Scholl, S., Thatcher, N., Wagstaff, 
J., Zielinski, C., Faulkner, I. and Mellstedt, H., 2014. Therapeutic vaccines for cancer: an overview of 
clinical trials. Nature Reviews.Clinical Oncology, 11 (9), 509-524.  
Melief, C.J., and van der Burg, S.H., 2008. Immunotherapy of established (pre)malignant disease by 
synthetic long peptide vaccines. Nature Reviews.Cancer, 8 (5), 351-360.  
Melief, C.J., van Hall, T., Arens, R., Ossendorp, F. and van der Burg, S.H., 2015. Therapeutic cancer 
vaccines. The Journal of Clinical Investigation, 125 (9), 3401-3412.  
Mellor, A.L., Chandler, P., Baban, B., Hansen, A.M., Marshall, B., Pihkala, J., Waldmann, H., Cobbold, 
S., Adams, E. and Munn, D.H., 2004. Specific subsets of murine dendritic cells acquire potent T cell 
regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. 
International Immunology, 16 (10), 1391-1401.  
Meng, S., Li, L., Zhou, M., Jiang, W., Niu, H. and Yang, K., 2018. Distribution and prognostic value of 
tumorinfiltrating T cells in breast cancer. Molecular Medicine Reports, 18 (5), 4247-4258.  
Mercader, M., Bodner, B.K., Moser, M.T., Kwon, P.S., Park, E.S., Manecke, R.G., Ellis, T.M., Wojcik, 
E.M., Yang, D., Flanigan, R.C., Waters, W.B., Kast, W.M. and Kwon, E.D., 2001. T cell infiltration of 
the prostate induced by androgen withdrawal in patients with prostate cancer. Proceedings of the 
National Academy of Sciences of the United States of America, 98 (25), 14565-14570.  
Metheringham, R.L., Pudney, V.A., Gunn, B., Towey, M., Spendlove, I. and Durrant, L.G., 2009. 
Antibodies designed as effective cancer vaccines. Mabs, 1 (1), 71-85.  
Miller, A.M., Lundberg, K., Ozenci, V., Banham, A.H., Hellstrom, M., Egevad, L. and Pisa, P., 2006. 
CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. 
Journal of Immunology (Baltimore, Md.: 1950), 177 (10), 7398-7405.  
Minn AJ. Interferons and the immunogenic effects of cancer therapy. Trends Immunol. (2015) 
36:725–37. 10.1016/j.it.2015.09.007 
Montes, M., Rufer, N., Appay, V., Reynard, S., Pittet, M.J., Speiser, D.E., Guillaume, P., Cerottini, J.C., 
Romero, P. and Leyvraz, S., 2005. Optimum in vitro expansion of human antigen-specific CD8 T cells 
for adoptive transfer therapy. Clinical and Experimental Immunology, 142 (2), 292-302.  
Muniyan, S., Chaturvedi, N.K., Dwyer, J.G., Lagrange, C.A., Chaney, W.G. and Lin, M.F., 2013. Human 
prostatic acid phosphatase: structure, function and regulation. International Journal of Molecular 
Sciences, 14 (5), 10438-10464.  
Nafie, S., Mellon, J.K., Dormer, J.P. and Khan, M.A., 2014. The role of transperineal template 
prostate biopsies in prostate cancer diagnosis in biopsy naive men with PSA less than 20 ng ml(-1.). 
Prostate Cancer and Prostatic Diseases, 17 (2), 170-173.  
Naito, Y., Saito, K., Shiiba, K., Ohuchi, A., Saigenji, K., Nagura, H. and Ohtani, H., 1998. CD8+ T cells 
infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer 
Research, 58 (16), 3491-3494.  
Nardone, V., Botta, C., Caraglia, M., Martino, E.C., Ambrosio, M.R., Carfagno, T., Tini, P., Semeraro, 
L., Misso, G., Grimaldi, A., Boccellino, M., Facchini, G., Berretta, M., Vischi, G., Rocca, B.J., Barone, 
A., Tassone, P., Tagliaferri, P., Del Vecchio, M.T., Pirtoli, L. and Correale, P., 2016. Tumor infiltrating 
T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients 
201 
 
subjected to salvage radiotherapy after biochemical relapse. Cancer Biology & Therapy, 17 (11), 
1213-1220.  
Nelson, B.H., 2004. IL-2, regulatory T cells, and tolerance. Journal of Immunology (Baltimore, Md.: 
1950), 172 (7), 3983-3988.  
Nelson, W.G., De Marzo, A.M. and Isaacs, W.B., 2003. Prostate cancer. The New England Journal of 
Medicine, 349 (4), 366-381.  
Ness, N., Andersen, S., Valkov, A., Nordby, Y., Donnem, T., Al-Saad, S., Busund, L.T., Bremnes, R.M. 
and Richardsen, E., 2014. Infiltration of CD8+ lymphocytes is an independent prognostic factor of 
biochemical failure-free survival in prostate cancer. The Prostate, 74 (14), 1452-1461.  
Nizard, M., Roussel, H., Diniz, M.O., Karaki, S., Tran, T., Voron, T., Dransart, E., Sandoval, F., Riquet, 
M., Rance, B., Marcheteau, E., Fabre, E., Mandavit, M., Terme, M., Blanc, C., Escudie, J.B., Gibault, 
L., Barthes, F.L.P., Granier, C., Ferreira, L.C.S., Badoual, C., Johannes, L. and Tartour, E., 2017. 
Induction of resident memory T cells enhances the efficacy of cancer vaccine. Nature 
Communications, 8, 15221.  
Nouri-Shirazi, M., Banchereau, J., Bell, D., Burkeholder, S., Kraus, E.T., Davoust, J. and Palucka, K.A., 
2000. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific 
immune responses. Journal of Immunology (Baltimore, Md.: 1950), 165 (7), 3797-3803.  
Nurieva, R., Wang, J. and Sahoo, A., 2013. T-cell tolerance in cancer. Immunotherapy, 5 (5), 513-
531.  
Oizumi, S., Deyev, V., Yamazaki, K., Schreiber, T., Strbo, N., Rosenblatt, J. and Podack, E.R., 2008. 
Surmounting tumor-induced immune suppression by frequent vaccination or immunization in the 
absence of B cells. Journal of Immunotherapy (Hagerstown, Md.: 1997), 31 (4), 394-401.  
Olson, B.M., Frye, T.P., Johnson, L.E., Fong, L., Knutson, K.L., Disis, M.L. and McNeel, D.G., 2010. 
HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunology, 
Immunotherapy: CII, 59 (6), 943-953.  
Olson, B.M., Jankowska-Gan, E., Becker, J.T., Vignali, D.A., Burlingham, W.J. and McNeel, D.G., 2012. 
Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 
blockade. Journal of Immunology (Baltimore, Md.: 1950), 189 (12), 5590-5601.  
Omilusik, K.D., and Goldrath, A.W., 2017. The origins of memory T cells. Nature, 552 (7685), 337-
339.  
Ossendorp, F., Mengede, E., Camps, M., Filius, R. and Melief, C.J., 1998. Specific T helper cell 
requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility 
complex class II negative tumors. The Journal of Experimental Medicine, 187 (5), 693-702.  
Ostroumov, D., Fekete-Drimusz, N., Saborowski, M., Kuhnel, F. and Woller, N., 2018. CD4 and CD8 
T lymphocyte interplay in controlling tumor growth. Cellular and Molecular Life Sciences: CMLS, 75 
(4), 689-713.  
Parker, C., Nilsson, S., Heinrich, D., Helle, S.I., O'Sullivan, J.M., Fossa, S.D., Chodacki, A., Wiechno, 
P., Logue, J., Seke, M., Widmark, A., Johannessen, D.C., Hoskin, P., Bottomley, D., James, N.D., 
Solberg, A., Syndikus, I., Kliment, J., Wedel, S., Boehmer, S., Dall'Oglio, M., Franzen, L., Coleman, R., 
Vogelzang, N.J., O'Bryan-Tear, C.G., Staudacher, K., Garcia-Vargas, J., Shan, M., Bruland, O.S., Sartor, 
202 
 
O. and ALSYMPCA Investigators, 2013. Alpha emitter radium-223 and survival in metastatic prostate 
cancer. The New England Journal of Medicine, 369 (3), 213-223.  
Parkin, J., and Cohen, B., 2001. An overview of the immune system. Lancet (London, England), 357 
(9270), 1777-1789.  
Pascolo, S., Bervas, N., Ure, J.M., Smith, A.G., Lemonnier, F.A. and Perarnau, B., 1997. HLA-A2.1-
restricted education and cytolytic activity of CD8 (+) T lymphocytes from beta2 microglobulin 
(beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. The Journal of 
Experimental Medicine, 185 (12), 2043-2051.  
Pasero, C., Gravis, G., Guerin, M., Granjeaud, S., Thomassin-Piana, J., Rocchi, P., Paciencia-Gros, M., 
Poizat, F., Bentobji, M., Azario-Cheillan, F., Walz, J., Salem, N., Brunelle, S., Moretta, A. and Olive, 
D., 2016. Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs 
Natural Killer Cell Antitumor Activity. Cancer Research, 76 (8), 2153-2165.  
Patel, P.M., Ottensmeier, C.H., Mulatero, C., Lorigan, P., Plummer, R., Pandha, H., Elsheikh, S., 
Hadjimichael, E., Villasanti, N., Adams, S.E., Cunnell, M., Metheringham, R.L., Brentville, V.A., 
Machado, L., Daniels, I., Gijon, M., Hannaman, D. and Durrant, L.G., 2018. Targeting gp100 and TRP-
2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T 
cell responses that are associated with favourable clinical outcome in a phase I/II trial. 
Oncoimmunology, 7 (6), e1433516.  
Pedersen, G.K., Andersen, P. and Christensen, D., 2018. Immunocorrelates of CAF family adjuvants. 
Seminars in Immunology, 39, 4-13.  
Pernar, C.H., Ebot, E.M., Wilson, K.M. and Mucci, L.A., 2018. The Epidemiology of Prostate Cancer. 
Cold Spring Harbor Perspectives in Medicine, 8 (12), 10.1101/cshperspect.a030361.  
Peshwa, M.V., Shi, J.D., Ruegg, C., Laus, R. and van Schooten, W.C., 1998. Induction of prostate 
tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with 
prostatic acid phosphatase peptide. The Prostate, 36 (2), 129-138.  
Petrylak, D.P., Tangen, C.M., Hussain, M.H., Lara, P.N.,Jr, Jones, J.A., Taplin, M.E., Burch, P.A., Berry, 
D., Moinpour, C., Kohli, M., Benson, M.C., Small, E.J., Raghavan, D. and Crawford, E.D., 2004. 
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory 
prostate cancer. The New England Journal of Medicine, 351 (15), 1513-1520.  
Petrylak, D.P., Vogelzang, N.J., Chatta, G.S., Fleming, M.T., Smith, D.C., Appleman, L.J., Hussain, A., 
Modiano, M., Singh, P., Tagawa, S.T., Gore, I., McClay, E.F., Mega, A.E., Sartor, A.O., Somer, B.G., 
Wadlow, R.C., Shore, N.D., Stambler, N., DiPippo, V.A. and Israel, R.J., 2015. A phase 2 study of 
prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with 
progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or 
enzalutamide (abi/enz). Jco, 33 (7), 144-144.  
Pipkin, M.E., Sacks, J.A., Cruz-Guilloty, F., Lichtenheld, M.G., Bevan, M.J. and Rao, A., 2010. 
Interleukin-2 and inflammation induce distinct transcriptional programs that promote the 
differentiation of effector cytolytic T cells. Immunity, 32 (1), 79-90.  
Podrazil, M., Horvath, R., Becht, E., Rozkova, D., Bilkova, P., Sochorova, K., Hromadkova, H., 
Kayserova, J., Vavrova, K., Lastovicka, J., Vrabcova, P., Kubackova, K., Gasova, Z., Jarolim, L., Babjuk, 
M., Spisek, R., Bartunkova, J. and Fucikova, J., 2015. Phase I/II clinical trial of dendritic-cell based 
immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, 
castration-resistant prostate cancer. Oncotarget, 6 (20), 18192-18205.  
203 
 
Potosky, A.L., Davis, W.W., Hoffman, R.M., Stanford, J.L., Stephenson, R.A., Penson, D.F. and Harlan, 
L.C., 2004. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the 
prostate cancer outcomes study. Journal of the National Cancer Institute, 96 (18), 1358-1367.  
Pritchard, C.C., Morrissey, C., Kumar, A., Zhang, X., Smith, C., Coleman, I., Salipante, S.J., Milbank, 
J., Yu, M., Grady, W.M., Tait, J.F., Corey, E., Vessella, R.L., Walsh, T., Shendure, J. and Nelson, P.S., 
2014. Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced 
prostate cancer. Nature Communications, 5, 4988.  
Pudney, V.A., Metheringham, R.L., Gunn, B., Spendlove, I., Ramage, J.M. and Durrant, L.G., 2010. 
DNA vaccination with T-cell epitopes encoded within Ab molecules induces high-avidity anti-tumor 
CD8+ T cells. European Journal of Immunology, 40 (3), 899-910.  
Qazilbash, M.H., Wieder, E., Thall, P.F., Wang, X., Rios, R., Lu, S., Kanodia, S., Ruisaard, K.E., Giralt, 
S.A., Estey, E.H., Cortes, J., Komanduri, K.V., Clise-Dwyer, K., Alatrash, G., Ma, Q., Champlin, R.E. and 
Molldrem, J.J., 2017. PR1 peptide vaccine induces specific immunity with clinical responses in 
myeloid malignancies. Leukemia, 31 (3), 697-704.  
Quezada, S.A., Simpson, T.R., Peggs, K.S., Merghoub, T., Vider, J., Fan, X., Blasberg, R., Yagita, H., 
Muranski, P., Antony, P.A., Restifo, N.P. and Allison, J.P., 2010. Tumor-reactive CD4 (+) T cells 
develop cytotoxic activity and eradicate large established melanoma after transfer into 
lymphopenic hosts. The Journal of Experimental Medicine, 207 (3), 637-650.  
Quinn, D.I., Petrylak, D.P., Pieczonka, C.M., Sandler, A., DeVries, T., Sheikh, N.A. and Drake, C.G., 
2014. A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential 
enzalutamide in metastatic castration-resistant prostate cancer (mCRPC). Jco, 32 (15), e16071-
e16071.  
Quinn, M., and Babb, P., 2002. Patterns and trends in prostate cancer incidence, survival, 
prevalence and mortality. Part I: international comparisons. BJU International, 90 (2), 162-173.  
Quintero, I.B., Araujo, C.L., Pulkka, A.E., Wirkkala, R.S., Herrala, A.M., Eskelinen, E.L., Jokitalo, E., 
Hellstrom, P.A., Tuominen, H.J., Hirvikoski, P.P. and Vihko, P.T., 2007. Prostatic acid phosphatase is 
not a prostate specific target. Cancer Research, 67 (14), 6549-6554.  
Rammensee, H.G., Falk, K. and Rotzschke, O., 1993. Peptides naturally presented by MHC class I 
molecules. Annual Review of Immunology, 11, 213-244.  
Reading, J.L., Galvez-Cancino, F., Swanton, C., Lladser, A., Peggs, K.S. and Quezada, S.A., 2018. The 
function and dysfunction of memory CD8 (+) T cells in tumor immunity. Immunological Reviews, 
283 (1), 194-212.  
Reis, S.T., Pontes-Junior, J., Antunes, A.A., Sousa-Canavez, J.M., Abe, D.K., Cruz, J.A., Dall'oglio, M.F., 
Crippa, A., Passerotti, C.C., Ribeiro-Filho, L.A., Viana, N.I., Srougi, M. and Leite, K.R., 2011. Tgf-beta1 
expression as a biomarker of poor prognosis in prostate cancer. Clinics (Sao Paulo, Brazil), 66 (7), 
1143-1147.  
Rekoske, B.T., Smith, H.A., Olson, B.M., Maricque, B.B. and McNeel, D.G., 2015. PD-1 or PD-L1 
Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization. 
Cancer Immunology Research, 3 (8), 946-955.  
Richards, J., Lim, A.C., Hay, C.W., Taylor, A.E., Wingate, A., Nowakowska, K., Pezaro, C., Carreira, S., 
Goodall, J., Arlt, W., McEwan, I.J., de Bono, J.S. and Attard, G., 2012. Interactions of abiraterone, 
204 
 
eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for 
increasing abiraterone exposure or combining with MDV3100. Cancer Research, 72 (9), 2176-2182.  
Riches, J.C., Davies, J.K., McClanahan, F., Fatah, R., Iqbal, S., Agrawal, S., Ramsay, A.G. and Gribben, 
J.G., 2013. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for 
cytokine production. Blood, 121 (9), 1612-1621.  
Ricupito, A., Grioni, M., Calcinotto, A., Hess Michelini, R., Longhi, R., Mondino, A. and Bellone, M., 
2013. Booster vaccinations against cancer are critical in prophylactic but detrimental in therapeutic 
settings. Cancer Research, 73 (12), 3545-3554.  
Roberts, A.D., Ely, K.H. and Woodland, D.L., 2005. Differential contributions of central and effector 
memory T cells to recall responses. The Journal of Experimental Medicine, 202 (1), 123-133.  
Roden, A.C., Moser, M.T., Tri, S.D., Mercader, M., Kuntz, S.M., Dong, H., Hurwitz, A.A., McKean, D.J., 
Celis, E., Leibovich, B.C., Allison, J.P. and Kwon, E.D., 2004. Augmentation of T cell levels and 
responses induced by androgen deprivation. Journal of Immunology (Baltimore, Md.: 1950), 173 
(10), 6098-6108.  
Rojas-Martinez, A., Manzanera, A.G., Sukin, S.W., Esteban-Maria, J., Gonzalez-Guerrero, J.F., 
Gomez-Guerra, L., Garza-Guajardo, R., Flores-Gutierrez, J.P., Elizondo Riojas, G., Delgado-Enciso, I., 
Ortiz-Lopez, R., Aguilar, L.K., Butler, E.B., Barrera-Saldana, H.A. and Aguilar-Cordova, E., 2013. 
Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to 
surgery in patients with prostate cancer. Cancer Gene Therapy, 20 (11), 642-649.  
Rollings, C.M., Sinclair, L.V., Brady, H.J.M., Cantrell, D.A. and Ross, S.H., 2018. Interleukin-2 shapes 
the cytotoxic T cell proteome and immune environment-sensing programs. Science Signaling, 11 
(526), 10.1126/scisignal.aap8112.  
Romee, R., Rosario, M., Berrien-Elliott, M.M., Wagner, J.A., Jewell, B.A., Schappe, T., Leong, J.W., 
Abdel-Latif, S., Schneider, S.E., Willey, S., Neal, C.C., Yu, L., Oh, S.T., Lee, Y.S., Mulder, A., Claas, F., 
Cooper, M.A. and Fehniger, T.A., 2016. Cytokine-induced memory-like natural killer cells exhibit 
enhanced responses against myeloid leukemia. Science Translational Medicine, 8 (357), 357ra123.  
Rosenberg, S.A., 2014. IL-2: the first effective immunotherapy for human cancer. Journal of 
Immunology (Baltimore, Md.: 1950), 192 (12), 5451-5458.  
Ross, S.H., and Cantrell, D.A., 2018. Signaling and Function of Interleukin-2 in T Lymphocytes. 
Annual Review of Immunology, 36, 411-433.  
Ross, S.H., Rollings, C., Anderson, K.E., Hawkins, P.T., Stephens, L.R. and Cantrell, D.A., 2016. 
Phosphoproteomic Analyses of Interleukin 2 Signaling Reveal Integrated JAK Kinase-Dependent and 
-Independent Networks in CD8 (+) T Cells. Immunity, 45 (3), 685-700.  
Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, Zitvogel L. Gut microbiome 
influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 
2018;359(6371):91–7. 
Russell, J.H., and Ley, T.J., 2002. Lymphocyte-mediated cytotoxicity. Annual Review of Immunology, 
20, 323-370.  
Saad, F., 2013. Evidence for the efficacy of enzalutamide in postchemotherapy metastatic castrate-
resistant prostate cancer. Therapeutic Advances in Urology, 5 (4), 201-210.  
205 
 
Saif, J.M., Vadakekolathu, J., Rane, S.S., McDonald, D., Ahmad, M., Mathieu, M., Pockley, A.G., 
Durrant, L., Metheringham, R., Rees, R.C. and McArdle, S.E., 2014. Novel prostate acid phosphatase-
based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour 
growth in mice. European Journal of Immunology, 44 (4), 994-1004.  
Sakaguchi, S., Yamaguchi, T., Nomura, T. and Ono, M., 2008. Regulatory T cells and immune 
tolerance. Cell, 133 (5), 775-787.  
Sakhdari, A., Mujib, S., Vali, B., Yue, F.Y., MacParland, S., Clayton, K., Jones, R.B., Liu, J., Lee, E.Y., 
Benko, E., Kovacs, C., Gommerman, J., Kaul, R. and Ostrowski, M.A., 2012. Tim-3 negatively 
regulates cytotoxicity in exhausted CD8+ T cells in HIV infection. PloS One, 7 (7), e40146.  
Salinas, C.A., Tsodikov, A., Ishak-Howard, M. and Cooney, K.A., 2014. Prostate cancer in young men: 
an important clinical entity. Nature Reviews.Urology, 11 (6), 317-323.  
Sallusto, F., Lenig, D., Forster, R., Lipp, M. and Lanzavecchia, A., 1999. Two subsets of memory T 
lymphocytes with distinct homing potentials and effector functions. Nature, 401 (6754), 708-712.  
Santegoets, S.J., Stam, A.G., Lougheed, S.M., Gall, H., Jooss, K., Sacks, N., Hege, K., Lowy, I., Scheper, 
R.J., Gerritsen, W.R., van den Eertwegh, A.J. and de Gruijl, T.D., 2014. Myeloid derived suppressor 
and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with 
prostate GVAX and ipilimumab. Journal for Immunotherapy of Cancer, 2, 31-014-0031-3. 
eCollection 2014.  
Santegoets, S.J., Stam, A.G., Lougheed, S.M., Gall, H., Scholten, P.E., Reijm, M., Jooss, K., Sacks, N., 
Hege, K., Lowy, I., Cuillerot, J.M., von Blomberg, B.M., Scheper, R.J., van den Eertwegh, A.J., 
Gerritsen, W.R. and de Gruijl, T.D., 2013. T cell profiling reveals high CD4+CTLA-4 + T cell frequency 
as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunology, 
Immunotherapy: CII, 62 (2), 245-256.  
Scheiermann, J., and Klinman, D.M., 2014. Clinical evaluation of CpG oligonucleotides as adjuvants 
for vaccines targeting infectious diseases and cancer. Vaccine, 32 (48), 6377-6389.  
Schellhammer, P.F., Chodak, G., Whitmore, J.B., Sims, R., Frohlich, M.W. and Kantoff, P.W., 2013. 
Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from 
sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. 
Urology, 81 (6), 1297-1302.  
Schenkel, J.M., Fraser, K.A., Beura, L.K., Pauken, K.E., Vezys, V. and Masopust, D., 2014. T cell 
memory. Resident memory CD8 T cells trigger protective innate and adaptive immune responses. 
Science (New York, N.Y.), 346 (6205), 98-101.  
Scher, H.I., Fizazi, K., Saad, F., Taplin, M.E., Sternberg, C.N., Miller, K., de Wit, R., Mulders, P., Chi, 
K.N., Shore, N.D., Armstrong, A.J., Flaig, T.W., Flechon, A., Mainwaring, P., Fleming, M., Hainsworth, 
J.D., Hirmand, M., Selby, B., Seely, L., de Bono, J.S. and AFFIRM Investigators, 2012. Increased 
survival with enzalutamide in prostate cancer after chemotherapy. The New England Journal of 
Medicine, 367 (13), 1187-1197.  
Scholz, M., Yep, S., Chancey, M., Kelly, C., Chau, K., Turner, J., Lam, R. and Drake, C.G., 2017. Phase 
I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic 
castrate-resistant prostate cancer. ImmunoTargets and Therapy, 6, 11-16.  
Schreiber, T.H., Deyev, V.V., Rosenblatt, J.D. and Podack, E.R., 2009. Tumor-induced suppression of 
CTL expansion and subjugation by gp96-Ig vaccination. Cancer Research, 69 (5), 2026-2033.  
206 
 
Schweizer, M.T., Cheng, H.H., Tretiakova, M.S., Vakar-Lopez, F., Klemfuss, N., Konnick, E.Q., 
Mostaghel, E.A., Nelson, P.S., Yu, E.Y., Montgomery, B., True, L.D. and Pritchard, C.C., 2016. 
Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. Oncotarget, 
7 (50), 82504-82510.  
Schymura, M.J., Kahn, A.R., German, R.R., Hsieh, M.C., Cress, R.D., Finch, J.L., Fulton, J.P., Shen, T. 
and Stuckart, E., 2010. Factors associated with initial treatment and survival for clinically localized 
prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1). BMC Cancer, 10, 152-
2407-10-152.  
Sckisel, G.D., Mirsoian, A., Minnar, C.M., Crittenden, M., Curti, B., Chen, J.Q., Blazar, B.R., Borowsky, 
A.D., Monjazeb, A.M. and Murphy, W.J., 2017. Differential phenotypes of memory CD4 and CD8 T 
cells in the spleen and peripheral tissues following immunostimulatory therapy. Journal for 
Immunotherapy of Cancer, 5, 33-017-0235-4. eCollection 2017.  
Seaman, M.S., Peyerl, F.W., Jackson, S.S., Lifton, M.A., Gorgone, D.A., Schmitz, J.E. and Letvin, N.L., 
2004. Subsets of memory cytotoxic T lymphocytes elicited by vaccination influence the efficiency 
of secondary expansion in vivo. Journal of Virology, 78 (1), 206-215.  
Sette, A., Vitiello, A., Reherman, B., Fowler, P., Nayersina, R., Kast, W.M., Melief, C.J., Oseroff, C., 
Yuan, L., Ruppert, J., Sidney, J., del Guercio, M.F., Southwood, S., Kubo, R.T., Chesnut, R.W., Grey, 
H.M. and Chisari, F.V., 1994. The relationship between class I binding affinity and immunogenicity 
of potential cytotoxic T cell epitopes. Journal of Immunology (Baltimore, Md.: 1950), 153 (12), 5586-
5592.  
Sfanos, K.S., Bruno, T.C., Maris, C.H., Xu, L., Thoburn, C.J., DeMarzo, A.M., Meeker, A.K., Isaacs, W.B. 
and Drake, C.G., 2008. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and 
Treg skewing. Clinical Cancer Research: An Official Journal of the American Association for Cancer 
Research, 14 (11), 3254-3261.  
Sfanos, K.S., Bruno, T.C., Meeker, A.K., De Marzo, A.M., Isaacs, W.B. and Drake, C.G., 2009. Human 
prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. The Prostate, 69 (15), 1694-
1703.  
Sfanos, K.S., and De Marzo, A.M., 2012. Prostate cancer and inflammation: the evidence. 
Histopathology, 60 (1), 199-215.  
Sharma, R., and Das, A., 2018. IL-2 mediates NK cell proliferation but not hyperactivity. Immunologic 
Research, 66 (1), 151-157.  
Sharpe, A.H., Wherry, E.J., Ahmed, R. and Freeman, G.J., 2007. The function of programmed cell 
death 1 and its ligands in regulating autoimmunity and infection. Nature Immunology, 8 (3), 239-
245.  
Shaulov, A., and Murali-Krishna, K., 2008. CD8 T cell expansion and memory differentiation are 
facilitated by simultaneous and sustained exposure to antigenic and inflammatory milieu. Journal 
of Immunology (Baltimore, Md.: 1950), 180 (2), 1131-1138.  
Sheikh, N.A., Petrylak, D., Kantoff, P.W., Dela Rosa, C., Stewart, F.P., Kuan, L.Y., Whitmore, J.B., 
Trager, J.B., Poehlein, C.H., Frohlich, M.W. and Urdal, D.L., 2013. Sipuleucel-T immune parameters 
correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-
resistant prostate cancer. Cancer Immunology, Immunotherapy: CII, 62 (1), 137-147.  
207 
 
Shimura, S., Yang, G., Ebara, S., Wheeler, T.M., Frolov, A. and Thompson, T.C., 2000. Reduced 
infiltration of tumor-associated macrophages in human prostate cancer: association with cancer 
progression. Cancer Research, 60 (20), 5857-5861.  
Shin, M.S., Kim, H.S., Lee, S.H., Park, W.S., Kim, S.Y., Park, J.Y., Lee, J.H., Lee, S.K., Lee, S.N., Jung, 
S.S., Han, J.Y., Kim, H., Lee, J.Y. and Yoo, N.J., 2001. Mutations of tumor necrosis factor-related 
apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic 
breast cancers. Cancer Research, 61 (13), 4942-4946.  
Shroder, F.H., Damhuis, R.A., Kirkels, W.J., De Koning, H.J., Kranse, R., Nus, H.G. and Blijenberg, B.G., 
1996. European randomized study of screening for prostate cancer--the Rotterdam pilot studies. 
International Journal of Cancer, 65 (2), 145-151.  
Shui, I.M., Lindstrom, S., Kibel, A.S., Berndt, S.I., Campa, D., Gerke, T., Penney, K.L., Albanes, D., Berg, 
C., Bueno-de-Mesquita, H.B., Chanock, S., Crawford, E.D., Diver, W.R., Gapstur, S.M., Gaziano, J.M., 
Giles, G.G., Henderson, B., Hoover, R., Johansson, M., Le Marchand, L., Ma, J., Navarro, C., Overvad, 
K., Schumacher, F.R., Severi, G., Siddiq, A., Stampfer, M., Stevens, V.L., Travis, R.C., Trichopoulos, D., 
Vineis, P., Mucci, L.A., Yeager, M., Giovannucci, E. and Kraft, P., 2014. Prostate cancer (PCa) risk 
variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort 
Consortium. European Urology, 65 (6), 1069-1075.  
Silva, A., Mount, A., Krstevska, K., Pejoski, D., Hardy, M.P., Owczarek, C., Scotney, P., Maraskovsky, 
E. and Baz Morelli, A., 2015. The combination of ISCOMATRIX adjuvant and TLR agonists induces 
regression of established solid tumors in vivo. Journal of Immunology (Baltimore, Md.: 1950), 194 
(5), 2199-2207.  
Simon, S., and Labarriere, N., 2017. PD-1 expression on tumor-specific T cells: Friend or foe for 
immunotherapy? Oncoimmunology, 7 (1), e1364828.  
Simon, S., Vignard, V., Florenceau, L., Dreno, B., Khammari, A., Lang, F. and Labarriere, N., 2015. PD-
1 expression conditions T cell avidity within an antigen-specific repertoire. Oncoimmunology, 5 (1), 
e1104448.  
Simons, J.W., and Sacks, N., Granulocyte-macrophage colony-stimulating factor-transduced 
allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. 2006 
Slovin, S.F., Wang, X., Hullings, M., Arauz, G., Bartido, S., Lewis, J.S., Schöder, H., Zanzonico, P., Scher, 
H.I., Sadelain, M. and Riviere, I., 2013. Chimeric antigen receptor (CAR+) modified T cells targeting 
prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate 
cancer (CMPC). Jco, 31 (6), 72-72.  
Small, E.J., Lance, R.S., Gardner, T.A., Karsh, L.I., Fong, L., McCoy, C., DeVries, T., Sheikh, N.A., 
GuhaThakurta, D., Chang, N., Redfern, C.H. and Shore, N.D., 2015. A Randomized Phase II Trial of 
Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic 
Castration-Resistant Prostate Cancer. Clinical Cancer Research: An Official Journal of the American 
Association for Cancer Research, 21 (17), 3862-3869.  
Smith, D.S., and Catalona, W.J., 1995. Interexaminer variability of digital rectal examination in 
detecting prostate cancer. Urology, 45 (1), 70-74.  
Smyth, M.J., Hayakawa, Y., Takeda, K. and Yagita, H., 2002. New aspects of natural-killer-cell 
surveillance and therapy of cancer. Nature Reviews.Cancer, 2 (11), 850-861.  
208 
 
Soares, A., Govender, L., Hughes, J., Mavakla, W., de Kock, M., Barnard, C., Pienaar, B., Janse van 
Rensburg, E., Jacobs, G., Khomba, G., Stone, L., Abel, B., Scriba, T.J. and Hanekom, W.A., 2010. Novel 
application of Ki67 to quantify antigen-specific in vitro lymphoproliferation. Journal of 
Immunological Methods, 362 (1-2), 43-50.  
Sonpavde, G., Slawin, K.M., Spencer, D.M. and Levitt, J.M., 2010. Emerging vaccine therapy 
approaches for prostate cancer. Reviews in Urology, 12 (1), 25-34.  
Spary, L.K., Salimu, J., Webber, J.P., Clayton, A., Mason, M.D. and Tabi, Z., 2014. Tumor stroma-
derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14 (+) PD-
L1 (+) phenotype in prostate cancer. Oncoimmunology, 3 (9), e955331.  
Spies, E., Reichardt, W., Alvarez, G., Groettrup, M. and Ohlschlager, P., 2012. An artificial PAP gene 
breaks self-tolerance and promotes tumor regression in the TRAMP model for prostate carcinoma. 
Molecular Therapy: The Journal of the American Society of Gene Therapy, 20 (3), 555-564.  
Sprent, J., Zhang, X., Sun, S. and Tough, D., 2000. T-cell proliferation in vivo and the role of cytokines. 
Philosophical Transactions of the Royal Society of London.Series B, Biological Sciences, 355 (1395), 
317-322.  
Steimle, V., C. A. Siegrist, A. Mottet, B. Lisowska-Grospierre, B. Mach. 1994. Regulation of MHC class 
II expression by interferon-γ mediated by the transactivator gene CIITA. Science 265:106. 
Steinbrink, K., Graulich, E., Kubsch, S., Knop, J. and Enk, A.H., 2002. CD4 (+) and CD8 (+) anergic T 
cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor 
activity. Blood, 99 (7), 2468-2476.  
Steinman, R.M., 1991. The dendritic cell system and its role in immunogenicity. Annual Review of 
Immunology, 9, 271-296.  
Stone, J.D., Chervin, A.S. and Kranz, D.M., 2009. T-cell receptor binding affinities and kinetics: 
impact on T-cell activity and specificity. Immunology, 126 (2), 165-176.  
Street, S.E., Cretney, E. and Smyth, M.J., 2001. Perforin and interferon-gamma activities 
independently control tumor initiation, growth, and metastasis. Blood, 97 (1), 192-197.  
Stutman O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-
nude mice. Science. 1974;183:534–536. 
Sutherland, J.S., Goldberg, G.L., Hammett, M.V., Uldrich, A.P., Berzins, S.P., Heng, T.S., Blazar, B.R., 
Millar, J.L., Malin, M.A., Chidgey, A.P. and Boyd, R.L., 2005. Activation of thymic regeneration in 
mice and humans following androgen blockade. Journal of Immunology (Baltimore, Md.: 1950), 175 
(4), 2741-2753.  
Tagawa, S.T., Milowsky, M.I., Morris, M., Vallabhajosula, S., Christos, P., Akhtar, N.H., Osborne, J., 
Goldsmith, S.J., Larson, S., Taskar, N.P., Scher, H.I., Bander, N.H. and Nanus, D.M., 2013. Phase II 
study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 
for metastatic castration-resistant prostate cancer. Clinical Cancer Research: An Official Journal of 
the American Association for Cancer Research, 19 (18), 5182-5191.  
Taitt, H.E., 2018. Global Trends and Prostate Cancer: A Review of Incidence, Detection, and 
Mortality as Influenced by Race, Ethnicity, and Geographic Location. American Journal of Men's 
Health, 12 (6), 1807-1823.  
209 
 
Takahashi, H., Feuerhake, F., Kutok, J.L., Monti, S., Dal Cin, P., Neuberg, D., Aster, J.C. and Shipp, 
M.A., 2006. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme 
inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic 
apoptotic pathway in diffuse large B-cell lymphoma subtypes. Clinical Cancer Research: An Official 
Journal of the American Association for Cancer Research, 12 (11 Pt 1), 3265-3271.  
Takase, H., Yu, C.R., Mahdi, R.M., Douek, D.C., Dirusso, G.B., Midgley, F.M., Dogra, R., Allende, G., 
Rosenkranz, E., Pugliese, A., Egwuagu, C.E. and Gery, I., 2005. Thymic expression of peripheral tissue 
antigens in humans: a remarkable variability among individuals. International Immunology, 17 (8), 
1131-1140.  
Tanaka K, Kasahara M (1998) The MHC class I ligand-generating system: roles of 
immunoproteasomes and the interferon-4gMY-inducible proteasome activator PA28. 
Immunological Reviews 163: 161–176. 
Tario, J.D.,Jr, Chen, G.L., Hahn, T.E., Pan, D., Furlage, R.L., Zhang, Y., Brix, L., Halgreen, C., Jacobsen, 
K., McCarthy, P.L. and Wallace, P.K., 2015. Dextramer reagents are effective tools for quantifying 
CMV antigen-specific T cells from peripheral blood samples. Cytometry.Part B, Clinical Cytometry, 
88 (1), 6-20.  
Telesca, D., Etzioni, R. and Gulati, R., 2008. Estimating lead time and overdiagnosis associated with 
PSA screening from prostate cancer incidence trends. Biometrics, 64 (1), 10-19.  
Teply, B.A., Luber, B., Denmeade, S.R. and Antonarakis, E.S., 2016. The influence of prednisone on 
the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer. Prostate 
Cancer and Prostatic Diseases, 19 (1), 72-78.  
Thomas, D.A., and Massague, J., 2005. TGF-beta directly targets cytotoxic T cell functions during 
tumor evasion of immune surveillance. Cancer Cell, 8 (5), 369-380.  
Thompson, I.M., Pauler, D.K., Goodman, P.J., Tangen, C.M., Lucia, M.S., Parnes, H.L., Minasian, L.M., 
Ford, L.G., Lippman, S.M., Crawford, E.D., Crowley, J.J. and Coltman, C.A.,Jr, 2004. Prevalence of 
prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. The 
New England Journal of Medicine, 350 (22), 2239-2246.  
Tian, S., Maile, R., Collins, E.J. and Frelinger, J.A., 2007. CD8+ T cell activation is governed by TCR-
peptide/MHC affinity, not dissociation rate. Journal of Immunology (Baltimore, Md.: 1950), 179 (5), 
2952-2960.  
Tietze, J.K., Wilkins, D.E., Sckisel, G.D., Bouchlaka, M.N., Alderson, K.L., Weiss, J.M., Ames, E., Bruhn, 
K.W., Craft, N., Wiltrout, R.H., Longo, D.L., Lanier, L.L., Blazar, B.R., Redelman, D. and Murphy, W.J., 
2012. Delineation of antigen-specific and antigen-nonspecific CD8 (+) memory T-cell responses 
after cytokine-based cancer immunotherapy. Blood, 119 (13), 3073-3083.  
Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., 
Carvajal, R.D., Sosman, J.A., Atkins, M.B., Leming, P.D., Spigel, D.R., Antonia, S.J., Horn, L., Drake, 
C.G., Pardoll, D.M., Chen, L., Sharfman, W.H., Anders, R.A., Taube, J.M., McMiller, T.L., Xu, H., 
Korman, A.J., Jure-Kunkel, M., Agrawal, S., McDonald, D., Kollia, G.D., Gupta, A., Wigginton, J.M. 
and Sznol, M., 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The 
New England Journal of Medicine, 366 (26), 2443-2454.  
Topham, N.J., and Hewitt, E.W., 2009. Natural killer cell cytotoxicity: how do they pull the trigger? 
Immunology, 128 (1), 7-15.  
210 
 
Tough, D.F., and Sprent, J., 1998. Bystander stimulation of T cells in vivo by cytokines. Veterinary 
Immunology and Immunopathology, 63 (1-2), 123-129.  
Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J., Robert, L., Chmielowski, B., 
Spasic, M., Henry, G., Ciobanu, V., West, A.N., Carmona, M., Kivork, C., Seja, E., Cherry, G., Gutierrez, 
A.J., Grogan, T.R., Mateus, C., Tomasic, G., Glaspy, J.A., Emerson, R.O., Robins, H., Pierce, R.H., 
Elashoff, D.A., Robert, C. and Ribas, A., 2014. PD-1 blockade induces responses by inhibiting 
adaptive immune resistance. Nature, 515 (7528), 568-571.  
Ugel, S., De Sanctis, F., Mandruzzato, S. and Bronte, V., 2015. Tumor-induced myeloid deviation: 
when myeloid-derived suppressor cells meet tumor-associated macrophages. The Journal of Clinical 
Investigation, 125 (9), 3365-3376.  
Van Rompay, M.I., Solomon, K.R., Nickel, J.C., Ranganathan, G., Kantoff, P.W. and McKinlay, J.B., 
2019. Prostate cancer incidence and mortality among men using statins and non-statin lipid-
lowering medications. European Journal of Cancer (Oxford, England: 1990), 112, 118-126.  
Velcheti, V., Karnik, S., Bardot, S.F. and Prakash, O., 2008. Pathogenesis of prostate cancer: lessons 
from basic research. The Ochsner Journal, 8 (4), 213-218.  
Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillère R, Hannani D, Enot DP, Pfirschke C, Engblom C, 
Pittet MJ, Schlitzer A, Ginhoux F, Apetoh L, Chachaty E, Woerther PL, Eberl G, Bérard M, Ecobichon 
C, Clermont D, Bizet C, Gaboriau-Routhiau V, Cerf-Bensussan N, Opolon P, Yessaad N, Vivier E, Ryffel 
B, Elson CO, Doré J, Kroemer G, Lepage P, Boneca IG, Ghiringhelli F, Zitvogel L. The intestinal 
microbiota modulates the anti-cancer immune effects of cyclophosphamide. Science. 
2013;342:971–976. 
Vigano, S., Utzschneider, D.T., Perreau, M., Pantaleo, G., Zehn, D. and Harari, A., 2012. Functional 
avidity: a measure to predict the efficacy of effector T cells? Clinical & Developmental Immunology, 
2012, 153863.  
Vitkin, N., Nersesian, S., Siemens, D.R. and Koti, M., 2019. The Tumor Immune Contexture of 
Prostate Cancer. Frontiers in Immunology, 10, 603.  
Vonderheide, R.H., and Glennie, M.J., 2013. Agonistic CD40 antibodies and cancer therapy. Clinical 
Cancer Research: An Official Journal of the American Association for Cancer Research, 19 (5), 1035-
1043.  
Voutsas, I.F., Anastasopoulou, E.A., Tzonis, P., Papamichail, M., Perez, S.A. and Baxevanis, C.N., 2016. 
Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-
2/neu hybrid peptide. Journal for Immunotherapy of Cancer, 4, 75-016-0183-4. eCollection 2016.  
Wagstaffe, H.R., Mooney, J.P., Riley, E.M. and Goodier, M.R., 2018. Vaccinating for natural killer cell 
effector functions. Clinical & Translational Immunology, 7 (1), e1010.  
Wang, M.C., Valenzuela, L.A., Murphy, G.P. and Chu, T.M., 1979. Purification of a human prostate 
specific antigen. Investigative Urology, 17 (2), 159-163.  
Wang, W., Erbe, A.K., Hank, J.A., Morris, Z.S. and Sondel, P.M., 2015. NK Cell-Mediated Antibody-
Dependent Cellular Cytotoxicity in Cancer Immunotherapy. Frontiers in Immunology, 6, 368.  
Wang, X., He, Q., Shen, H., Lu, X.J. and Sun, B., 2019. Genetic and phenotypic difference in CD8 (+) 
T cell exhaustion between chronic hepatitis B infection and hepatocellular carcinoma. Journal of 
Medical Genetics, 56 (1), 18-21.  
211 
 
Wang, X., and Lin, Y., 2008. Tumor necrosis factor and cancer, buddies or foes? Acta 
Pharmacologica Sinica, 29 (11), 1275-1288.  
Wang, Y.J., Fletcher, R., Yu, J. and Zhang, L., 2018. Immunogenic effects of chemotherapy-induced 
tumor cell death. Genes & Diseases, 5 (3), 194-203.  
Wargowski, E., Johnson, L.E., Eickhoff, J.C., Delmastro, L., Staab, M.J., Liu, G. and McNeel, D.G., 2018. 
Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic 
castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine. Journal for 
Immunotherapy of Cancer, 6 (1), 21-018-0333-y.  
Wherry, E.J., and Kurachi, M., 2015. Molecular and cellular insights into T cell exhaustion. Nature 
Reviews.Immunology, 15 (8), 486-499.  
Wherry, E.J., Teichgraber, V., Becker, T.C., Masopust, D., Kaech, S.M., Antia, R., von Andrian, U.H. 
and Ahmed, R., 2003. Lineage relationship and protective immunity of memory CD8 T cell subsets. 
Nature Immunology, 4 (3), 225-234.  
Williams, J.B., Horton, B.L., Zheng, Y., Duan, Y., Powell, J.D. and Gajewski, T.F., 2017. The EGR2 
targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the 
tumor microenvironment. The Journal of Experimental Medicine, 214 (2), 381-400.  
Witherspoon, L., Breau, R.H. and Lavallee, L.T., 2019. Evidence-based approach to active 
surveillance of prostate cancer. World Journal of Urology, .  
Wolchok, J.D., Yuan, J., Houghton, A.N., Gallardo, H.F., Rasalan, T.S., Wang, J., Zhang, Y., 
Ranganathan, R., Chapman, P.B., Krown, S.E., Livingston, P.O., Heywood, M., Riviere, I., Panageas, 
K.S., Terzulli, S.L. and Perales, M.A., 2007. Safety and immunogenicity of tyrosinase DNA vaccines 
in patients with melanoma. Molecular Therapy: The Journal of the American Society of Gene 
Therapy, 15 (11), 2044-2050.  
Wong, P., and Pamer, E.G., 2004. Disparate in vitro and in vivo requirements for IL-2 during antigen-
independent CD8 T cell expansion. Journal of Immunology (Baltimore, Md.: 1950), 172 (4), 2171-
2176.  
Wong, P., and Pamer, E.G., 2001. Cutting edge: antigen-independent CD8 T cell proliferation. 
Journal of Immunology (Baltimore, Md.: 1950), 166 (10), 5864-5868.  
Xiang, W., Shi, R., Kang, X., Zhang, X., Chen, P., Zhang, L., Hou, A., Wang, R., Zhao, Y., Zhao, K., Liu, 
Y., Ma, Y., Luo, H., Shang, S., Zhang, J., He, F., Yu, S., Gan, L., Shi, C., Li, Y., Yang, W., Liang, H. and 
Miao, H., 2018. Monoacylglycerol lipase regulates cannabinoid receptor 2-dependent macrophage 
activation and cancer progression. Nature Communications, 9 (1), 2574-018-04999-8.  
Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EK, et al. Naive tumor-specific CD4(+) T cells 
differentiated in vivo eradicate established melanoma. The Journal of experimental medicine. 
2010;207(3):651–67. Epub 2010/02/17. pmid:20156973; PubMed Central PMCID: 
PMCPmc2839147. 
Yamamoto, R., Nishikori, M., Kitawaki, T., Sakai, T., Hishizawa, M., Tashima, M., Kondo, T., Ohmori, 
K., Kurata, M., Hayashi, T. and Uchiyama, T., 2008. PD-1-PD-1 ligand interaction contributes to 
immunosuppressive microenvironment of Hodgkin lymphoma. Blood, 111 (6), 3220-3224.  
212 
 
Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, Iwakura Y, Oshima K, Morita H, 
Hattori M, Honda K, Ishikawa Y, Hara E, Ohtani N. Obesity-induced gut microbial metabolite 
promotes liver cancer through senescence secretome. Nature. 2013;499:97–101. 
Yuan, J., Ku, G.Y., Gallardo, H.F., Orlandi, F., Manukian, G., Rasalan, T.S., Xu, Y., Li, H., Vyas, S., Mu, 
Z., Chapman, P.B., Krown, S.E., Panageas, K., Terzulli, S.L., Old, L.J., Houghton, A.N. and Wolchok, 
J.D., 2009. Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial 
of patients with melanoma. Cancer Immunity, 9, 5.  
Zitvogel L, et al. Cancer and the gut microbiota: an unexpected link. Sci Transl Med. 
2015;7(271):271ps271. 
Zhang, N., and Bevan, M.J., 2011. CD8 (+) T cells: foot soldiers of the immune system. Immunity, 35 
(2), 161-168.  
Zhao, S.G., Lehrer, J., Chang, S.L., Das, R., Erho, N., Liu, Y., Sjostrom, M., Den, R.B., Freedland, S.J., 
Klein, E.A., Karnes, R.J., Schaeffer, E.M., Xu, M., Speers, C., Nguyen, P.L., Ross, A.E., Chan, J.M., 
Cooperberg, M.R., Carroll, P.R., Davicioni, E., Fong, L., Spratt, D.E. and Feng, F.Y., 2019. The Immune 
Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. Journal 
of the National Cancer Institute, 111 (3), 301-310.  
Zhou, F., 2009. Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing 
and presentation. International Reviews of Immunology, 28 (3-4), 239-260.  
Zhou, X., Sun, L., Jing, D., Xu, G., Zhang, J., Lin, L., Zhao, J., Yao, Z. and Lin, H., 2018. Galectin-9 
Expression Predicts Favorable Clinical Outcome in Solid Tumors: A Systematic Review and Meta-
Analysis. Frontiers in Physiology, 9, 452.  
Zhu, Z., Cuss, S.M., Singh, V., Gurusamy, D., Shoe, J.L., Leighty, R., Bronte, V. and Hurwitz, A.A., 2015. 
CD4+ T Cell Help Selectively Enhances High-Avidity Tumor Antigen-Specific CD8+ T Cells. Journal of 
Immunology (Baltimore, Md.: 1950), 195 (7), 3482-3489.  
 
